Amgen brings nearly four decades of experience in the research, development, manufacturing, and supply of innovator biologics to its portfolio of novel and biosimilar therapies for inflammatory diseases. To learn more, please visit www.AmgenBiosimilars.eu and www.AmgenPipeline.com.
The EULAR Strategic Objectives
2018 - 2023

1. **ESOR** - By 2023, EULAR will be the leading provider of education in rheumatic and musculoskeletal diseases (RMDs).

2. **Congress** - By 2023, EULAR will provide the foremost RMD congress experience, building on the heritage of our outstanding annual meeting.

3. **QOC** - By 2023, EULAR will deliver pre-eminent comprehensive quality of care (QOC) frameworks for the management of people with RMDs.

4. **Research** - By 2023, EULAR will have established a European centre for RMD research to advance high quality collaborative research.

5. **Advocacy** - By 2023, EULAR’s activities and related advocacy will have increased participation in work by people with RMDs.

6. **Governance, Infrastructure, Financials** - By 2023, EULAR will have established governance, workflows and infrastructure to deliver the EULAR strategic objectives.

www.eular.org
Table of Contents

Welcome Message  ÷  3
Organising Committees  ÷  4
General Information  ÷  5
  - Information about your participation  ÷  6
  - EULAR Corporate Social Responsibility Statement  ÷  9
  - Networking opportunities  ÷  9
  - Scientific information  ÷  9
  - Information on industry related activities  ÷  10

Scientific Programme
Congress at a Glance:
  - Wednesday, 13 June 2018  ÷  13
  - Thursday, 14 June 2018  ÷  14
  - Friday, 15 June 2018  ÷  16
  - Saturday, 16 June 2018  ÷  18
Wednesday, 13 June 2018
  - Scientific Programme  ÷  19
Thursday, 14 June 2018
  - Scientific Programme  ÷  32
  - Guided Poster Tours  ÷  49
  - Scientific Poster Session I  ÷  50
Friday, 15 June 2018
  - Scientific Programme  ÷  81
  - Guided Poster Tours  ÷  98
  - Scientific Poster Session II  ÷  99
Saturday, 16 June 2018
  - Scientific Programme  ÷  130
  - Guided Poster Tours  ÷  137
  - Scientific Poster Session III  ÷  138
Health Professionals in Rheumatology Programme and Posters  ÷  171
PARE Programme and Posters  ÷  183
EULAR Related Meetings  ÷  189

Partner Programme
Satellite Symposia  ÷  191
Company Profiles  ÷  201
Acknowledgements  ÷  215
Exhibitors’ List  ÷  216
Exhibition Plan  ÷  217
Congress Venue Overview Plan  ÷  218

The acronym ‘PARE’ used in the programme stands for ‘People with Arthritis/Rheumatism in Europe’
The acronym ‘HPR’ used in the programme stands for ‘Health Professionals in Rheumatology’
ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Madrid, Spain
12–15 June 2019
Dear Colleagues,

I wish you a warm welcome to the 19th EULAR Annual European Congress of Rheumatology in Amsterdam. Our annual EULAR Congress has become a major event in the calendar of world rheumatology, and Amsterdam 2018 will again provide a unique event for the exchange of scientific and clinical information. It offers a platform to facilitate interactions between medical doctors, scientists, health professionals, patients and professionals representing the pharmaceutical industry, from across Europe and around the world.

This will be a particularly exciting congress - we will launch the EULAR Strategy 2018-2023 and highlight remarkable progress in several recent initiatives, including the EULAR School of Rheumatology and our ground breaking ‘Don't Delay, Connect Today’ campaign.

EULAR is built on three fundamental pillars, integrating patient (PARE), health professional and rheumatology national associations. This partnership underpinning the work of EULAR is a unique stimulus to prosper advances in our field, for example via treatment recommendations, political advocacy, and research leadership. Accordingly, our congress is of the highest quality delivering a rich resource of contemporary, yet accessible information, serving a vital role in our unstinting efforts to reduce the impact, burden and cost of rheumatic and musculoskeletal diseases for individuals and society.

EULAR 2018 will address a wide range of topics including innovation in population, health service, clinical, translational and basic science. The WIN/HOT track for the busy clinician requiring an update on What is New and How to Treat the major rheumatic diseases has become an admired and ‘must see’ highlight of the EULAR Congress. Sessions dedicated to People with Arthritis and Rheumatism in Europe (PARE), Health Professionals in Rheumatology (HPR) are further jewels in our programme. High quality health care industry sessions provide in-depth and focussed insights.

Our poster presentations and poster tours provide a highly interactive exchange of knowledge and solutions amongst participants. We will be discussing the best of the more than 5,000 submitted abstracts, testament to the rich vein of creativity and energy currently evident in our discipline. In Amsterdam, together we will further promote the reputation of the EULAR Congress as the most innovative and informative venue for clinical research for the practising physician. Finally, it is a particular pleasure to celebrate the participation of the EULAR EMEUNET organisation of young rheumatologists that continues to attract young colleagues to the meeting. Together we must disseminate the message that rheumatology is one of the most attractive and successful disciplines in global medicine.

We are very happy to revisit the City of Amsterdam. In 2006, we relished the magnificent ambiance of canals and canalside houses, galleries, astonishing museums (think Rembrandt, Vermeer, Rubens, Steen and Van Gogh), the Anne Frank House, theatres, music and culinary pleasures. The city has flourished since, offering an ever-more diverse and enriching experience, hopefully bathed in early summer sunshine! Whereas balmy warmth may be uncertain, there is no doubt that Amsterdam will provide an excellent background for scientific and clinical exchanges, international collaborations and renewal of friendships. We take great pleasure in welcoming you all to EULAR 2018, and hope that your stay in Amsterdam will be informative, educational and, last but not least, enjoyable.

Johannes W. J. Bijlsma
EULAR President
Organising Committees

**EULAR EXECUTIVE COMMITTEE**

- President
  Prof. Johannes W. J. Bijlsma, Netherlands
- President-Elect
  Prof. Iain B. McInnes, United Kingdom
- Past President
  Prof. Gerd R. Burmester, Germany
- Vice-President representing national PARE organisations
  Mr Dieter Wiek, Germany
- Vice-President representing the Health Professionals in Rheumatology
  Prof. Tanja Stamm, Austria
- Treasurer
  Prof. Annamaria Iagnocco, Italy
- General Secretary
  Prof. Ruxandra Ionescu, Romania
- Editor in Chief of the ‘Annals of the Rheumatic Diseases - The EULAR Journal’
  Prof. Josef S. Smolen, Austria
- Editor in Chief of ‘RMD Open’
  Prof. Bernard Combe, France
- Liaison to EMEUNET
  Dr Elena Nikiphorou, United Kingdom
- * Liaison to the American College of Rheumatology ACR
  Prof. Désirée van der Heijde, Netherlands
- * Liaison Officer, EU Public Affairs
  Mr Neil Betteridge, United Kingdom
- * Liaison to the FOREUM Foundation
  Prof. Steffen Gay, Switzerland
- * President UEMS Section of Rheumatology
  Dr Jean Dudler, Switzerland
- * Executive Director
  Dr Julia Rautenstrauch, Switzerland

**EULAR STANDING COMMITTEE CHAIRS**

(ex officio members of the EULAR Executive Committee)

- Investigative Rheumatology
  Prof. Xavier Mariette, France
- Clinical Affairs
  Prof. Ulf Müller-Ladner, Germany
- Education and Training
  Prof. Nemanja Damjanov, Serbia
- Epidemiology and Health Services Research
  Prof. Laure Gossec, France
- Musculoskeletal Imaging
  Dr Lene Terslev, Denmark
- Paediatric Rheumatology
  Prof. Berent Prakken, Netherlands
- PARE
  Ms Nele Caeyers, Belgium
- Health Professionals in Rheumatology
  Prof. Annette de Thurah, Denmark

**EULAR CONGRESS PROGRAMME COMMITTEE**

**Scientific, Health Professionals, PARE**

- The EULAR Executive Committee Members (excluding functions marked with ‘*’)
- The EULAR Standing Committee Chairs
- Chair of the Scientific Programme Committee
- Chair of the Abstract Selection Committee
- Past-Chair of the Scientific Programme Committee
- Prof. Francis Berenbaum, France
- Prof. Leonard Calabrese, United States
- Prof. Loreto Carmona, Spain
- Prof. Piet Geusens, Netherlands
- Prof. Martin Herrmann, Germany
- Prof. John Isaacs, United Kingdom
- Mr Marios Kouloumas, Cyprus
- Prof. Anne-Marie Malfait, United States
- Dr Elena Neumann, Germany
- Dr Caroline Ospelt, Switzerland
- Dr Daniel Prieto-Alhambra, United Kingdom
- Dr Yeliz Prior, United Kingdom
- Dr Sofia Ramirez, Netherlands
- Prof. Alexander So, Switzerland
- Dr Leonie Taams, United Kingdom
- Prof. Tsutomu Takeuchi, Japan
- Prof. Lai-Shan Tam, China
- Prof. Angela Tincani, Italy
- Prof. Filip van den Bosch, Belgium
- Prof. David Walsh, United Kingdom

* These functions are not included in the Congress Programme Committee
CONGRESS VENUE: DATES AND LOCATION

The Annual European Congress of Rheumatology EULAR 2018 is held at:
RAI Amsterdam
Europaplein
NL 1078 GZ Amsterdam
Netherlands
Website:  www.rai.nl

The congress opens on Wednesday, 13 June 2018 at 12:00 and closes on Saturday, 16 June 2018 at 14:45.
The EULAR 2018 Congress Opening Plenary Session takes place on Wednesday, 13 June 2018 from 13:00 to 14:00.
A networking platform, for scientific exchange, is held in the evening of Wednesday, 13 June 2018 at the congress venue itself.

RAI Amsterdam is situated 8 minutes from Amsterdam’s city centre and 15 minutes from Amsterdam Airport Schiphol. EULAR 2018 delegates can easily reach the congress venue by public transport.

REGISTRATION AREA OPENING HOURS

<table>
<thead>
<tr>
<th>Day</th>
<th>Date:</th>
<th>Time:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>12 June 2018</td>
<td>17:00 - 20:00</td>
</tr>
<tr>
<td>Wednesday</td>
<td>13 June 2018</td>
<td>07:30 - 20:00</td>
</tr>
<tr>
<td>Thursday</td>
<td>14 June 2018</td>
<td>07:45 - 19:15</td>
</tr>
<tr>
<td>Friday</td>
<td>15 June 2018</td>
<td>07:45 - 19:15</td>
</tr>
<tr>
<td>Saturday</td>
<td>16 June 2018</td>
<td>08:00 - 15:00</td>
</tr>
</tbody>
</table>

SCIENTIFIC SECRETARIAT

EULAR Secretariat
Seestrasse 240
CH-8802 Kilchberg/Zurich
Switzerland
Tel:  +41 44 716 3030
Fax:  +41 44 716 3039
Email: congress@eular.org
Website:  www.congress.eular.org / www.eular.org

ORGANISING SECRETARIAT

In charge of registration, abstract handling, partnership & investment opportunities, hotel reservations

EULAR 2018
c/o MCI SUISSE SA
Rue du Pré-Bouvier 9
CH-1242 Satigny, Geneva
Switzerland
Tel:  +41 22 33 99 590
Fax:  +41 22 33 99 601
Email: eular@mci-group.com
Website:  www.mci-group.com

LOCAL ORGANISING AGENCY

For social events, excursions, transfers, company events

MCI Amsterdam
Schipluidenlaan 4
1062 HE Amsterdam
Netherlands
Tel:  +31 20 570 96 00
Email: eular18.soc@mci-group.com
Website:  www.mci-group.com/thennetherlands
Information about your Participation

ADMISSION TO THE EULAR CONGRESS

In respect of Dutch and European laws and regulations, as well as due to current health and safety rules and legislation in effect, registration and/or admittance to the EULAR Congress shall be limited solely to participants who are 18 years of age or older. Registration by anyone who is under 18 is unauthorised and in violation of these terms and conditions and will automatically result in the forfeit of their registration. Identification is to be provided to congress staff upon request. Participants below 18 years of age will not be granted access to any part of the congress at any time. This is also valid for children accompanied by their parents and for any other unregistered person. If access to the congress is needed and no registration is available, the person should contact the registration desk. The congress management will take a final decision.

CANCELLATION OF CONGRESS

It is mutually agreed that in the event of total or partial cancellation of the congress due to fire, strike, natural disaster (either threatened or actual), government regulations or causes which would prevent its scheduled opening or continuance, the contractual relationship between EULAR and the participant will be terminated immediately and EULAR shall determine an equitable basis for the eventual refund of a portion of the registration or other fees after due consideration of expenditures and commitments already made. Under no circumstances is EULAR responsible for any participant expenses (such as travel and lodging) or any other incidental or consequential damages.

EULAR CONGRESS MOBILE APP

Since 2003 EULAR has offered a congress programme and guide for mobile devices, at that time pioneering in this upcoming technology. In the last seven years, we have also offered a planning tool, the internet based itinerary planner. Schedules made in the planner can be transferred easily to your smartphone or tablet on iOS, Android or WindowsPhone. Apart from general information, the app contains the complete congress programme with all sessions and lectures, all abstracts in full text and all symposia. Links between these elements allow for changes to content to be made easily. The location of session and meeting rooms is shown interactively so you know instantly where the next event takes place. A support desk for mobile devices is located in the EULAR Village.

Promote the EULAR Congress Mobile App by using the hashtag #EULAR2018App.

DATA SCANNING SYSTEM

The EULAR 2018 Congress will use a new generation of delegate badges including a chip acting as a sensor. This tool will collect anonymised data with the primary objective of improving future EULAR Congresses by understanding the use EULAR Participants make of available services and opportunities, and by better understanding the various interactions as well as the topics of interest. As a participant at the congress, you will not be impacted but your contribution will be key to the success of future EULAR Congresses. All tracked data will be anonymous and only has a very small operating radius inside the conference rooms and the venue. Please ensure that you return your badge either to the registration area or to the clearly designated collection points - which will be located near to the exits of the conference venue - before your final departure from the event. These badges will be recycled.

DRESS CODE

Dress will be informal throughout the congress. EULAR reserves the right to refuse access if it is deemed necessary for the comfort and safety of all delegates.

General Information

CHARGING STATIONS FOR SMARTPHONES AND MOBILE DEVICES

Charging stations for smartphones and other mobile devices are available in the registration area and exhibition area.

CLOAKROOM

A cloakroom service for coats and reasonably-sized luggage is available during the opening hours of the congress in the registration area, Hall 2.

CYBER CAFÉ

Two Cyber Cafés are located in the exhibition area and EULAR Village, Hall 1.

CONGRESS DOCUMENTS AND BADGES

Name badges can be printed and activated at the self-service stations, located at the registration area in Hall 2 for regular delegates. Invited speakers, guests, PARE and patients can obtain their badges from the manned registration counters. Name badges must be worn visibly at all time during the congress and in the exhibition area.

CONGRESS EVALUATION

We would be grateful if you could take a few minutes to support the onsite staff member who may approach you to gain your opinion about the congress and the scientific programme. This will help us to continue to improve the congress in the future.

CLIMATE

Amsterdam is at its best from May (when the tulips are out) to August (when the days are the longest). The climate is moderate maritime, with warm summers and cool winters, and typically high humidity. You always have a chance of seeing rain in Amsterdam.

CREDIT CARDS

Major Credit Cards (Visa, American Express, Eurocard/ Mastercard, Diners Club) are accepted in most hotels, restaurants and shops.

CURRENCY

The currency in the Netherlands is Euro (1 Euro= 100 cents).
ELECTRICITY
The electricity power supply in the Netherlands is 220 Volts with a European standard plug.

FOOD AND BEVERAGE
During official coffee breaks, complimentary coffee and tea will be served in the EULAR Village and exhibition area, Hall 1. Lunch will be provided from these areas on Thursday and Friday. A self-service restaurant and sandwich bars are available at the congress venue.

HELP POINT FOR SMARTPHONES AND MOBILE DEVICES
A Help Point for phones and other mobile devices as well as recharge options for such devices will be available in the EULAR Village. The EULAR Mobile Congress App can also be downloaded there.

AMSTERDAM & THE NETHERLANDS (FACTS ABOUT)
The Netherlands is the main constituent country of the Kingdom of the Netherlands. It is a small, densely populated country located in Western Europe with three island territories in the Caribbean. Amsterdam is the country’s capital, while The Hague holds the Dutch seat of government and parliament. The port of Rotterdam is the largest port in Europe and was the world’s largest port between 1962 and 2004. The name Holland is also frequently and incorrectly used to refer informally to the whole of the country of the Netherlands.

‘Netherlands’ literally means ‘lower countries’, influenced by its low land and flat geography, with only about 50 percent of its land exceeding one metre above sea level. Most of the areas below sea level are man-made. Since the late 16th century, large areas (polders) have been reclaimed from the sea and lakes, amounting to nearly 17 percent of the country’s current land mass. The Netherlands is the world’s second-largest exporter of food and agricultural products, after the United States. This is partly due to the fertility of the soil and the mild climate. The Netherlands was the third country in the world to have an elected parliament, and since 1848 it has been governed as a parliamentary democracy and a constitutional monarchy, organised as a unitary state. The Netherlands has a long history of social tolerance and is generally regarded as a liberal country, having legalised abortion, prostitution and euthanasia, while maintaining a progressive drugs policy. In 2001, it became the world’s first country to legalise same-sex marriage.

The Netherlands is also a part of the Schengen Area and has a market-based mixed economy. In 2013, the United Nations World Happiness Report ranked the Netherlands as the seventh-happiest country in the world, reflecting its high quality of life.

When people think of the Netherlands, many of them think of tulips and windmills but the country has much more to offer. Amsterdam was founded in the Middle Ages near a dam on the River Amstel. The city truly blossomed in the early 17th century, when it became the world’s largest centre for trade and art. The historic heart of the city known as the ‘Grachtengordel’ (canal ring) has remained beautifully intact to this day.

Today, with two leading universities and several laboratories, Amsterdam is now firmly on the world map as a knowledge centre. The city attracts many prominent academics as well as those involved in innovative science and research. Amsterdam is a historic city with a modern outlook that meshes business growth with sustainable initiatives. The city is regarded as one of the top 10 most important commercial centres in the world.

Amsterdam has been a centre of creativity and culture for centuries. The famous Rijksmuseum features works by 17th century Dutch Masters such as Rembrandt and Vermeer. The Van Gogh Museum houses some of the eponymous artist’s greatest works. Other heritage treasures include the Anne Frank House, the Rembrandt House and the baroque Royal Palace on Dam Square. Even frequent visitors will always find something new to appreciate.

Amsterdam is a vibrant, dynamic city in which people feel free. Free to be who they are, and to write or say what they want. The city is famous for its tolerance. This has been expressed since the 17th century in the city’s wide diversity of
people, businesses and events. With 180 different cultures, Amsterdam is amongst the most diverse cities in the world.

A recent report published by the Economist Intelligence Unit found that Amsterdam is among the safest cities in the world, ranking fifth on the global index and second in Europe. Amsterdam is therefore a place in which international EULAR delegates will be able to move freely and safely. Just 15 minutes from the centre of Amsterdam, the villages of Marken and Volendam offer an unrivalled collection of authentic Dutch houses and windmills.

GETTING AROUND IN AMSTERDAM

Amsterdam has an outstanding public transportation system, but the compact city centre means most facilities and sights are within walking distance of each other. The city’s network of canals also offers a unique transport opportunity. Amsterdam’s compact size means that almost everything is within walking distance. Nevertheless, the public transport network is efficient, modern, reliable and inexpensive. Amsterdam’s public transport company is GVB, which transports one million passengers within greater Amsterdam by tram, bus, metro and ferry every day. An efficient train system completes the offering.

Taxis

Amsterdam has a variety of taxi firms which supplements its excellent public transportation network. TCA operates 1500 drivers and 1300 vehicles. Taxi fares from RAI Amsterdam to hotels and to the airport in Amsterdam are regulated by special flat rates to guarantee that delegates are not overcharged. Passengers at Amsterdam Airport Schiphol can also opt for electrically powered Tesla taxis. These vehicles make a major contribution to sustainable mobility at the airport.

Metro

The Amsterdam Metro is a mixed subway and above-ground commuter rail with various lines. Tram 4 runs between the RAI (Europaplein stop), Amsterdam’s city centre and Amsterdam Central Station. You can reach the RAI from the Amstel railway station by taking Metro 51 and Bus 65. Metro 51 also runs to Amsterdam Central Station. Metro 50 runs regularly between the Amsterdam Sloterdijk and Gein stations and stops at the RAI Amsterdam station.

Cycling

Amsterdam is the most bicycle-friendly large cities in the world and is a centre of bicycle culture with good facilities for cyclists such as bike paths and bike racks. In 2013, there were about 1,200,000 bicycles in Amsterdam outnumbering the amount of citizens in the city. Bicycle rentals are readily available throughout the city. Central Station, Leidseplein and Dam Square are all major rental hubs.

INSURANCE AND LIABILITY

It is strongly recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. EULAR and MCI as organisers cannot accept any responsibility for personal injuries, or loss of, or damage to, private property belonging to congress participants.

LANGUAGE/OFFICIAL LANGUAGE

The official congress language is English. No simultaneous translation is provided.

SOCIAL MEDIA/PHOTOGRAPHY RULES AND REGULATIONS AT EULAR 2018

The intention at EULAR 2018 is to facilitate the sharing of content within the scientific, health professional and patient communities while still respecting the copyrights and intellectual property of the presenters. Picture-taking/filming and/or live streaming for commercial use and in the commercial area is not permitted. Recording or live streaming of congress presentations/ sessions is not allowed in any way (neither image, nor sound). Presenters and chairs have the right to request no photographs during their presentation/session/activities. In compliance with Dutch laws on promotional activities for medical events and satellite symposia, published photographs should not include any ‘trade names’, ‘brand names’ and/or any product advertisement. At all times, when permitted, photographs must be taken in a non-disruptive manner. Full guidelines can be downloaded on www.congress.eular.org.

PRESS CENTRE

The press and media area is located in rooms G101-G111. Facilities such as computers, photocopier, and internet access are available for registered media and press representatives.

SECURITY

Please pay particular attention to your personal belongings, especially when walking in the city centre or using the public transportation system, and inside the congress venue. Any security problems or concerns within the congress venue should be reported to a member of the EULAR or MCI staff. Security staff will handle all emergency situations and everyone is required to follow instructions announced via the public information system. Emergency exits are marked with green exit signs.

SERVICES FOR THE DISABLED

All session rooms at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly in the EULAR Village.

SHOPPING IN AMSTERDAM

Amsterdam’s specialist stores make shopping in the city unique. Amsterdam’s best shops are in charming canal houses on cobbledstone streets. This village-like atmosphere makes shopping a delight.

SMOKING POLICY

Smoking is not permitted at the congress venue.

SOCIAL MEDIA

Share your best moments of EULAR on your social media platforms by using the hashtag #EULAR2018. Please also refer to the EULAR Social Media Policy which can be downloaded at www.congress.eular.org.

TELEPHONES

Please respect your fellow colleagues and friends by operating your mobile devices in silent mode in all session rooms and poster areas.
TIME
The Netherlands follows Central European Time (CET) which is UTC +1 hour in winter and UTC +2 in summer.

TIPPING
Locals in Amsterdam usually tip when they have received good service. In general, people tend to tip 10 percent in restaurants (however restaurants do not charge extra on the bill). Tipping taxicab drivers and hotel personnel is also customary in Amsterdam.

TRANSPORTATION
EULAR provides transportation passes to duly registered delegates, who booked the accommodation through MCI, the official congress housing bureau, enabling them to travel on the public transportation network between their hotel and the congress venue during the EULAR Congress.

EULAR Corporate Social Responsibility Statement
EULAR is aware of the environmental, economic and social impact of holding a large congress, and is working closely with its partners to ensure that environmentally, economically and socially friendly policies are in place. For the Amsterdam congress, EULAR has made the following sustainable arrangements:

HEALTHY FOOD
All buffets for lunches and coffee breaks offer healthy options meaning that there is always a choice of fresh fruit or vegetables. A smaller selection of dietary offerings is also available. Local products have been prioritised.

PRINTING
EULAR is committed to ensuring that printing is kept to a minimum to reduce the amount of waste paper. No abstract book and no preliminary programme for EULAR 2019 will be printed. All abstracts will be available online as well as the preliminary programme. This will save printing approximately 24,000,000 pages.

LOCAL SUPPLIERS
EULAR wishes to have a positive local impact. When sourcing materials and suppliers, EULAR gives priority to local partners to avoid a negative impact on the environment and to positively impact the local economy.

SERVICES FOR THE DISABLED
EULAR wishes to make the congress experience comfortable for all attendees. All rooms and areas at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly within the EULAR Village.

Networking Opportunities

OPENING PLENARY SESSION
Wednesday, 13 June 2018 – 13:00-14:00 - Hall 7.1
The Opening Plenary Session will take place this year in the early afternoon.

NETWORKING PLATFORM
Wednesday, 13 June 2018 – 20:00-22:00 - Strand Zuid
All registered participants are cordially invited to meet and greet old and new friends.

EULAR CONGRESS DINNER
Friday, 15 June 2018 - 20:30-24:00
Price: EUR 95 per person (not included in the registration fee)
The EULAR 2018 Congress Dinner will take place on board the Ocean Diva.
The Congress Dinner is always a great opportunity to fine dine and meet with friends and colleagues from around the world in a relaxed atmosphere, this year enjoying the unmatched charm and fascination of Amsterdam.
In the city of canals, how could we better welcome our participants and friends than on a superb vessel? The Ocean Diva, an impressive cruise ship, will take us for a tour on the Amsterdam waters in a trendy, high quality and friendly Dutch atmosphere.
Seats being very limited, rush to register and don’t miss the unique opportunity of networking with colleagues and friends while enjoying Dutch cuisine at its best!

Scientific Information

CERTIFICATE OF ATTENDANCE
A certificate of attendance will be sent by email to all attendees who fill out the congress evaluation survey. Please update your contact details at the Yellow Towers available throughout the congress venue in order to ensure that the certificate reaches you.

CONTINUING MEDICAL EDUCATION (CME) CREDITS
CME approval was still under review at the time of printing. Please consult the EULAR Website www.congress.eular.org or the EULAR App for further information.

POSTERS
The scientific posters and health professionals in rheumatology posters are displayed in the poster areas in halls 1, 5 and 6 from Thursday to Saturday. They are changed on a daily basis. PARE posters are displayed on a permanent basis close to the PARE Room, located in Hall 5.
Official poster viewing will take place at the following times:
- Thursday 14 June 2018 11:45 - 13:30
- Friday 15 June 2018 11:45 - 13:30
- Saturday 16 June 2018 10:30 - 12:00
Guided poster tours on selected topics will take place during the official poster viewing times.
Delegates interested in the work of the EULAR Study Groups have the possibility to browse through electronic posters of the different projects and working groups near the EULAR Village.

**SPEAKERS’ PREVIEW ROOM**
The speakers’ preview room is located in room K101/K102, near Hall 2, and is open at the following times:

- **Wednesday** 13 June 2018 08:00 - 20:00
- **Thursday** 14 June 2018 08:00 - 19:00
- **Friday** 15 June 2018 08:00 - 19:00
- **Saturday** 16 June 2018 08:00 - 14:30

The preview room is equipped with computers. All speakers are required to check-in their presentation at least 2 hours before their session, or on the day before for the early morning sessions.

**SCIENTIFIC SESSIONS (ACCESS TO)**
The meeting rooms for scientific sessions vary in size. Should the room be full, we invite you to use the overflow facilities located in the registration area, Hall 2 or to attend a different session. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a scientific session. The maximum capacity of the rooms are determined by the local safety and security regulations and must be respected by law.

**Information on Industry Related Activities**

**EXHIBITION**
During the congress, EULAR will present an attractive exhibition to the congress participants.
The abstract poster presentation areas are placed around the exhibition in Halls 1, 5 and 6. Coffee and other refreshments are available within the exhibition during official breaks.
The exhibition hours are as follows:

- **Wednesday** 13 June 2018 12:00 - 18:00
- **Thursday** 14 June 2018 08:00 - 17:15
- **Friday** 15 June 2018 08:00 - 17:15
- **Saturday** 16 June 2018 08:00 - 14:00

**EXHIBITION ACCESS (RESTRICTED)**
For medical conferences taking place in Europe, all participants as well as all contributors are subject to European laws, rules and regulations clarified by the ‘Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2011 on the Community code relating to medicinal products for human use’.
The relevant European laws, rules and regulations and their Dutch application clearly state that:
- Patients and patient advocates should have no access to the areas where prescription medicines are promoted and should not receive any materials containing product advertisements (irrespective of their nationality)
- Pharmaceutical companies can only actively promote prescription medicines in their interactions with healthcare professionals that are entitled to prescribe or supply prescription medicines (in the country where the professional is practicing its profession)

As such and in full respect of the applicable regulations, EULAR has decided to implement the following processes:
- The commercial and the non-commercial parts of the exhibition will be clearly identified
- Healthcare professionals who are entitled to prescribe or supply prescription medicines (in the country where the professional is practicing its profession) will be clearly identified to enable pharmaceutical companies to appropriately engage with them
- Congress participants registered as PARE representatives or as patients will be clearly identified and will not have access to the commercial part of the exhibition and satellite symposia including brand advertisement. The access to all other official parts of the congress including the non-commercial part of the exhibition is unrestricted

We kindly ask all registered participants to follow the specific instructions they will receive together with the congress documents. Onsite staff and dedicated signs are there to help participants navigate the exhibition halls.

**PRIVATE EVENTS POLICY**
All requests from companies/organisations to host private events during the congress must have been approved prior to the congress by the EULAR Secretariat.

**SATELLITE SYMPOSIA (ACCESS TO)**
The meeting rooms for satellite symposia vary in size. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a satellite symposium. The maximum capacity of the rooms are determined by the local safety and security regulations and must be respected by law.
Access to satellite symposia featuring product advertisement is restricted to healthcare professionals that are entitled to prescribe or supply prescription medicines (in the country where the professional is practicing its profession).

**SATELLITE SYMPOSIA (TIMINGS)**
A number of satellite symposia are organised during EULAR 2018 at the following times:

- **Wednesday** 13 June 2018 18:15 - 19:45
- **Thursday** 14 June 2018 08:15 - 09:45
- **Friday** 15 June 2018 08:15 - 09:45
- **Saturday** 15 June 2018 17:30 - 19:00

Further information is available in the satellite booklet, included in your congress bag and on pages 191 to 199 of this programme.
Satellite symposia are governed by the EULAR Guidelines. All symposia and special events must be approved by EULAR. Other symposia are strictly prohibited during the official programme, as outlined in the EULAR Code of Practice.
### Future Congresses

#### Annual European Congress of Rheumatology 2019
Madrid, Spain, 12-15 June 2019

#### Annual European Congress of Rheumatology 2020
Frankfurt, Germany, 3-6 June 2020
Keep in touch with rheumatology

Update your contact details at the ‘yellow towers’!

 расположен коды доступа к записи сессий
 расположен подписку на журнал EULAR - Annals of the Rheumatic Diseases (ARD)
 расположен сертификат участия на EULAR 2018

* if purchased
** the patient and exhibitor registration categories do not include the complimentary subscription to the ARD
## Congress at a Glance

**WEDNESDAY, 13 JUNE 2018**

<table>
<thead>
<tr>
<th>TIME</th>
<th>Hall 7.1</th>
<th>Hall 3</th>
<th>Auditorium</th>
<th>Elicium 2</th>
<th>Hall 7.2</th>
<th>Forum</th>
<th>Elicium 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-14:00</td>
<td><strong>EULAR 2018 Opening Plenary session</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15-15:45</td>
<td>What is New (WIN)/How to Treat (HOT) WIN: Systemic lupus: issues about pregnancy WIN: Recent advances in the treatment of lupus</td>
<td>Challenges in Clinical Practice session Little arthritis in PsA and axSpA with newly onset arthritis - does it matter?</td>
<td>Clinical Science Session Cancer and inflammation</td>
<td>From Bench to Bedside Psychological distress and pain; not all in the mind</td>
<td>Challenges in Clinical Practice session Inflammation in the shadow of fibromyalgia</td>
<td>From Bench to Bedside Shaping the future in systemic sclerosis</td>
<td>Basic and Translational Science session Basic mechanisms of inflammation</td>
</tr>
<tr>
<td>15:45-16:15</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15-17:45</td>
<td>Abstract session Opening Plenary Abstract session</td>
<td>Abstract session From NSAIDs to bDMARDs in SpA: what is new?</td>
<td>Abstract session RA therapy - new molecules and new strategies</td>
<td>Abstract session Doctor, how bad will my rheumatoid arthritis become? RA - prognosis, predictors and outcomes</td>
<td>Abstract session Immunobiology of vasculitis</td>
<td>Abstract session Envisioning new horizons for people with osteoarthritis</td>
<td>Abstract session Fracture risk and consequences</td>
</tr>
<tr>
<td>20:00-22:00</td>
<td><strong>NETWORKING PLATFORM - STRAND ZUID</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15-15:45</td>
<td>HPR session Health Professionals Welcome session</td>
<td>The Young Rheumatologist Statistics made simple: a practical approach to complex concepts</td>
<td>PARE session E-health for better care</td>
<td>EULAR Projects in Paediatric Rheumatology EULAR Projects in Paediatric Rheumatology and UCAN</td>
<td>Practical skills session* Crystal I</td>
<td>Practical skills session* Ultrasound basic I</td>
<td></td>
</tr>
<tr>
<td>15:45-16:15</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15-17:45</td>
<td>Joint session HPR/PARE New drugs - new perspectives: clinical and regulatory issues concerning biosimilars</td>
<td>Abstract session Movement in musculoskeletal pain; from risk to management</td>
<td>PARE session Don’t Delay, Connect Today!</td>
<td>Abstract session Let's improve diagnosis and treatment of orphan diseases</td>
<td>Abstract session New driving molecules in systemic sclerosis</td>
<td>Abstract session A rollercoaster from bench to bedside and back again: paediatric rheumatology in the 21st century</td>
<td></td>
</tr>
<tr>
<td>18:15-19:45</td>
<td>Health Professionals session Delay in treatment and the role of health professionals</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

*** See detailed satellite symposia programme on pages 191 to 199
**Congress at a Glance**

**THURSDAY, 14 JUNE 2018**

<table>
<thead>
<tr>
<th>TIME</th>
<th>Hall 7.1</th>
<th>Hall 3</th>
<th>Auditorium</th>
<th>Elicium 2</th>
<th>Hall 7.2</th>
<th>Forum</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:15-09:45</strong></td>
<td></td>
<td></td>
<td><strong>Satellite symposium</strong>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>09:45-10:15</strong></td>
<td></td>
<td></td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10:15-11:45</strong></td>
<td></td>
<td><strong>What is New (WIN)/ How to Treat (HOT)</strong></td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WIN: Advances in the diagnosis and monitoring of vasculitis</td>
<td>Biologics in RA. Improving and maintaining the response</td>
<td>SLE, Sjögren’s and APS - new criteria, novel diagnostic tools and co-morbidities</td>
<td>The ‘A-B-C’ of PsA (Assessment, Biologicals, Co-morbidities)</td>
<td>RA: such a pain, and beyond</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HOT: Recent advances in the treatment of systemic vasculitides</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td><strong>11:45-13:30</strong></td>
<td></td>
<td>POSTER VIEWING AND LUNCH</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13:30-15:00</strong></td>
<td></td>
<td><strong>What is New (WIN)/ How to Treat (HOT)</strong></td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>Clinical Science session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WIN: What is new in the treatment of myositis?</td>
<td>Clinics in the diagnosis and classification of spondyloarthritis</td>
<td>Reproductive issues in rheumatology</td>
<td>Clinical challenges in giant cell arteritis in 2018</td>
<td>Paediatric Rheumatology session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HOT: Recent advances in the treatment of systemic sclerosis</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>Clinical Science session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Satellite symposium***</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Paediatric Rheumatology session</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>11:50-13:30</strong></td>
<td>GUIDED POSTER TOURS**</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Paediatric Rheumatology session</td>
</tr>
<tr>
<td><strong>15:00-15:30</strong></td>
<td></td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15:30-17:00</strong></td>
<td></td>
<td><strong>What is New (WIN)/ How to Treat (HOT)</strong></td>
<td>Challenges in Clinical Practice session</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>From Bench to Bedside</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WIN: About diagnosis and classification of spondyloarthritis</td>
<td>To taper or not to taper in RA</td>
<td>Can we improve the care of gout?</td>
<td>“Why does BMI matter?”</td>
<td>What is lupus - Syndrome or different entities?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HOT: Recent advances in the management of spondyloarthritis</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td><strong>17:30-19:00</strong></td>
<td></td>
<td></td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
</tr>
</tbody>
</table>

**In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2

*** See detailed satellite symposia programme on pages 191 to 199**
In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2
*** See detailed satellite symposia programme on pages 191 to 199

<table>
<thead>
<tr>
<th>Elicium 1</th>
<th>Amtrium</th>
<th>Emerald</th>
<th>PARE Room</th>
<th>E106/E107</th>
<th>D201/D202</th>
<th>D203/D204</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic and Translational Science session</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat and fatty acids: targets for therapy?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COFFEE BREAK**

<table>
<thead>
<tr>
<th>Abstract session</th>
<th>HPR Abstract session</th>
<th>Abstract session</th>
<th>PARE session</th>
<th>Abstract session</th>
<th>Abstract session</th>
<th>Abstract session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Can imaging improve diagnosis and outcome in rheumatic diseases</td>
<td>Singing power to the people</td>
<td>Fires and firefighters: switching the immune system on and off</td>
<td>Inclusive school environment for young people with RMDs</td>
<td>The building blocks of systemic inflammation</td>
<td>The crystal maze - etiology and management</td>
<td>Treatments: friend or foe?</td>
</tr>
</tbody>
</table>

**POSTER VIEWING AND LUNCH**

**GUIDED POSTER TOURS**

<table>
<thead>
<tr>
<th>Basic and Translational Science session</th>
<th>HPR session</th>
<th>Clinical Science session</th>
<th>PARE session</th>
<th>EULAR Projects</th>
<th>Practical skills session*</th>
<th>Practical skills session*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint EULAR - EFIS session: I’ve got a B in my bonnet</td>
<td>Sustainable healthcare in rheumatology and the role of health professionals</td>
<td>SSc: From registries to trials - do we have sufficient data and the appropriate design?</td>
<td>Patient involvement in research: the future of collaborative research. Lessons from the field of rheumatology and beyond</td>
<td>EULAR Projects in Musculoskeletal Imaging</td>
<td>Crystal II</td>
<td>MRI</td>
</tr>
</tbody>
</table>

**COFFEE BREAK**

<table>
<thead>
<tr>
<th>Basic and Translational Science session</th>
<th>HPR session</th>
<th>Practical skills session*</th>
<th>PARE session</th>
<th>EULAR Projects in Health Professionals</th>
<th>Practical skills session*</th>
<th>Practical skills session*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetics, epigenetics and disease: is it all in the genes?</td>
<td>It’s your move: promoting physical activity in people with RMDs</td>
<td>Data visualisation: tables and graphs for publication and presentation I</td>
<td>Challenges of patient organisations’ in the 21st century</td>
<td>The EULAR Exercise Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis</td>
<td>Capillaroscopy I</td>
<td>Ultrasound advanced I</td>
</tr>
</tbody>
</table>

**Basic and Translational Science session**

<table>
<thead>
<tr>
<th>Basic and Translational Science session</th>
<th>Satellite symposium***</th>
<th>Satellite symposium***</th>
<th>Satellite symposium***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune senescence and ageing</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2
*** See detailed satellite symposia programme on pages 191 to 199
## Congress at a Glance

### FRIDAY, 15 JUNE 2018

<table>
<thead>
<tr>
<th>TIME</th>
<th>Hall 7.1</th>
<th>Hall 3</th>
<th>Auditorium</th>
<th>Elicium 2</th>
<th>Hall 7.2</th>
<th>Forum</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15-09:45</td>
<td></td>
<td></td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td>Satellite symposium***</td>
<td></td>
</tr>
<tr>
<td>09:45-10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15-11:45</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>Abstract session</td>
</tr>
<tr>
<td></td>
<td>WIN: Infectious complications of rheumatic disease (treatment)</td>
<td>Biologics in RA. More, more and more about safety</td>
<td>Clinical and therapeutic aspects of vasculitis</td>
<td>Axial spondyloarthritis: on the interface between healthy and diseased</td>
<td>Present and future treatments for SLE, SJögren and APS</td>
<td>From cartilage to bone</td>
</tr>
<tr>
<td></td>
<td>HOT: Advances in the management of osteoporosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45-13:30</td>
<td>POSTER VIEWING AND LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50-13:30</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Challenges in Clinical Practice session</td>
<td>From Bench to Bedside</td>
<td>Clinical Science session</td>
<td>The Young Rheumatologist</td>
<td>Clinical Science session</td>
</tr>
<tr>
<td></td>
<td>WIN: Check-point inhibitors: what are they used for?</td>
<td>Challenges in systemic lupus diagnosis</td>
<td>Pathophysiology and biomarkers in PsA: what impact?</td>
<td>The art of diagnosis of axial SpA</td>
<td>Understanding the language of basic research, epidemiology and health services articles</td>
<td>Joint EULAR - ESSR session: the role of MR imaging in rheumatic diseases and its clinical implications</td>
</tr>
<tr>
<td></td>
<td>HOT: Immune related adverse events upon check-point inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-17:00</td>
<td>What is New (WIN)/How to Treat (HOT)</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Paediatric Rheumatology session</td>
</tr>
<tr>
<td></td>
<td>WIN: How to diagnose rheumatoid arthritis early?</td>
<td>Advances in biologic therapy of small vessel vasculitis</td>
<td>Tapering and flaring in PsA and SpA</td>
<td>Prevention of OA: yes we can!</td>
<td>Big data for musculoskeletal research</td>
<td>From big data to personalised medicine in paediatric rheumatic diseases</td>
</tr>
<tr>
<td></td>
<td>HOT: Recent advances in the treatment of rheumatoid arthritis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30-19:00</td>
<td>Satellite symposium***</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Satellite symposium***</td>
</tr>
</tbody>
</table>

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2
*** See detailed satellite symposia programme on pages 191 to 199
In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2
*** See detailed satellite symposia programme on pages 191 to 199
# Congress at a Glance

## SATURDAY, 16 JUNE 2018

<table>
<thead>
<tr>
<th>TIME</th>
<th>Auditorium</th>
<th>Elicium 2</th>
<th>Hall 7.2</th>
<th>Forum</th>
<th>Elicium 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>09:00-10:30</strong></td>
<td>What is New (WIN)/ How to Treat (HOT)</td>
<td>Challenges in Clinical Practice session</td>
<td>Clinical Science session</td>
<td>Paediatric Rheumatology session</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>WIN: What can new insights in the pathogenesis of psoriasis and psoriatic arthritis teach the rheumatologist?</td>
<td>The GI tract in systemic sclerosis - is there light at both ends?</td>
<td>RA: is it all in your head?</td>
<td>Battling hyperinflammation in paediatric rheumatic diseases</td>
<td>Gut bacteria: the boss of the immune system</td>
</tr>
<tr>
<td></td>
<td>HOT: New approaches in the treatment of psoriatic arthritis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10:30-12:00</strong></td>
<td>POSTER VIEWING AND COFFEE BREAK</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:00-13:30</strong></td>
<td>EULAR Projects in Clinical Affairs Recommendation session ESSCA</td>
<td>Challenges in Clinical Practice session</td>
<td>Clinical Science session</td>
<td>From Bench to Bedside</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>Fractures: more than bone alone</td>
<td>Emerging topics in the management of the antiphospholipid syndrome</td>
<td>The links between gout and kidney function</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13:45-14:45</strong></td>
<td>Clinical and Basic Translational Highlight session</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Scientific Programme Wednesday 13 June 2018

07:30 - 20:00 Registration area (Hall 2)

Registration

13:00 - 14:00 Hall 7.1
EULAR 2018 Opening Plenary session

14:15 - 15:45 Hall 7.1
Challenges in Clinical Practice session
Little arthritis in PsA and axSpA with newly onset arthritis - does it matter?

Learning objectives:
• To gain insight into how to translate data from clinical trials (of patients with PsA with polyarthritis) to daily clinical practice with patients with oligoarthritis
• To identify extra-spinal musculoskeletal manifestations in axSpA and their impact in the monitoring and treatment of patients with axSpA

Chair(s):
Helena Marzo-Ortega (United Kingdom)
Laura Coates (United Kingdom)

Elena Nikiphorou (United Kingdom) 14:20
Abstract N° SP0002
Case 1 presentation: PsA beyond the typical poly-articular phenotype: how to deal with this in clinical practice?

Douglas Veale (Ireland) 14:30
Case 1 discussion: How to use RCT data to guide treatment decisions in real life?

Alexandre Sepriano (Portugal) 15:00
Abstract N° SP0003
Case 2 presentation: AxSpA patient with peripheral manifestations

Maxime Dougados (France) 15:10
Abstract N° SP0004
Case 2 discussion: Extra-spinal manifestations in axSpA, are they forgotten?

14:15 - 15:45 Auditorium
Clinical Science session
Cancer and inflammation

Learning objectives:
To understand the interplay between cancer and RMDs, especially inflammatory disorders, both from a basic and clinical perspective

Chair(s):
Eva Baecklund (Sweden)
Karen Visser (Netherlands)

Maria Suarez-Almazor (United States) 14:20
Abstract N° SP0005
RMD as comorbidity in cancer patients

Xavier Mariette (France) 14:40
The role of TNF in cancer

Campbell Roxburgh (United Kingdom) 15:00
Inflammation in cancer: friend or foe

What is New (WIN) & How to Treat (HOT) session
WIN session

Angela Tincani (Italy) 14:20
Abstract N° SP0001
WIN: Systemic lupus: issues about pregnancy

Thomas Dörner (Germany) 15:00
WIN: Recent advances in the treatment of lupus

14:15 - 15:45 Hall 3
What is New (WIN) & How to Treat (HOT) session
WIN session

Angela Tincani (Italy)
Abstract N° SP0001
WIN: Systemic lupus: issues about pregnancy

Thomas Dörner (Germany)
Abstract N° SP0005
WIN: Recent advances in the treatment of lupus
**13 June 2018**

**A. Horne (Sweden)**
15:20
**B. Delcoigne, J. Asling**
Abstract N° OP0001
Risk of malignancy in children with juvenile idiopathic arthritis: a register-based cohort study

**S. C. Kim (United States)**
15:30
A. Pawar, R. J. Desai, S. Gale, M. Klearman, K. Sarsour, D. H. Solomon, S. Schneeweiss
Abstract N° OP0002
No difference in the risk of malignancy in tocilizumab versus TNF inhibitor initiators in patients with rheumatoid arthritis: a multi-database cohort study

---

**14:15 - 15:45**

**Elicium 2**

**Challenges in Clinical Practice session**

**Inflammation in the shadow of fibromyalgia**

**Learning objectives:**
- To understand the mechanisms by which the central nervous system amplifies pain from inflamed joints and symptoms such as fatigue
- Be alert to and recognise fibromyalgia and central symptom augmentation in people with arthritis
- How to use these skills to optimise the balance between disease modifying and pain management approaches for the individual

**Chair(s):**
David Walsh (United Kingdom)
Annette van der Helm-van Mil (Netherlands)

Anne-Priscille Trouvin (France) 14:20
Abstract N° SP0008
Case 1 presenter: It’s in the brain but it’s not psychological: when nociceptive turns to nociplastic

Serge Perrot (France) 14:30
Case 1 discussant: Clinical case with RA in whom apparent high disease activity is confounded by FM; how does changing diagnosis change management and outcome?

Neelam Hassan (United Kingdom) 15:00
Abstract N° SP0009
Case 2 presenter: Fibromyalgia onset of systemic lupus erythematosus?

Ernest Choy (United Kingdom) 15:10
Case 2 discussant: Clinical case with FM later diagnosed with CTD; how does changing diagnosis change management and outcome?

---

**14:15 - 15:45**

**Forum**

**From Bench to Bedside**

**Shaping the future in systemic sclerosis**

**Learning objectives:**
- To understand the key mechanisms in SSc pathophysiology that facilitate new treatment options
- To show how animal models can facilitate new drug developments
- To pinpoint which drugs most likely will make it to clinics

**Chair(s):**
Caroline Ospelt (Switzerland)
John Pauling (United Kingdom)

Christopher Denton (United Kingdom) 14:20
Abstract N° SP0010
Fibroblast-Matrix-Vessel: the unhappy triad

---

**14:15 - 15:45**

**Hall 7.2**

**From Bench to Bedside**

**Psychological distress and pain; not all in the mind**

**Learning objectives:**
- To understand how psychological distress changes central pain processing, augmenting the sensory component of pain
- To gain an appreciation of how pain and affect share common mechanisms
- To develop a framework for psychological interventions within the physical and medical management of arthritis pain

**Chair(s):**
Jonathan Cavanagh (United Kingdom)
Alexander So (Switzerland)

Victoria Chapman (United Kingdom) 14:20
What do preclinical models tell us about why psychological distress is so bad for arthritis pain?

Benedikt Sundermann (Germany) 14:40
Abstract N° SP0006
Distress and pain; integrated brain pathways

Rob Smeets (Netherlands) 15:00
Abstract N° SP0007
Dealing with psychological distress to optimise outcomes for arthritis pain

A. M. Rathbun (United States) 15:20
Z. Evans, M. Shardell, M. Yau, J. Gallo, E. Stuart, M. Schuler, M. Hochberg
Abstract N° OP0003
Association between disease severity and onset of depression in knee osteoarthritis

B. A. C. Nascimento (Brazil) 15:30
B. K. Vitturi, B. R. Alves, F. Campos, D. Y. Torigoe
Abstract N° OP0004
Cognitive impairment in rheumatoid arthritis patients: a case-control study

---
Jörg Distler (Germany) 14:40
Abstract N° SP0011
Is there a universal translator? Which (animal) models tell us most?

Daniel Furst (United States) 15:00
Abstract N° SP0012
Novel SSc drugs that really will make it to clinics!

H. Bittern (Germany) 15:20
A. Carvalho-Marques, O. Cabral-Marques, C. Fouodo, I. König, H. Heidecke, G. Riemekasten, S. Schinke
Abstract N° OP0005
Patterns of 31 new autoantibodies against G protein-coupled receptors and growth factors in systemic sclerosis can be described by latent factors

R. Spiera (United States) 15:30
Abstract N° OP0006
Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial JBT101-SSc-001

Moleda Lamkanfi (Belgium) 14:20
Inflammasome biology matters

Y. Zhao (China) 14:40
W. Li, K. Vasilev
Abstract N° OP0007
Growth differentiation factor 11 attenuates inflammatory arthritis through antagonising NF-κB signaling pathway

Daniel Kastner (United States) 14:50
New insights into monogenic autoimmune inflammatory diseases

M. Saito (Japan) 15:10
Abstract N° OP0008
Modeling an autoimmune inflammatory immunoproteasome disease nakajo-nishimura syndrome with human pluripotent stem cell-derived myeloid cell lines

Johannes Roth (Germany) 15:20
Abstract N° SP0013
S100-alarmins: potential therapeutic targets for arthritis

14:15 - 15:45  Elicium 1

Basic and Translational Science session

Basic mechanisms of inflammation

Learning objectives:
• Provide a state-of-the-art on basic mechanisms of inflammation
• Discuss how these mechanistic insights may be translated into clinical benefit

Chair(s):
Marco Gattorno (Italy)
Tadej Avcin (Slovenia)

14:15 - 15:45  Emerald

The Young Rheumatologist

Statistics made simple: a practical approach to complex concepts

Learning objectives:
• To learn how to report statistical analysis in clinical journals and how to describe the analytical methods and the corresponding results in a comprehensible way to the practicing clinician
• To understand the conceptual difference between confounding, effect modification and mediation and how to handle these in statistical analysis of observational data
• To learn how to ‘build’ multivariable models taking both clinical and statistical criteria into account and how to decide upon the ‘best’ model

Chair(s):
Lewis Carpenter (United Kingdom)
Sofia Ramiro (Netherlands)

Pedro Machado (United Kingdom) 14:20
How to report statistics in rheumatology journals: reaching out to the clinical reader

Sam Norton (United Kingdom) 14:40
Confounders, effect modifiers and mediators: is it all the same?
Stian Lydersen (Norway) 15:00
Abstract N° SP0016
Stepwise or not to stepwise? The do’s and don’ts of multivariable modelling

E. Myasoedova (United States) 15:20
J. M. Davis III, S. J. Achenbach, E. L. Matteson, C. S. Crowson
Abstract N° OP0009
Rising prevalence of functional disability in patients with rheumatoid arthritis over 20 years

D. H. Solomon (United States) 15:30
Abstract N° OP0010
Use of claims and electronic medical record data to predict RA disease activity

14:15 - 15:45  PARE Room

PARE session
E-health for better care

Learning objectives:
• To present digital health care solutions that enable better access to health care
• To show how apps can contribute to patient health care and to organisation attractiveness
• To outline relevant issues of data protection and patient safety

Chair(s):
Kristijonas Mazuras (Lithuania)
Gerlinde Bendzuck (Germany)

Jutta Richter (Germany) 14:20
Abstract N° SP0017
Bits and bytes: fitting medical information - PICASO the platform for improved personal, coordinated care

Victoria Romero Pazos (Spain) 14:40
Ésaude - a digital platform that unites tools to provide personalised health

Mitchell Silva (Belgium) 15:00
Abstract N° SP0018
Smart wearables - the right tool for health monitoring and improving quality of health?

S. R. Stones (United Kingdom) 15:20
on behalf of Young PARE working group
Abstract N° OP0011-PARE
A week to tweet: findings from young PARE’s online course for twitter novices

S. Trope (France) 15:30
Abstract N° OP0012-HPR
Creation of the first digital training designed for patients with rheumatoid arthritis by patient organisation in rheumatology

14:15 - 15:45  E106/E107

EULAR Projects in Paediatric Rheumatology

EULAR Projects in Paediatric Rheumatology and UCAN

Learning objectives:
• Insight in the strength of collaboration across borders
• Understanding of what the UCAN project means for paediatric rheumatology worldwide

Chair(s):
Nico Wulffraat (Netherlands)
Wineke Armbrust (Netherlands)

Rae Yeung (Canada) 14:20
UCAN as a tool for personalised medicine in paediatric rheumatology

Nicola Ruperto (Italy) 14:38
UCAN and PRINTO aligned to link bed and bedside: perspective from the bed

Sebastian Vastert (Netherlands) 14:56
UCAN and PRINTO aligned to link bed and bedside: perspective from the benchside

Vicki Seyfert-Margolis (United States) 15:14
Abstract N° SP0020
How digital tools can help to cross borders in international collaborations

P. Drechsel (Germany) 15:32
J. Klotsche, M. Niewerth, G. Horneff, K. Minden
Abstract N° OP0013
Pregnancy outcomes in DMARD exposed patients with juvenile idiopathic arthritis - results of the biologic register JUMBO
14:15 - 15:45  D201/D202
Practical skills session*
**Crystal I**

*Learning objectives:*
To learn how to use a microscope to detect and interpret crystals in synovial fluid from scratch

**Chair(s):**
Anne K. Tausche (Germany)
Eliseo Pascual (Spain)

**Tutor(s):**
Francisca Sivera (Spain)
José Pimentao (Portugal)
Francesca Oliviero (Italy)
Eleonora Norkuviene (Lithuania)

14:15 - 15:45  D203/D204
Practical skills session*
**Ultrasound basic I**

**Chair(s):**
George A. W. Bruyn (Netherlands)
Wolfgang A. Schmidt (Germany)

**Esperanza Naredo (Spain)**

Abstract N° SP0021
How to assess dactylitis + demo

**Marcin Szudlarek (Denmark)**

Abstract N° SP0022
How to assess bone erosions - indications, pitfalls and new techniques + demo

**Ulrich Fredberg (Denmark)**

Abstract N° SP0023
How to assess mechanical and inflammatory tendinitis + demo

**Maria-Antonietta d’Agostino (France)**

Abstract N° SP0024
How to assess and score enthesitis in clinical practice + demo

**Tutor:**
Sara Nysom (Denmark)

15:45 - 16:15  Exhibition and EULAR Village (Hall 1)
Coffee break

16:15 - 17:45  Hall 7.1
Abstract session
**Opening Plenary Abstract session**

**Chair(s):**
Thomas Dörner (Germany)
Robert B. M. Landewé (Netherlands)

D. Solomon (United States) 16:20
R. J. Glynn, J. G. MacFadyen, P. Libby, T. Thuren, B. M. Everett, P. M. Ridker
Abstract N° OP0014
Serum urate, gout, and cardiovascular disease in a randomised controlled trial of canakinumab: a cantos secondary analysis

P. B. M. Poppelaars (Netherlands) 16:30
L. H. D. van Tuyl, M. Boers
Abstract N° OP0015
Mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years follow up

G. Cai (Australia) 16:40
D. Aitken, L. Laslett, C. Hill, L. March, A. E. Wluka, Y. Wang, L. Blizzard, F. Cicuttini, T. Winzenberg, G. Jones
Abstract N° OP0016
A multicentre randomised controlled trial of zoledronic acid for osteoarthritis of the knee with bone marrow lesions

J. R. Curtis (United States) 16:50
R. Chen, Z. Li, T. Arora, K. G. Saag, N. C. Wright, S. Daigle, M. Kilgore, E. Delzell
Abstract N° OP0017
The impact of the duration of bisphosphonate drug holidays on hip fracture rates

S. Møller-Bisgaard (Denmark) 17:00
Abstract N° OP0018
The value of adding MRI to a clinical treat-to-target strategy in rheumatoid arthritis patients in clinical remission: clinical and radiographic outcomes from the imagine-RA randomised controlled trial

D. J. Wallace (United States) 17:10
Abstract N° OP0019
Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
M. Aringer (Germany) 17:20

Abstract N° OP0020
Validation of new systemic lupus erythematosus classification criteria

J. C. Robson (United Kingdom) 17:30

Abstract N° OP0021
Draft classification criteria for the anca associated vasculitides

16:15 - 17:45 Hall 3

Abstract session
From NSAIDs to bDMARDs in SpA: what is new?

Chair(s):
Anna Moltó (France)
Adrian Ciurea (Switzerland)
L. Couvaras (France) 16:20
D. Wendling, V. Pauly, V. Pradel, A. Moltó, P. Lafforgue, T. Pham
Abstract N° OP0022
Is a primary good response to NSAIDs predictive of the subsequent response to the first TNF inhibitor in patients with recent axial spondyloarthritis?

U. Lindström (Sweden) 16:30
T. Olofsson, S. Wedrén, I. Qirjazo, J. Askling
Abstract N° OP0023
Effect of anterior uveitis, psoriasis and inflammatory bowel disease on drug-survival for TNF-inhibitors in ankylosing spondylitis

U. Lindström (Sweden) 16:40
T. Olofsson, S. Wedrén, I. Qirjazo, J. Askling
Abstract N° OP0024
What happens to patients with ankylosing spondylitis who start a first biologic? A Swedish study of treatment trajectories in clinical practice

V. Rios Rodriguez (Germany) 16:50
K.-G. Hermann, H. Haibel, C. Althoff, O. Behmer, J. Sieper, D. Poddubny
Abstract N° OP0025
Identification of predictors of structural damage progression in the sacroiliac joints in patients with early axial spondyloarthritis on a long-term anti-TNF treatment

N. V. Kwatra (United States) 17:00
Abstract N° OP0026
Adalimumab serum concentration fails to predict achievement of sustained remission or absence of flare for patients with non-radiographic axial spondyloarthritis in the ABILITY-3 study

B. S. Koo (Republic of Korea) 17:10
Abstract N° OP0027
Characteristics of cytokines and changes in interleukin-17 levels in the synovial fluid of patients with ankylosing spondylitis on treatment with biologics

T. Dubinina (Russian Federation) 17:20
Abstract N° OP0028
Efficacy and safety of BCD-085, a novel IL-17 inhibitor, in ankylosing spondylitis. Results of phase 2 clinical study

J. Paccou (France) 17:30
M. Nachury, C. Duchemin, P. Desreumaux, R.-M. Filpo, B. Pariente
Abstract N° OP0029
Clinical effect of vedolizumab on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease

D. van der Heijde (Netherlands) 17:40
Abstract N° LB0001
Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2B, randomised, double-blind, placebo-controlled, dose-ranging study
Abstract session

**RA therapy - new molecules and new strategies**

Chair(s):
Thams Hugle (Switzerland)
Raphaele Seror (France)

E. G. Brilman (Netherlands)  16:20
J. A. van der Pol, P. H. de Jong, A. E. Weel,
J. M. Hazes, T. W. Huizinga, C. F. Allaart
Abstract N° OP0030
Corticosteroid bridging strategies with methotrexate monotherapy in early rheumatoid and undifferentiated arthritis; a comparison of efficacy and toxicity in the treach and improved studies

R. Costello (United Kingdom)  16:30
A. Marsden, M. Movahedi, M. Lunt, R. Emsley,
W. G. Dixon
Abstract N° OP0031
The importance of assessing multiplicative and additive interaction: examining the effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes

M. A. Lopez-Olivo (United States)  16:40
J. H. Tayar, N. V. Zamora, G. Pratt,
M. E. Suarez-Almazor
Abstract N° OP0032
Malignancies and serious infections in randomised controlled trials of Janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta-analysis

R. B. Mueller (Switzerland)  16:50
H. Schulze-Koops, D. E. Furst, S. Cohen, K. Kwok,
A. Maniccia, L. Wang, E. Akylbekova, G. Ackermann,
J. von Kempis
Abstract N° OP0033
Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies

V. Stouten (Belgium)  17:00
J. Joly, S. Pazmino, K. van der Elst, D. De Cock,
R. Westhovens, P. Verschueren on behalf of the CareRA study group
Abstract N° OP0034
Long-term effectiveness of the COBRA Slim remission induction and treat to target strategy in patients with early rheumatoid arthritis lacking classical markers of poor prognosis: 2 year results of the CareRA trial

J. Smolen (Austria)  17:10
S. Cohen, P. Emery, W. Rigby, Y. Tanaka, Y. Zhang,
A. Friedman, A. Othman, H. Camp, A. Pangan
Abstract N° OP0035
Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate

G. Burmester (Germany)  17:20
J. Kremer, F. van den Bosch, Y. Li, Y. Zhou,
A. Othman, A. Pangan, H. Camp
Abstract N° OP0036
A phase 3 randomised, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective JAK-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDs

J. Kaine (United States)  17:30
J. Tesser, R. DeMasi, L. Takiya, L. Wang, M. Snyder,
H. Fan, V. Bandi, J. Wollenhaupt
Abstract N° OP0037
Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies

Abstract session

**Doctor, how bad will my rheumatoid arthritis become? RA - prognosis, predictors and outcomes**

Chair(s):
Cornelia Allaart (Netherlands)
Arthur Pratt (United Kingdom)

C. H. Brahe (Denmark)  16:20
S. Krabbe, M. Østergaard, L. Ørnbjerg, D. Glinatsi,
H. Røgind, H. S. Jensen, H. Hermann, N. Norregaard,
S. Jacobsen, L. Terslev, T. K. Huynh, D. V. Jensen,
N. Manilio, K. Asmussen, P. B. Frandsen, M. Boesen,
Z. Rasti-madabadi, L. M. Carlsen, J. Møller,
N. S. Krogh, M. L. Hetland
Abstract N° OP0038
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in remission in routine care - 2-year outcomes and identification of predictors

J. Gwinnutt (United Kingdom)  16:30
K. Hyrich, M. Lunt, A. Barton, S. Verstappen
on behalf of RAMS coinvestigators
Abstract N° OP0039
High disease activity and disability at one year in two clusters of patients with rheumatoid arthritis defining themselves as in an acceptable state at treatment initiation

G. Liiso-Ribera (United Kingdom)  16:40
F. Humby, A. Nerviani, M. A. Boutet, S. Kelly,
M. Bombardieri, M. Lewis, R. Hands, V. Rocher,
F. Bene, C. Buckley, P. C. Taylor, I. B. McInnes,
C. Pitzalis
Abstract N° OP0040
Synovial cell infiltration in ACPA-ve patients displays similar signatures to other seronegative inflammatory arthritis. Results from the pathobiology of early arthritis cohort (PEAC)
L. E. Burgers (Netherlands) 16:50
J. A. van der Pol, T. W. J. Huizinga, C. F. Allaart,
A. H. M. van der Helm-van Mil
Abstract N° OP0041
Does treatment strategy influence the ability to achieve and
sustain DMARD-free remission in RA? Results of a longitudinal study comparing an intensive DAS-steered
strategy with treat-to-target in routine care

L. Hunt (United Kingdom) 17:00
J. Nam, E. M. Hensor, K. Mankia, E. Rowbotham,
A. J. Grainger, P. Emery
Abstract N° OP0042
In ACPA positive at-risk individuals, which MRI and US
findings best predict development of clinical synovitis?

K. F. Baker (United Kingdom) 17:10
A. Skelton, D. Lendrem, B. Thompson, A. G. Pratt,
J. D. Isaacs
Abstract N° OP0043
Predictors of drug-free remission in rheumatoid arthritis: results from the prospective biomarkers of remission in rheumatoid arthritis (BioRRA) study

J. Widdifield (Canada) 17:20
S. Bernatsky, A. Huang, E. C. Sayre, M. Paterson,
D. Lacaille
Abstract N° OP0044
After how long of disease duration does the increased mortality risk appear in recent onset rheumatoid arthritis?

D. Keebler (United States) 17:30
E. Teng, J. Chia, D. Lee, J. Galanter, J. Peake,
K. Tuckwell
Abstract N° OP0045
Adverse event reporting rates and placebo/standard-of-care-arm ACR responses vary by region in rheumatoid arthritis trials

16:15 - 17:45  Hall 7.2

Abstract session

Immunobiology of vasculitis

Chair(s):
Eamonn S. Molloy (Ireland)
Maria C. Cid (Spain)

D. O. Bunch (United States) 16:20
J. Deng, E. A. McInnis, P. Bekker, J. L. Hillson,
T. J. Schall, C. J. Jennette, P. Nachman, J. Deng
Abstract N° OP0046
Effect of a selective C5AR antagonist, avacopan (CCX168), on plasma complement levels in ANCA associated vasculitis (AAV)

A. von Borstel (Netherlands) 16:30
L. L. Lintermans, P. Heeringa, A. Rutgers,
C. A. Stegeman, J. S. Sanders, W. H. Abdulahad
Abstract N° OP0047
Circulating CD24HICD38HI regulatory B cells influence TH17 cell responses in patients with ANCA-associated vasculitides

Y. Wada (Japan) 16:40
M. Sudo, T. Kuroda, M. Nakano, I. Narita
Abstract N° OP0048
The utility of serum angiopeptin-1 and angiopeptin-2 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis

R. Hid Cadena (Netherlands) 16:50
R. D. Reitsema, W. H. Abdullahad, M. G. Huitema,
A. M. Boots, P. Heeringa, E. Brouwer
Abstract N° OP0049
Aberrant vista expression on CD45RA+CD25DIM TH cells in giant cell arteritis

A. C. Hessels (Netherlands) 17:00
J. Tuin, J. S. F. Sanders, M. G. Huitema,
E. F. C. van Rossum, F. J. W. Koper, A. P. van Beek,
C. A. Stegeman, A. Rutgers
Abstract N° OP0050
Gene polymorphisms of the glucocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 1 affect relevant clinical outcomes in ANCA associated vasculitis

D. Prieto-Peña (Spain) 17:10
J. Loricerà, J. Martin-Varillas, M. Calderón-Goercke,
J. Nárváez, E. Aurrecoechea, I. Villa, S. Castañeda,
C. Gómez-Aragón, A. Mera, E. Pérez-Pampín,
V. Aldasoro, N. Álvez-Rivas, N. Fernández-Llanio,
M. Álvarez-Buerlo, L. Marena-Rojas, F. Sivera,
E. Galíndez-Agirregoikoa, R. Solans-Laqué,
S. Romero-Yuste, I. Martínez-Rodríguez, I. Banzo,
V. Calvo-Río, N. Palmou-Fontana, B. Atienza-Mateo,
J. Hernández, M. González-Gay, R. Blanco
Abstract N° OP0051
Evolution of the vascular involvement objectified by PET/TAC in patients with giant cell arteritis treated with tocilizumab

A. Antovic (Sweden) 17:20
M. Kostic, F. Mobarrez, A. Nordin, J. Vojinovic,
A. Bruchfeld, I. Gunnarsson
Abstract N° OP0052
Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis

A. Mekinian (France) 17:30
N. Wesner, L. Drevon, A. Guedon, J. B. Fraison,
S. Trad, J. E. Kahn, A. Aouba, J. Gillard,
M. Ponsoye, T. Hanslik, C. Gourguechon, E. Liozon,
K. Laribi, J. Rossignol, O. Merine, L. Ades,
F. Carrat, P. Fenaux, O. Fain
Abstract N° OP0053
Inflammatory disorders associated with trisomy 8 myelodysplastic syndromes: French retrospective case study control
Abstract session

Envisioning new horizons for people with osteoarthritis

Chair(s):
Roberta Ramonda (Italy)
Jeremie Sellam (France)

E. Mulrooney (Norway) 16:20

Abstract N° OP0054
Pain in hand osteoarthritis and the associations with radiographic osteoarthritis severity and psychological factors

Z. Zhu (China) 16:30
J. Chang, Z. Liao, T. Meng, S. Zheng, F. Cicuttini, T. Winzenberg, A. Wluka, D. Jiang, W. Han, C. Ding

Abstract N° OP0055

F. Roemer (Germany) 16:40
M. Englund, A. Turkiewicz, A. Struglics, A. Guermazi, L. S. Lohmander, S. Larsson, R. Frobell

Abstract N° OP0056
Molecular and structural biomarkers of inflammation at 2 years after acute ACL injury do not predict structural knee osteoarthritis at 5 years

A. Diaz (France) 16:50

Abstract N° OP0057
Efficacy and safety of a distraction-rotation knee brace (ODRA) in medial knee osteoarthritis - a phase III randomised controlled trial (ergonomie study)

M. Minten (Netherlands) 17:00

Abstract N° OP0058
Low-dose radiation therapy as treatment for hand and knee osteoarthritis: two double-blinded RCT’s

F. Eckstein (Austria) 17:10
M. Hochberg, A. Guermazi, H. Quehring, A. Aydemir, S. Wax, P. Fleuranceau-Morel, A. Reinstrup Bihlet, I. Byrjalsen, J. Ragnar Andersen

Abstract N° OP0059
Efficacy and safety of intra-articular sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomised, placebo-controlled, phase II study

M. Jansen (Netherlands) 17:20

Abstract N° OP0060
Knee joint distraction compared with high tibial ostetomty and total knee arthroplasty: two-year clinical, structural, and biomarker outcomes

S. Kennedy (United States) 17:30
H. Ghandehari, C. Swearingen, J. Tambiah, M. Hochberg

Abstract N° OP0061
Treatment of knee osteoarthritis with SM04690 improved WOMAC A1 ‘pain on walking’ - results from a 52 week, randomised, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, WNT pathway inhibitor

S. Reichenbach (Switzerland) 17:40
S. Heldner, A. Lenz, D. Felson, P. Jüni

Abstract N° LB0002
Biomechanical therapy for osteoarthritis of the knee: a randomised controlled trial (BIOTOK)

Abstract session

Fracture risk and consequences

Chair(s):
Daniel Prieto-Alhambra (United Kingdom)
Willem F. Lems (Netherlands)
M. Sehgal (United States) 16:20
A. Mithal, A. Mithal, G. Singh

Abstract N° OP0062
Osteoporotic hip fractures in men: a rising concern

P. Ungprasert (Thailand) 16:30
K. Wijarnpreecha, C. Thongprayoon, W. Cheungpasitporn

Abstract N° OP0063
Peripheral arterial disease and risk of osteoporotic hip fracture: a systematic review and meta-analysis of cohort studies

L. Senolt (Czech Republic) 16:40
O. Ruzickova, K. Pavelka, O. Sleglova

Abstract N° OP0064
General bone loss in patients with erosive and non-erosive hand osteoarthritis during three years

C. Romera-Lopez (Spain) 16:50
C. Fernández-Carbajal, M. Martínez-Vidal, T. Pedraz

Abstract N° OP0065
Osteoporosis and vertebral fractures are associated with disease activity and radiographic damage in patients with axial spondyloarthritis
P. Szafors (France) 17:00
C. Lukas, T. Barnetche, J. Morei, C. Gaujoux-Viala, B. Combe, H. Che
Abstract N° OP0066
Risk of fracture and low mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis

A. Casabella (Italy) 17:10
B. Ruaro, S. Paolino, C. Pizzorni, E. Alessandri, C. Seriolo, D. Fasciolo, G. Botticella, L. Molfetta, P. Odetti, B. Seriolo, M. Cutolo
Abstract N° OP0067
Dickkopf-1 (DKK1) serum levels and bone quality (TBS evaluation) in patients with systemic sclerosis and rheumatoid arthritis

R. Mazzucchelli (Spain) 17:20
E. Pérez-Fernandez, J. Quirós, N. Crespí-Villarías, A. García-Vadillo
Abstract N° OP0068
Short term effects of ambient air pollution on osteoporotic hip fracture. An ecological study in a period of 16 years

J. C. Alvarenga (Brazil) 17:30
S. Boyd, R. Pereira
Abstract N° OP0069
The relationship between estimated bone strength by finite element analysis at the peripheral skeleton to areal BMD and TBS at lumbar spine in adults

Learning objectives:
To provide healthcare professionals with reference information on both science and regulation underpinning the use of biosimilars

Chair(s):
Yvonne van Eijk-Hustings (Netherlands)
Dieter Wiek (Germany)

Tore K. Kvien (Norway) 16:20
Abstract N° SP0024
An up-date on biosimilars

Tracy French (United Kingdom) 16:38
Abstract N° SP0025
Shared decision making in switching to biosimilars

Franz König (Austria) 16:56
Statistical and regulatory aspects of biosimilars

Dieter Wiek (Germany) 17:14
Abstract N° SP0026
Biosimilars - the changing views of EULAR’s Member Organisations of PARE

M. Cvancarova Smástuen (Norway) 17:32
M. Brandvold, R. Andenæs
Abstract N° OP0070-HPR
Is patients’ satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey

16:15 - 17:45 Emerald

Abstract session
Movement in musculoskeletal pain; from risk to management

Chair(s):
David Walsh (United Kingdom)
Laure Gossec (France)

A. L. Beukenhorst (United Kingdom) 16:20
Abstract N° OP0071
The prevalence of pain flares: impact of definition

K. Aiii (Sweden) 16:30
M. Andersson, A. Bremander, E. Haglund, I. Larsson, S. Bergman
Abstract N° OP0072
Sleep problems and fatigue as a predictor for the onset of chronic widespread pain over a 5- and 18-year perspective. A 20-year prospective study

K. L. Druce (United Kingdom) 16:40
J. McBeth
Abstract N° OP0073
Central sensitisation predicts fatigue independently of musculoskeletal pain

J.-H. Kang (Republic of Korea) 16:50
Abstract N° OP0074
Association between brain-derived neurotrophic factor gene polymorphisms and fibromyalgia in a Korean population: a multi-center study

G. Tran (United Kingdom) 17:00
E. Hensor, P. O’Connor, S. Kingsbury, P. Conaghan
Abstract N° OP0075
Ultrasound-detected shoulder pathologies cluster into groups with different clinical associations: data from a prospective study of 500 community referrals for shoulder pain

B. Gavilán-Carrera (Spain) 17:10
Abstract N° OP0076
Isotemporal substitution of sedentary time with physical activity in fibromyalgia: association with quality of life and disease impact. The Al-Ándalus project
Abstract N° OP0077
Effectiveness of 8-weeks supervised and non-supervised aerobic exercise programs on clinic findings, functional status and quality of life in the patients with fibromyalgia syndrome

A. G. Karatepe
Abstract N° OP0078
Is the efficacy of physical therapy related to the pain in the patient’s mind?

B. Köse, F. G. Yurdakul, Y. Garip, H. Bodur

Abstract N° SP0027
Don't Delay, Connect Today - implementation of the EULAR Campaign in Romania

H. L. Bankova (Bulgaria)

cutin@euli.org

B. Boteva
Abstract N° OP0079-PARE
Awareness week for rheumatic diseases - 8-14 May 2017

K. Koutsogianni (Greece)

E. Tsourlidaki, J. Papadakis, R. Stara, L. Papadaki on behalf of the Arthritis Foundation of Crete
Abstract N° OP0080-PARE
Photo album of people with rheumatic diseases under the title: ‘there are some people… our people!!’

Abstract N° OP0081
Phenotypic subgroups in IgG4-related disease - a cluster analysis

G. Hatemi (Turkey)


Abstract N° OP0082
Apremilast for Behçet’s syndrome: a phase III randomised, placebo-controlled, double-blind study (RELIEF)

T. Koga (Japan)


Abstract N° OP0083
Serum fibroblast growth factor 2 is a useful biomarker to distinguish adult onset Still disease from sepsis

J. B. Kuemmerle-Deschner (Germany)


Abstract N° OP0084
Safety of long-term (up to 6 years) canakinumab therapy (<2, 2–<4 and 4–<8mg/kg) in patients aged <4 to 65 years from beta-confident registry

Y. Guex-Crosier (Switzerland)

C. S. Foster, K. Nakai, H. Goto, K. Douglas, S. Pathai, M. Kron, A. P. Song, J. van Calster, A. Adán

Abstract N° OP0085
Long-term efficacy and safety of adalimumab by immunosuppressant use in patients with non-infectious uveitis in the visual III trial

S. Tiosano (Israel)

R. Shapiro, O. Gendelman, D. Comaneshter, E. Pras, A. D. Cohen, H. Amital

Abstract N° OP0086
Increased risk of ischemic heart disease and mortality among FMF patients - perspective from a big database
M. Kostine (France)  17:20
Abstract N° OP0088
Immune-related adverse events of cancer immunotherapy - when inflammatory side effects are associated with survival: a single-centre prospective cohort study

B. Mehta (United States)  17:30
W. Briggs, P. Efthimiou
Abstract N° OP0083
Temporal trends and mortality of hospitalised patients with adult onset Still's disease: a nationwide estimate

16:15 - 17:45  D201/D202
Abstract session
New driving molecules in systemic sclerosis
Chair(s):
Gabriele Valentini (Italy)
Mike O. Becker (Switzerland)

G. Boletto (France)  16:20
Abstract N° OP0089
Abatacept is effective in experimental digestive and lung tissue fibrosis

U. A. Walker (Switzerland)  16:30
Abstract N° OP0090
Mitochondrial DNA mutations and respiratory chain dysfunction in lung fibrosis of systemic sclerosis

C. Antinozzi (Italy)  16:40
C. Corinaldesi, V. Ricci, V. Raparelli, M. Vasile, F. Del Galdo, G. Valesini, A. Lenzi, S. Basili, C. Crescioli
Abstract N° OP0091
CXCL10/CXCL11 serum measurement as potential predictor of systemic sclerosis

I. Antonopoulos (Greece)  16:50
D. Daoussis, D. J. Papachristou, T. Dimitroulas, T. Sidiroopoulos, S.-N. Liossis
Abstract N° OP0092
Decreased Dickkopf-1 expression in clinically uninvolved skin from patients with systemic sclerosis

W. Marut (Netherlands)  17:00
Abstract N° OP0093
Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis

E. Romano (Italy)  17:10
M. Manetti, I. Rosa, B. S. Fioretto, L. Ibba-Manneschi, M. Matucci-Cerinic, S. Guiducci
Abstract N° OP0094
SLIT2/ROBO4 axis may contribute to angiogenesis disturbance in systemic sclerosis (SSc)

C. Frantz (France)  17:20
S. Pezet, J. Avouac, Y. Allanore
Abstract N° OP0095
Soluble CD163 as a potential biomarker in systemic sclerosis

16:15 - 17:45  D203/D204
Abstract session
A rollercoaster from bench to bedside and back again: paediatric rheumatology in the 21st century
Chair(s):
Lovro Lamot (Croatia)
Eve Smith (United Kingdom)

J. Nakamura (Japan)  16:20
Abstract N° OP0096
Adeno-associated virus vector-mediated interleukin-10 induction prevents vascular inflammation in a murine model of Kawasaki disease

C. Fisher (United Kingdom)  16:30
D. Eleftheriou, D. Sen, Y. Ioannou
Abstract N° OP0097
Stimulated monocyte-derived macrophages from patients with enthesitis related arthritis secrete higher levels of IL23 and lower levels of interferon gamma compared to healthy controls

M. Kostik (Russian Federation)  16:40
E. Susputin, A. Levina, M. Guseva, M. Dubko, L. Snegireva, T. Likhacheva, A. Kazantseva, M. Makhova, A. Sokoleno, E. Imyanitov, V. Chasnyk
Abstract N° OP0098
Clinical picture and spectrum of conditions associated with NLRP12 gene mutations

S. J. W. Shoop-Worrall (United Kingdom)  16:50
S. M. M. Verstappen, J. E. McDonagh, W. Thomson, K. L. Hyrich on behalf of CAPS
Abstract N° OP0099
Remission in JIA can be predicted from one year following diagnosis in a UK multicentre inception cohort
I. Redeker (Germany) 17:00
F. Hoffmann, K. Albrecht, J. Klotsche, A. Zink, K. Minden
Abstract N° OP0100
Increase in direct healthcare costs in juvenile idiopathic arthritis over the past 10 years - results of a health insurance claims data analysis

H. Chaplin (United Kingdom) 17:10
Y. Ioannou, D. Sen, H. Lempp, S. Norton
Abstract N° OP0101
Exploring pain and the impact of JIA on adolescents and young adults: a mixed-methods study

A. M. Barendregt (Netherlands) 17:20
Abstract N° OP0102
Prolonged image acquisition time after contrast agent administration results in increased synovial thickness on post-contrast MRI of JIA patients: standardisation is key

F. De Benedetti (Italy) 17:30
Abstract N° OP0103
Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis

Georg Schett (Germany) 18:50
Monitoring and treatment of bone inflammation

M. Y. Ansari (United States) 19:10
M. N. Khan, I. Ahmad, T. M. Haqqi
Abstract N° OP0105
ZCCHC6 deletion downregulates IL-6 and reduces the severity of experimental osteoarthritis in mice

Matthias Gunzer (Germany) 19:20
Fine structure analysis to detect bone pores

18:15 - 19:45 Amtrium

Health Professionals session

Delay in treatment and the role of health professionals

Learning objectives:
• To provide awareness of different types of treatment delay in RMDs
• To provide knowledge of reasons and present possible interventions to address patient delay

Chair(s):
Jette Primdahl (Denmark)
Erika Mosor (Austria)

Rebecca Stack (United Kingdom) 18:20
Abstract N° SP0030
Reasons for delay in help seeking at the onset of symptoms

Kristien van der Elst (Belgium) 18:38
Abstract N° SP0031
Are illness perception and coping style associated with patient delay?

Souzi Makri (Belgium) 18:56
Abstract N° SP0032
The patients’ perspective on delay in treatment

Bruno Fautrel (France) 19:14
Abstract N° SP0033
Delay in treatment from the GP perspective

S. J. Bartlett (Canada) 19:32
Abstract N° OP0106
Who is not reaching remission in early RA and why? Predictors for persistent disease activity in the first year differ in men and women and are related to lifestyle and treatment

20:00 - 22:00 Strand Zuid

Networking Platform
Scientific Programme Thursday 14 June 2018

07:45 - 19:15 Registration area (Hall 2)

Registration

08:15 - 09:45 Elicium 1

Basic and Translational Science session

Fat and fatty acids: targets for therapy?

Learning objectives:
• Adipose tissue derived factors alter inflammatory responses
• Inflammation in turn also alters the adipose tissue
• Adipokines and free fatty acids affect systemic but also local inflammation

Chair(s):
Ladislav Senolt (Czech Republic)
Maria Bokarewa (Sweden)

Henk Schipper (Netherlands) 08:20
Abstract N° SP0034
Adipose tissue and inflammation

S. Bosello (Italy) 08:40
E. De Lorenzis, G. Canestrari, G. Natalello, C. Di Mario, L. Gigante, A. Barini, A. Barini, L. Verardi, B. Tolusso, G. Ferraccioli, E. Gremaese
Abstract N° OP0107
Adipocytokines imbalance is associated with vascular damage in systemic sclerosis

Jorge Caamano (United Kingdom) 08:50
Abstract N° SP0035
Lymphoid cluster formation in adipose tissue

09:45 - 10:15 Exhibition and EULAR Village (Hall 1)
Coffee break

10:15 - 11:45 Hall 7.1

What is New (WIN) & How to Treat (HOT) session

WIN & HOT session

Hendrik Schulze-Koops (Germany) 10:20
WIN: Advances in the diagnosis and monitoring of vasculitis

John H. Stone (United States) 11:00
HOT: Recent advances in the treatment of systemic vasculitides

10:15 - 11:45 Hall 3

Abstract session

Biologics in RA. Improving and maintaining the response

Chair(s):
Gianfranco Ferraccioli (Italy)
Aurelie Najm (France)

L. Garcia Montoya (United Kingdom) 10:20
Abstract N° OP0109
In RA patients with initial response to rituximab, early depth of B cell depletion is associated with long-term maintenance of therapy

U. Arad (Israel) 10:30
O. Elkayam
Abstract N° OP0110
Serum tocilizumab through concentrations are associated with clinical disease activity index scores in adult rheumatoid arthritis patients
Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective, randomised, controlled study (the second year of the SURPRISE study)

M. J. l’Ami (Netherlands) 10:50
J. Ruwaard, C. L. Krieckaert, M. T. Nurmohamed, T. Rispens, G. Wolbink
Abstract N° OP0112
Therapeutic drug monitoring to optimize switching between biologic agents in rheumatoid arthritis

E. van Mulligen (Netherlands) 11:00
A. E. A. M. Weel, T. M. Kuijper, J. J. Luime, J. M. W. Hazes, P. H. P. de Jong
Abstract N° OP0113
Gradual tapering TNF blockers versus conventional synthetic DMARDs in patients with rheumatoid arthritis in sustained remission: first year results of the randomised controlled TARA-study

Y. Ishikawa (United States) 11:10
Abstract N° OP0114
ANA development is associated with poor response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis

W. Dankers (Netherlands) 11:20
Abstract N° OP0115
Improved response to etanercept is associated with serum vitamin D levels in rheumatoid arthritis

S. Retamozo (Spain) 11:30
Abstract N° OP0116
Influence of epidemiology and ethnicity on systemic expression of primary Sjögren syndrome in 9974 patients

F. Ceccarelli (Italy) 11:00
A. Chistolino, C. Perricone, E. Rando, C. Pirone, E. Cipriano, I. Lecce, L. Massaro, F. Morello, F. R. Spinelli, C. Alessandri, G. Valesini, F. Conti
Abstract N° OP0121
Lupus anticoagulant is associated with thrombotic events in healthy carriers: results from a prospective longitudinal study
M. Petri (United States) 11:10
D. W. Goldman, L. S. Magder
Abstract N° OP0122
Validation of remission and lupus low disease activity state as predictors of organ damage in SLE

P. Conigliaro (Italy) 11:20
Abstract N° OP0123
Evaluation of retinal microvasculature by optical coherence tomographic angiography in systemic lupus erythematosus patients mirrors systemic involvement

K. Dutton (United Kingdom) 11:30
A. Psarras, Y. El-Sherbiny, M. Y. Md Yusof, P. Emery, E. Vital
Abstract N° OP0124
In SLE patients in sustained low disease activity, novel interferon assays predict flares and glucocorticoid requirements

10:15 - 11:45  Elicium 2
Abstract session
The 'A-B-C' of PsA (Assessment, Biologicals, Co-morbidities)

Chair(s):
Laura Coates (United Kingdom)
Dennis McGonagle (United Kingdom)

S. Puksic (Norway) 10:20
Abstract N° OP0125
DAPSA and ultrasound show different perspectives of psoriatic arthritis activity: results from a longitudinal observational study of patients starting treatment with biologic DMARDs

P. Bosch (Austria) 10:30
R. Husic, A. Ficjan, J. Gretler, A. Lackner, W. Graninger, C. Duftner, J. Hermann, C. Dejaco
Abstract N° OP0126
Evaluating low disease activity definitions in psoriatic arthritis using ultrasound

T. H. Cheng (Hong Kong) 10:40
Abstract N° OP0127
Can achieving minimal disease activity (MDA) prevent progression of subclinical atherosclerosis and arterial stiffness? A two-year prospective cohort study in psoriatic arthritis

10:15 - 11:45  Hall 7.2
Abstract session
RA: such a pain, and beyond

Chair(s):
Vivian Bykerk (United States)
Elena Nikiphorou (United Kingdom)

J. Lampa (Sweden) 10:20
T. Olofsson, J. K. Wallman, A. Jöud, M. E. Schelin, S. Ernestam, R. van Vollenhoven, S. Saevarsdottir
Abstract N° OP0132
Unacceptable, refractory pain despite inflammation control in early rheumatoid arthritis and its relation to treatment strategy: results from the randomised controlled SWEFOT trial
C. R. Silva (Portugal) 10:30
C. Duarte, R. Ferreira, E. Santos, J. A. da Silva
Abstract N° OP0134
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis: a path analysis

Y.-C. Tsai (Taiwan, Province of China) 10:40
S.-F. Luo, M.-J. Chiou, C.-F. Kuo
Abstract N° OP0135
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

H. Westerlind (Sweden) 10:50
M. Holmqvist, L. Ljung, T. Frisell, J. Askling
Abstract N° OP0136
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

K. Krueger (Germany) 11:00
R. Eder, C. Mueller, K. Rietzler
Abstract N° OP0137
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

N. B. Karaca (Turkey) 11:10
G. Arın, A. Özçadırcı, F. B. Oflaz, S. Apraş Bilgen, E. Ünal
Abstract N° OP0138
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

N. M. T. Roodenrijs (Netherlands) 11:20
M. J. H. de Haïr, J. W. G. Jacobs, P. M. J. Welsing, D. M. F. M. van der Heijde, J. M. van Laar, G. Nagy
on behalf of the Task Force Difficult-to-Treat RA
Abstract N° OP0139
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

R. Mu (China) 11:30
Abstract N° OP0140
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

Y. Allanore (France) 10:30
Abstract N° OP0142
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

N. Del Papa (Italy) 10:40
E. Zaccara, W. Maglione, G. Di Luca, R. Andracco, C. Vitali
Abstract N° OP0143
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

C. Brunì (Italy) 10:50
D. P. Tashkin, V. Steen, Y. Allanore, O. Distler, J. Grots, M. Matucci-Cerinic, D. E. Furst on behalf of EUSTAR, Scleroderma Lung Study I and II centres
Abstract N° OP0144
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

R. Janardana (India) 11:00
A. Irodi, P. P. Chebbi, L. Rv, D. Danda, G. Mahasampath
Abstract N° OP0145
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

N. Ciang (Hong Kong) 11:10
R. Ng, A. Leung, J. Chan, K. Kwok, G. Ho, R. Ho
Abstract N° OP0146
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

S. Zhang (China) 11:20
B. Yan
Abstract N° OP0147
Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis

Abstract session
Quickly emerging: science in SSC, myositis and related syndromes

Chair(s):
Maurizio Cutolo (Italy)
Pedro Machado (United Kingdom)

J. Gutiérrez (Mexico) 10:20
Abstract N° OP0141
Ultrasound diagnostic and predictive value of interstitial lung disease in systemic sclerosis. Diagnostic and predictive value of ultrasound in the assessment of interstitial lung disease

Y. Allanore (France) 10:30
Abstract N° OP0142
Rituximab in systemic sclerosis: safety and efficacy data from the EUSTAR network

N. Del Papa (Italy) 10:40
E. Zaccara, W. Maglione, G. Di Luca, R. Andracco, C. Vitali
Abstract N° OP0143
Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomised controlled study

C. Brunì (Italy) 10:50
D. P. Tashkin, V. Steen, Y. Allanore, O. Distler, J. Grots, M. Matucci-Cerinic, D. E. Furst on behalf of EUSTAR, Scleroderma Lung Study I and II centres
Abstract N° OP0144
Intravenous versus oral cyclophosphamide (CYC) for the treatment of interstitial lung involvement (ILD) and skin involvement in systemic sclerosis (SSc): safety and efficacy evaluation in a large multi-centre scleroderma cohort

R. Janardana (India) 11:00
A. Irodi, P. P. Chebbi, L. Rv, D. Danda, G. Mahasampath
Abstract N° OP0145
Scleroderma related interstitial lung disease and mycophenolate: long-term outcomes

N. Ciang (Hong Kong) 11:10
R. Ng, A. Leung, J. Chan, K. Kwok, G. Ho, R. Ho
Abstract N° OP0146
Scleroderma related interstitial lung disease and mycophenolate: long-term outcomes

S. Zhang (China) 11:20
B. Yan
Abstract N° OP0147
Aberrant activation of type I interferon system in anti-MDA5 dermatomyositis patients
Abstract session
Can imaging improve diagnosis and outcome in rheumatic diseases

Chair(s):
Philip Conaghan (United Kingdom)
Mikkel Østergaard (Denmark)

S. Møller-Bisgaard (Denmark) 10:20

Abstract N° OP0149
An MRI guided treat-to-target strategy in rheumatoid arthritis patients in clinical remission improved MRI inflammation but not damage progression - results from the imagine-RA randomised controlled trial

L. B. Nordberg (Norway) 10:30

Abstract N° OP0150
Ultrasound power Doppler activity predicts clinical joint swelling in early rheumatoid arthritis patients: secondary analyses from the ARCTIC trial

A. G. Pratt (United Kingdom) 10:40
K. Iqbal, D. W. Lendrem, B. Hargreaves, B. Thompson, J. D. Isaacs

Abstract N° OP0151
Routinely recorded musculoskeletal ultrasound findings impact clinicians’ diagnostic behaviour maximally in autoantibody-seronegative patients attending an early arthritis clinic

R. Singh (United Kingdom) 10:50
I. Sahbudin, M. Maybury, K. Raza, A. Filer

Abstract N° OP0152
Is sonographic phenotype of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Birmingham early arthritis cohort

R. M. Ten Brinck (Netherlands) 11:00
D. M. Boeters, H. W. van Steenbergen, A. H. van der Helm-van Mil

Abstract N° OP0153
Resolution of symptoms of patients with clinically suspect arthralgia is paralleled by disappearance of MRI-detected subclinical inflammation; a longitudinal study

M. Stein (Canada) 11:10
E. Rampakakis, J. S. Sampalis

Abstract N° OP0154
Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve rheumatoid arthritis management: interim analysis of the ECHO study

S. N. Christansen (Denmark) 11:20
M. Østergaard, O. Slot, L. Terslev

Abstract N° OP0155
Ultrasound as an outcome measurement tool for optimised monitoring of gout. Validation of the OMERACT ultrasound definitions of gout elementary lesions

B. D. Nielsen (Denmark) 11:30

Abstract N° OP0156
Simple assessment of conventional 18F-FDG PET/CT accurately diagnoses cranial arteritis in glucocorticoid-naive GCA patients: a case-control study

HPR Abstract session
Singing power to the people

Chair(s):
Thea Vliet Vlieland (Netherlands)
Agnes Kocher (Switzerland)

M. Reisland (Norway) 10:20
M. Rygg, E. B. Nordal, A. M. Selvaag

Abstract N° OP0157-HPR
Agreement between JIA patients and parents on disease perception analysed by the Norwegian version of the JAMAR questionnaire

R. Zuidema (Netherlands) 10:30
B. van Gaal, I. Meek, E. van den Ende, S. van Dulmen, J. Fransen, R. Nijhuis

Abstract N° OP0158-HPR
Effectiveness of an e-health tailored self-management program for patients with rheumatoid arthritis: an explorative RCT

S. Rongen-van Dartel (Netherlands) 10:40
W. Mûskens, F. Lamers-Karnebeek, B. Radovits-Persijn, E. Denissen-Cranenburg, C. Vogel, F. Hoeks-van Dinther, A. Wennemers, P. van Riel

Abstract N° OP0159-HPR
Reumanet Bernhoven: introduction and evaluation of an online self-management tool and personal health environment for patients with rheumatoid arthritis (RA)
E. Santos (Portugal) 10:50
C. Duarte, R. Ferreira, A. M. Pinto, R. Geenen, J. A. P. da Silva on behalf of ‘Promoting happiness through excellence of care’
Abstract N° OP0160-HPR
Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modeling approach

S. Halls (United Kingdom) 11:00
E. Dures, S. Hewlett, S. Ryan, R. Jenkins, J. van Tonder
Abstract N° OP0161-HPR
The development of self-management training for innovative departments (STRIDE): a skills-training programme for rheumatology teams to enhance support for self-management

F. Pérez-Ruiz (Spain) 11:10
A. So, P. Kandaswamy, R. Karra, K. Kelton, S. Perk, T. Bardin
Abstract N° OP0162-HPR
Estimating health-related quality of life for gout patients: a post-hoc analysis of utilities from the clear trials

Y. Prior (United Kingdom) 11:20
L. Sammut, C. Vasilica on behalf of the MSKHUB Patient and Public Research Advisory Group (PRAG) and the MSKHUB Health Professionals Reference Group (HRPG)
Abstract N° OP0163-HPR
Development of an online self-management platform for people with rheumatic and musculoskeletal conditions (mskhub.com)

A. Moltó (France) 11:30
Abstract N° OP0164-HPR
Impact of a nurse-led program of patient self-assessment and self-management axial spondyloarthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDSPA)

K. Li (United States) 10:30
K. Campbell, S. Garret, C. Brodmerkel, J. Krueger
Abstract N° OP0166-HPR
Comparative evaluation of cellular and molecular changes associated with selective IL-23 blockade vs IL-12/23 blockade in psoriasis skin

K. Yoshimoto (Japan) 10:40
N. Seki, K. Suzuki, K. Sugahara, K. Chiba, T. Takeuchi
Abstract N° OP0167-HPR
A low molecular weight bafi signaling inhibitor, BIK-13, ameliorates B cell activation in vitro and in vivo autoimmune models and consequently suppresses production of IgG and cytokines

K. Jeucken (Netherlands) 10:50
P. Kucharzewinska, C. X. Maracle, J. P. van Hamburg, H. K. Olsson, S. W. Tas
Abstract N° OP0168-HPR
NIK-IKK complex interaction controls NF-KB-dependent inflammatory activation of the endothelium in response to LTβR ligation

D. M. Boeters (Netherlands) 11:00
L. E. Burgers, T. W. Huizinga, A. H. van der Helm-van Mil
Abstract N° OP0169-HPR
A combination of proteins as measured within the multi-biomarker disease activity score at presentation of RA identifies a group of ACPA-negative RA patients with high likelihood of developing DMARD-free sustained remission

D. M. De Graaf (Netherlands) 11:10
Abstract N° OP0170-HPR
Human IL-38 reduces joint inflammation in a mouse model of gouty arthritis

C. Romero-Sanchez (Colombia) 11:20
Abstract N° OP0171-HPR
Leptin levels, overweight and P gingivalis presence contribute to the mechanism of systemic inflammation in first-degree relatives of rheumatoid arthritis individuals

A. Scanu (Italy) 11:30
C. Giraudo, F. Galuppini, V. Lazzarin, G. Pennelli, S. Sivolella, F. Oliivero, P. Galozzi, M. Rugge, R. Stramare, R. Luisetto, L. Punzi
Abstract N° OP0172-HPR
LPS-induced periodontitis promotes arthritis development in mice
10:15 - 11:45  PARE Room

PARE session
Inclusive school environment for young people with RMDs

Learning objectives:
• To showcase the role of patient organisations in supporting children with RMDs to access education
• To present the ideal world versus the reality - the view of the young people with RMDs

Chair(s):
Peter Boyd (Ireland)
Alessia Alunno (Italy)
Els Janssens (Belgium)

Els Janssens (Belgium) 10:20
Abstract N° SP0037
Bednet: learning opportunities for bedridden children

Sophie Ainsworth (United Kingdom) 10:38
Abstract N° SP0038
Raising awareness of invisible illnesses in schools and education

Tanita Wilhelmer (Austria) 10:56
Abstract N° SP0039
I graduated! Education for children and adolescents with RMDs

Mirjam Kepic (Slovenia) 11:14
Abstract N° SP0040
Parents support for children with RMDs in education

L. van Nieuwkoop (Netherlands) 11:32
L. van Geene, R. Janssen
Abstract N° OP0173-PARE
Youth-r-coach, a program for youth with a chronic disease

10:15 - 11:45  E106/E107

Abstract session
The building blocks of systemic inflammation

Chair(s):
Yi Zhao (China)
Christopher Sjowall (Sweden)
A. Psarras (United Kingdom)

A. Psarras (United Kingdom) 10:20
Abstract N° OP0180
Type I interferon is produced by non-haematopoietic tissue resident cells but not PDCS in pre-clinical autoimmunity and SLE

W. I. White (United States) 10:30
Abstract N° OP0174
Alteration of mediators of vascular inflammation by anifrolumab in the phase IIb muse study in SLE

W. Lambers (Netherlands) 10:40
H. Westra, B. Doornbos-van der Meer, M. Jonkman, H. Bootsma, K. de Leeuw
Abstract N° OP0175
Interferon signature might serve as early biomarker for development of lupus and correlates strongly with myxovirus-resistance protein A

E. Rivière (France) 10:50
Abstract N° OP0176
RNA sequencing detection of gene dysregulation in B cells sorted from salivary gland tissue and peripheral blood reveals new pathways involved in Sjögren’s syndrome pathophysiology

U. Nakshbandi (Netherlands) 11:00
Abstract N° OP0177
BCL6 identifies ectopic germinal centers in salivary gland biopsies in primary Sjögren’s syndrome patients

A. Ruiz Roman (Spain) 11:10
Abstract N° OP0178
Analysis of B cells subsets in first degree relatives of patients with systemic lupus erythematosus

R. J. Bende (Netherlands) 11:20
L. M. Slot, T. A. Wormhoudt, M. J. Kwakkenbos, A. H. van Kampen, A. Jongejan, J. E. Guikema, C. J. van Noesel
Abstract N° OP0179
Molecular documentation of the clonal evolution of a diffuse large B cell lymphoma out of clonally expanded rheumatoid factor-expressing B cells in a Sjögren’s syndrome patient

J. Unger (Austria) 11:30
Abstract N° OP0181
Patient perspectives of people with primary Sjögren’s syndrome: a multicentre qualitative European study
10:15 - 11:45  D201/D202

Abstract session

The crystal maze - etiology and management

Chair(s):
Hyon K. Choi (United States)
Frederic Lioté (France)
J. A. Singh (United States)
J. D. Cleveland

Abstract N° OP0182
Gout and dementia in the elderly: a medicare claims study

F. Perez-Ruiz (Spain)
S. P. Chinchilla, J. Atxotegi

Abstract N° OP0183
Association between HFE genotypes and clinical severity characteristics of calcium pyrophosphate crystal arthritis

L. Calabrese (United States)
T. Fields, A. Yeo, P. Lipsky

Abstract N° OP0184
The frequency of flares in subjects with chronic refractory gout treated with pegloticase is related to variation in the level of plasma urate

G. Singh (United States)
A. Mithal

Abstract N° OP0185
Emergency department visits for gout: a dramatic increase in the past decade

F. P. Ramos (Brazil)
A. T. Barbosa, R. B. Souza, F. Seragioli, R. D. N. Giorgi, R. F. Rosa

Abstract N° OP0186
Nephrolithiasis as a complication of gout: a cross-sectional study with helical computed tomography

L. Dai (China)

Abstract N° OP0187
Fructose-containing beverages is an independent risk factor for gout early-onset in south China

E. H. Kang (Republic of Korea)
A. Shin, M. H. Kim, Y.-J. Ha, Y. J. Lee, Y. Song, S. C. Kim

Abstract N° OP0188
Effects of allopurinol versus febuxostat on cardiovascular risk in Korean patients with gout: a nation-wide cohort study

H. K. Ea (France)

Abstract N° OP0189
Identification of new and rare variants in ABCG2, SLC22A1 and ALDH16A1 genes in crystal-proven early-onset gout

10:15 - 11:45  D203/D204

Abstract session

Treatments: friend or foe?

Chair(s):
Daniel Aletaha (Austria)
Meghna Jani (United Kingdom)
A. Anis (Canada)
M. Atiquzzaman, J. Kopec, M. E. Karim, H. Wong

Abstract N° OP0190
The role of NSAIDs in the association between osteoarthritis and cardiovascular diseases: a population-based cohort study

K. Soeltoft (Denmark)
J. Hallas, M. C. M. Wasko, A. B. Pedersen, S. P. Ulrichsen, T. Ellingsen

Abstract N° OP0191
All-cause mortality and cardiovascular death in hydroxychloroquine users in rheumatoid arthritis patients - a population based Danish cohort study

J. R. Curtis (United States)
F. Xie, L. Chen, H. Yun, E. Levitan, P. Muntner

Abstract N° OP0192
Methotrexate use and the risk for cardiovascular disease among rheumatoid patients initiating biologic disease-modifying antiinflammatory drugs

J. R. Curtis (United States)
F. Xie, H. Yun, E. Levitan, P. Muntner

Abstract N° OP0193
Tocilizumab and the risk for cardiovascular disease events among rheumatoid arthritis patients: a direct comparison in real world setting

J. H. Hwang (Republic of Korea)
Z. Guo, M. E. Weinblatt, N. A. Shadick

Abstract N° OP0194
The association between serum uric acid and arterial stiffness in a low-risk, large population of middle-aged Korean

E. Alemao (United States)

Abstract N° OP0195
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study

10:15 - 11:45  D203/D204

Abstract session

Treatments: friend or foe?

Chair(s):
Daniel Aletaha (Austria)
Meghna Jani (United Kingdom)
A. Anis (Canada)
M. Atiquzzaman, J. Kopec, M. E. Karim, H. Wong

Abstract N° OP0190
The role of NSAIDs in the association between osteoarthritis and cardiovascular diseases: a population-based cohort study

K. Soeltoft (Denmark)
J. Hallas, M. C. M. Wasko, A. B. Pedersen, S. P. Ulrichsen, T. Ellingsen

Abstract N° OP0191
All-cause mortality and cardiovascular death in hydroxychloroquine users in rheumatoid arthritis patients - a population based Danish cohort study

J. R. Curtis (United States)
F. Xie, L. Chen, H. Yun, E. Levitan, P. Muntner

Abstract N° OP0192
Methotrexate use and the risk for cardiovascular disease among rheumatoid patients initiating biologic disease-modifying antiinflammatory drugs

J. R. Curtis (United States)
F. Xie, H. Yun, E. Levitan, P. Muntner

Abstract N° OP0193
Tocilizumab and the risk for cardiovascular disease events among rheumatoid arthritis patients: a direct comparison in real world setting

J. H. Hwang (Republic of Korea)
Z. Guo, M. E. Weinblatt, N. A. Shadick

Abstract N° OP0194
The association between serum uric acid and arterial stiffness in a low-risk, large population of middle-aged Korean

E. Alemao (United States)

Abstract N° OP0195
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study
X. Pundole (United States) 11:30
M. Sarangdhar, M. E. Suarez-Almazor
Abstract N° OP0197
Rheumatic and musculoskeletal adverse events associated with immune checkpoint inhibitors: data mining of the US food and drug administration adverse event reporting system

11:45 - 13:30 Exhibition, EULAR Village (Hall 1) and Poster areas
Poster viewing and lunch

11:50 - 13:30 Poster area
Guided poster tours
Guided poster tours on various topics are taking place during the official poster viewing. For details on the various tours on Thursday, please refer to page 49. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

13:30 - 15:00 Hall 7.1
What is New (WIN) & How to Treat (HOT) session
WIN & HOT session
Hector Chinoy (United Kingdom) 13:35
Abstract N° SP0041
WIN: What is new in the treatment of myositis?
Jacob M. van Laar (Netherlands) 14:15
Abstract N° SP0042
HOT: Recent advances in the treatment of systemic sclerosis

13:30 - 15:00 Hall 3
Clinical Science session
Can we halt progression of structural damage in axial SpA?

Learning objectives:
- To learn how to best measure structural progression in axSpA, both at a research and clinical practice level
- To review what we have learnt from RCTs on the effect of treatment (namely TNFI) on structural progression in axSpA
- To discuss the pitfalls of RCTs when addressing the effect of treatment on structural progression and the possible role for observational studies to address this question

Chair(s):
Alexandre Sepriano (Portugal)
Lianne Gensler (United States)

Désirée van der Heijde (Netherlands) 13:35
Abstract N° SP0043
How to capture clinically relevant structural progression in axSpA

Xenofon Baraliakos (Germany) 13:55
Abstract N° SP0044
What do we learn from RCTs on the treatment effect on structural progression in axSpA?

Robert B. M. Landewé (Netherlands) 14:15
Do observational studies give us the answer on the treatment effect on structural progression in axSpA?

L. S. Gensler (United States) 14:35
M. Gianfrancesco, M. H. Weisman, M. A. Brown, M. Lee, T. Leach, M. Rahbar, J. D. Reveille, M. M. Ward
Abstract N° OP0198
Combined effects of tumor necrosis factor inhibitors and NSAIDs on radiographic progression in ankylosing spondylitis

M. Dougados (France) 14:45
Abstract N° OP0199
Sustained remission of inflammation is associated with reduced structural damage on sacroiliac joint magnetic resonance imaging in patients with early axial spondyloarthritis: evidence to support the concept of treat-to-target

13:30 - 15:00 Auditorium
Clinical Science session
Reproductive issues in rheumatology

Learning objectives:
- To evaluate the relationship between oestrogens and systemic autoimmune diseases
- To select options for contraception, medically assisted reproductive techniques and hormonal replacement therapy
- To discuss the possible sexual impairment of men and women with rheumatic diseases
- To understand the clinical approach to pregnant patients with different rheumatic diseases in the real life setting

Chair(s):
Radboud Dolhain (Netherlands)
Karen Schreiber (United Kingdom)

Maurizio Cutolo (Italy) 13:35
Abstract N° SP0045
Oestrogens, immune response and autoimmune diseases
Frauke Förger (Switzerland) 13:53
Hormonal treatment in patients with different autoimmune rheumatic diseases

Monika Østensen (Norway) 14:11
Abstract N° SP0046
What we need to consider in physician-patient communication on sexual problems in different rheumatic conditions

Rebecca Fischer-Betz (Germany) 14:29
Abstract N° SP0047
Challenges in the management of different rheumatologic disorders during pregnancy: lessons from the registries

M. E. B. Clowse (United States) 14:47
Abstract N° OP0200
Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database

13:30 - 15:00 Elicium 2
Challenges in Clinical Practice session
Clinical challenges in giant cell arteritis in 2018

Learning objectives:
To discuss recent advances of pathogenesis and therapeutics in the context of daily clinical decisions

Chair(s):
Eamonn S. Molloy (Ireland)
Kirsten de Groot (Germany)

Francesco Muratore (Italy) 13:35
Abstract N° SP0048
Case 1 presentation: A case of pulseless stroke

Carlo Salvareani (Italy) 13:45
Case 1 discussion: Visual loss and strokes in GCA: clinical manifestations, diagnosis and management

Mark A. Matza (United States) 14:15
Abstract N° SP0049
Case 2 presentation: Head games with GCA and GCS

John H. Stone (United States) 14:25
Case 2 discussion: Advances in therapy of GCA: the role of biologics

13:30 - 15:00 Hall 7.2
Clinical Science session
Do we still need biopsies to diagnose Sjögren’s and autoimmune myositis?

Learning objectives:
To address the opportunities of imaging to avoid biopsies in diagnostics and new therapies in Sjögren

Chair(s):
Hendrika Bootsma (Netherlands)
Eugen Feist (Germany)

Sandrine Jousse-Joulin (France) 13:35
Abstract N° SP0050
Opportunities and challenges of imaging in Sjögren’s

Louise Diedrichsen (Denmark) 13:55
Value of imaging in myositis in 2018

Hendrika Bootsma (Netherlands) 14:15
The value of histologic confirmation in Sjögren’s and myositis

S. Sciascia (Italy) 14:35
Abstract N° OP0201
Clinical outcomes and response to anti-thrombotic treatment among patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicenter cohort study

C. Vitali (Italy) 14:45
Abstract N° OP0202
Gene expression profiles in primary Sjögren’s syndrome with and without systemic manifestations

13:30 - 15:00 Forum
Paediatric Rheumatology session
How monogenetic autoinflammatory diseases help to understand and treat rheumatic diseases

Learning objectives:
- Insight in the relationship between mechanisms and clinical features in autoinflammatory diseases
- Recognise how monogenetic diseases can help to better understand the pathophysiology of complex rheumatic diseases

Chair(s):
Petra Hissink-Mueller (Netherlands)
Tadej Avcin (Slovenia)

Dirk Foell (Germany) 13:35
Pathogenesis of autoinflammatory diseases mimicking adult-onset rheumatic conditions
Seza Ozen (Turkey) 14:00
Abstract N° SP0051
Clinical presentation of autoinflammatory diseases in children and adults: how not to miss these patients

Marco Gattorno (Italy) 14:25
New therapeutic options: IL-1 and beyond

J. F. Swart (Netherlands) 14:50
S. de Roock, R. J. Niwelstein, I. Slaper-Cortenbach, J. J. Boelens, N. Wulffraat
Abstract N° OP0203
Safety and efficacy of intravenous administration of bone-marrow derived mesenchymal stromal cells in therapy refractory juvenile idiopathic arthritis patients, a phase IB/IIA pilot-study

13:30 - 15:00  Elicium 1

Basic and Translational Science session
Joint EULAR - EFIS session:
I've got a B in my bonnet

Learning objectives:
• Describe different aspects of B cell biology and function relevant to rheumatic disease
• Provide an overview of the latest developments in this area of research

Chair(s):
Xavier Mariette (France)
Andreas Radbruch (Germany)

Leendert Trouw (Netherlands) 13:35
Abstract N° SP0052
Posttranslational modification of autoantibodies in RA

A. Musters (Netherlands) 13:55
Abstract N° OP0204
Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis - a validation cohort

Andreas Radbruch (Germany) 14:05
Abstract N° SP0053
Memory plasma cells in systemic auto-immune diseases - a roadblock to tolerance induction

C. Fehres (Netherlands) 14:25
Abstract N° OP0205
April induces a novel subset of IGA+ regulatory B cells that suppress inflammation through the expression of IL-10 and PD-L1

Claudia Mauri (United Kingdom) 14:35
Abstract N° SP0054
Regulatory B cells in rheumatic disease (or in systemic auto-immune diseases)

13:30 - 15:00  Amtrium

Health Professionals session
Sustainable healthcare in rheumatology and the role of health professionals

Learning objectives:
• To describe how integrated care in rheumatology contributes to sustainable healthcare
• To provide and overview of the roles of various members of the integrated healthcare team
• To discuss barriers and challenges towards expanding the role of integrated care

Chair(s):
Annette de Thurah (Denmark)
Sandra Mintz (United States)

Hubertus J.M. Vrijhoef (Netherlands) 13:35
Abstract N° SP0055
How can integrated healthcare contribute to sustainable healthcare in rheumatology?

Yvonne van Eijk-Hustings (Netherlands) 14:00
Sustainable healthcare, and the role of the nurses

Barbara Slusher (United States) 14:25
Abstract N° SP0056
Sustainable healthcare - it takes a village

A.-M. T. Sweeney (Denmark) 14:50
O. R. Madsen, L. Dreyer, A. Hansen
Abstract N° OP0206-HPR
Outpatient follow up on demand for patients with rheumatoid arthritis - a two-year randomised controlled trial

13:30 - 15:00  Emerald

Clinical Science session
SSc: from registries to trials - do we have sufficient data and the appropriate design?

Learning objectives:
• To understand the structure and importance of registries in SSc
• To understand the power of predictive parameters for clinical practice
• To outline the needs and future trial designs

Chair(s):
Otylia Kowal-Bielecka (Poland)
Tania Santiago (Portugal)

Marco Matucci-Cerinic (Italy) 13:35
Abstract N° SP0057
The course of SSc: what can we learn from registries?

Gabriela Riemekasten (Germany) 13:55
Outcome of organ dysfunction: what can be predicted?
Oliver Distler (Switzerland) 14:15
Future trial designs to predict and improve outcome

C. Frantz (France) 14:35
Abstract N° OP0207
The outcomes of limited cutaneous systemic sclerosis patients: a EUSTAR database study

A. H. L. Low (Singapore) 14:45
G. G. Teng, S. Pettersson, P. F. De Sessions, Q. Fan, A. Law, A. Santosa, A. Lim, J. Thumboo
Abstract N° OP0208
A proof-of-concept double-blind randomised placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease

13:30 - 15:00  PARE Room

PARE session
Patient involvement in research: The future of collaborative research. Lessons from the field of rheumatology and beyond

Learning objectives:
• To learn from best practices of patient engagement in different disease areas
• To explore patient involvement in guideline development and health care innovations
• To explore how to evaluate patient involvement

Chair(s):
Jürgen Clausen (Germany)
Laure Gossec (France)
Courtney Coleman (United Kingdom) 13:35
Abstract N° SP0058
Patient involvement in research in pneumology

Iain B. McInnes (United Kingdom) 13:55
EULAR’s RheumaMap - research to transform the lives of people with RMDs

Codruta Zabalan (Romania) 14:15
EULAR’s Patient research partner network - patients’ future involvement in research

E. R. Dorris (Ireland) 14:35
N. Nestor, A. G. Wilson
Abstract N° OP0209-PARE
The patient voice in arthritis research: a collaborative approach to embedding PPI into research strategy

C. G. Schoemaker (Netherlands) 14:45
W. Armbrust, J. F. Swart, E. Versluis, W. Olsder, N. M. Wulffraat
Abstract N° OP0210-PARE
Dutch juvenile idiopathic arthritis patients, carers and clinicians creating a research agenda together following the James Lind alliance method

13:30 - 15:00  E106/E107

EULAR Projects
EULAR Projects in Musculoskeletal Imaging

Chair(s):
Lene Terslev (Denmark)
Esperanza Naredo (Spain)
Peter Mandl (Austria) 13:35
Implementation and role of modern musculoskeletal imaging in rheumatological practice in Europe

Gilles Fournier (Denmark) 13:55
Abstract N° SP0060
First step in producing EULAR Recommendations for the use of imaging in patient with mechanical back pain

Maria-Antonietta d’Agostino (France) 14:15
EULAR Recommendations for the reporting of musculoskeletal ultrasound studies in rheumatology

Frédérique Gandjbakhch (France) 14:35
Preview on EULAR Recommendations/Criteria for the appropriate use of musculoskeletal ultrasound in rheumatology clinical practice

13:30 - 15:00  D201/D202

Practical skills session*
Crystal II

Learning objectives:
To learn how to use a microscope to detect and interpret crystals in synovial fluid from scratch

Chair(s):
Eliseo Pascual (Spain)
Anne K. Tausche (Germany)

Tutor(s):
Francisca Sivera (Spain)
José Pimentao (Portugal)
Francesca Oliviero (Italy)
Eleonora Norkuniene (Lithuania)

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
13:30 - 15:00  D203/D204

**Practical skills session**

**MRI**

**Learning objectives:**
To learn how to use MRI for assessment of inflammation and damage in psoriatic arthritis, osteoarthritis, axial spondyloarthritis and rheumatoid arthritis in clinical practice

**Chair(s):**
Mikkel Østergaard (Denmark)
Kay-Geert Hermann (Germany)

**Mikkel Østergaard (Denmark) 13:35**
Abstract N° SP0061
How to use MRI in the diagnosis and management of psoriatic arthritis + clinical cases

**Philip Conaghan (United Kingdom) 13:55**
Abstract N° SP0062
How to use MRI in the diagnosis and management of osteoarthritis + clinical cases

**Signe Moeller-Bisgaard (Denmark) 14:15**
Should we use MRI in clinical remission to guide step-down or step-up of therapy? + Clinical cases

**Kay-Geert Hermann (Germany) 14:35**
How to read full MRIs of axial and peripheral joints in RA and SpA - an introduction

15:00 - 15:30  Exhibition and EULAR Village (Hall 1)
Coffee break

15:30 - 17:00  Hall 3

**Challenges in Clinical Practice session**

**To taper or not to taper in RA**

**Learning objectives:**
To understand the usefulness of biomarkers and imaging in evaluation of RA

**Chair(s):**
Maya Buch (United Kingdom)
Jacques Morel (France)

**Kenneth Baker (United Kingdom) 15:35**
Abstract N° SP0065
Case 1 presentation: Non-biological DMARD case presentation

**John D. Isaacs (United Kingdom) 15:45**
Case 1 discussion: To taper or not to taper non-biological DMARD

**Joanna Kedra (France) 16:15**
Abstract N° SP0066
Case 2 presentation: Biological DMARD case presentation

**Bruno Fautrel (France) 16:25**
Abstract N° SP0067
Case 2 discussion: To taper or not to taper biological DMARD

15:30 - 17:00  Auditorium

**Clinical Science session**

**Can we improve the care of gout?**

**Learning objectives:**
- To outline the key developments in advanced imaging in gout
- To understand and discuss the utility of the current sets of guidelines available for gout
- The strategies that can be employed to improve gout therapy

**Chair(s):**
Alexander So (Switzerland)
Eliseo Pascual (Spain)

**Victoria Navarro-Compán (Spain) 15:35**
Abstract N° SP0063
WIN: About diagnosis and classification of spondyloarthritis

**Sofia Ramiro (Netherlands) 16:15**
Abstract N° SP0064
HOT: Recent advances in the management of spondyloarthritis

**Nicola Dalbeth (New Zealand) 15:35**
Abstract N° SP0068
DECT imaging in gout - ready for prime time?

**Abhishek Abhishek (United Kingdom) 15:55**
Abstract N° SP0069
Improving adherence in gout therapy

**Thomas Bardin (France) 16:15**
Abstract N° SP0070
What are gout guidelines good for?

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Clinical Science session

‘Why does BMI matter?’

Learning objectives:
• To understand common pathophysiological mechanisms linking adiposity and inflammation
• To obtain insights into the role of obesity in the development of RA
• To understand the impact of BMI and obesity on disease/treatment outcomes in RA

Chair(s):
Vivian Bykerk (United States)
Stefano Alivernini (Italy)

Fat and inflammation in RA - biological concepts

Till Uhlig (Norway) 15:35
Is obesity a risk for RA?

Patrick Kiely (United Kingdom) 16:15
Does obesity influence RA outcomes?

L. Baganz (Germany) 16:35
A. Richter, K. Albrecht, M. Schneider, G.-R. Burmester, A. Zink, A. Strangfeld
Abstract N° SP0072
What is the impact of poor prognostic factors on the achievement of low disease activity or remission in patients with rheumatoid arthritis?

L. Linde (Denmark) 16:45
M. L. Hetland
Abstract N° OP0214
Baseline comorbidities and overweight predict functional status and health-related quality of life 9 years later - a longitudinal cohort study of 428 patients with rheumatoid arthritis receiving standard care

Clinical Science session

Musculoskeletal pain; feeding the opioid epidemic

Learning objectives:
• To be aware of the increasing problem of medical opioid abuse on both sides of the Atlantic
• The limitations of opioids as analgesics for chronic musculoskeletal pain
• How novel opioid analgesics might yet cause more benefit than harm

Chair(s):
Francis Berenbaum (France)
Candy McCabe (United Kingdom)

Weiya Zhang (United Kingdom) 15:35
Opioids; do they really work for arthritis pain, or is the benefit mainly placebo?

Christoph Stein (Germany) 16:15
Are all opioids the same?

V. Rantalaiho, H. Kautiainen, L. J. Virta, K. Puolakka
Abstract N° OP0215
Time-related trends in opioid purchases among patients with early inflammatory arthritides

E. R. Vina (United States) 16:45
Abstract N° OP0216
Examining modifiable psychological & social health factors associated with use of osteoarthritis oral analgesic treatment

From Bench to Bedside

What is lupus - syndrome or different entities?

Learning objectives:
• To understand the updated pathogenic mechanisms of systemic lupus
• To discuss the possible role of autoantibodies as biomarkers
• To understand the clinical evolution of patients towards a full blown disease picture

Chair(s):
Ljudmila Stojanovic (Serbia)
Georges Bertsias (Greece)
### Basic and Translational Science session

#### Genetics, epigenetics and disease: is it all in the genes?

**Learning objectives:**
- To understand how genetic and epigenetic traits influence each other
- To learn how genetic/epigenetic data can inform about disease mechanisms
- To understand how rare genetic variants can be analysed and what they can tell us about disease pathogenesis

**Chair(s):**
- Anne Barton (United Kingdom)
- Diane van der Woude (Netherlands)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>David Daikh (United States)</strong></td>
<td>15:35</td>
</tr>
<tr>
<td>Pathogenic mechanisms of SLE - what we know in 2018?</td>
<td></td>
</tr>
<tr>
<td><strong>Pier Luigi Meroni (Italy)</strong></td>
<td>15:53</td>
</tr>
<tr>
<td>Abstract N° SP0075</td>
<td></td>
</tr>
<tr>
<td>Autoantibodies - not always what they seem</td>
<td></td>
</tr>
<tr>
<td><strong>Marta Mosca (Italy)</strong></td>
<td>16:11</td>
</tr>
<tr>
<td>Early SLE versus mimickers - what should we consider in 2018?</td>
<td></td>
</tr>
<tr>
<td><strong>Sindhu Johnson (Canada)</strong></td>
<td>16:29</td>
</tr>
<tr>
<td>Presentation of the new SLE classification criteria</td>
<td></td>
</tr>
<tr>
<td><strong>M. B. Lauvsnes (Norway)</strong></td>
<td>16:47</td>
</tr>
<tr>
<td>Abstract N° OP0217</td>
<td></td>
</tr>
<tr>
<td>A permeable blood-brain barrier is not required for neuropsychiatric manifestations in SLE and PSS</td>
<td></td>
</tr>
</tbody>
</table>

**Amtrium**

### Health Professionals session

**It’s your move: promoting physical activity in people with RMDs**

**Learning objectives:**
To understand current, state-of-the-art physical activity in RMDs

**Chair(s):**
- Els van den Ende (Netherlands)
- Thomas Davergne (France)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Keegan Knittle (Finland)</strong></td>
<td>15:35</td>
</tr>
<tr>
<td>Abstract N° SP0077</td>
<td></td>
</tr>
<tr>
<td>New insights into strategies to effectively promote physical activity</td>
<td></td>
</tr>
<tr>
<td><strong>Zhivko Yankov (Bulgaria)</strong></td>
<td>15:53</td>
</tr>
<tr>
<td>Patient’s perspective on physical activity: good reasons for being active</td>
<td></td>
</tr>
<tr>
<td><strong>Karen Hambly (United Kingdom)</strong></td>
<td>16:11</td>
</tr>
<tr>
<td>Abstract N° SP0078</td>
<td></td>
</tr>
<tr>
<td>The patient perspective on physical activity and work participation in RMDs</td>
<td></td>
</tr>
<tr>
<td><strong>Maura D. Iversen (United States)</strong></td>
<td>16:29</td>
</tr>
<tr>
<td>Abstract N° SP0079</td>
<td></td>
</tr>
<tr>
<td>Major achievements and future challenges in physical activity</td>
<td></td>
</tr>
<tr>
<td><strong>T. Thomsen (Denmark)</strong></td>
<td>16:47</td>
</tr>
<tr>
<td>Abstract N° OP0219-HPR</td>
<td></td>
</tr>
<tr>
<td>The efficacy of motivational counselling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: 22 months follow-up of a randomised, parallel-group trial</td>
<td></td>
</tr>
</tbody>
</table>

**Emerald**

### Practical skills session*

**Data visualisation: tables and graphs for publication and presentation I**

**Learning objectives:**
To learn how tables and graphs should be designed for publication and presentation

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>M. L. Vecellio (United Kingdom)</strong></td>
<td>16:50</td>
</tr>
<tr>
<td>A. Cortes, C. J. Cohen, R. Fischer, B. P. Wordsworth</td>
<td></td>
</tr>
<tr>
<td>Abstract N° OP0218</td>
<td></td>
</tr>
<tr>
<td>Investigating the regulatory snps at the RUNX3 locus associated with ankylosing spondylitis</td>
<td></td>
</tr>
</tbody>
</table>

*In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2*
**15:30 - 17:00**  
**PARE Room**

**PARE session**

**Challenges of patient organisations' in the 21st century**

**Learning objectives:**
- To outline organisations’ challenges in a society that is getting older - less - more colorful
- To showcase how organisations can achieve sustainability
- To portrait organisations’ efforts to overcome gaps in patient health care

**Chair(s):**
Neil Betteridge (United Kingdom)  
Corinna Elling-Audersch (Germany)

**Winfried Kösters (Germany)**  
15:35  
Abstract N° SP0081  
Patient organisations’ challenges in a world that is getting older - less - more colorful

**Elsa Mateus (Portugal)**  
15:55  
Abstract N° SP0082  
How a user-led organisation for RMDs enables citizen participation in Portugal

**Katerina Koutsogianni (Greece)**  
16:15  
Abstract N° SP0083  
Gaps in patient treatment - what patient organisations can do

**V. Krafft (Switzerland)**  
16:35  
S. M. Engel  
Abstract N° OP0220-PARE  
Development of the Swiss national strategy ‘musculoskeletal diseases' 2017-2022 by the Swiss league against rheumatism

**T. Ngcozana (United Kingdom)**  
16:45  
A. Bhatia  
Abstract N° OP0221-PARE  
Know their numbers: what do RA patients know about their own biomedical data?

---

**15:30 - 17:00**  
**E106/E107**

**EULAR Projects in Health Professionals**

**The EULAR Excercise**

**Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis**

**Learning objectives:**
- To learn about the work of the task force that developed the EULAR Recommendations for physical activity in inflammatory and osteoarthritis, i.e. the process and its results

**Chair(s):**
Bente Appel Esbensen (Denmark)  
Thijs Swinnen (Belgium)

**Maura D. Iversen (United States)**  
15:35  
Abstract N° SP0084  
Why physical activity and exercise works

**Anne-Kathrin Rausch Osthoff (Switzerland)**  
15:53  
Abstract N° SP0085  
The evidence for physical activity in inflammatory arthritis and osteoarthritis

**Karín Niedermann (Switzerland)**  
16:11  
Abstract N° SP0086  
The development and purpose of the EULAR Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis

**Michael Nurmohamed (Netherlands)**  
16:29  
Abstract N° SP0087  
How to deal with cardiovascular risk factors for physical activity and implement the PA recommendations in the rheumatologic practice

**S. Pettersson (Sweden)**  
16:47  
I. Demmemaier, B. Nordgren, A. B. Dufour, C. H. Opava  
Abstract N° OP0222-HPR  
Physical capacity contributes marginally in explaining variations of fatigue in persons moderately affected by rheumatoid arthritis

---

**15:30 - 17:00**  
**D201/D202**

**Practical skills session*  
Capillaroscopy I**

**Learning objectives:**
- How to differentiate normal from abnormal capillaroscopic images
- How to score to capillaroscopic images
- How to distinguish the major capillaroscopic patterns

**Chair(s):**
Maurizio Cutolo (Italy)  
Vanessa Smith (Belgium)

**Vanessa Smith (Belgium)**  
15:35  
Abstract N° SP0088  
The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease

**Alberto Sulli (Italy)**  
15:55  
Scoring the capillaroscopic images

**Ariane L. Herrick (United Kingdom)**  
16:15  
Abstract N° SP0089  
How to distinguish the major capillaroscopic patterns

**Maurizio Cutolo (Italy)**  
16:35  
How capillaroscopy can predict disease severity and prognosis

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Practical skills session*  
Ultrasound advanced I

Chair(s):
Mads Ammitzboll (Denmark)  
Marion Kortekaas (Netherlands)

Ingrid Möller (Spain) 15:35
Abstract N° SP0090
US for pulley lesions - clinical relevance + demo

David Bong (Spain) 15:55
Abstract N° SP0091
US for peripheral nerve entrapments + demo

Sandrine Jousse-Joulin (France) 16:15
Abstract N° SP0092
US for scoring Sjögren disease

Nemanja Damjanov (Serbia) 16:35
US for impingement syndromes + demo

Tutor:
Sara Nysom (Denmark)

Basic and Translational Science session

Immune senescence and ageing

Learning objectives:
- Describe the relevance of senescence in the functioning of the immune system
- Novel insights into senescence and inflammation
- To learn about therapeutic opportunities involving immune rejuvenation

Chair(s):
Berent J. Prakken (Netherlands)  
Erik Lubberts (Netherlands)

Arne Akbar (United Kingdom) 17:35
Cellular senescence and inflammation

Deena Gibson (United Kingdom) 18:00
The neonatal immune system and inflammation

M. Varela-Eirín (Spain) 18:25
A. Varela-Vázquez, C. Páino, A. Casado-Díaz,  
J. M. Quesada-Gómez, E. Fonseca, T. Aasen,  
A. Tabernero, J. R. Caeiro, A. Blanco, M. D. Mayán
Abstract N° OP0223
Targeting chondrocyte plasticity via CONNEXIN43 modulation attenuates cellular senescence in osteoarthritis

Femke van Wijk (Netherlands) 18:35
Abstract N° SP0093
Rejuvenation of the immune system following haematopoietic stem cell transplantation

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Guided Poster Tours

Thursday, 14 June 2018

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis on the date of the poster tour.

11:50 - 13:30  Poster area

**Poster tour T1: Genetics - from cause to cure**
Chair(s): Caroline Ospelt (Switzerland), Rachel Knevel (Netherlands)
Abstracts N°: THU0001-THU0010
See page 50

**Poster tour T2: Adapting the adaptive immune system in health and disease**
Chair(s): Leonie Taams (United Kingdom), Hans-Ulrich Scherer (Netherlands)
Abstracts N°: THU0023-THU0032
See page 51

**Poster tour T3: Seeking the origins of rheumatoid arthritis**
Chair(s): João E. Fonseca (Portugal), Felice Rivellesse (United Kingdom)
Abstracts N°: THU0050-THU0059
See page 52

**Poster tour T4: RA: not just about the joints!**
Chair(s): Elena Nikiphorou (United Kingdom), Jacob M. van Laar (Netherlands)
Abstracts N°: THU0135-THU0144
See page 56

**Poster tour T5: Anti-TNF: old drugs now but still full of promises**
Chair(s): Xavier Mariette (France), Diane van der Woude (Netherlands)
Abstracts N°: THU0182-THU0191
See page 58

**Poster tour T6: Spondyloarthritis: causes, questions and consequences**
Chair(s): Robert B. M. Landewé (Netherlands), Marloes van Onna (Netherlands)
Abstracts N°: THU0227-THU0236
See page 60

**Poster tour T7: The impact of treatment on the burden of psoriatic disease**
Chair(s): Filip van den Bosch (Netherlands), Laura Coates (United Kingdom)
Abstracts N°: THU0280-THU0289
See page 62

**Poster tour T8: Cardiovascular co-morbidities in SLE**
Chair(s): Eric F. Morand (Australia), Antonis Fanouriakis (Greece)
Abstracts N°: THU0344-THU0341
See page 65

**Poster tour T9: SSC, myositis, related syndromes - a bouquet of surprises**
Chair(s): Ulf Müller-Ladner (Germany), Peter Korsten (Germany)
Abstracts N°: THU0387-THU0396
See page 67

**Poster tour T10: New data on osteoporosis and fracture prevention**
Chair(s): Piet Geusens (Netherlands), Sandrine Bours (Netherlands)
Abstracts N°: THU0469-THU0478
See page 70

**Poster tour T11: Pain in the joint; managing a widespread problem**
Chair(s): David Walsh (United Kingdom), Francesco Carubbi (Italy)
Abstracts N°: THU0516-THU0525
See page 72

**Poster tour T12: A colourful journey through the landscape of paediatric rheumatology**
Chair(s): Berent J. Prakken (Netherlands), Gabriella Giancane (Netherlands)
Abstracts N°: THU0546-THU0555
See page 73

**Poster tour T13: Life is not a smooth trip - how pregnancy and life events interfere in rheumatic disease management**
Chair(s): Laure Gossec (France), Santiago Rodrigues-Manica (Portugal)
Abstracts N°: THU0671-THU0680
See page 79

**Poster tour T14: Winds of change**
Chair(s): Annette de Thurah (Denmark), Anne-Kathrin Rausch Osthoff (Switzerland)
Abstracts N°: THU0710-HPR-THU0719-HPR
See page 177

12:00 - 13:30  Poster area

**Poster tour T15: PARE Poster Tour I**
Chair(s): Dieter Wiek (Germany), Elsa Mateus (Portugal)
Abstracts N°: PARE0001-PARE0008
See page 188

---

Thursday, 14 June 2018

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis on the date of the poster tour.
Scientific Poster Session I

Thursday, 14 June 2018

Poster viewing 11:45-13:30
Guided poster tours 11:50-13:30

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis on the date of the poster tour.

**TOPIC: GENOMICS, GENETIC BASIS OF DISEASE AND ANTIGEN PRESENTATION**

**Poster tour T1: Genetics - from cause to cure**

Chair(s): Caroline Ospelt (Switzerland), Rachel Knevel (Netherlands)

Abstracts N°: THU0001-THU0010

**THU0001**

**THU0002**

**THU0003**

**THU0004**

**THU0005**
Whole genome linkage and exome sequencing analyses in Takayasu arteritis families / E. Tahir Turanlı - I. Karacan - S. N. Eskişioğlu - S. Sahin - O. Kasapcopur - A. Tolun - E. Seyahi*

**THU0006**

**THU0007**
Genetic variants in SLE susceptibility loci XKR6 and GLT1D1, are associated with childhood-onset SLE in a Korean cohort / Y. B. Joo* - J. Lim - B. P. Tsao - S. K. Neth - K. Kim - S. C. Bae

**THU0008**
Linking genetics to T cell phenotype in JIA: rational for IL-2 therapy / A. Yarwood* - A. Hinks - S. Smith - J. Bowes - S. Eyre - W. Thomson

**THU0009**
Towards precision medicine in connective tissue diseases: genomic and transcriptomic studies / T. Briggs* - J. A. Reynolds - G. Rice - V. Bondet - E. Bruce - E. Crow - D. Duffy - B. Parker - I. N. Bruce

**THU0010**

**THU0011**
Location and interaction of Igg hypervariable regions with porphyromonas gingivalis peptidylarginine deiminase citrullinated peptides, a highlight to understand the association model of rheumatoid arthritis and periodontal disease: in silico analysis / M. Acevedo-Godoy - P. Hernandez - A. Árnay - D. M. Castillo - J. E. Castellanos - J. M. Bello-Gualtero - W. Bautista-Molano - C. Romero-Sánchez*

* Presenting author

THU0013  DOWNREGULATION OF MICRONNA MAY CONTRIBUTE TO ACTIVATION OF THE INTERFERON SIGNALLING PATHWAY IN THE IDIOPATHIC INFLAMMATORY MYOPATHIES / J. E. Parkes* - H. Chinyo - P. J. Day - J. A. Lamb

THU0014  GENETIC SCREENING FOR IDENTIFYING HUMAN GENES REGULATING FIBROSIS IN SYSTEMIC SCLEROSIS / M. Krishnan* - U. Unniyamprathu - S. Albani - A. H. L. Low


TOPIC: ADAPTIVE IMMUNITY (T CELLS AND B CELLS) IN RHEUMATIC DISEASES

THU0020  TOCILIZUMAB DECREASES THE PRO-PRO-INFLAMMATORY PATHWAY OF PLATELETS IN RHEUMATOID ARTHRITIS: IDENTIFICATION OF A NEW MECHANISM OF ACTION ASSOCIATED WITH POSITIVE RESPONSE? / C. Prum Delepine - C. Derambure - N. Vitecoq - T. Lequerre*

THU0021  DIFFERENTIAL EFFECTS OF TR14 VERSUS DICLOFENAC ON COX/LOX PATHWAYS REVEALED BY RNASEQ / O. Vittecoq - T. Lequerre*

THU0022  ANALYSIS OF 47 NON-MHC ANKYLOSING SPONDYLITIS SUSCEPTIBILITY LOCI REVEALS SHARED ASSOCIATED VARIANTS ACROSS CAUCASIANS AND CHINESE HAN / X. Zheng - Q. Li - X. Li - Y. Zhang - X. Wu - Q. Wei - K. Cesnulevicius - T. Mccaffrey*
THU0035

THU0036

THU0037
LEPTIN ENHANCED THE EXPRESSION OF AUTOANTIBODIES AND INFLAMMATORY CYTOKINES OF B CELLS VIA ACTIVATING ERK1/2 AND JAK/STAT3,5 PATHWAYS IN SYSTEMIC LUPUS ERYTHEMATOSUS / H. Chen* - F. Yuan - Y. Zou

THU0038

THU0039
INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR REGULATES THE PHENOTYPE AND FUNCTION OF CD21+ B CELLS / M. Erlandsson - C. Wasen - G. Gravina - M. I. Bokarewa*

THU0040

THU0041

THU0042

THU0043

THU0044
IMPAIRED AUTOPHAGY INDUCES DEFECTIVE FUNCTION OF REGULATORY B CELLS IN ANKYLOSING SPONDYLITIS / C. Shuizhong - X. Zhangyu - Z. Guan - S. Huiyong* - W. Yanfeng

THU0045

THU0046
SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY (SM04755) AS A POTENTIAL TOPICAL TREATMENT FOR PSORIASIS / V. B. Deshmukh* - M. Pedraza - L. Lamangian - Y. Yazici

THU0047

THU0048
SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY (SM04755) AS A POTENTIAL TOPICAL TREATMENT FOR PSORIASIS / V. B. Deshmukh* - M. Pedraza - L. Lamangian - Y. Yazici

THU0049
IMPAIRED AUTOPHAGY INDUCES DEFECTIVE FUNCTION OF REGULATORY B CELLS IN ANKYLOSING SPONDYLITIS / C. Shuizhong - X. Zhangyu - Z. Guan - S. Huiyong* - W. Yanfeng

THU0050
HYPOXIA INDUCES PRODUCTION OF CITRULLINATED PROTEINS IN HUMAN FIBROBLAST-LIKE SYNOVIOCYTES THROUGH REGULATING HIF1A / R. Yu* - C. Li - L. Sun - L. Jian - Z. Ma - J. Zhao - X. Liu

THU0051
TNF RECEPTOR 2 PLAYS AN IMMUNOREGULATORY AND ANTI-INFLAMMATORY ROLE IN ARTHRITIS / W.-Y. Tseng* - I.-S. Huang - F. Clanchy - K. Mcnamee - F. Mccann - R. O. Williams

THU0052

THU0053

THU0054
IMPAIRED AUTOPHAGY INDUCES DEFECTIVE FUNCTION OF REGULATORY B CELLS IN ANKYLOSING SPONDYLITIS / C. Shuizhong - X. Zhangyu - Z. Guan - S. Huiyong* - W. Yanfeng

THU0055

THU0056
SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY (SM04755) AS A POTENTIAL TOPICAL TREATMENT FOR PSORIASIS / V. B. Deshmukh* - M. Pedraza - L. Lamangian - Y. Yazici

THU0057
THU0058

THU0059

THU0060

THU0061

THU0062
WNT5A INVOLVEMENT IN MIGRATION, INVASION AND THE PRO-INFLAMMATORY PHENOTYPE OF RHEUMATOID SYNOVIOCYTES / A. Rodríguez-Trillo* - N. Mosquera - A. Mera - A. González - C. Conde

THU0063

THU0064
ANTIBODIES AGAINST CARBAMYLATED PROTEINS FROM PATIENTS WITH RHEUMATOID ARTHRITIS ACTIVATE ENDOTHELIAL CELLS / A. Pecani* - T. Colasanti - F. R. Spinelli - C. Barbati - F. Conti - G. Valesini - C. Alessandri

THU0065
RESULTS OF TREATMENT OF ARTHROSCOPIC AND TRADITIONAL SYNOVECTOMY OF THE KNEE JOINT IN RHEUMATOID ARTHRITIS / A. Kasimov* - I. Khujanazarov

THU0066

THU0067
ASSOCIATION OF HIGH TITERS OF ANTI-CARBAMYLATED PROTEINS ANTIBODIES WITH DECREASED BONE MINERAL DENSITY IN EARLY ARTHRITIS PATIENTS / C. Regueiro* - A. M. Ortiz - M. D. Boveda - S. Castañeda - I. Gonzalez-Alvaro - A. Gonzalez

THU0068

THU0069

THU0070
THE TRANSCRIPTION FACTORS IKAROS AND AIOLOS ARE EXPRESSED IN THE SYNOVIAL MEMBRANE OF EARLY RHEUMATOID ARTHRITIS PATIENTS IN ASSOCIATION WITH SYNOVIAL LYMPHOID AGGREGATES / F. Rivellesse - M. Congia - D. Mauro* - M. Bombardi - M. Lewis - C. Pitzalis

THU0071

THU0072

THU0073

THU0074

THU0075

THU0076

THU0077

THU0078
BERBERINE AMELIORATES BONE EROSIONS IN COLLAGEN-INDUCED ARTHRITIS RAT MODELS VIA SUPPRESSING THE EXPRESSION OF IL-17A / J. Yue* - J. Xu - H. Li - J. Wang - N. Zheng - H. Yao - L.-S. Tam - I. L. Qin

THU0079

* Presenting author


THU0082 IMPAIRED LEFT VENTRICULAR RELAXATION AND ITS ASSOCIATION WITH INFLAMMATORY MARKERS IN COLLAGEN-INDUCED ARTHRITIS / L. M. Sokotedi* - F. S. Michel - C. Mogane - P. H. Dessein - A. M. Milien


THU0086 INTERLEUKIN 17 RECEPTOR D (IL-17RD) REDUCES INCIDENCE OF COLLAGEN INDUCED ARTHRITIS / M. Molendijk* - A. M. Mus - P. S. AsnawiJadija - D. Baeten - E. Lubberts

THU0087 MICRORNA-1915-3P IN SERUM EXOSOME IS ASSOCIATED WITH DISEASE ACTIVITY OF RHEUMATOID ARTHRITIS IN KOREA / M.-K. Lim* - J. Song - S. A. Kim - J. Yoo


THU0089 IL-17A+GM-CSF+ NEUTROPHILS ARE THE MAJOR INFLATING CELLS IN INTERSTITIAL LUNG DISEASE IN AN AUTOIMMUNE ARTHRITIS MODEL / O. C. Kwon* - E.-J. Lee - E.-J. Chang - W. J. Seo - J. S. Oh - S. Hong - C.-K. Lee - B. Yoo - Y.-G. Kim


THU0093 NADPH OXIDASES ASSOCIATED PRODUCTION OF REACTIVE OXYGEN SPECIES IN RHEUMATOID ARTHRITIS / S.-J. Yoo* - S. W. Kang - J. Kim - I. S. Yoo - C. Park


THU0096 ROLE OF SPHINGOSINE-1-PHOSPHATE RECEPTOR 3 SIGNALING IN COLLAGEN-INDUCED ARTHRITIS / T. Inoue* - S.-J. Yoo* - S. W. Kang - J. Kim - I. S. Yoo - C. Park

THU0097 NADPH OXIDASE ASSOCIATED PRODUCTION OF REACTIVE OXYGEN SPECIES IN RHEUMATOID ARTHRITIS / S.-J. Yoo* - S. W. Kang - J. Kim - I. S. Yoo - C. Park

THU0100 WORK IMPAIRMENT IN RHEUMATOID ARTHRITIS IS HIGHLY CORRELATED WITH DEPRESSION / A. D. Housset* - J. Galloway


* Presenting author


AUTOANTIBODY PROFILING FOR RESPONSE TO BARCITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND NO OR LIMITED EXPOSURE TO METHOTREXATE / I. Martirís Gamboa - H. Bang - M. Issa - S. Zuckerman - A. Cardoso - T. Holzkaemper - F. De Leonards - I. de la Torre - Y. Tanaka - E. Feist*

AUGMENTED TREATMENT AND LOW DOSE CORTICOSTEROIDS MIGHT DECREASE MORTALITY IN EARLY ARTHRITIS: RESULTS FROM THE RECORD LINKAGE OF CLINICAL AND ADMINISTRATIVE DATABASES / G. Sakellariou* - C. A. Sciri - F. Rumi - G. Carrara - C. Cerra - S. Migliazza - R. Caporali - C. Montecucco

FREQUENCY AND PREDICTORS OF SUSTAINED REMISSON IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING DRUGS / G. Zanframundo* - S. Bugatti - A. Manzo - F. Benaglio - G. Sakellario - C. Montecucco - R. Caporali

THE INFLUENCE OF AGE AND SEX ON THE PROGRESSION OF RHEUMATOID ARTHRITIS / L. Gjertsson* - J. Nilsson - M. Andersson - M. Leu Agellin on behalf of BARFOT study group


PSYCHOLOGICAL AND FUNCTIONAL STATES PREDICT DISEASE FLARE FOLLOWING TNF INHIBITOR TAPERING IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF DATA FROM THE OPTIMISING TNF TAPERING IN RA (OPTITRA) COHORT / K. Bechman* - F. E. Sin - F. Ibrahim - S. Norton - D. Scott - A. Cope - J. Galloway

LIPID PROFILE AND CARDIOVASCULAR RISK IN SUBJECTS AT RISK FOR DEVELOPING RHEUMATOID ARTHRITIS / L. van Boheemen* - M. van Beers - T. D. van Schaardenburg - M. T. Nummohamed

CHEMOKINE CCL18 ENRICHED IN SYNOVIAL FLUID IS INVOLVED IN JOINT DESTRUCTION THROUGH PROMOTING MIGRATION OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS / Y.-Q. Mo G.-C. Zhang - J. Jing - J.-D. Ma - L. Dai*


SMOKING IS NEGATIVELY ASSOCIATED WITH CLINICAL RESPONSE TO CONCOMITANT PRENIDONE USE IN EARLY RHEUMATOID ARTHRITIS / M. Safy* - M. De Hair - P. Welsing - J. Van Laar - J. Jacobs

VITAMIN D IN INDIVIDUALS BEFORE ONSET OF RHEUMATOID ARTHRITIS: RELATION TO VITAMIN D BINDING PROTEIN AND ITS ASSOCIATED GENETIC VARIANTS / M. Brink* - L. Johansson - E. Nygren - L. Arlöstig - J. Hultdin - S. Rantapää-Dahlqvist


MEDICATION ADHERENCE AND COST-RELATED MEDICATION NON-ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS, A MIXED METHOD STUDY IN IRAN / P. Heidari* - W. Cross - M. Nazarzina - K. Crawford


IMPACT OF RESIDENTIAL AREA ON THE PROFILE OF RHEUMATOID ARTHRITIS PATIENTS INITIATING THEIR FIRST BIOLOGIC DMARD: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / R. Joshi* - M. Movahedi - E. Rampakakis - C. Thorne - A. Cesta - J. S. Sampalis - C. Bombardier on behalf of other OBRI Investigators

THE SEVERITY OF KERATOCONJUNCTIVITIS SICCA IN RHEUMATOID ARTHRITIS CORRELATES WITH THE MEDICAL OUTCOME STUDY 36-ITEM SHORT FORM HEALTH SURVEY (SF-36) SCORE BUT NOT THE DISABILITY INDEX (HAQ-DI) / R. O. Akintayo* - B. H. Olaosebikan

DO BIOLOGICAL DMARDS PREVENT LONG-TERM ARTICULAR DAMAGE BY RHEumatoid ARTHRITIS IN ROUTINE CLINICAL CARE? / S. Baghban* - L. Krens - M. Henstra - M. Vermeer - K. van der Elst - H. Bernelot Moens

PREDICTIVE VALUE OF CD19 SERUM LEVELS FOR LONG-TERM THERAPEUTIC RESPONSE AND UTILITY AS BIOMARKER FOR OPTIMIZATION, IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB / S. Melchor* - E. Rodríguez - J.-L. Pablos - P. E. Carreira


* Presenting author
THU0131 LEVELS OF CXCL13 AND SICAM1 CORRELATE WITH DISEASE ACTIVITY SCORE IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH TOCILIZUMAB (TCZ) / T. Sornasse* - C. Gabay - M. Townsend - R. Laubender - J. Wang - K. Tuckwell


**TOPIC: RHEUMATOID ARTHRITIS - COMORBIDITY AND CLINICAL ASPECTS**

**Poster tour T4: RA: not just about the joints!**

**Chair(s):** Elena Nikphorou (United Kingdom), Jacob M. van Laar (Netherlands)

**Abstracts N°:** THU0135-THU0144

**THU0135** USING FRAX® AND PERIPHERAL BONE MINERAL DENSITY FOR IDENTIFYING POTENTIAL CANDIDATES FOR OSTEOPOROSIS THERAPY AMONG RHEUMATOID ARTHRITIS PATIENTS / O. Nikliniskaya* - N. Toropstova


**THU0138** OCCURRENCE OF IN-STENT RESTENOSIS AFTER CORONARY DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / O. C. Kwon* - W. J. Seo - J. S. Oh - S. Hong - C.-K. Lee - B. Yoo - Y.-G. Kim


**THU0142** THE PROGNOSIS OF HEART FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Meissner* - M. Schäfer - B. Manger - M. Zänker - W. Ochs - J. Listing - A. Strangfeld

**THU0143** VASCULAR WALL INFLAMMATION IN RHEUMATOID ARTHRITIS PATIENTS DECREASES AFTER 6 MONTHS OF ANTI-INFLAMMATORY THERAPY WITH METHOTREXATE OR ADALIMUMAB AS MEASURED BY 18F-FDG-PET/CT / A. Blanken* - R. Agca - A. Voskuijl - R. Boellaard - C. van der Laken - M. Nurmohamed


**THU0145** CHANGES IN BONE METABOLISM AND TRABECULAR BONE SCORE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / A. Corrado* - A. Mele - E. Sanpaolo - A. Trotta - R. Colia - F. P. Cantatore

**THU0146** GLYCEMIC PROFILE AND INSULIN RESISTANCE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / A. M. Brandy-García* - A. Lorenzo Martín - S. Alonso Castro - M. Alperi López - F. J. Ballina García

**THU0147** TREATMENT RESPONSE IN ANTIDEPRESSANTS-TREATED RA PATIENTS WITH DEPRESSIVE AND ANXIETY DISORDERS RECEIVING DMARDS AND BIOLOGICS ON A FIVE-YEAR FOLLOW-UP / A. Abramkin* - T. Lisitsyna - D. H. Solomon - J. Asking


**THU0150** IMPACT OF COMORBIDITY BURDEN AND OBESITY ON THE EFFECTIVENESS OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS / A. Blanken* - R. Agca - A. Voskuijl - R. Boellaard - C. van der Laken - M. Nurmohamed

**THU0151** ASSESSMENT OF COMPLIANCE OF RHEUMATOID ARTHRITIS PATIENTS IN COGNITIVE DYSFUNCTION / E. Grunina* - A. Tkachev


**THU0153** THE EFFECT OF 5-YEARs B-DMARDS TREATMENT ON DIFFERENT 10-YEARS CARDIOVASCULAR RISK SCORES APPLIED IN RHEUMATOID ARTHRITIS PATIENTS / F. Cacciapaglia* - M. Fornaro - D. Renna - F. Cafarelli - G. Lopalco - M. G. Anelli - C. Scioscia - G. Lapadula - F. Iannone

* Presenting author


**TOPIC:** RHEUMATOID ARTHRITIS - BIOLOGICAL DMARDS

**Poster tour T5:** Anti-TNF: old drugs now but still full of promises

**Chair(s):** Xavier Mariette (France), Diane van der Woude (Netherlands)

**Abstracts N°:** THU0182-THU0191


**THU0184**  IMPACT OF IMMUNOGENICITY ON CLINICAL EFFICACY AND ADMINISTRATION RELATED REACTION IN TNF INHIBITORS: A POOLED-ANALYSIS FROM THREE BIOLOGICAL STUDIES IN PATIENTS WITH RHEUMATOID ARTHRITIS / P. Emery* - M. Weinblatt - J. S. Smolen - E. Keystone - M. Genovese - J. Vencovsky - J. Kay - E. Hong - Y. Baek - J. Ghl


**THU0187**  CIRCULATING AUTOANTIBODIES AS INDICATORS TO PREDICT THE CLINICAL RESPONSE TO INFLIXIMAB IN RHEUMATOID ARTHRITIS / L. Lourido* - C. Ruiz-Romero - F. Picchi - C. Perez-Pampin - C. Regueiro - A. Mera-Varela - A. Gonzalez - K. Hambardzumyan - S. Saervaardottir - P. Nilsson - F. J. Blanco

**THU0188**  EFFICACY OF INFlixIMAB FOR SUPPRESSING RADIOGRAPHIC PROGRESSION OF CERVICAL LESIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON WITH METHOTREXATE, THREE YEARS OF FOLLOW-UP / A MULTICENTER REGISTRY STUDY / Y. Kanayama* - T. Kojima - Y. Hirano - N. Takahashi - N. Ishiguro on behalf of TBCR study group


**THU0190**  CLINICAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS RECEIVING ADALIMUMAB WHO DID OR DID NOT PARTICIPATE IN THE PATIENT SUPPORT PROGRAM: A SUBANALYSIS OF THE PASSION STUDY / A. Ostor* - S. Wassenberg - P. Zueger - J. Kalabic - M. Wu - I. Lagunes Galindo - F. van den Bosch


**THU0192**  RETENTION RATES FOR ETANERCEPT: COMPARING THE ORIGINAL WITH A BIOSIMILAR / A. Strangfeld* - L. Baganz - P. Herzer - J. Braun - A. Gräßler - A. Zink


**THU0195**  PREVALENCE OF OCCULT HEPATITIS B CARRIER STATUS AND ITS ASSOCIATED FACTORS IN PATIENTS WITH RHEUMATOID DISEASES UNDERGOING BIOLOGICAL THERAPIES / C. Mok* - L. Y. Ho - K. L. Chan - S. M. Tse - C. H. To

* Presenting author
THU0196
DO CONTEXTUAL FACTORS INFLUENCE SURVIVAL ON DRUG BIOSIMILARS IN CLINICAL PRACTICE? / D. Di Giuseppe* - T. Frisell - E. Lindqvist - L. Jacobsson - C. Turesson - C. Sjöwall - J. Askling on behalf of ARTIS group

THU0197
EFFECTS OF TOCILIZUMAB, AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, ON SERUM LIPID AND ADIPOKINE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Hoffman - M. A. Rahat - J. Feld - M. Elias - I. Rosner - L. Kaly - I. Lavi - D. Zisman*

THU0198
IMMUNOGENICITY ASSOCIATED WITH A TRANSITION FROM ADALIMUMAB REFERENCE PRODUCT TO ABP 501 IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Krishnan* - D. Mytch - N. Zhang - H. Wang - A. Kalliyaperumal

THU0199
A PILOT STUDY TO ASSESS THE RELATIONSHIP BETWEEN SMOKING AND DRUG INEFFECTIVITY IN RHEUMATOID ARTHRITIS - PART OF A QUALITY IMPROVEMENT PROJECT AIMED AT SMOKING CESSATION / G. Starritt* - D. Brennan

THU0200
SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS; A HIGH NUMBER OF PATIENTS ACHIEVE DOPPLER REMISSION AFTER 24 WEEKS / H. B. Hammer* - I. M. J. Hansen - P. Jarvinen - M. Leirisalo-Repo - M. Ziegelasch - B. Aguilar - L. Terslev

THU0201

THU0202

THU0203

THU0204
REAL WORLD EXPERIENCE OF BIOSIMILAR SWITCHING AT THE NORFOLK & NORWICH UNIVERSITY HOSPITAL, UNITED KINGDOM / L. Steel* - T. Marshall - M. Loke

THU0205

THU0206

THU0207

THU0208

THU0209

THU0210
SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH CSDMARDS IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE OSCAR STUDY / M. Safy* - M. J. De Hair - M. E. Born - M. R. Kok

THU0211

THU0212
REINVESTMENT OF BIOSIMILAR SAVINGS: WHAT ARE THE BEST OPTIONS? / M. Martin* - R. Campbell - J. Jacob

THU0213

THU0214
PREDICTIVE FACTORS FOR ACHIEVING LOW DISEASE ACTIVITY AT 52 WEEKS ARE DIFFERENT BETWEEN YOUNG AND ELDERLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT / N. Takahashi* - T. Matsubara - N. Ishiguro on behalf of the TBCR study group

THU0215

THU0216
SERUM CXCL16 LEVELS IN RF+/ACPA+ RHEUMATOID ARTHRITIS PATIENTS BEFORE AND AFTER TREATMENT WITH DMARDS / R. Ramamoorthy* - T. N. Tamilselvam - B. Kumar

THU0217

THU0218

THU0219

* Presenting author
THU0220
DISCONTINUATION OF BIOLOGIC DMARDS IN A REAL-LIFE POPULATION OF PATIENTS IN REMISSION: OUTCOME AND PREDICTORS / S. Arnold* - V. K. Jaeger - A. Scherer - U. A. Walker - D. Kyburz

THU0221

THU0222
MULTISWITCH - FROM REFERENCE PRODUCT ETANERCEPT TO BIOSIMILAR AND BACK AGAIN - REAL-WORLD DATA FROM A CLINIC-WIDE MULTISWITCH EXPERIENCE / V. Sigurdardottir* - A. Svárd

THU0223

THU0224

THU0225

THU0226
SERIAL INTERFERON-GAMMA RELEASE ASSAYS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGIC AGENTS / Y. J. Huang* - Y. F. Fang - Y. F. Chen - P. H. Tsai - C. F. Kuo - K. H. Yu - S. F. Luo

TOPIC: SPONDYLOARTHITIS - CLINICAL ASPECTS (OTHER THAN TREATMENT)

THU0227
SPINAL FRACTURE RISK IN ANKYLOSING SPONDYLITIS IN WESTERN AUSTRALIA / M. Oggnjenovic* - W. Raymond - H. Keen - C. Inderjeeth - D. Preen - J. Nosset

THU0228
ABSOLUTE REDUCTION OF PERIPHERAL CD4+CD25+FOX3+T REGULATORY CELLS IN PATIENTS WITH SPONDYLOARTHROPATHY-RELATED OCLUSION / X. Liu* - G. Chai - Y. Duan - C. Gao - X. Li

THU0229

THU0230

THU0231

THU0232

THU0233

THU0234

THU0235

THU0236

THU0237
ULTRASONOGRAPHIC EVALUATION OF DISTAL PATELLAR ENTHESIS IN PATIENTS AFFECTED BY ENTHEROPATIC SPONDYLOARTHROPATHY-RELATED OCULOPATHY / X. Liu* - G. Chai - Y. Duan - C. Gao - X. Li

THU0238

THU0239
CLINICAL OUTCOMES OF ABATACEPT VERSUS TNF INHIBITORS IN ACPA-POSITIVE PATIENTS WITH RHEUMATOID ARTHRITIS AND PREDICTORS / S. Arnold* - V. K. Jaeger - A. Scherer - U. A. Walker - D. Kyburz

THU0240
THE SIZE AND FREQUENCY OF BONE MARROW EDEMA ON SACROILIAC JOINT MRI DIFFERS IN A CLUSTER-WISE DESIGN / S. Ramiro - R. Landewé - M. Dougados - D. van der Heijde

THU0241

THU0242

* Presenting author

THU0244  HIGH PREVALENCE OF CLINICAL SPONDYLOARTHRITIS FEATURES IN PATIENTS WITH HIDRADENITIS SUPPURATIVA / A. Rondags - K. R. van Straalen - S. Arends - H. H. van der Zee - E. Prens - B. Horvath - A. Spoorenberg*


THU0248  ASSOCIATION OF KINESIOPHOBIA, AEROBIC FUNCTIONAL EXERCISE, FUNCTIONAL IMPAIRMENT AND DISEASE ACTIVITY OF PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS / D. Peres - N. Tordi - Y. Sagawa - D. Wendling - C. Prati*

THU0249  MORE THAN 60% PATIENTS WITH SPONDYLOARTHRITIS REPORT PERIPHERAL MANIFESTATIONS: AN ANCILLARY ANALYSIS OF THE ASAS-COMOSPA STUDY / C. López-Medina* - A. Moltó - M. Dougdos


THU0253  THE CHRONIC SPINAL PAIN IN SPONDYLOARTHRITIS, OSTEARTHRITIS, AND FIBROMYALGIA: THE ROLE OF CENTRAL SENSITIZATION / F. F. Ayhan* - O. F. Celek - M. A. Gulü

THU0254  RELATION BETWEEN SUBCLINICAL ULTRASONOGRAPHIC CHANGES OF THE ANTERIOR CHEST WALL JOINTS AND PULMONARY FUNCTION TESTS IN AXIAL SPONDYLITIS PATIENTS / F. I. Abdelrahman* - M. Mortada - W. Mansour - A. B. Abdulsattar

THU0255  LOW BONE MINERAL DENSITY IS COMMON IN AXIAL SPONDYLOARTHRITIS / G. Fitzgerald* - T. Anachebe - F. O’ Shea


THU0257  ASSOCIATIONS BETWEEN TRABECULAR BONE SCORE AND VERTEBRAL FRACTURES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / H. R. Kim* - Y. S. Hong - K. Y. Kang


THU0261  CAN PATIENTS WITH SPONDYLOARTHRITIS BE IDENTIFIED IN THE PRIMARY CARE SETTING? / A. Spoorenberg*

THU0262  IDENTIFYING PATIENTS WITH AXIAL SPONDYLOARTHRITIS FROM A COHORT OF PATIENTS WITH CHRONIC BACK PAIN IN ORTHOPEDICS CARE (AWAIRE STUDY) / J. Braun* - T. Mosch - I. Fischer - U. Kütz


THU0264  IMPACT OF EXTRA-ARTICULAR MANIFESTATIONS ON PATIENT-REPORTED OUTCOMES IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: INTERIM RESULTS FROM THE COMPLETE STUDIES / L. Bessette* - J. Sieper

THU0265  PATIENTS WITH AXIAL SPONDYLOARTHRITIS RARELY HAVE 1 OR 2 INFLAMMATORY BACK PAIN PARAMETERS / M. de Hooge* - G. V. Varkas - D. Elewaut - F. van den Bosch


Chair(s): Filip van den Bosch (Netherlands), Laura Coates (United Kingdom)

THU0269

THU0270
The Propensity to Fat Metaplasia of Sacroiliac Joint in Spondyloarthritis: Results from the Single Regional Center Cohort / S. Y. Lee* - S. W. Lee - W. T. Chung - J. W. Jung

THU0271

THU0272

THU0273
Prevalence of Vertebral Fractures in Ankylosing Spondylitis: A Meta-Analysis / J. Sahuguet - J. Mancini - P. Laftorge - T. Pham*

THU0274

THU0275

THU0276

THU0277

THU0278
Serum Calprotectin is Correlated with Disease Activity in Early Axial Spondyloarthritis but Does Not Predict Radiographic Progression at 2 Years: Results from the Desir Cohort / X. Romand* - M. H. Paclet - A. Courtier - M.-V.-C. Nguyen - F. Berenbaum - D. Wendling - P. Gaudin - A. Baillet

THU0279
Gender Difference in Psychological Status and Sleep Quality in the Patients with Ankylosing Spondylitis / Y. Jiang* - Q. Lv - J. Qi - D. Huang - X. Zhang - M. Yang - Y. Zhang - J. Gu

TOPIC: PSORIATIC ARTHRITIS

Poster tour T7: The impact of treatment on the burden of psoriatic disease

Chair(s): Filip van den Bosch (Netherlands), Laura Coates (United Kingdom)

Abstracts N°: THU0280-THU0289

THU0280
Early and Long-Term Treatment Response as Well as High Tolerability Lead to High Treatment Satisfaction of a Therapy with Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Non-Interventional Study Sustain / J. Wendler - E. Movahovich - J. Behrens - F. Hamann - P. Wagener - F. Behrens*

THU0281

THU0282
The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PSA) Attending Rheumatology Clinics / C. Fernández-Carballido* - W. P. Maksymowych - R. G. Lambert

THU0283
Patients with Psoriatic Arthritis who are Not Eligible for Randomised Clinical Trials for the Inhibitors have Similar Treatment Response and Drug Survival. Results from the ICEBio Registry / O. Palsos - B. Guðbjörnsson - G. A. Johannsdottir - A. Gunnarsdottir - P. S. Gunnarsson - T. J. Love - E. Rúnarsdóttir

THU0284

THU0285

THU0286

* Presenting author


THU0290  EFFECTS OF BIOLOGIC DMARDS ON PHYSICAL FUNCTION IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF NETWORK META-ANALYSES / A. Ruyssen-Witrand* - C. Capin - S. Hartz - S. Liu Leage

THU0291  INCIDENCE OF SERIOUS GASTROINTESTINAL EVENTS AND INFLAMMATORY BOWEL DISEASE AMONG TILORAKIZUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: DATA FROM 3 LARGE RANDOMISED CLINICAL TRIALS / M. Gooderham - B. E. Elewski - D. M. Pariser - H. Sofen - A. M. Mendelsohn* - N. Cichanowitz - Q. Li - C. La Rosa


THU0295  FACTORS-associated WITH PATIENT-PHYSICIAN DISCORDANCE IN A PROSPECTIVE COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS: AN ASIAN PERSPECTIVE / C. Wang* - Y. H. Kwan - W. Fong - S. Q. Xiong - Y. Y. Leung


THU0301  A NOVEL ROLE FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE (PSAID) / K. Johnson - J. Ye - V. Chandran - D. Gladman*


THU0303  THE EARLY PSORIATIC ARTHRITIS SCREENING QUESTIONNAIRE IDENTIFIES PATIENTS WITH PSORIATIC ARTHRITIS AMONGST TREATED PATIENTS WITH PSORIASIS / K. Nadeau - F. Briggs - S. O'Neill - D. Sumpton - G. Cains - J. Woods - D. Chessman*


THU0307  QT INTERVAL AND ITS CORRELATIONS WITH TRADITIONAL RISK FACTORS OF DEVELOPMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH ACTIVE EARLY PSORIATIC ARTHRITIS / E. Markelova* - D. Novikova - T. Korotava - I. Kirilova - E. Loginova


* Presenting author

THU0311 IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM TWO PHASE 3 STUDIES (FUTURE 2 AND FUTURE 3) / J. K. Walliman* - G. Schett - I. B. McInnes - E. Quebe-Fehling - L. Rasouliyan - L. Pricop - A. E. Fasth - C. Gaillez on behalf of the FUTURE 2 and FUTURE 3 study groups


THU0314 IXEKIZUMAB MAKES VERY LOW DISEASE ACTIVITY AND REMISSION WITH PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS FOR UP TO 1 YEAR: SPIRIT-P1 AND SPIRIT-P2 TRIALS / L. C. Coates* - M. E. Husni - E. Lespessailles - L. Kerr - G. Gallo


THU0316 GENDER DIFFERENCES IN BIOLOGIC TREATMENT OUTCOMES - A STUDY OF 1750 PATIENTS WITH PSORIATIC ARTHRITIS USING DANISH HEALTH CARE REGISTERS / P. Højgaard - C. Ballegaard - R. Cordtz - K. Zobbe - M. Clausen - L. E. Kristensen - B. Glintborg - L. Dreyer


THU0319 OVERALL SAFETY OF 7-WEEK SECUKINUMAB EXPOSURE DURING PREGNANCY IN WOMEN WITH PSORIATIC ARTHRITIS / M. Meroni* - E. Generali - M. G. Guidelli - M. Parodi - M. Cutolo - C. Selmi

THU0320 A SHORT, EASILY READABLE, ONLY 3-ITEM TOOL - BRISTOL RHEUMATOID ARTHRITIS FATIGUE SCALE (BRAF) - IS VALID IN PATIENTS WITH PSORIATIC ARTHRITIS / M. Haroon* - K. Iqbal - M. Ashraf - P. Gallagher - O. FitzGerald

THU0321 ACUTE PHASE MARKERS IN PSORIATIC ARTHRITIS IDENTIFY PATIENTS WITH A MORE SEVERE PHENOTYPE / M. Haroon* - M. Ahmad - O. Mason - O. FitzGerald

THU0322 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 FUTURE 2 STUDY / P. Nash* - I. B. McInnes - P. Rahman - A. B. Gottlieb - B. Kirkham - K. Ding - L. Pricop on behalf of the FUTURE 2 study group


THU0326 DISCONTINUATION AND SWITCHING PATTERNS OF TUMOR NECROSIS FACTOR INHIBITOR (TNFI) THERAPY IN TNFI-NAIVE AND TNFI-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS/SPONDYLOARTHITIS (PSA/SPA) REGISTRY / P. Mease* - M. Liu - B. Gerhansen - P. Hur - J. Greenberg

THU0327 REAL WORLD (RW) EXPERIENCE WITH AN ANTI-IL-17A INHIBITOR IN BIOLOGIC NAÏVE AND BIOLOGIC EXPERIENCED PSORIATIC ARTHRITIS (PSA) PATIENTS / R. Moon* - J. Hill - N. Booth - S. Lobosco

THU0328 MIR-499 POLYMERPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO PSORIATIC ARTHRITIS - PRELIMINARY STUDY / R. Sokolik* - J. Swierkot - M. Iwaszko - M. Kozlowski - L. Korman - P. Wiland - K. Bogunia-Kubik

THU0329 AN ITALIAN OBSERVATIONAL PROSPECTIVE STUDY ON PREDICTORS OF CLINICAL RESPONSE TO GOLIMUMAB AT 6 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS / R. Scrivo* - A. Giardino - C.Salvarani - R. Foti - A. Afeltra - O. Viapiana - F. Salaffi - F. Iannone on behalf of the Predicting MDA in PsA study group


THU0331 RELATIONSHIP BETWEEN THE NAIL ULTRASONOGRAPHIC EVALUATIONS AND CLINICAL FEATURES IN PATIENTS WITH PSORIATIC ARTHRITIS / S. Acer* - H. S. Baklacıoğlu - D. Erdem - M. T. Duruöz


THU0333 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1) / V. Chandran* - R. Fleischmann - E. Lespessailles - P. S. Hellwell - O. Benichou - J. Erickson - C. Shuler

* Presenting author
TOPIC: SLE, SJÖGREN’S AND APS - CLINICAL ASPECTS (OTHER THAN TREATMENT)

Poster tour T8: Cardiovascular co-morbidities in SLE

THU0334
PATTERNS OF ASPIRIN USE IN SLE PREGNANCIES WITHIN A MULTINATIONAL INCEPTION COHORT AND RELATIONSHIP TO PREECLAMPSIA RISK FACTORS / A. Mendel* - S. Bernatsky - E. Vinet on behalf of SLICC Investigators

THU0335
FACTORS ASSOCIATED WITH DEVELOPMENT AND MORTALITY OF PULMONARY HYPERTENSION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / J. S. Kim* - D. Kim - Y. B. Joo - S. Won - J. Lee - J. Shin - S. C. Bae

THU0336

THU0337
NONBACTERIAL THROMBOTIC ENDOCARDITIS (NBTE) IN SLE: PREVALENCE, CLINICAL CHARACTERISTICS AND SEROLOGICAL PROFILE / D. V. Tannai* - M. Bindroo - D. Raval - W. Kazi - S. Bajaj - R. Gupta

THU0338
OUTCOME OF STROKE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A NESTED CASE-CONTROL STUDY / L. K. Tsai - C. C. Mok* - Y. P. Fu

THU0339

THU0340
PROLONGED REMISSION IS ASSOCIATED WITH A REDUCED RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / S. Fasano* - D. P. Margiotta - L. Pierro - A. Riccardi - A. Afeiira - G. valentini

THU0341
LOW VITAMIN D IS ASSOCIATED WITH THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS / M. Petrini* - W. Fu - D. W. Goldman

THU0342

THU0343

THU0344

THU0345
SENSITIVITY AND SPECIFICITY OF ANTIBODIES AGAINST CARBAMYLATED PROTEINS IN A MONOCENTRIC COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERITAMATOSUS AND RHEUMATOID ARTHRITIS / B. Özdemir* - O. Kucuksaahin - T. H. Yeşil - S. Akan - S. Erten

THU0346
DETERMINANTS OF SONOGRAPHIC GLANDULAR DAMAGE IN A LARGE COHORT OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME AND ITS IMPACT ON SALIVARY GLAND DYSFUNCTION / C. Baldini* - N. Luciano - F. Ferro - E. Calabresi - E. Elefante - V. Donati - S. Bombardieri - M. Mosca

THU0347
AQUAPORIN-4 IMMUNOGLOBULIN G ANTIBODY POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER AND SYSTEMIC AUTOIMMUNE DISEASES OVERLAP SYNDROME: A SINGLE CENTER EXPERIENCE / E. Martin Nares* - G. Hernández Molina - H. Fragoso Loyo

THU0348
TIME ON DIALYSIS ADVERSELY AFFECTS RENAL TRANSPLANT OUTCOME IN LUPUS NEPHRITIS / E. Ntanuki* - V. Vassiliou - A. Velo Garcia - A. D. Salama - D. A. Isenberg

THU0349
ANTIBODIES TO PHOSPHATIDYLSERINE-PROTHROMBIN COMPLEX AND ANNEXIN V AS RISK FACTORS FOR THE DEVELOPMENT OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / E. Belolipetskaia* - I. Beliaeva - V. Mazurov - S. Lapin - O. Tkachenko - V. Guseva - O. Inamova

THU0350

THU0351

THU0352

THU0353

THU0354

THU0355
SAFETY AND TOLERABILITY OF SLE-200: A PROSPECTIVE STUDY OF A FAST TRACK APPROACH TO SURGERY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / I. Padjen* - M. Eroeg - M. Cerovec - M. Bakula - M. Mayer - R. Stevanovic - B. Anic

* Presenting author


THU0360 A VALIDATION STUDY OF THE GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE (GAPSS) IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND PREGNANCY MORBIDITY / K. Schreiber* - M. Radin - I. Cecchi - M. M. Cuadrado - L. Marzo - D. Roccatello - S. Sciascia

THU0361 CHARACTERIZATION OF NOVEL AUTOANTIBODIES TO AHNAK1 SPECIFICALLY PRESENTED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / K. Nozawa* - Y. Matsuhashi - K. Do - Y. Takasaki - K. Yamaji - N. Tamura


THU0365 POTENTIAL PREDICTIVE FACTORS INFLUENCING ESSDAI OF PRIMARY SJÖGREN'S SYNDROME PATIENTS / M. Maślinska* - J. Dmowska-Chalaba - M. Mariczak - B. Kwiatkowska

THU0366 STUDY OF THE ROLE OF MICRO-RNA 20A EXPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS IN AN EGYPTIAN COHORT / M. S. Elkhafifa - M. Zehairy - M. Tayel - M. Yehia - D. Eiber - D. Alkhaffash - N. Baddour


THU0369 CREATION OF A WEIGHTED SLICC SLE CLASSIFICATION CRITERIA AND COMPARISON WITH PROPOSED EULAR/ACR SLE CLASSIFICATION CRITERIA / M. Petri* - D. W. Goldman - L. S. Magder on behalf of SLICC

THU0370 THE SIGNIFICANCE OF NON-MYDRIATIC FUNDS EXAMINATION OPERATED BY RHEUMATOLOGISTS IN SCREENING FOR RETINOPATHY OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / M. Yang* - Q. Lv - Z. Lin - J. Qi - X. Guo - J. Gu

THU0371 CORRELATION BETWEEN IRREGULAR MENSTRUATION AND DISEASE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS: 1 YEAR COHORT STUDY / N. Oguro* - N. Yajima - M. Saito


THU0373 THE MARKERS USEFUL IN PREDICTING LUPUS NEPHRITIS IN CLINICAL PRACTICE / P. Dąbrowski* - K. Marczak - A. Gala-Bądzińska - K. Gargasz - M. Dąbrowska

THU0374 FACTORS ASSOCIATED WITH HIGH-DOSE CORTICOSTEROID USE IN SLE PATIENTS AFTER INITIATION OF SLE THERAPY / K. Schroeder - J. Paik - R. W. Hoffman* - S. Geilwicks


THU0376 CHARACTERISTICS OF PRIMARY SJÖGREN'S SYNDROME PATIENTS WITH MORPHOLOGICAL CHANGES OF THE PAROTID GLANDS IN MR IMAGING / S. Shkireeva* - O. M. Lesnyak - E. G. Zotkin

THU0377 WIRE-LOOP LESION IS ASSOCIATED WITH SEROLOGICAL IMMUNE ABNORMALITY, BUT NOT RENAL PROGNOSIS IN LUPUS NEPHRITIS / T. Zhoshima* - S. Haru - M. Kawano


THU0380 HIGH LEVELS OF CIRCULATING TYPE I, II AND III INTERFERONS DEFINE DISTINCT PATIENT SUBSETS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / A. C. Venhoff - I. Jandova - R. E. Volland - J. Thiel - N. Venhoff*

THU0381 CHARACTERIZATION OF NOVEL AUTOANTIBODIES TO AHNAK1 SPECIFICALLY PRESENTED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / K. Nozawa* - Y. Matsuhashi - K. Do - Y. Takasaki - K. Yamaji - N. Tamura

THU0382 FATIGUE IN CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: CONTRIBUTING FACTORS AND EFFECTS ON THE QUALITY OF LIFE / X. Du* - Y. Zhuang - Q. Zhao - H. Chen - B. Shen

THU0383 PERFORMANCE OF MUSCULOSKELETAL INVOLVEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: AN ULTRASOUND STUDY IN 114 PATIENTS / Y. Geng*

THU0384 SALIVARY GLAND ULTRASONOGRAPHY AND STIMULATED SALIVARY FLOW CORRELATED WITH SALIVARY GLAND BIOPSY AMONG PATIENTS WITH SJÖGREN SYNDROME AND SICCA SYMPTOMS: EXPERIENCE FROM A SINGLE MEDICAL CENTER IN TAIWAN / Y. P. Tsao* - M. H. Chen - S. Y. Wu - C. Y. Wu - W. S. Chen - C. C. Lai - C. Y. Tsai


* Presenting author
TOPIC: SCLENDERMATA, MYOSITIS AND RELATED SYNDROMES

Poster tour T9: SSc, myositis, related syndromes - a bouquet of surprises

Chair(s): Ulf Müller-Ladner (Germany), Peter Korsten (Germany)

Abstracts N°: THU0387-THU0396

THU0387
HIGH-THROUGHPUT QUANTITATIVE HISTOLOGY IN SYSTEMIC SCLEROSIS SKIN DISEASE USING COMPUTER VISION / C. Correa* - M. Hinchcliff - M. Mahoney

THU0388

THU0389

THU0390

THU0391
CLINICAL VALUE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ESOPHAGEAL DysMOTILITY IN SYSTEMIC SCLEROSIS / C. Sobrino Grande* - C. Pijuan Moratalla - N. Almeida Arostegui - L. Goro spo Sarasúa - C. de la Puente Bujidos

THU0392

THU0393

THU0394

THU0395
INFLUENCE OF SETTING UP AN UPPER LIMIT OF THE MRSS AS AN INCLUSION CRITERION IN SSC CLINICAL TRIALS ON THE RATIO OF SKIN FIBROSIS PROGRESSION VS. IMPROVEMENT - AN ANALYSIS OF THE GENIROS COHORT / C. Miha* - R. Dobrota - S. Assassi - M. Mayes - O. Distler on behalf of GENIROS collaboration

THU0396

THU0397
THE PROGNOSTIC VALUE OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS AND A TWO-YEAR FOLLOW-UP OF FORCED VITAL CAPACITY / A. A. Mohamed* - M. Hassanien

THU0398
UNEXPLAINED IRON DEFICIENCY IS FREQUENT IN SYSTEMIC SCLEROSIS / A. Sari* - A. Gill - S. I. Nihtyanova - V. H. Ong - C. P. Denton

THU0399

THU0400

THU0401

THU0402

THU0403

THU0404

THU0405
THE ASSOCIATION BETWEEN BASELINE SERUM RESISTIN LEVELS AND THE DEVELOPMENT OF NEW DIGITAL ULCERS IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS / F. Pignataro* - D. P. E. M. G. Danieli - A. Capucci - A. Gabrielli

THU0406

THU0407
EVALUATION OF SOLUBLE AND MEMBRANE HLA-G IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ROLE OF THESE MOLECULES IN THE PATHOGENESIS OF THE DISEASE / G. Murdaca* - P. conti ni - S. Negri ni - M. Borro - F. Puppo

* Presenting author


THU0410  SURVIVAL OF PATIENTS WITH MUSCLE BIOPSY PROVEN IDIOPATHIC INFLAMMATORY MYOPATHY BASED ON A STUDY IN A TERTIARY UNIVERSITY CENTRE / K. Gulyás* - E. Pál - T. Minier - T. Berki - L. Czirjak - C. Varju


THU0412  ABSOLUTE REDUCTION OF PERIPHERAL CD4+ REGULATORY T CELL SUBSET OF PATIENTS WITH SYSTEMIC SCLEROSIS AND ITS RESTORATION BY SHORT-TERM AND LOW DOSE IL-2 TREATMENT / L. Shang* - J. Yuan - Q. Li - X. Liu - J. Luo - C. Gao - X. Li - H. Gao

THU0413  NORMALIZATION OF NAILFOLD MICROFLUORESCENCE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SEVERE SYSTEMIC SCLEROSIS / M. Boonstra* - D. C. Noordhoek - L. J. Beaart-van de Voere - T. W. Huizinga - J. K. de Vries-Bouwstra


THU0419  ASSOCIATION OF INFLAMMATORY MARKERS C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION RATE WITH PULMONARY FUNCTION TESTS AND EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX (ECSG-AI) IN SYSTEMIC SCLEROSIS - ASSOCIATED INTERSTITIAL LUNG DISEASE IN FOLLOW UP STUDY / O. B. Ovsyannikova* - O. Koneva - L. Ananieva


THU0421  PREVALENE AND CLINICAL CORRELATES OF SMALL AIRWAY OBSTRUCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS / K. Gulyás* - M. Vujovic - A. Blanka Protic

THU0422  PERFORMANCE OF EULAR/ACR 2017 IDIOPATHIC INFLAMMATORY MYOPATHIES CLASSIFICATION CRITERIA IN A REAL WORLD COHORT / R. A. Gómez - A. Braillard Pocard - M. Pino - G. Medina - D. Dubinsky


THU0426  ETHNIC VARIATION IN SYSTEMIC SCLEROSIS MORBIDITY AND MORTALITY / H. Al-Sheikh - Z. Ahmad - S. R. Johnson

THU0427  COMPARABLE CARDIOVASCULAR DISEASE VERSUS NEOPLASM RATES BUT HIGHER FREQUENCY OF DEPRESSION IN SYSTEMIC SCLEROSIS VERSUS RHEUMATOID ARTHRITIS: A MULTICENTRE COMPARATIVE STUDY OF COMORBIDITIES / S. Panopoulos* - M. G. Marrazza - A. Mazzzone - M. G. Marrazza - A. Mazzzone

THU0428  SKIN CHANGE SCORES IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) PATIENTS ARE ASSOCIATED WITH OVERALL DISEASE SEVERITY / T. Nevskaya* - M. Barón - B. Zhong - C. A. Baxter - D. R. Ramey - X. Lian - M. Remy Jardin

* Presenting author
TOPIC: VASCULITIS

THU0433


THU0434


THU0435


THU0436

INCIDENCE, INCAPACITY, MORTALITY AND CHRONIC RENAL DAMAGE OF ANCA-ASSOCIATED GLOMERULONEPHRITIS IN A 20 YEAR POPULATION-BASED COHORT / A. Berti* - E. Corne-C-Le Gall - D. Corne - E. Matteson - C. S. Crowson - S. Sethi - F. Fervenza - U. Specks

THU0437


THU0438


THU0439


THU0440


THU0441

ENDOTHELIAL DISFUNCTION IN POLYMYALGIA RHEUMATICA / D. Birra* - L. Santoro - S. Bosello - A. Nesci - M. Bagnasco - M. A. Cimmino - D. Saverino

THU0442


THU0443

A PROBABILITY SCORE FROM A FAST TRACK CLINIC TO AID THE MANAGEMENT OF SUSPECTED GIANT CELL ARTERITIS / F. Laskou* - F. Coath - S. Mackie - S. Banerjee - T. Aung - B. Dasgupta

THU0444


THU0445


THU0446


THU0447


THU0448


THU0449

DIAGNOSTIC PERFORMANCE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN A COHORT OF UNSELECTED SPANISH PATIENTS / J. Loreiro-Amigo* - J. Mestre Torres - C. L. Franco Jarava - A. Marín Sánchez - R. Solans Laquè

THU0450


THU0451


THU0452


THU0453


* Presenting author

THU0455 AGE IS MORE CLOSELY ASSOCIATED WITH POSITIVE TEMPORAL ARTERY BIOPSY OVER BIOPSY LENGTH IN LARGE VETERANS ADMINISTRATION DATABASE STUDY / M. B. Morcos* - S. Chung - B. Ng

THU0456 THE CLINICO-HISTOPATHOLOGICAL ALGORITHM FOR DIFFERENTIAL DIAGNOSIS OF BUERGER’S DISEASE, TAKAYASU ARTERITIS AND ATHEROSCLEROTIC OCCLUSIVE DISEASE / M. Bagriy* - O. Zimba


THU0461 COMPARISON BETWEEN CLINICAL PROFILE AND OUTCOME OF PATIENTS WITH JUVENILE ONSET AND ADULT ONSET TAKAYASU ARTERITIS / R. A. Goel* - D. Danda - G. Joseph - A. Nair - R. Ravindran - V. Jeyaseelan

THU0462 LONG-TERM FOLLOW-UP RESULTS OF TAKAYASU ARTERITIS COHORT: A TERTIARY-SINGLE CENTER STUDY / S. Kaynayz Tahra* - F. Alibaz-Onar - H. Diresskeneli


THU0464 INCREASED FREQUENCY OF OBSTRUCTIVE SLEEP APNEA SYNDROME IN BEHCET’S SYNDROME PATIENTS WITH VENA CAVA SUPERIOR THROMBOSIS / A. Gokturk - S. N. Esatoglu* - Y. Ozguler - E. Atahan - B. Musellim - V. Hamuryudan - H. Yazici - E. Seyahi


THU0466 SEXUAL DISFUNCTION AND DEPRESSION IN BEHCET’S DISEASE - ARE THERE DIFFERENCES REGARDING PATIENT’S ORIGIN / T. Kenitidis* - A.-C. Pecher - T. Schmalen - M. Henes - J. C. Henes


THU0468 SERUM ANGIOGENESIS BIOMARKERS PREDICT DISEASE OUTCOME IN GIANT CELL ARTERITIS / Y. van Sleen* - M. Sandovici - W. Abdullahad - J. Bizzet - A. Boots - E. Brouwer

TOPIC: OSTEOPOROSIS

Poster tour T10: New data on osteoporosis and fracture prevention
Chair(s): Piet Geusens (Netherlands), Sandrine Bours (Netherlands)
Abstracts N*: THU0469-THU478


THU0471 RISK FACTORS OF LOW BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC SCLEROSIS / S. V. Rajkumar

THU0472 FACTORS ASSOCIATED WITH READINESS FOR ADOPTING OSTEOPOROSIS TREATMENT CHANGE / M. I. Danila* - D. Monova - M. Stambolova - R. Shumnalieva


THU0477 FACTORS ASSOCIATED WITH THE INITIATION OF TREATMENT AFTER FRAILITY FRACTURE IN A FRACUTURE SERVICE / A. Saavedra* - A. Naranjo - S. Ojeda - R. Lopez - A. Molina - C. Alonso - I. Bernardino - C. Rodríguez-Lozano


* Presenting author


THU0481 PHYSICAL PERFORMANCE FACTORS INFLUENCING GAIT SPEED IN PATIENTS SURGICALLY TREATED FOR OSTEOPORTORIC HIP FRACTURES / B. R. Kim

THU0482 RELATIONSHIP BETWEEN MILD VERTEBRAL BODY DEFORMITY AND KELLOGREN-LAWRENCE’S OSTEOARTHRITIS LEVEL WITH THE PREVALENCE OF NON-TRAUMATIC DORSAL AND LUMBAR BACK PAIN IN FEMALE PATIENTS WITH RISK OF OSTEOPORTORIC VERTEBRAL COLLAPSE / C. A. Guillen-Astete* - C. Ijoán - J. R. Quiñones-Torres - M. Vázquez Díaz


THU0486 THE VITAMIN D RECEPTOR EXPRESSION IN SKELETAL MUSCLE OF WOMEN WITH DISTAL RADIUS FRACTURE / H. S. Gong* - K. Kim

THU0487 AN AUDIT OF THE USE OF PERCUTANEOUS VERTEROPLASTY FOR OSTEOPORTORIC VERTEBRAL fractures IN A UK RHEUMATOLOGY CLINIC / J. Pinnell* - H. Mennis - M. Dhillon - K. Chauhuri

THU0488 AGE AT THE TIME OF HIP FRACTURE IN PATIENTS WITH RHEUMATOID ARTHRITIS IS GREATER THAN IT WAS 10 YEARS AGO, BUT IS STILL YOUNGER THAN THAT OF THE GENERAL POPULATION / K. Arai* - J. Ajiro


THU0492 PRELIMINARY STUDY OF THE BONE MASS IN LUNG TRANSPLANTED PATIENTS IN TREATMENT WITH DENOSUMAB / M. Barceló-Bru* - B. Rodríguez-Diez

THU0493 ARE BISPHOSPHONATES SOLELY RESPONSIBLE FOR ATYPICAL FEMORAL FRACTURES? A CASE SERIES / M. S. Jamali* - C. Cockill - S. Knights


THU0496 SKELETAL DEFICIT DUE TO ALTERED BONE QUALITY IN TYPE 1 DIABETES MELLITUS / S. Mohsin* - J. J. Sunny - K. Menon - S. Kaimala on behalf of CMHS, UAEU


THU0498 CORE ENDURANCE AND POSTURAL STABILITY IMPAIRMENTS IN OSTEOPORTORIC WOMEN: A CASE-CONTROL STUDY / S. Toprak Celenay* - D. Ozier Kaya


THU0500 EFFECTS OF LONG-TERM USE OF UNFRACTIONATED HEPARIN (UFH) OR LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) ON BONE MINERAL DENSITY (BMD) IN PATIENTS WITH NEPHROTIC SYNDROME / S. V. Monov* - D. Monova - R. Shumalleva


THU0505 INFLUENCE OF ORAL BISPHOSPHONATE ON EFFECT OF DENOSUMAB ON OSTEOPORTORIS IN PATIENTS WITH JAPANESE RHEUMATOID ARTHRITIS; 36 MONTHS OF FOLLOW-UP - A MULTICENTER REGISTRY STUDY / Y. Kanayama* - Y. Hirano - N. Takahashi - S. Asai - N. Ishiguro - T. Kojima on behalf of TBCR-BONE study group

* Presenting author
TOPIC: FIBROMYALGIA


THU0507 HETEROGENEITY OF FIBROMYALGIA: PSYCHOPATHOLOGICAL CHARACTERISTICS OF DIFFERENT SUBTYPES AND EFFICACY OF THERAPY / A. Sarapulova* - O. Teplyakova

THU0508 EVALUATION OF TISSUE SPECIFIC AUTOANTIBODIES IN FIBROMYALGIA PATIENTS WITH SICCA AND/OR XEROSTOMIA / E. Applbaum* - A. Lichtbroun


THU0510 HYPERSENSITIVITY, ALEXITHYMIA AND DISEASE CHARACTERISTICS OF PATIENTS PRESENTING WITH SYMPTOMS OF FIBROMYALGIA / H. Jacobs* - B. A. Grillet - D. De Bacquer

THU0511 HYPERBARIC OXYGEN THERAPY (HBOT) TREATMENT IN FIBROMYALGIA / M. Muratore* - L. Quarta - P. Sarzi Puttini - G. Cosentino - A. Grimaldi - E. Quarta

THU0512 IS THERE A ROLE OF SERUM NESFATIN-1 LEVEL IN FIBROMYALGIA? / B. Bilgici - Y. Akyol - Y. Ulus - S. S. Urkmez - O. Kuru*


THU0514 EFFECTS OF ADD-ON TRANSCRANIAL DIRECT CURRENT STIMULATION ON PAIN IN KOREAN PATIENTS WITH FIBROMYALGIA / J.-H. Kang* - K.-E. Lee - D.-J. Park - S.-S. Lee

THU0515 SOMATOSENSORY TEMPORAL DISCRIMINATION IS IMPAIRED IN FIBROMYALGIA / Z. Gunendi* - M. Polat - D. Vurallı - B. Cengiz

Poster tour T11: Pain in the joint; managing a widespread problem

Chair(s): David Walsh (United Kingdom), Francesco Carubbi (Italy)

Abstracts N°: THU0516-THU0525


THU0520 ASSESSMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH FIBROMYALGIA BY CAROTID-FEMORAL PULSE WAVE VELOCITY - RESULTS OF A PROSPECTIVE STUDY / K. Triantafyllias* - M. Stortz - M. de Blasi - C. Leistner - J. Weinmann-Menke - A. Schwarting

THU0521 A SIMPLE INDEX BASED ON SCORES ON A MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE (MDHAQ) PROVIDES INFORMATION QUITE SIMILAR TO ACR CRITERIA FOR FIBROMYALGIA IN ROUTINE CARE / J. Schmukler - I. Castrejon - T. Pincus*

TOPIC: BACK PAIN, MECHANICAL MUSCULOSKELETAL PROBLEMS, LOCAL SOFT TISSUE DISORDERS

THU0522 EXPERIMENTAL TENDINOPATHY TREATMENT WITH SM04755, A TOPICAL SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY / V. Deshmukh* - T. Seo - Y. Yazici

THU0523 DO WE NEED STEROID INJECTION AFTER ULTRASOUND GUIDED PERCUTANEOUS LAVAGE OF A ROTATOR CUFF CALCIFICATION? RESULTS AT 3 MONTHS OF A DOUBLE BLINDED RANDOMISED CONTROLLED STUDY / C. Darrietrot-Laffite* - S. Varin - G. Coiffier - J.-D. Albert - G. Cormier - B. Le Goff

THU0524 IS THERE ANY EFFECT OF KINESIOTAPING ON RADIAL NERVE IN PATIENTS WITH UNILATERAL LATERAL EPICONDYLITIS? A RANDOMISED- SINGLE BLIND STUDY / B. Mansiz-Kaplan* - S. Vural - O. F. Celik - H. Genc

THU0525 EFFECT OF LOCAL INSULIN INJECTION IN THE TREATMENT OF MILD TO MODERATE CARPAL TUNNEL SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS / S. R. Kamel - H. A. Sadek - O. A. Sayed

THU0526 ACUTE PARASPINAL MUSCLE NECROSIS WITH CRACK COCAINE AND HEROIN: A CASE REPORT / A. Masood* - L. Attipoe - D. D’Cruz - S. Al-Saraj - S. Williams - K. Sabzevari

THU0527 EFFECTS OF MANUAL THERAPY, SACROILIAC AND LUMBAR EXERCISES IN PATIENTS WITH SACROILIAC JOINT DYSFUNCTION SYNDROME / A. Javadov - A. Ketenci

THU0528 THE RELIEF OF CHRONIC LOW BACK PAIN (CLBP) IMMEDIATELY AFTER ONE SESSION OF LOW LEVEL LASER ACUPUNCTURE THERAPY (LLAT) / D. Houssien* - A. Houssien

* Presenting author

THU0530 CHRONIC LOW BACK PAIN AND DEPRESSION: SIGNIFICANT DECREASE WITH GLUCOSAMINE-CHONDROITIN SULFATE TREATMENT IN A LARGE, COMMUNITY-BASED, PILOT, OPEN PROSPECTIVE INTERVENTIONAL STUDY / G. Singh* - L. Alexeeva - D. Goryachev - A. Barinov - A. Mithal


THU0532 TO ASSESS WHETHER THERE IS AN ASSOCIATION BETWEEN HYPERMOBILITY AND SPORTS INJURY / J. A. Nathan* - K. Davies


THU0534 THE EFFECT OF LUMBAR STABILIZATION EXERCISE ON THE BALANCE AND CLINICAL HEALTH / K. Barut* - E. Taştıban - F. Sendur

THU0535 SAFETY AND EFFICACY OF PLATELET-RICH PLASMA IN TREATMENT OF CARPAL TUNNEL SYNDROME: A RANDOMISED CONTROLLED TRIAL / L. Bagherzadeh* - S. A. Raeissadat - A. Karimzadeh - M. Hashemi


THU0537 ASSOCIATION BETWEEN BIG FIVE PERSONALITY TRAITS AND RESPONSE TO MULTIDISCIPLINARY PROGRAM IN PATIENTS WITH CHRONIC LOW BACK PAIN: A PROSPECTIVE STUDY / M. E. Ibrahim* - K. Weber - S. Genevay


THU0540 INCREASED WORK CAPACITY IN CHRONIC LOW BACK PAIN PATIENTS AFTER A MULTIDIMENSIONAL PROGRAM ASSOCIATED WITH DECREASE IN FEAR AND APPREHENSION / M. Norberg* - L. Belgrand

THU0541 THE EFFECT OF PHYSICAL THERAPY ON CLINICAL AND QUALITY OF LIFE IN CHRONIC NECK PAIN PATIENTS: A RANDOMISED CONTROLLED TRIAL / N. Şaşin* - M. Şaşin

THU0542 EVALUATION OF THE EFFECTIVENESS OF ULTRASOUND GUIDED EPIDURAL CORTICOSTEROID INJECTION AND PULSED ELECTROMAGNETIC FIELD STIMULATION IN CHRONIC LOW BACK PAIN / S. A. Tabra* - M. ElSergany - M. E. Mowafy - H. Khalifa - G. Elsharnopy


THU0544 STUDY OF THE EFFECTS OF OZONE VERSUS STEROID INJECTION ON PATIENTS WITH RECALCITRANT TENNIS ELBOW; A CLINICAL TRIAL / S. A. Tabra* - M. ElSergany - M. E. Mowafy - H. Khalifa - G. Elsharnopy

THU0545 CHARACTERISING A MOUSE MODEL OF TEMPOROMANDIBULAR JOINT (TMJ) ARTHRITIS TO STUDY OROFACIAL PAIN AND INFLAMMATION / X. Kodji* - J. D. S. Valente - F. Lundy - I. El Karim - S. D. Brain

TOPIC: PAEDIATRIC RHEUMATOLOGY

Poster tour T12: A colourful journey through the landscape of paediatric rheumatology

Chair(s): Berent J. Prakken (Netherlands), Gabriella Giancane (Netherlands)

Abstracts N°: THU0546-THU0555

THU0546 CHILDREN WITH PSORIASIS ALSO SHOW ENTHESOPATHY SIGNS RELATED TO SKIN DISEASE ACTIVITY / T. C. Meneghetti - C. Chen - J. Guo - D. J. Lovell - H. I. Brunner on behalf of EULAR/PRES TASK FORCE

THU0547 REAL-WORLD EFFECTIVENESS OF EARLY AGGRESSIVE TREATMENT WITH BIOLOGICAL DISEASE-MODIFYING ANTIHEMATIC DRUGS FOR THE TREATMENT OF NEWLY DIAGNOSED POLYARTICULAR FORM OF JUVENILE IDIOPATHIC ARTHRITIS / E. M. Morgan - C. Chen - J. Guo - D. J. Lovell - H. I. Brunner on behalf of EULAR/PRES TASK FORCE


THU0549 ABSENCE OF ASSOCIATION BETWEEN HYPERMOBILITY AND SPORTS INJURY / I. O. Dayanur - E. Kaya Mutlu - M. A. Akçetin - A. O. Akdemir

THU0550 NEW IL10 RECEPTOR GENE MUTATION ASSOCIATED TO A SPECTRUM OF INFLAMMATORY APHTHOSIS AND B. Murthy - K. Lin - J. A. Passarell - A. Martini - D. J. Lovell on behalf of the PRINTO and PRCSG working groups.


THU0580 THE ACR RECOMMENDATIONS FOR JIA IN DAILY CLINICAL PRACTICE: ARE THEY FOLLOWED OR WOULD TREAT-TO-TARGET THERAPY LEAD TO BETTER RESULTS? / J. F. Swart* - S. de Roock - P. van Dijkhuizen - N. Wulfraat


THU0585 PERSONALISED TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS - FUTURE OR FICTION? PRELIMINARY RESULTS OF USING S100A8A9, S100A12 AND VASCULAR ENDOTHELIAL CADHERIN AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS / K. Orczyk* - E. Smolewska


THU0587 CLINICAL AND THERAPEUTIC ASPECTS OF A SOUTH ASIAN POPULATION OF SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS IN A TERTIARY CARE PAEDIATRIC RHEUMATOLOGY CENTER IN SRI LANKA / M. Adikari* - A. Subasinghe - M. de Silva


THU0590 THE ROLE OF STAT4 RS7574865 G/T AND IFR5 RS2004640 G/T GENE POLYMORPHISM IN JUVENILE IDIOPATHIC ARTHRITIS SUSCEPTIBILITY AMONG RUSSIAN PAEDIATRIC POPULATION / M. Krylov* - E. Fedorov - S. Salugina - N. Konovalova - D. Varlamov


THU0592 PERSONALISED TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS - FUTURE OR FICTION? PRELIMINARY RESULTS OF USING S100A8A9, S100A12 AND VASCULAR ENDOTHELIAL CADHERIN AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS / K. Orczyk* - E. Smolewska


THU0594 CLINICAL AND THERAPEUTIC ASPECTS OF A SOUTH ASIAN POPULATION OF SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS IN A TERTIARY CARE PAEDIATRIC RHEUMATOLOGY CENTER IN SRI LANKA / M. Adikari* - A. Subasinghe - M. de Silva

* Presenting author
THU0599


THU0600

HIGH VACCINE COVERAGE RATES ARE NOT ENOUGH: VACCINATION DELAY AND RISK FOR VACCINE-PREVENTABLE DISEASES IN PAEDIATRIC PATIENTS WITH RHEUMATIC DISEASES WITH AND WITHOUT IMMUNOSUPPRESSIVE THERAPY / T. Welzel* - T. Zumbrunn - J. Bonhoeffer - E. Cannizzaro Schneider - M. Hofer - D. Kaiser - V. Hentgen - A. Woerner on behalf of Juvenile Inflammatory Rheumatism (JIR) Cohort

THU0601


THU0602

TARGETING GENERATION Z: DEVELOPMENT AND VALIDATION OF AN ILLUSTRATED TRANSITION READINESS QUESTIONNAIRE FOR ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / H. Lothy - M. El Gaafary - N. El Aroussy - D. Mekkawy - Y. Farag - Y. El Miedany* on behalf of PRINTO Egypt

THU0603

DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN JUVENILE IDIOPATHIC ARTHRITIS: MOVING TOWARDS TARGETED INDIVIDUALIZED TREATMENT STRATEGY / S. I. Nasef - G. El Deriny - M. Eissa - M. A. Mortada - W. Hassan - M. Mekkawy - Y. El Miedany*

THU0604


THU0605


TOPIC: OTHER ORPHAN DISEASES

THU0606


THU0607


THU0608


THU0609

CLINICAL CHARACTERISTICS AND OUTCOME OF SPANISH PATIENTS WITH ACUTE MYELITIS ASSOCIATED WITH AUTOIMMUNE DISEASES / A. González García* - W. A. Sifuentes Giraldo - S. Sainz de la Maza - I. Barbolla Díaz - J. L. Patier de la Peña - L. Manzano Espinosa

THU0610


THU0611

ANAKINRA TREATMENT IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: A SINGLE-CENTER EXPERIENCE / B. Ergezen* - S. Uğurcu - H. Ozdogan

THU0612


THU0613

THE FREQUENCY AND CHARACTERISTICS OF HEADACHE IN BEHCET’S DISEASE AND ITS EVALUATION BY TRANSCRANIAL DOPPLER ULTRASONOGRAPHY / F. Salgür - D. Üsküdar Cansu - N. Uzuner - C. Korkmaz*

THU0614


THU0615

ANATOMIC RELATION OF ADVERSE EVENTS (RAEES) ASSOCIATED WITH CHECKPOINT INHIBITORS: 12 CASES FROM A SINGLE REFERENCE CENTER / D. F. L. Liew* - J. L. Y. Leung - C. McMaster - D. S. Lui - G. D. Tse

THU0616

HIGH VACCINE COVERAGE RATES ARE NOT ENOUGH: VACCINATION DELAY AND RISK FOR VACCINE-PREVENTABLE DISEASES IN PAEDIATRIC PATIENTS WITH RHEUMATIC DISEASES WITH AND WITHOUT IMMUNOSUPPRESSIVE THERAPY / T. Welzel* - T. Zumbrunn - J. Bonhoeffer - E. Cannizzaro Schneider - M. Hofer - D. Kaiser - V. Hentgen - A. Woerner on behalf of Juvenile Inflammatory Rheumatism (JIR) Cohort

THU0617


THU0618

HYPOPHOSPHATASIA IN FRENCH TERTIARY CARE HOSPITALS / E. Ebstein* - T. Thomas - B. Cortet - K. Briot - C. Roux

THU0619

THE FREQUENCY OF EXON-10 MUTATIONS IN MEFV GENE IN ‘PROBABLE’ DIAGNOSED FMF PATIENTS ACCORDING TO TEL HASHOMER CRITERIA / F. Cosan* - Y. Aronson - O. M. Gedar Totuk

THU0620

ON DEMAND USE OF ANAKINRA FOR THE ATTACKS OF FAMILIAL MEDITERRANEAN FEVER (FMF) / H. Babaoğlu* - M. A. Öztürk - A. Tufan

THU0621


* Presenting author

THU0624 COLCHICINE: AN EFFECTIVE TREATMENT OPTION FOR UNCLASSIFIED AUTOINFLAMMATORY DISEASES IN CHILDREN / J. B. Kueemmerle-Deschner* - A-L. Schock - S. Hansmann - S. M. Benseler


THU0627 DEMOGRAPHICS AND PRESENTING ORGAN INVOLVEMENT IN A COHORT OF PATIENTS WITH SARCOIDOSIS / K. Sheht* - G. Jeyasahnagura - J. Simard - S. Shoor

THU0628 DIFFERENCES IN CLINICAL MANIFESTATIONS OF BEHET’S SYNDROME BY GENDER: CROSS-SECTIONAL ANALYSIS IN A UK COHORT / L. Chadwick* - T. Blake - N. J. Goodson - D. Situnayake - R. J. Moots


THU0630 IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS IN SPANISH PATIENTS / L. Villalobos* - W. A. Giraldo-Sifuentes - P. Moran-Alvarez - J. Arroyo Palomo - A. Briones-Figueroa - C. Ritti - J. L. Morell-Hita


THU0632 IDENTIFICATION OF ABBRENT T CELL PHENOTYPE IN EPISODIC ANGIOEDEMA WITH HYPEREOSINOPHILIA (GIECH SYNDROME) IN 30 PATIENTS: FREQUENCY, CLINICAL IMPLICATION AND PROGNOSIS / N. Abisror* - B. S. Belov - S. G. Radenska-Lopovok


THU0634 IMPACT OF SHOULDER ULTRASOUND IN QUALITY OF CARE INDICATORS IN PATIENTS WITH RECENT ONSET PAIN / C. A. Guillen-Astete* - R. Penedo Alonso - C. De La Casa Resino

THU0635 IMPACT OF SECOND-LINE THERAPY WITH ABATACEPT VERSUS OTHER TARGETED DMARDS ON THE RISK OF INFECTION-RELATED HOSPITALIZATIONS AND ASSOCIATED COSTS AMONG RA PATIENTS IN THE UNITED STATES / D. Paul* - L. McDonald - A. Marshall - T. Curtice - M. Lingohr-Smith - B. Menges - J. Lin


THU0637 LONGITUDINAL STUDY OF LONG-TERM POVERTY AND PERSISTENT DEPRESSIVE SYMPTOMS IN SLE / E. Yelin* - J. Yazdany - L. Trupin - N. McCormick - P. Katz

TOPIC: PUBLIC HEALTH, HEALTH SERVICES RESEARCH AND HEALTH ECONOMICS

THU0640 PHARMACOLOGICAL TREATMENT AMONG NEWLY DIAGNOSED PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN THE UNITED STATES / A. Marshall* - K. Gupta - M. Pazirandeh - M. Bonafede - D. Mcmorrow


THU0643 IMPACT OF SHOULDER ULTRASOUND IN QUALITY OF CARE INDICATORS IN PATIENTS WITH RECENT ONSET OF PAIN / C. A. Guillen-Astete* - R. Penedo Alonso - C. De La Casa Resino

THU0644 PERCEPTIONS OF BIOSIMILARS AMONG PRACTICING RHEUMATOLOGISTS: RESULTS FROM A MULTICOUNTRY STUDY IN EUROPE / C. A. Guillen-Astete* - R. Penedo Alonso - C. De La Casa Resino

THU0645 IMPACT OF SECOND-LINE THERAPY WITH ABATACEPT VERSUS OTHER TARGETED DMARDS ON THE RISK OF INFECTION-RELATED HOSPITALIZATIONS AND ASSOCIATED COSTS AMONG RA PATIENTS IN THE UNITED STATES / D. Paul* - L. McDonald - A. Marshall - T. Curtice - M. Lingohr-Smith - B. Menges - J. Lin


THU0648  ‘AS A PRACTITIONER I FEEL ENRICHED’: RHEUMATOLOGY TUTORS’ EXPERIENCES OF DELIVERING A MANAGED GROUP COGNITIVE-BEHAVIOURAL FATIGUE PROGRAMME TO PATIENTS WITH RHEUMATOID ARTHRITIS (RA) / E. Dures* - A. Hammond - S. Hewlett on behalf of the RAFT group

THU0649  UNDERSTANDING ETHNIC DIFFERENCES IN THE UTILIZATION OF EXERCISE FOR OSTEOARTHRITIS / E. R. Vina* - D. Ran - M. J. Hannon - C. K. Kwok


THU0651  THE INFLUENCE OF AGE, GENDER, EMPLOYMENT STATUS, OR EDUCATION ON THE CHOICE OF BIO-SIMILAR VS. BIO-ORIGINAL VARIANT OF THE SAME BDMARD IN PATIENTS WITH RA OR AS STARTING BIOLOGICAL THERAPY - REAL LIFE DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA / J. Zavada* - L. Nekvindova - K. Pavelka - J. Vencovsky on behalf of collaborators of the ATTRA registry

THU0652  COMPARATIVE COST PER RESPONSE FOR FOUR CLINICAL OUTCOMES OF TOCILIZUMAB MONOTHERAPY VERSUS ADAHIMULAB MONOTHERAPY IN A HEAD-TO-HEAD RANDOMIZED DOUBLE-BLIND SUPERIORITY TRIAL (ADACTA) IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. Best* - J. Pei

THU0653  CHANGES IN RHEUMATOLOGY PROVISION AND PRACTICE IN A PUBLICLY-FUNDED SINGLE PAYER HEALTHCARE SYSTEM / J. Widdifield* - S. Bernatsky - V. Aullwala - C. Barber - L. Eder - C. Hofstetter - B. Kuriya - V. Ling - A. Lydiatt - M. Paterson - J. Pope - C. Thorne


THU0656  SYSTEMIC LUPUS ERYTHEMATOSUS IN COLOMBIA: A BIBLIOGRAPHIC ANALYSIS / J. E. Barahona-Correa*

THU0657  EFFECTS OF ADAHIMULAB INITIATION ON CORTICOSTEROID UTILIZATION AND MEDICAL COSTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Qiao - K. L. Winthrop* - J. Griffith - C. M. Kaplan - C. A. Spivey - A. Postlethwaite - J. Wang


THU0659  EUROHAEMUVA; ARE THE LARGEST EUROPEAN RHEUMATOLOGY SOCIETIES THE ONES WITH THE MOST ORAL COMMUNICATIONS? / M. Paulino Huertas*


THU0661  OSTEOPOROSIS SCREENING, PRIMARY PREVENTION, AND TREATMENT IN GLUCOCORTICOID TREATED INDIVIDUALS WITH RHEUMATOLOGIC DISEASE / P. Onkka - S. Khandelwal - N. Shakoor - J. Block - L. Fogg


THU0664  TREATMENT ADHERENCE TO CONVENTIONAL AND BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS / C. H. Feldman - J. Li - C. Gopalakrishnan - J. M. Franklin - S. C. Kim*


THU0667  DISEASE, WORK AND PERSONAL RELATED FACTORS ASSOCIATED WITH PRESENTEESM IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY SURVEY (NRAS) / S. Verstappen* - M. Gignac - L. Lunt - D. Beaton - A. Bosworth - M. Bezzant - K. Walker-Bone

THU0668  CHOICE OF INITIAL BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG IMPACTS HEALTHCARE RESOURCE USE AMONG PATIENTS WITH RAPIDLY PROGRESSING RHEUMATOID ARTHRITIS / A. J. Klink - K. Tuell - B. A. Feinberg

THU0669  A SELF-REPORT SYMPTOM CHECKLIST ON A MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE (MDHAQ) TO CAPTURE A ‘POSITIVE REVIEW OF SYSTEMS’ AS A STANDARD, QUANTITATIVE, AND INFORMATIVE ‘SCIENTIFIC’ CLUE TO FIBROMYALGIA SIMILAR TO MODIFIED CRITERIA FOR FIBROMYALGIA / T. Pincus* - R. Szymialis - T. Curtice* - K. Gultro - B. A. Feinberg

THU0670  A REUMATOLOGIST’S EVALUATION OF HOW EFFICIENCIES IN THE MANAGEMENT OF PAINFUL LUMBAR SYNDROME IN WORK DISABILITY Creates BENEFITS & SAVINGS / V. M. Flores Rodriguez* - F. Diaz Gonzalez - S. Bustabad Reyes - M. Carballo Correa

* Presenting author
TOPIC: EPIDEMIOLOGY, RISK FACTORS FOR DISEASE OR DISEASE PROGRESSION

Poster tour T13: Life is not a smooth trip - how pregnancy and life events interfere in rheumatic disease management

Chair(s): Laure Gossec (France), Santiago Rodrigues-Manica (Portugal)

Abstracts N°: THU0671-THU0680

THU0671  STANDARDISED MORTALITY RATES FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN WESTERN AUSTRALIA FROM 1980 TO 2015 / W. D. Raymond* - D. Preen - H. Keen - C. Inderjeeth - J. Nossent

THU0672  IMPACT OF PREGNANCY ON PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN WOMEN WITH AXIAL SPONDYLOARTHRITIS / K. Ursin* - S. Lydersen - J. Skomsvoll - M. Wallenius

THU0673  DISEASE ACTIVITY DURING AND AFTER PREGNANCY IN WOMEN WITH PSORIATIC ARTHRITIS / K. Ursin* - S. Lydersen - J. Skomsvoll - M. Wallenius


THU0676  A SYSTEMATIC REVIEW AND META-ANALYSIS OF VIRAL EXPOSURES AS A RISK FACTOR FOR RHEUMATOID ARTHRITIS / F. Kudaeva* - M. R. Speechley - J. E. Pope

THU0677  PNEUMOCOCCAL ANTIBODY PROTECTION IN RHEUMATOLOGICAL PATIENTS RECEIVING BDMARD THERAPY - A CROSS-SECTIONAL STUDY / S. Rasmussen* - K. Fuursted - K. Nielsen - N. Parks - M. Sorensen - P. Leutscher - C. Rasmussen


THU0679  INCREASED HOSPITALIZATION RATES FOLLOWING HEART FAILURE DIAGNOSIS IN RHEUMATOID ARTHRITIS / E. Myasoedova* - J. M. Davis, III - S. J. Achenbach - E. L. Matteson - S. Setoguchi - S. E. Gabriel - C. S. Crowson

THU0680  SURVIVAL ANALYSIS OF PATIENTS WITH CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE / T. Xu* - X. Zhang


THU0682  HUMAN HISTOCOMPATIBILITY ANTIGENS (HLA) CLASS 1 IN ANTERIOR UVEITIS PATIENTS WITH AND WITHOUT SPONDYLOARTHRITIS / A. Godzenko* - I. Guseva - I. Razumova

THU0683  PREDICTORS FOR PRETERM DELIVERY AMONG PREGNANT WOMEN WITH RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS / C. J. F. Smith* - F. Forger - C. Chambers


THU0685  CARDIOVASCULAR RISK ESTIMATION IN SLE PATIENTS: A COMPARISON OF THREE ALGORITHMS / D. Chimaera* - C. Sánchez-Piedra - F. Díaz-González - S. Bustabad on behalf of EPISER 2016 working group


THU0688  DO CERTAIN DMARDS INCREASE RISK OF NEW-ONSET TYPE 2 DIABETES? EVALUATION OF PATIENTS’ BASELINE CHARACTERISTICS / E. Alemao* - Z. Guo - L. Ferri - L. Burns

THU0689  VARIABILITY OF PAIN LEVELS IS EXPLAINED BY SELF-REPORTED DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS / L. Jelliffe-Pawlowski - H. Keen - C. Inderjeeth - J. Nossent

THU0690  RETROSPECTIVE ANALYSIS OF TEMPORAL ARTERY BIOPSY AND ITS IMPACT IN THE MANAGEMENT OF GIANT CELL ARTERITIS / G. Kasavkar* - A. Sinha

THU0691  ASSOCIATION BETWEEN PERIODONTITIS AND CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS UNDER BIOLOGICAL TREATMENT / H.-H. Chen* - D.-Y. Chen - L.-G. Huang


* Presenting author
THU0697  RISK OF MAJOR CONGENITAL MALFORMATIONS ASSOCIATED WITH EXPOSURE TO CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN WOMEN WITH INFLAMMATORY ARTHRITIS: A POPULATION-BASED COHORT STUDY / M. A. De Vera* - E. C. Sayre - N. W. Tsao - A. Howren

THU0698  CLINICAL OUTCOME OF ULTRASONOGRAPHIC DETECTED UNDIFFERENTIATED SYNOVITIS IN PATIENTS WITH POLYARTHRALGIA / M. Mortada* - F. I. ABDELRAHMAN - S. Aiyun

THU0699  PREDICTORS OF FRACTURE AND LOW BONE MINERAL DENSITY IN PATIENTS WITH HISTORY OF PARENTAL FRACTURE / M. Bukhari


THU0701  UPDATED INCIDENCE AND COSTS OF HIP FRACTURES IN ELDERLY ITALIAN POPULATION / P. Piscitelli* - M. Feola - C. Neglia - C. Rao - E. Rizzo - U. Tarantino


THU0706  PRESENCE OF EXTRACTABLE NUCLEAR ANTIGENS (ENA) ANTIBodies IN A LARGE POPULATION-BASED COHORT FROM THE NETHERLANDS / S. Arends* - L. Brouwer - C. Roozendaal - B. Doestzada - H. Bootsma - K. de Leeuw

THU0707  ANALYSIS OF ANTINUCLEAR ANTIBODIES IN BREAST CANCER PATIENTS / A. Neppel - M. C. C. Machoski - T. A. F. G. Santos* - R. Nishara - T. L. Skare


THU0709  REUMAHEART - A PORTUGUESE POPULATION BASED STUDY ON CARDIOVASCULAR RISK FACTORS / V. M. Da Silva Domingues* - A. Rodrigues - S. Dias - J. Branco - H. Canhão on behalf of EpiReuma

* Presenting author
Scientific Programme Friday 15 June 2018

07:45 - 19:15 Registration area (Hall 2)

08:15 - 09:45 Elicium 1

Basic and Translational Science session

Special delivery: intercellular communication

Learning objectives:
- Discuss different types of intercellular communication
- Describe how this is relevant to rheumatic diseases

Chair(s):
Leonie Taams (United Kingdom)
Florence Apparailly (France)

Daniel Davis (United Kingdom) 08:20
Abstract N° SP0094
Membrane nanotubes: reaching out to other cells

W. Fu (United States) 08:40
J. Wei, A. Hettinghouse, W. He, C. Liu
Abstract N° OP0224
ADAMTS-12 protects against inflammatory arthritis through interacting with proinflammatory CTGF

Marca H. M. Wauben (Netherlands) 08:50
Extracellular vesicles as couriers of the immune system

M. H. van den Bosch (Netherlands) 09:10
A. B. Blom, E. J. Geven, E. N. Blaney Davidson, P. M. van der Kraan, P. L. van Lent
Abstract N° OP0225
S100A9 mediates acute nociceptive pain in experimental synovitis

09:45 - 10:15 Exhibition and EULAR Village (Hall 1)

Coffee break

10:15 - 11:45 Hall 7.1

What is New (WIN) & How to Treat (HOT) session

WIN & HOT session

Olivier Lortholary (France) 10:20
WIN: Infectious complications of rheumatic diseases (treatment)

Christian Roux (France) 11:00
Abstract N° SP0096
HOT: Advances in the management of osteoporosis

10:15 - 11:45 Hall 3

Abstract session

Biologics in RA.
More, more and more about safety

Chair(s):
Bernard Combe (France)
Diederik De Cock (United Kingdom)

S. K. Chen (United States) 10:20
Abstract N° OP0226
Risk of hospitalised infection and initiation of abatacept versus TNF inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study

M. George (United States) 10:30
Abstract N° OP0227
Timing of abatacept before elective arthroplasty and post-operative outcomes

M. George (United States) 10:40
Abstract N° OP0228
Comparative risk of biologic therapies and risk of glucocorticoids in patients with rheumatoid arthritis undergoing elective arthroplasty
M. Jani (United Kingdom) 10:50
W. G. Dixon, M. Lunt, D. De Cock, J. D. Isaacs, A. W. Morgan, A. G. Wilson, D. Plant, K. Watson, A. Barton, K. Hyrich on behalf of BSRBR Control Centre Consortium
Abstract N° OP0229
The association of biologic drug-levels with infection risk: results from the British society for rheumatology biologics register for rheumatoid arthritis

G. Boleto (France) 11:00
Abstract N° OP0230
Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-centre study

A. Barbulescu (Sweden) 11:10
J. Askling, T. Frisell on behalf of ARTIS
Abstract N° OP0231
Gastro-intestinal perforations among rheumatoid arthritis patients treated with biologic DMARDs: a nationwide Swedish cohort study

K. Hambardzumyan (Sweden) 11:20
Abstract N° OP0232
Female gender and positive rheumatoid factor predict low serum infliximab levels and positive anti-drug antibodies, which associate with treatment failure on infliximab in patients with early rheumatoid arthritis. Report from the SWEFOT trial population

G. R. Burmester (Germany) 11:30
Abstract N° OP0233
Long-term safety of adalimumab in adult patients from global clinical trials across multiple indications: an updated analysis in 29,987 patients representing 56,951 patient-years

D. Saadoun (France) 10:30
P. Cacoub, S. N. Si ahmed, Y. ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, L. Quatuccio, M. Hegazy, T. Poynard, M. Resche Rigon
Abstract N° OP0235
Interferon-free antivirals for hepatitis C virus-associated cryoglobulinemia vasculitis: a long-term follow-up study

A. Berti (Italy) 10:40
E. Matteson, C. S. Crowson, U. Specks, D. Cornec
Abstract N° OP0236
Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20 year population-based cohort study

N. L. Mallalieu (United States) 10:50
J. H. Stone, P. Villiger, M. Klearman, L. Brockwell, S. Dimonaco, J. E. Charion
Abstract N° OP0237
A comparison of PK and PD outcomes of tocilizumab in giant cell arteritis after SC and IV dosing

S. Monti (Italy) 11:00
A. Craven, C. Klersy, C. Montecucco, R. Caporali, R. Watts, P. A. Merkel, R. Luqmani
Abstract N° OP0238
Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. Analysis from the DCVAS study

J. Noscent (Australia) 11:10
W. Raymond, H. Keen, C. Inderjeeth, D. Preen
Abstract N° OP0239
Pregnancy outcomes in patients with IgA vasculitis

A. Rubbert-Roth (Switzerland) 11:20
T. Neumann, P. Rein, H. Prillwitz, J. von Kempis
Abstract N° OP0240
Favourable longterm outcome in patients with giant cell arteritis treated with tocilizumab. Real-life data from a Swiss centre

A. Mekinian (France) 11:30
Abstract N° OP0241
Efficacy of tocilizumab in Takayasu arteritis: multicenter French retrospective study of 46 patients
Abstract session
Axial spondyloarthritis: on the interface between healthy and diseased

Chair(s):
Denis Poddubnyy (Germany)
Manouk de Hooge (Belgium)
X. Baraliakos (Germany) 10:20
H. Boehm, A. Samir Barakat, G. Schett, J. Braun
Abstract N° OP0242
Fatty lesions detected on MRI scans in patients with ankylosing spondylitis are based on the deposition of fat in the vertebral bone marrow

X. Baraliakos (Germany) 10:30
Abstract N° OP0243
Prevalence of inflammatory and chronic changes suggestive of axial spondyloarthritis in magnetic resonance images of the axial skeleton in individuals < 45 years in the general population as part of a large community study (SHIP)

J. de Winter (Netherlands) 10:40
M. de Hooge, M. van de Sande, J. de Jong, L. van Hoeven, A. de Koning, I. J. Berg, R. Ramonda, D. Baeten, D. van der Heijde, A. Weel, R. Landewé
Abstract N° OP0244
An ASAS-positive MRI of the sacroiliac joints can also occur in healthy individuals, runners and women with postpartum back pain

S. Seven (Denmark) 10:50
P. Hededal, M. Østergaard, L. Morsel-Carlsen, I. J. Sørensen, B. Bonde, G. Thamsborg, O. Hendricks, N. R. Jørgensen, S. J. Pedersen
Abstract N° OP0245
Ability of MRI of the sacroiliac joints to differentiate patients with axial spondyloarthritis from women, who have given birth, patients with disc herniation, persons with hard physical work, long-distance runners and healthy males

A. Sepriano (Netherlands) 11:00
S. Ramiro, R. Landewé, M. Dougados, D. van der Heijde
Abstract N° OP0246
Inflammation on MRI of spine and sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis: the 5 years data of the DESIR cohort

A. Sepriano (Netherlands) 11:10
Abstract N° OP0247
Performance of referral strategies for spondyloarthritis: a population-based nationwide study

R. B. M. Landewé (Netherlands) 11:20
Abstract N° OP0248
Potential differences in axial spondyloarthritis disease activity categorisation using different minimum values for high-sensitivity CRP in ankylosing spondylitis disease activity score calculation and different definitions of disease flare

R. G. Lambert (Canada) 11:30
Abstract N° OP0249
The contribution of structural MRI lesions to detection of sacroiliitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort

Abstract session
Present and future treatments for SLE, Sjögren and APS

Chair(s):
David Isenberg (United Kingdom)
Alessia Alumno (Italy)
T. Dörner (Germany) 10:20
Abstract N° OP0250
A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary Sjögren’s syndrome

E. Morand (Australia) 10:30
J. T. Merrill, D. A. Isenberg, A. H. Kao, C. Vazquez-Mateo, S. Wax, P. Chang, K. Pudota, C. Aranow, D. Wallace
Abstract N° OP0251
Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase IIB address II study and its long-term extension

R. F. van Vollenhoven (Netherlands) 10:40
Abstract N° OP0252
Organ damage progression and long-term safety of belimumab (BEL) in patients with systemic lupus erythematosus (SLE): an extension of pivotal phase III BLISS studies
R. Furie (United States) 10:50
Abstract N° OP0253
A phase III randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class III or IV lupus nephritis

M. Urowitz (Canada) 11:00
Abstract N° OP0254
A propensity score-matched (PSM) analysis of organ damage in patients with systemic lupus erythematosus (SLE) from the pooled bliss long-term extension (LTE) trials versus the Toronto lupus cohort (TLC)

H. Sánchez Pérez (Spain) 11:10
D. Isenberg
Abstract N° OP0255
Identification of clinical and serological predictive factors of response to rituximab treatment in systemic lupus erythematosus (SLE) patients

W.-S. Chen (Taiwan, Province of China) 11:20
C.-Y. Tsai, C.-C. Chang
Abstract N° OP0256
Hydroxychloroquine reduces risk of incident diabetes mellitus in primary Sjögren syndrome patients: a propensity score matched population-based cohort study

T. Colasanti (Italy) 11:30
F. R. Spinelli, C. Barbati, L. Massaro, F. Ceccarelli, M. Vomero, F. Morello, V. Orefice, F. Conti, G. Valesini, C. Alessandri
Abstract N° OP0257
Decrease of autophagy in peripheral blood mononuclear cells from systemic lupus erythematosus patients treated with belimumab

10:15 - 11:45  Forum

Abstract session
From cartilage to bone

Chair(s):
Georg Schett (Germany)
Stephan Blüml (Austria)

D. Amantini (France) 10:20
Abstract N° OP0258
Efficacy of the highly selective ADAMTS-5 inhibitor GLPG1972 in the rat meniscocente model

T. M. Haqqi (United States) 10:30
N. M. Khan
Abstract N° OP0259
ZCCHC5, a LTR retrotransponson-derived neofunctionalised gene, is essential for the transcriptional activity of SOX9 and the expression of COL2A1 in chondrocytes and is downregulated in OA cartilage

L. M. Topping (United Kingdom) 10:40
C. Vinci, H. Rhys, L. Norling, A. Nissim
Abstract N° OP0260
Targeting neutrophil microvesicles to damaged cartilage using antibodies to post-translationally modified collagen II

L. Zhu (United Kingdom) 10:50
H. Ismail, A. Chanalaris, M. Gardiner, T. L. Vincent on behalf of ECHO
Abstract N° OP0261
Retinoic acid is regulated by cartilage injury and is anti-inflammatory in hand osteoarthritis

E. M. van Helvoort (Netherlands) 11:00
Abstract N° OP0262
Disease modifying effects of the canine IL4-10 fusion protein in the canine groove model of osteoarthritis

C.-H. Lee (Republic of Korea) 11:10
J. M. Baek, Y. J. Choi, W.-H. Yoo, M. S. Lee, J.-Y. Kim
Abstract N° OP0263
Claudin-11 regulates bone homeostasis via bi-directional EPHB4-EPHRINB2 signaling

Y. Henrotin (Belgium) 11:20
Abstract N° OP0264
Glucosepane: a new biomarker of the severity of osteoarthritis

C. Fenton (United Kingdom) 11:30
C. Doig, S. Fareed, A. Naylor, C. Wehmeyer, C. Buckley, G. Lavery, M. Cooper, K. Raza, R. Hardy
Abstract N° OP0265
Local reactivation of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 mediates the development of glucocorticoid-induced bone loss

10:15 - 11:45  Elicium 1

Abstract session
Seeking the pathophysiology of rheumatoid arthritis and spondylarthritis

Chair(s):
João E. Fonseca (Portugal)
Dirk Elewaut (Belgium)
L. G. van Baarsen (Netherlands) 10:20
M. J. de Hair, J. F. Semmelink, I. Y. Choi, D. M. Gerlag, P. P. Tak
Abstract N° OP0266
Synovial tissue profiling in auto anti-body positive at risk individuals reveals gene signatures associated with later development of rheumatoid arthritis

B. Kolarz (Poland) 10:30
M. Dryglewska, M. Ciesla, A. Selwa, M. Majdan
Abstract N° OP0267
The PADI4 gene promoter methylation level is associated with anti-PADI4 antibodies level and RA activity

C.-R. Wang (Taiwan, Province of China) 10:40
S.-Y. Chen, A.-L. Shiau, C.-L. Wu
Abstract N° OP0268
Apoptosis of synovial fibroblasts induced by P53-derived hybrid peptides through dissociating the binding of P73 with IASPP to increase PUMA and BAX expression

S. R. Finlay (United Kingdom) 10:50
S. Alivernini, A. Elmesmari, B. Tolusso, L. Perticca, C. Di Mario, A. Capacci, A. Filer, G. Ferraccioli, I. McInnes, E. Gremses, M. Kurowska-Stolarska
Abstract N° OP0269
Activation of MERTK+CD206+ subpopulation of human synovial tissue-resident macrophages limits inflammatory response

K. Mankia (United Kingdom) 11:00
Abstract N° OP0270
IGA anti-CCP antibodies are detectable in the saliva but not sputum of individuals at risk of developing rheumatoid arthritis

D. Benfaremo (Italy) 11:10
M. M. Luchetti, F. Ciccia, C. Avellini, T. Spadoni, S. Svegliati, M. Ciferri, A. Gabrielli
Abstract N° OP0271
Gastrointestinal damage and microbial translocation are involved in the development of immune system activation in inflammatory bowel disease-associated spondyloarthritis

G. R. Gulino (Belgium) 11:20
M. van Mechelen, R. Lories
Abstract N° OP0272
Inflammation at barrier tissues such as skin and gut triggers mild joint inflammation and is influenced by biomechanical stress induced by forced-running

L. van Duivenvoorde (Netherlands) 11:30
M. van Tok, D. Pots, I. Blijdorp, M. Armaka, G. Kollias, M. van de Sande, D. Baeten
Abstract N° OP0273
Transmembrane TNF signaling through TNF-RI induces SpA-like inflammation, whereas signaling through TNF-RII is crucial for new bone formation

Abstract session HPR
Supporting self-management
Chair(s):
Mwidimi Ndosi (United Kingdom)
Fernando Estévez-López (Spain)

G. Fernandes (Brazil) 10:20
F. Jennings, M. Cabral, R. Santos, J. Natour
Abstract N° OP0274-HPR
A functional exercise programme improves pain and health related quality of life in patients with fibromyalgia: a randomised controlled trial

I. Ahlstrand (Sweden) 10:40
P. Wagman, C. Håkansson, M. Björk
Abstract N° OP0275-HPR
Occupational balance and its relation to performance of valued life activities in persons with rheumatoid arthritis in working age

A. Jones, J. Natour, R. Silva
Abstract N° OP0276-HPR
Evaluation of the effectiveness of a progressive resistance training program for patients with fibromyalgia: a randomised controlled trial

S. A. Just (Denmark) 11:00
Abstract N° OP0277-HPR
Patient reported outcomes and safety in patients undergoing synovial biopsy: comparison of arthroscopic, ultrasound-guided portal-forceps and ultrasound-guided needle biopsy techniques, in five centres across Europe

M. Martin (United Kingdom) 11:10
A. Gilbert, C. Jeffries
Abstract N° OP0278-HPR
A national survey of the utilisation and experience of hydrotherapy in the management of axial spondyloarthritis: the patients' perspective

A. Bremander (Sweden) 11:20
K. Malm, M. L. Andersson on behalf of the BARFOT study group
Abstract N° OP0280-HPR
Physical activity in established RA and variables associated with physical activity maintenance over a seven year period
M. van Heuckelum (Netherlands) 11:30
E. Mathijssen, M. Vervoort, A. Boonen, A. Pasma, R. Hebing, H. Vonkeman, M. Wenink, B. van den Bent, L. van Dijk

Abstract N° OP0281-HPR
Preferences of patients with rheumatoid arthritis regarding disease modifying anti-rheumatic drugs: a discrete choice experiment

10:15 - 11:45  Emerald

Abstract session
From gene to function

Chair(s):
Leonid Padyukov (Sweden), Annette van der Helm-van Mil (Netherlands)
E. López-Isac (Spain) 10:20

Abstract N° OP0282
New systemic sclerosis risk loci identified through a meta-GWAS strategy


Abstract N° OP0283
Cross-disease meta-analysis in four systemic autoimmune diseases to identify shared genetic etiologies

P.-A. Juge (France) 10:40

Abstract N° OP0284
MUC5B promoter variant RS35705950 is a risk factor for rheumatoid arthritis - interstitial lung disease

10:15 - 11:45  PARE Room

Abstract session
PARE Abstract session

Learning objectives:
From abstract to concrete - the variety of activities of PARE organisations

Chair(s):
Kate Betteridge (United Kingdom)
Polina Pchelnikova (Russian Federation)
Magdalena Misuno (Poland) 10:20
Edgar Stene Prize 2018: My personal champion - supporting my everyday life with a rheumatic and musculoskeletal disease (RMD)

C. R. Ziegler (Denmark) 10:30
Abstract N° OP0290-PARE
Keep an eye out for invisible pains - a Danish campaign
J. F. M. Holla (Netherlands) 10:40
J. Brontsema, N. Schenk, R. Jansen, R. Vreeneeoor, M. Fluit, W. F. Peter, I. E. Bultink
Abstract N° OP0291-PARE
Running with rheumatism: a 7-week training programme for novice runners with inflammatory rheumatic disease

A. Lacovou (Cyprus) 10:50
Abstract N° OP0292-PARE
The creation of the ‘aqua re-action’. A methodologically based aquatic physical intervention/rehabilitation program for people with RMDs

P. Wegscheider (Austria) 11:00
G. Schaffer
Abstract N° OP0293-PARE
Problems, goals and urgent wishes of young Austrians diagnosed with rheumatic disorders: a report

A. Higginbottom (United Kingdom) 11:20
S. Blackburn, R. Taylor, C. Rhodes, L. Campbell, K. Dziedzic
Abstract N° OP0294-PARE
Addressing key challenges of lay involvement in musculoskeletal research: co-applicants and trial steering committees

S. De Jong (Netherlands) 11:20
Abstract N° OP0295-PARE
‘Kweek begrip’: the launch of our creative campaign across the Netherlands on worldarthritisday aims to increase awareness about RMDs in general and people living with RMDs in particular

N. Haroon (Canada) 11:30
B. Kuriya, J. Widdifield, J. Luo, S. Vigod
Abstract N° OP0296
The risk of deliberate self-harm in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study

10:15 - 11:45 E106/E107

Abstract session
More money or more education and collaboration?
Chair(s):
Bruno Fautrel (France)
Juliane Stocker (Netherlands)
S. A. Bergstra (Netherlands) 10:20
J. Tavares-Costa, M. Garzo-Elizondo, K. Salomon-Escoto, N. Govind, C. Allaart, R. Landewé
Abstract N° OP0297
Disease activity in rheumatoid arthritis patients is influenced by countries’ socioeconomics: results from the METEOR registry

M. A. Lopez-Olivo (United States) 10:30
A. Matusevich, S. B. Cantor, G. Pratt, M. E. Suarez-Almazor
Abstract N° OP0298
The comparative effectiveness of cycling tumor necrosis factor inhibitor (TNFi) versus swapping to a nonTNFi on patient-reported functional ability of patients with rheumatoid arthritis

E. van Mulligen (Netherlands) 10:40
A. E. A. M. Weel, T. M. Kuijper, J. J. Luime, J. M. W. Hazes, P. H. P. de Jong
Abstract N° OP0299
Cost-effectiveness of tapering TNF blockers versus conventional synthetic DMARDs in rheumatoid arthritis: first year results of the randomised controlled TARA-study

A. Barr (United Kingdom) 10:50
D. Pickles, N. Fadi, J. Dou, C. Vandevelder, S. Dubash, J. E. Freeston, H. Marzo-Ortega
Abstract N° OP3000
Reducing avoidable biologic drug wastage through collaboration between patients and care providers: the Leeds spondyloarthritis service experience

S. S. Pazmino (Belgium) 11:00
R. Westhoven, J. Joly, V. Stouten, D. De Cock, K. van der Elst, P. Verschueren on behalf of the CareRA study group
Abstract N° OP3001
Two year cost-effectiveness analysis of the carera trial in early RA: a piggy back study

A. Ahrari (Canada) 11:10
Abstract N° OP3002
An evaluation of utilisation patterns and appropriateness of laboratory tests among new referrals to rheumatologists: choosing unwisely!

A. Moltó (France) 11:20
Abstract N° OP3003
Systematic screening of comorbidities improves vaccination rates, skin cancer screening and vitamin D supplementation in patients with axial spondyloarthritis: results of the COMEDSPA prospective, controlled, one year randomised trial

M. Kostine (France) 11:30
Abstract N° OP3004
Multidisciplinary collaboration among young specialists: results of an ongoing international survey by young organisations
Abstract session

The changing therapeutic landscape of PsA

Chair(s):
Douglas Veale (Ireland)
Kurt de Vlam (Belgium)

E. Kampylafka (Germany)  10:20
I. d Oliveira, C. Linz, V. Lerchen, M. Englbrecht,
D. Simon, M. Sticherling, J. Rech, A. Kleyer,
G. Schett, A. J. Hueber
Abstract N° OP0305
Disease interception in psoriasis patients with sub-clinical joint inflammation by interleukin 17 inhibition with secukinumab - data from a prospective open label study

D. van der Heijde (Netherlands)  10:30
P. Mease, R. Landewé, S. Mpofo, P. Rahman,
H. Tahir, A. Singhal, E. Boettcher, S. Navarra,
X. Zhu, A. Readie, L. Pricop, K. Abrams
Abstract N° OP0306
Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: analysis by prior anti-TNF therapy and concomitant methotrexate use

P. J. Mease (United States)  10:40
H. Kellner, A. Morita, A. J. Kivitz, K. A. Papp,
S. Aslanyan, B. Berner, S. Chen, A. Eldred,
F. Behrens
Abstract N° OP0307
Efficacy and safety of risankizumab, a selective IL-23P19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial

A. Deodhar (United States)  10:50
A. B. Gottlieb, W.-H. Boehncke, B. Dong, Y. Wang,
Y. Zhuang, W. Barchuk, X. L. Xu, E. Hsia
Abstract N° OP0308
Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2A, randomised, double-blind, placebo-controlled study

P. Mease (United States)  11:00
D. Gladman, A. Kavanaugh, P. Nakasato,
B. Guerette, L. Teng, P. Nash
Abstract N° OP0309
Characterization of clinical benefits in subjects classified as ACR20 non-responders at week 104 of apremilast treatment: sub-analysis of 3 long-term, phase III trials

J. Pinto-Tasende (Spain)  11:10
F. Maceiras-Pan, C. García-Porrúa,
J. A. Mosquera-Martinez, L. Fernandez-Dominguez,
B. Correa-Rey, M. Pombo-Suarez
Abstract N° OP0310
Prevalence of risk factors and cardiovascular events across psoriatic arthritis patients treated with biological therapy

A.-S. Vandendorpe (Belgium)  11:20
K. De Vlam, R. Lories
Notable evolutions in the characteristics of psoriatic arthritis clinical trials populations in the era of biological treatments

M. Ellemoune (Canada)  11:30
M. Eraso, A. Maharaj, V. Chandran, L. Coates
on behalf of ILAR-PsA recommendations group,
Adebayo A, Sharma A, Toloza S, Vega-E L,
Vega-H O, Abogamal A, Ajibade A, Ayanlowo O,
Azevedo V, Bautista-M W, Carneiro S, Goldenstein-S,
C, Hernandez-V F, Ima-E U, Lima A, Medina-R J,
Mody G, Narang T, Ortega-L A, Ranza R
Abstract N° OP0312
International league of associations for rheumatology (ILAR) treatment recommendations for psoriatic arthritis in resource-poor countries

Abstract session

T/B be or not T/B: adaptive or innate immunity - that is the question

Chair(s):
Hendrik Schulze-Koops (Germany)
Marije Koenders (Netherlands)

R. D. Vergroesen (Netherlands)  10:20
L. M. Slot, F. S. van de Bovenkamp, M. T. Koning,
T. W. J. Huizinga, T. Rispens, R. E. M. Toes,
H. U. Scherer
Abstract N° OP0313
Molecular analysis of anti-citrullinated protein antibody variable regions indicates aberrant selection processes during ACPA B cell development

A. Floudas (Ireland)  10:30
M. Biniecka, C. Low, D. J. Veale, U. Fearon
Abstract N° OP0314
B cell phenotype and function in the synovium of ACPA+ and ACPA- rheumatoid arthritis patients

J. Y. Leong (Singapore)  10:40
J. G. Yeo, P. Chen, F. Ally, C. Chua, S. N. Hazirah,
P. Lu, L. Lai, L. D. T. Bathi, T. Arkachaisri,
D. J. Lovell, S. Albani
Abstract N° OP0315
Juvenile idiopathic arthritis patients exhibit persistence in CD4 memory T cells and distinct transcriptomic signature despite biologics therapy

G. Dekkema (Netherlands)  10:50
T. Bijma, W. Abdulahad, P. Jellema, A. van den Berg,
B. J. Kroesen, C. Stegeman, P. Heeringa,
J.-S. Sanders
Increased expression of microRNA-142-3P is associated with the functional defect of regulatory T cells in anti-neutrophil cytoplasmic antibody associated vasculitis
Abstract N° SP0097
WIN: Check-point inhibitors: what are they used for?
Ellen Kapiteijn (Netherlands) 13:35
Abstract N° SP0097
WIN: Check-point inhibitors: what are they used for?
Leonard Calabrese (United States) 14:15
Abstract N° SP0098
HOT: Immune related adverse events upon check-point inhibitors

Does it matter to the clinician: can pathophysiological knowledge lead to better patient care?
Georg Schett (Germany) 14:29

Pathophysiology of PsA: what is the role of cells and cytokines?
Rik Lories (Belgium) 13:35

Synovial markers in inflammatory arthritis: is this the new holy grail?
Bernard Lauwerys (Belgium) 13:53

Serum biomarkers in PsA: a novel tool in diagnosis and therapeutic monitoring?
Christopher T. Ritchlin (United States) 14:11

Challenges in systemic lupus diagnosis

Learning objectives:
• To be able to identify a very rare lung involvement in SLE
• To discuss how to differentiate specific and aspecific neuropsychiatric SLE features
Chair(s):
Pier Luigi Meroni (Italy)
Guillermo Pons-Estel (Argentina)
Margherita Zen (Italy) 13:35
Abstract N° SP0099
Case 1 presentation: Painful dyspnea
Andrea Doria (Italy) 13:45
Case 1 discussion: Shrinking lung
Antonis Fanouriakis (Greece) 14:15
Abstract N° SP0100
Case 2 presentation: Neuropsychiatric lupus or not?
Dimitrios Boumpas (Greece) 14:25
Case 2 discussion: Diagnosis of neuropsychiatric SLE: the problem of attribution

Guided poster tours
Guided poster tours on various topics are taking place during the official poster viewing. For details on the various tours on Friday, please refer to page 98. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

Poster viewing and lunch

11:45 - 13:30 Exhibition, EULAR Village (Hall 1) and Poster areas

11:50 - 13:30 Poster area

From Bench to Bedside
Pathophysiology and biomarkers in PsA: what impact?

Learning objectives:
• To review new insights into pathophysiology in PsA
• To identify markers of synovial inflammation and biomarkers in PsA
• To gain further insight into clinical consequences of different pathophysiological disease mechanisms and drivers in clinical decision-making
Chair(s):
Douglas Veale (Ireland)
Dirk Elewaut (Belgium)
Rik Lories (Belgium) 13:35

Pathophysiology of PsA: what is the role of cells and cytokines?
Rik Lories (Belgium) 13:35

Synovial markers in inflammatory arthritis: is this the new holy grail?
Bernard Lauwerys (Belgium) 13:53

Serum biomarkers in PsA: a novel tool in diagnosis and therapeutic monitoring?
Christopher T. Ritchlin (United States) 14:11

Does it matter to the clinician: can pathophysiological knowledge lead to better patient care?
Georg Schett (Germany) 14:29
Abstract N° OP0321
Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis

13:30 - 15:00  Elicium 2
Clinical Science session
The art of diagnosis of axial SpA

Learning objectives:
• To gain further insights into early phases of axial SpA, and how to diagnose it, addressing its challenges
• To review the pros and cons of imaging and laboratory testing in early axSpA
• To discuss how to disentangle the different types of back pain present in axSpA - inflammatory, degenerative and both
• To discuss the impact of an early diagnosis of axSpA, and what consequences it has for the patient receiving it

Chair(s):
Victoria Navarro-Compán (Spain)
Atul Deodhar (United States)

Martin Rudwaleit (Germany) 13:35
What is early axial SpA? Challenges for an early diagnosis

Anna Moltó (France) 13:55
The symptom of back pain - disentangle between inflammatory, degenerative or both?

Filip van den Bosch (Belgium) 14:15
Clinical impact of an early diagnosis in axial SpA

V. Navarro-Compán (Spain) 14:35
R. E. Nieto, C. Plasencia, D. Peiteado, A. Villalba, A. Balsa
Abstract N° OP0322
Are we treating with biological therapies women patients with real non-radiographic axial spondyloarthritis?

A. Ortolan (Italy) 14:45
M. van Lunteren, S. Ramiro, R. Ramonda, R. Landewé, H. Dagfinrud, L. Jacobsson, D. van der Heijde, F. A. van Gaalen
Abstract N° OP0323
Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the spondyloarthritis caught early cohort

Abstract N° OP0322
Are we treating with biological therapies women patients with real non-radiographic axial spondyloarthritis?

Abstract N° OP0323
Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the spondyloarthritis caught early cohort

13:30 - 15:00  Hall 7.2
The Young Rheumatologist
Understanding the language of basic research, epidemiology and health services articles

Learning objectives:
To properly understand the meaning of basic research, epidemiology and health services terminology and findings reported in published articles

Chair(s):
Iain B. McInnes (United Kingdom)
Loreto Carmona (Spain)

Iain B. McInnes (United Kingdom) 13:35
Understanding the language of basic research articles

William G. Dixon (United Kingdom) 13:55
Understanding the language of epidemiology articles

Loreto Carmona (Spain) 14:15
Understanding the language of health services articles

K. L. Grøn (Denmark) 14:35
E. Arkema, B. Glintborg, F. Mehnert, M. Østergaard, L. Dreyer, M. Nørgaard, N. S. Krogh, J. Askling, M. Heltand on behalf of all departments that have contributed with data and the ARTIS study group
Abstract N° OP0324
Risk of serious infections in rheumatoid arthritis patients treated with abatacept, rituximab and tocilizumab in Denmark and Sweden

J. Gandrup (United States) 14:45
J. Li, Z. Izadi, T. Ellingsen, J. Yazdany, G. Schmajuk
Abstract N° OP0325
Effect of three health it interventions on RA disease activity score documentation in an academic rheumatology clinic

13:30 - 15:00  Forum
Clinical Science session
Joint EULAR - ESSR session: the role of MR imaging in rheumatic diseases and its clinical implications

Learning objectives:
To learn about the radiologist’s and rheumatologist’s perspective of RA and SpA and to discuss possible differences

Chair(s):
Joachim Sieper (Germany)
Monique Reijnierse (Netherlands)

Benedikt Ostendorf (Germany) 13:35
Abstract N° SP0103
Indications and clinical implications of MR imaging in RA
Basic and Translational Science session
The stromal link to inflammation

Learning objectives:
- Chronic inflammation affects local stromal cells
- Stromal cells adapt to long-term inflammation with alterations in surface molecules, epigenetic and metabolomic changes
- Inflammatory memory alters the response to inflammatory factors of stromal cells

Chair(s):
Steffen Gay (Switzerland)
Kerstin Klein (Switzerland)

Chris Buckley (United Kingdom)
Stromal inflammatory memory: cellular priming and alterations

R. Stratton (United Kingdom)
Z. Taki, B. Abdi Ahmed, E. Gostjeva, C. Venturini, C. Denton, A. Salama, H. Lopez
Modelling the interaction between disease microenvironment and mesenchymal stem cells in scleroderma

Costantino Pitzalis (United Kingdom)
Treatment resistance: a role of fibroblasts and stromal cells?
13:30 - 15:00 Emerald

Practical skills session*
Data visualisation: tables and graphs for publication and presentation II

Learning objectives:
To learn how tables and graphs should be designed for publication and presentation

Maarten Boers (Netherlands) 13:35
Abstract N° SP0080
Data visualisation: tables and graphs for publication and presentation

13:30 - 15:00 PARE Room

Joint session PARE/Clinical
Innovative treatments for a better quality of life

Learning objectives:
• To present new innovative drugs
• To outline health interventions and technology assessment in support of people with RMDs
• To learn what drug safety parameters the patient has to consider when being treated with innovative drugs

Chair(s):
José A. P. da Silva (Portugal)
Eva Tzigounaki-Kritza (Greece)

Johannes W. J. Bijlsma (Netherlands) 13:35
Why JAK inhibitors can make a difference?

Jürgen Clausen (Germany) 13:55
Involvement of a patient organisation in health technology assessment

Ailsa M. Bosworth (United Kingdom) 14:15
Patient rights and safety concerns in an era of innovative therapies

A. M. Bosworth (United Kingdom) 14:35
S. Arora
Abstract N° OP0330-PARE
Love your heart, an online, interactive cardiovascular risk assessment programme for people with RA/IA

L. Alemo Munters (Sweden) 14:45
A. Beerman
Abstract N° OP0331-PARE
Behavior change experiences and needs of persons with rheumatic disease

13:30 - 15:00 E106/E107

EULAR Projects
EULAR Projects in Investigative Rheumatology

Learning objectives:
To review the last advances of some of the study groups involved in investigative rheumatology

Chair(s):
Xavier Mariette (France)
Timothy R. Radstake (Netherlands)

Johan Ronnelid (Sweden) 13:35
Autoantibody standardization in autoimmune diseases

Francesca Barone (United Kingdom) 13:55
From pathophysiology of Sjögren’s syndrome to new clinical trials

Maurizio Cutolo (Italy) 14:15
How neuro endocrine immunology impact rheumatic diseases?

Vanessa Smith (Belgium) 14:35
Microcirculation in rheumatic diseases

13:30 - 15:00 D201/D202

Practical skills session*
Laboratory course - from the clinic to the lab and back

Learning objectives:
• To discuss importance of ANA diagnostic and antiphospholipid syndrome
• To learn more about vasculitis and systemic autoimmunity
• To discuss new trends in biomarkers in inflammatory joint disease

Chair(s):
Gerd R. Burmester (Germany)
Thomas Dörner (Germany)

Thomas Dörner (Germany) 13:35
ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder

Pierre Miossec (France) 14:00
Vasculitis, systemic autoimmunity

Eugen Feist (Germany) 14:25
New trends in biomarkers in inflammatory joint disease

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Practical skills session*  
New assessments in clinical practice

Learning objectives:
- To learn how to perform a reliable physical examination
- To properly judge value of inflammatory biomarkers in clinical decision-making
- To properly value ultrasonography in clinical decision making

Chair(s):
Annamaria Iagnocco (Italy)  
Michael Doherty (United Kingdom)

Michael Doherty (United Kingdom)  13:35  
Abstract N° SP0114  
How to perform quick and reliable physical examination in rheumatology

Miriana Sefik-Bukilica (Serbia)  13:55  
Abstract N° SP0115  
Value of inflammatory biomarkers in clinical decision making

Lene Terslev (Denmark)  14:15  
Abstract N° SP0116  
Value of ultrasound in clinical decision making

Annamaria Iagnocco (Italy)  14:35  
Abstract N° SP0117  
Ultrasound scanning of RA patients in remission

Clinical Science session  
Advances in biologic therapy of small vessel vasculitis

Learning objectives:
To familiarise the audience with with new advances in treating SV vasculitis

Chair(s):
David Saadoun (France)  
Leonard Calabrese (United States)

David Jayne (United Kingdom)  15:35  
Complement inhibition in AAV

Frank Moosig (Germany)  15:55  
The evolving role of mepolizumab in EGPA

Benjamin Terrier (France)  16:15  
Abstract N° SP0120  
Current controversies in the use of rituximab for induction and maintenance of AAV disease

P. Brogan (United Kingdom)  16:35  
Abstract N° OP0332  
Paediatric open-label clinical study of rituximab for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

M. Felicetti (Italy)  16:45  
S. Monti, M. Bond, A. Berti, R. Padoan, G. Paolazzi, G. Brunori, L. Quartuccio, R. Caporali, F. Schiavon  
Abstract N° OP0333  
Survival in ANCA associated vasculitides: a retrospective multicentric analysis in northern Italy

What is New (WIN) & How to Treat (HOT) session

WIN & HOT session

Karim Raza (United Kingdom)  15:35  
WIN: How to diagnose rheumatoid arthritis early?

Maya Buch (United Kingdom)  16:15  
Abstract N° SP0118  
HOT: Recent advances in the treatment of rheumatoid arthritis

Clinical Science session  
Tapering and flaring in PsA and SpA

Learning objectives:
- To provide an overview of the current literature on tapering of DMARDs (incl. biologicals) in the setting of both peripheral and axial locomotor manifestations
- To discuss the concept of flare in PsA and SpA and how to manage it, both in its identification and clinical management

Chair(s):
Philippe Carron (Belgium)  
Uta Klitz (Germany)

Laura Coates (United Kingdom)  15:35  
Abstract N° SP0121  
Tapering in PsA - to do or not to do?

Denis Poddubnyy (Germany)  15:55  
Abstract N° SP0122  
Tapering in axial disease - to do or not to do?
The concept of flare and how to deal with it

Efficacy and safety of continuing versus withdrawing adalimumab (ADA) in maintaining remission in patients with non-radiographic axial spondyloarthritis (nr-axSpA)

High need for anti-TNF therapy after withdrawal strategy in early peripheral spondyloarthritis

Learning objectives:
• To understand why the prevalence of knee osteoarthritis has doubled since 1950 even after normalization for age and weight
• To envision how these new data could have an impact on prevention

Chair(s):
Francis Berenbaum (France)
Ida K. Haugen (Norway)

David Felson (United States) 15:35
Why has the prevalence of knee OA doubled in recent years?

Martin Englund (Sweden) 15:55
Physical activity and exercise: opportunities and challenges

Jeremie Sellam (France) 16:15
We are what we eat!

M. Cook (United Kingdom) 16:35
The effect of timing and duration of statin exposure on the risk of revision following total hip or knee arthroplasty: a population-based cohort study

F. Pan (Australia) 16:45
Association between metabolic syndrome and trajectories of knee pain: a 10.7-year follow-up study

Clinical Science session
Big data for musculoskeletal research

Learning objectives:
• To understand the challenges and opportunities arising from the use of big data for MSK research
• To learn about ongoing and future applications of BD/ML for rheumatologists including fracture prediction and phenotyping of OA
• To learn about the strengths and limitations of BD and relate methods for the evaluation of risk and benefit of drugs and devices for the treatment of arthritis and osteoporosis

Chair(s):
Daniel Prieto-Alhambra (United Kingdom)
Annemariek Driessen (Netherlands)

Sara Khalid (United Kingdom) 15:35
How big data and machine learning could change the game

Harrie Weinans (Netherlands) 16:15
Big data and machine learning for precision medicine in OA

Alexandre Sepriano (Portugal) 16:35
Big data for treatment effectiveness and safety

B. Mehta (United States) 16:55
Relationship of provider density on total joint replacement outcomes

L. Rodriguez-Rodriguez (Spain) 17:05
Development of a predictive model of radiological damage in patients with rheumatoid arthritis based on artificial intelligence
Paediatric Rheumatology session

From big data to personalised medicine in paediatric rheumatic diseases

Learning objectives:
• Understanding how pathogenic knowledge can be translated into novel tools for diagnosis, classification and treatment of rheumatic diseases
• Awareness of how new immunologic technology can lead to precision medicine

Chair(s):
Eve Smith (United Kingdom)
Yukiko Kimura (United States)
Alexandre Belot (France) 15:35

Abstract N° SP0127
The bumpy road from signaling pathways to personalised medicine in childhood SLE

Annet van Royen (Netherlands) 16:00

Abstract N° SP0128
Finding the needle in the haystack and using it: galectin 90 as a biomarker of juvenile dermatomyositis

Salvatore Albani (Singapore) 16:25

How the human immunome revolutionizes personalised treatment of paediatric inflammatory diseases

G. Giancane (Italy) 16:50

Abstract N° OP0340
Evidence-based recommendations for corticosteroid tapering/discontinuation in new onset juvenile dermatomyositis patients from the PRINTO trial

Basic and Translational Science session

Triple T: T cells, technologies and therapies

Learning objectives:
• Update on latest technological developments to study T cell state and fate
• Describe how peptide therapy can influence T cell function in autoimmune disease
• Discuss latest insights on T cell tolerance in RA

Chair(s):
Erik Lubberts (Netherlands)
Andrew Cope (United Kingdom)
Frits Koning (Netherlands) 15:35

Application of single cell technology to understand T cell heterogeneity

Frits Koning (Netherlands) 15:35

P. Fortea-Gordo (Spain) 15:55
L. Nuño, A. Villalba, D. Peiteado, I. Monjo, P. Sanchez-Mateos, A. Puig-Kröger, E. de Miguel, A. Balsa, M. E. Miranda Carus

Abstract N° OP0341
Increased frequency of circulating CD4+CXCR5-PD1HI peripheral helper T (CTPH) cells in patients with seropositive early rheumatoid arthritis (RA)

Leonie Taams (United Kingdom) 16:05

Abstract N° SP0129
Studying T cell function in RA and PsA

B. Paleja (Singapore) 16:25
A. Low, P. Kumar, S. Saidin, A. Lajam, L. D/O Thanna Bathi, L. Lai, C. Chua, S. Albani

Abstract N° OP0342
Altered frequency and function of MALT cells in systemic sclerosis revealed by high dimensional mass cytometry and transcriptome analysis

Ranjeny Thomas (Australia) 16:35

Towards T cell tolerance in RA

Health Professionals session

Navigating the world of digital health

Learning objectives:
To discuss the challenges for patients to seek, find and appraise health information from electronic resources

Chair(s):
Ann Bremander (Sweden)
Mari Klokkerud (Norway)
Elizabeth Heron (United Kingdom) 15:35

Constance Drossaert (Netherlands) 15:53

Abstract N° SP0132
Measuring digital health literacy

Line Raunsbaek - Knudsen (Denmark) 16:29

Abstract N° SP0133
Multi-media patient education based on entertainment education delivered to patients with low HL

M. Ferwerda (Netherlands) 16:47

Abstract N° OP0343-HPR
An economic evaluation of a tailored guided internet-based cognitive behavioural intervention for patients with rheumatoid arthritis as an addition to usual care
Clinical Science session
The rheumatologist-orthopedic surgeon connection in secondary fracture prevention

Learning objectives:
• To understand the procedures of the orthopedic surgeon in the treatment of the fracture
• To learn how patients with a recent fracture should be transferred to the fracture liaison service
• To learn about the assessment of risk of subsequent fracture for decisions about fracture prevention

Chair(s):
Roland D. Chapurlat (France)
Piet Geusens (Netherlands)
Karsten Dreinhöfer (Germany)
Kristina Åkesson (Sweden)
Willem F. Lems (Netherlands)
C. Libanati (Belgium)
F. Cosman, D. B. Crittenden, S. Ferrari, A. Khan, N. E. Lane, K. Lippuner, T. Matsumoto, C. E. Milmont, A. Grauer
W. F. Lems (Netherlands)

PARE session
What’s new: Latest advances in treatment in JIA and osteoarthritis

Learning objectives:
To show the latest advances in treatment and care in JIA and osteoarthritis

Chair(s):
Philip Conaghan (United Kingdom)
Victoria Romero Pazos (Spain)
Margreet Kloppenburg (Netherlands) 15:35

Abstract N° SP0136
Latest advances in treatment and management of OA

Tadej Avcin (Slovenia) 16:15

Abstract N° OP0346-PARE
A partnership in implementation: adapting an osteoarthritis guidebook across European cultures - with patients, for patients

Y. El Miedany (United Kingdom) 16:45

Abstract N° OP0347
Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking

EULAR Projects in Epidemiology and Health Services
Assessment and prevention of RMDs, what have we learned?

Chair(s):
Laure Gossec (France)
Axel Finckh (Switzerland)

Johan Askling (Sweden) 15:35

What randomised trials and observational studies have taught us in rheumatoid arthritis

Suzanne Verstappen (United Kingdom) 16:00

Prevention of RMDs - what have we learned?

Francis Guillemin (France) 16:25

Why not all effective interventions are worthwhile
15:30 - 17:00

**Practical skills session**

**Capillaroscopy II**

**Chair(s):**
Ariane L. Herrick (United Kingdom)
Alberto Sulli (Italy)

**Vanessa Smith (Belgium)** 15:35
Abstract N° SP0088
The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease

Alberto Sulli (Italy) 15:55
Scoring the capillaroscopic images

Ariane L. Herrick (United Kingdom) 16:15
Abstract N° SP0089
How to distinguish the major capillaroscopic patterns

Maurizio Cutolo (Italy) 16:35
Abstract N° SP0090
How capillaroscopy can predict disease severity and prognosis

17:30 - 19:00

**Basic and Translational Science session**

**High-end imaging: looking for the invisible**

**Learning objectives:**
- To learn about new, in vivo imaging possibilities to understand the events in inflamed tissues
- To learn about the possibilities of in vitro imaging with 30nm voxel size

**Chair(s):**
Stephanie Finzel (Germany)
Martin Herrmann (Germany)

**Stefan Uderhardt (United States)** 17:35
Abstract N° SP0139
The role of phagocytes at the inflammatory site

**James Brewer (United Kingdom)** 18:00
Abstract N° SP0140
Imaging the arthritic joint

**Silke Christiansen (Germany)** 18:25
Abstract N° SP0141
The ultra high resolution x-ray microscope in the analysis of calcified tissues

**B. Rocha (Spain)** 18:50
Abstract N° OP0348
Mass spectrometry imaging analysis of synovium differentiate patients with psoriatic and rheumatoid arthritis

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2
Guided Poster Tours

Friday, 15 June 2018

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a 'first-come-first-served' basis on the date of the poster tour.

11:50 - 13:30  Poster area

**Poster tour F1: Digging deep: basic and translational science in paediatric rheumatology**

Chair(s): Berent J. Prakken (Netherlands), Klaus Tenbrock (Germany)

Abstracts N°: FRI0001-FRI0006

See page 99

**Poster tour F2: Let's discuss RA outcomes**

Chair(s): John D. Isaacs (United Kingdom), Kenneth Baker (United Kingdom)

Abstracts N°: FRI0042-FRI0051

See page 101

**Poster tour F3: The hydra beast in RA: a multifaceted disease**

Chair(s): Elena Nikiphorou (United Kingdom) Peter C. Taylor (United Kingdom)

Abstracts N°: FRI0090-FRI0099

See page 103

**Poster tour F4: SpA pathophysiology: of mice and men...**

Chair(s): Dirk Elewaut (Belgium) Filip van den Bosch (Belgium)

Abstracts N°: FRI0148-FRI0157

See page 106

**Poster tour F5: Spondyloarthritis: it looks as if it is only imaging that matters**

Chair(s): Robert B. M. Landewé (Netherlands), Anna Moltó (France)

Abstracts N°: FRI0169-FRI0177

See page 107

**Poster tour F6: Gout epidemiology and therapy**

Chair(s): Alexander So (Switzerland) Abhishek Abhishek (United Kingdom)

Abstracts N°: FRI0220-FRI0229

See page 109

**Poster tour F7: The enemy in us**

Chair(s): Martin Herrmann (Germany) Yi Zhao (China)

Abstracts N°: FRI0255-FRI0263

See page 110

**Poster tour F8: Back to the future: how to mix the old and new treatments for SLE, Sjögren's and APS**

Chair(s): Angela Tincani (Italy) Micaela Fredi (Italy)

Abstracts N°: FRI0302-FRI0311

See page 112

**Poster tour F9: Shaping pathophysiology: new molecules - new views on pathways in SSc, myositis and related syndromes**

Chair(s): Ulf Müller-Ladner (Germany), Jeska de Vries (Netherlands)

Abstracts N°: FRI0396-FRI0406

See page 116

**Poster tour F10: Clinical and therapeutic advances in vasculitis**

Chair(s): Leonard Calabrese (United States) Valentin Schäfer (Germany)

Abstracts N°: FRI0474-FRI0483

See page 120

**Poster tour F11: Novelties in osteoarthritis: clinical aspects**

Chair(s): Francis Berenbaum (France), Félíne Kroon (Netherlands)

Abstracts N°: FRI0520-FRI0529

See page 122

**Poster tour F12: You can do better studies if you know how**

Chair(s): Loreto Carmona (Spain) Antonis Fanourakis (Greece)

Abstracts N°: FRI0600-FRI0609

See page 125

**Poster tour F13: Searching for outcome measures**

Chair(s): João E. Fonseca (Portugal) Vasco C. Romao (Portugal)

Abstracts N°: FRI0640-FRI0649

See page 127

**Poster tour F14: Education for better patients care**

Chair(s): Nemanja Damjanov (Serbia), Mirjana Bukilica (Serbia)

Abstracts N°: FRI0691-FRI0700

See page 129

**Poster tour F15: Bread and butter for clinicians**

Chair(s): Annette de Thurah (Denmark) Andrea Marques (Portugal)

Abstracts N°: FRI0737-HPR-FRI0746

See page 180

12:00 - 13:30  PARE Poster area

**Poster tour F16: PARE Poster Tour II**

Chair(s): Nele Caeyers (Belgium) Boryana Boteva (Bulgaria)

Abstracts N°: PARE0009-PARE0017

See page 188
**SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018**

---

**Scientific Poster Session II**

---

**Friday, 15 June 2018**

- **Poster viewing**: 11:45-13:30
- **Guided poster tours**: 11:50-13:30

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis on the date of the poster tour.

---

**TOPIC: BASIC SCIENCE IN PAEDIATRIC RHEUMATOLOGY**

**Poster tour F1:** Digging deep: basic and translational science in paediatric rheumatology

**Chair(s):** Berent J. Prakken (Netherlands), Klaus Tenbrock (Germany)

**Abstracts N°:** FRI0001-FRI0006

**FRI0001**


**FRI0002**


**FRI0003**


**FRI0004**

Granulocyte Macrophage Colony Stimulating Factor Is Secreted at Higher Levels from Stimulated Monocyte-Derived Macrophages from Patients with Enthesitis Related Arthritis and Is Significantly Enhanced by the Unfolded Protein Response / C. Fisher* - D. Eleftheriou - D. Sen - Y. Ioannou

**FRI0005**


**FRI0006**


---

**TOPIC: RHEUMATOID ARTHRITIS - PROGNOSIS, PREDICTORS AND OUTCOME**

**FRI0007**

Performance of Musculoskeletal Ultrasonography (MSUS) and Optimal Cutoff Criteria for Patients at Risk for Rheumatoid Arthritis: A Meta-Analysis / A. Castro* - J. Diaz - S. Kumar

**FRI0008**


* Presenting author
A COMPARISON OF THE JOINT SYNOVITIS AND TENOSYNOVITIS USING ULTRASONOGRAPHY AND HISTOPATHOLOGICAL FINDINGS IN PATIENTS WITH RHEUMATOID ARTHRITIS / A. Abe* - H. Ishikawa - A. Murasawa - K. Wakaki


CONVERTING PATIENT-REPORTED PHYSICAL FUNCTION OUTCOMES SCORES TO PROMIS METRIC SCORES IN PHASE 3 TRIALS OF BARCITINIB IN RHEUMATOID ARTHRITIS / C. O. Bingham III* - C. Gaich - A. M. DelLozier - A. Quebe - L. Sun - S. Otawa - J. Pope


NO RELATIONSHIPS BETWEEN ACPA AND PERIODONTITIS IN EARLY RHEUMATOID ARTHRITIS / F. Mechi* - C. Zehraouc - M. Meddad - S. Salah - M. Benidir - S. Merad - N. Saidi - O. Cheikh - N. Bliki - C. Dahou

AN EXPLORATORY STUDY ON THE ROLE OF VITAMIN D SUPPLEMENTATION IN IMPROVING PAIN AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS / G. Adami* - G. Sartori - R. Cipriani - P. Cappellini - M. Varenna - G. Orsolini - D. Gatti - M. Rossini on behalf of study group on Osteoporosis and Metabolic Skeletal Diseases of the Italian Society of Rheumatology (SIR)


ARE DISEASE ACTIVITY, DISABILITY OR PSYCHOLOGICAL FACTORS MOST ASSOCIATED WITH PATIENTS WITH RHEUMATOID ARTHRITIS BEING SATISFIED WITH THEIR CONDITION AFTER 12 MONTHS FOLLOWING TREATMENT ONSET? / J. Gwinnutt* - K. Hyrich - M. Lunt - A. Barton - S. Verstappen on behalf of RAMS coinvestigators


PATIENT-BASED DISEASE ACTIVITY SCORE PREDICTS FLARE BETTER THAN IMPROVEMENT - BLOOD TEST PROVIDES INSIGNIFICANT CONTRIBUTION / M.-H. A. Leung* - C.-S. Lau - E. Choy


COMPARISON OF CLINICAL AND ULTRASOUND MEASURES OF DISEASE ACTIVITY IN A LARGE NATIONAL ‘REAL LIFE’ COHORT OF RA PATIENTS / P. Zufferey* - D. W. Wu - Q. W. Mak - I. T. Cheng - T. K. Li - E. K. Li - L. S. Tam

* Presenting author

100 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018


FRI0035  DISEASE REMISSION IS MORE COMMON BUT LESS STRINGENT IN ANTI-CITRULLINATED PROTEIN-POSITIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING DRUGS / A. Manzo - S. Bugatti* - G. Zanfrumando - F. Benaglio - G. Sakellariou - C. Montecucco - R. Caporali


FRI0037  CHARACTERISTICS OF RECENT ELDERLY-ONSET RHEUMATOID ARTHRITIS PATIENTS / T. Oshige* - Y. Kaneko - T. Takeuchi


FRI0039  MEASURING HEALTH REALIZED QUALITY OF LIFE (EQ-SD) IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ONE YEAR TREATMENT WITH CSMARDS AND BIOLOGIC DMARDS / V. V. Boyadzhieva* - N. Stoilov - G. Petrova - R. Stoilov

FRI0040  DEVELOPMENT AND VALIDATION OF CLINICAL PREDICTORS FOR INADEQUATE RESPONSE TO TREAT-TO-TARGET METHOTREXATE THERAPY IN NEWLY DIAGNOSED RA PATIENTS / X. M. Teitsma* - J. W. Jacobs - E. Hardeman - X. M. Terwee - J. M. van Laar

FRI0041  ASSOCIATIONS BETWEEN TYMS POLYMORPHISMS AND RESPONSIVENESS TO OR TOXICITY OF METHOTREXATE IN RHEUMATOID ARTHRITIS / Y. H. Lee* - Y. H. Seo

**Poster tour F2:**  Let's discuss RA outcomes

**Chair(s):**  John D. Isaacs (United Kingdom), Kenneth Baker (United Kingdom)

**Abstracts N°:**  FRI0042-FRI0051

FRI0042  TENDER JOINTS HAVE LOW AGREEMENT WITH PATIENT’S EVALUATION OF SPONTANEOUS JOINT PAIN, JOINT SWELLING AND ULTRASOUND VERIFIED SYNOVITIS IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS / H. B. Hammer* - J. Sexton - B. Michelson - S. Provan - T. Uhlig - T. K. Kvien


FRI0050  TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR / G. Schett* - S. Finzel - S. Kraus - A. Regensburger - R. Kocijan - J. Rech

FRI0051  THE RISK OF ASEPTIC ARTHROPLASTY LOOSENING IN PATIENTS WITH RHEUMATOID ARTHRITIS / C. Böhler* - P. Weimann - F. Alasti - J. S. Smolen - R. Windhager - D. Aletaha

* Presenting author
TOPIC: RHEUMATOID ARTHRITIS - COMORBIDITY AND CLINICAL ASPECTS


FRI0053  THE CHANGING FACE OF RHEUMATOID ARTHRITIS AT THE END OF THE 20TH CENTURY - A COMPARATIVE POSTMORTEM CLINICOPATHOLOGIC STUDY OF 237 RHEUMATOID ARTHRITIS PATIENTS WITH AA AMYLOIDOSIS AND SYSTEMIC VASCULITIS / M. Bély - Á. Apáthy*

FRI0054  RISK FACTORS FOR POSTPARTUM FLARE IN RHEUMATOID ARTHRITIS - A ROMANIAN COHORT / A. Bobirca* - F. Bobirca - I. Ancuta - M. Micu - C. Ancuta - M. Bojina - C. Mihai - V. Stoica


FRI0056  CLINICAL FEATURES AT THE ONSET OF LYMPHOPROLIFERATIVE DISORDER IN PATIENTS WITH RHEUMATOID ARTHRITIS / D. Kobayashi* - S. Ito - Y. Wada - I. Narita - K. Nakazono


FRI0058  SERUM AND SYNOVIAL SURVIVIN ARE ASSOCIATED WITH EROSIIVE NOT ACTIVE RHEUMATOID ARTHRITIS / E. Baraka* - M. Serag El Din - A. El Shambly - M. Aboul Gheir

FRI0059  INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS OF A COHORT TREATED WITH METHOTREXATE MONOTHERAPY / E. Chamizo-Carmona* - C. Carrasco Cubero - S. M. Rojas Herrera - J. Malave Calzada - R. Veroz Gonzalez - L. M. Chaves Chaparro

FRI0060  ARE OLDER RA PATIENTS FRAIL, OR LONELY AND DEPRESSED? / F. Cleutjens* - A. Boonen - M. van Onna


FRI0063  RAPAMYCIN INDUCES REMISSION IN PATIENTS WITH REFRACTORY RHEUMATOID ARTHRITIS / H. Yao* - H. Niu - N. Yan - X. Sun - Z. Li - M. Chen - C. Gao - X. Li - C. Wang


FRI0070  COST-EFFECTIVENESS OF BIOLOGIC AGENTS FOR RHEUMATOID ARTHRITIS WAS SUPERIOR TO TRADITIONAL/CONVENTIONAL DMARDs WHEN ANALYSED WITH NUMBER NEEDED TO TREAT (NNT) METHOD / K. Harigane* - J. Song - S. K. Lee - Y. B. Park

FRI0071  COMORBIDITY AND CLINICAL ASPECTS / M. Bély - Á. Apáthy*


ADIPONECTIN LEVEL, INSULIN RESISTANCE, ENDOTHELIAL DYSFUNCTION IN FEMALES WITH RHEUMATOID ARTHRITIS AND COMORBID HYPERTENSION / O. Sirekono* - O. Kuryata - T. Lysunets


THE IMPORTANCE OF TRANSFERRIN SATURATION, SERUM FERRITIN, LOG FERRITIN AND TRANSFERRIN / LOG FERRITIN IN DIFFERENTIATING IRON DEFICIENCY ANEMIA FROM ANEMIA OF CHRONIC DISEASE IN RHEUMATOID ARTHRITIS PATIENTS / R. A. Abdel Noor* - M. H. Abu-Zaid - S. A. Elshweilk - E. S. Rabee - G. E. Khedr


ADJUSTMENT OF THE THRESHOLD MAY IMPROVE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. Velimkin - E. Troitskaya* - S. Villevalle - Z. Kobalava


REGIONAL AGE- AND SEX-SPECIFIC INTIMA-MEDIA THICKNESS CRITERIA IN YOUNG PATIENTS WITH RHEUMATOID ARTHRITIS / V. Omelchenko - E. Letyagina - M. Korolev* - R. Khapav - T. Propospelova - V. Konenkov

PSYCHOLOGICAL IMPACT IN RHEUMATOID ARTHRITIS: ROLE OF SPECIFIC TREATMENT AND ASSOCIATED MEASURES / X. Grapton* - P. Lemesle - L. Arabian - V. Strotz

ASSESSMENT OF COGNITIVE FUNCTION IN RHEUMATOID ARTHRITIS / Z. Kardos* - C. Oláh - M. Andrejkovics

ADJUSTMENT OF THE THRESHOLD MAY IMPROVE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. Velimkin - E. Troitskaya* - S. Villevalle - Z. Kobalava


DOES SUBCLINICAL INFLAMMATION EXPLAIN JOINT PAIN IN PATIENTS WITH ARTHRALGIA SUSPICIOUS FOR PROGRESSION TO RHEUMATOID ARTHRITIS? - RESULTS OF A CROSS-SECTIONAL MRI-STUDY / L. E. Burgers* - R. M. ten Brinck - D. M. Boeters - A. M. van der Helm-van Mil


DOES SUBCLINICAL INFLAMMATION EXPLAIN JOINT PAIN IN PATIENTS WITH ARTHRALGIA SUSPICIOUS FOR PROGRESSION TO RHEUMATOID ARTHRITIS? - RESULTS OF A CROSS-SECTIONAL MRI-STUDY / L. E. Burgers* - R. M. ten Brinck - D. M. Boeters - A. M. van der Helm-van Mil


IS SIDE EFFECTS AND TREATMENT RESPONSE TO METHOTREXATE ASSOCIATED TO COMORBIDITY IN EARLY RHEUMATOID ARTHRITIS / K. L. Pedersen* - J. Hallas - I. M. J. Hansen - P. Ahlquist - T. Ellingsen


* Presenting author

Poster tour F3: The hydra beast in RA: a multifaceted disease
Chair(s): Elena Nikiphorou (United Kingdom), Peter C. Taylor (United Kingdom)
Abstracts N°: FRI0090-FRI0099
TOPIC: RHEUMATOID ARTHRITIS - BIOLOGICAL DMARDS

FRI0100

FRI0101
UNMET NEEDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS. AN OBSERVATIONAL STUDY AND A REAL-LIFE EXPERIENCE FROM A SINGLE UNIVERSITY CENTER / E. Kaltsonoudis - E. Pelechas - P. V. Voulgaris - A. A. Drosos

FRI0102
REDUCTION OF ANTIDRUG ANTIBODY LEVELS AFTER SWITCHING TO RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH PREVIOUS FAILURE TO INFLIXIMAB OR ADALIMUMAB / A. Martinez-Feito* - C. Plascencia - V. Navarro-Compan - H. Hernández-Breijo - D. Pascual-Salcedo - P. Nozal - C. Diego - I. Monjo - L. Nuño - A. Balsa

FRI0103

FRI0104

FRI0105

FRI0106
IMPACT OF BIOLOGICAL AND TARGETED DMARDs ON WORK IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS: A META ANALYSIS OF RANDOMISED CONTROLLED TRIALS AND CONTROLLED COHORTS / C. Traverson* - A. tubery - C. Hua - F. Barchechath-Fiaisler - C. Lükas - B. Combe - J. Morel - C. Gaujoux-Viala

FRI0107
FIVE SUCCESSFUL PREGNANCIES WITH ANTENATAL ANAKINRA EXPOSURE / C. J. F. Smith* - C. Chambers

FRI0108

FRI0109

FRI0110

FRI0111

FRI0112
PERSISTENCE ON TUMOR NECROSIS FACTOR INHIBITOR (TNFI) MONOTHERAPY AFTER ACHIEVING REMISSION OR LOW DISEASE ACTIVITY (LDA) ON COMBINATION THERAPY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA) / D. A. Pappas* - H. J. Litman - T. Lesperance - S. Rebello - E. Kricorian - W. Hua - N. Accortt

FRI0113

FRI0114

FRI0115

FRI0117

FRI0118

FRI0120

* Presenting author
FRI0143

FRI0144
PATIENT-REPORTED OUTCOMES WITH SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS ARE SIMILAR REGARDLESS OF PRIMARY OR SECONDARY FAILURE WITH TUMOR NECROSIS FACTOR INHIBITORS / V. Strand* - S. Boklage - E. Mangan - M. Reaney - M. Iglesias-Rodriguez - T. Kimura

FRI0145
A BAYESIAN NETWORK-META-ANALYSIS ON EFICACY OF BIOLOGICS AND SMALL MOLECULES IN EARLY RHEUMATOID ARTHRITIS / V. Venerito* - F. Cacciapaglia - G. Lapadula - F. Iannone

FRI0146

FRI0147

TOPIC: SPONDYLOARTHROPATHIES - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS

Poster tour F4: SpA pathophysiology: of mice and men...

Chair(s): Dirk Elewaut (Belgium), Filip van den Bosch (Belgium)

Abstracts N°: FRI0148-FRI0157

FRI0148
A STUDY OF MICROBIAL TRANSLOCATION IN AN ANIMAL MODEL OF SPONDYLOARTHRITIS / M. Asquith* - M. Schlesman - S. Davin - L. Karstens - J. T. Rosenbaum

FRI0149
INFLAMMATION INTENSITY-DEPENDENT EXPRESSION OF OSTEINDUCTIVE WNT PROTEINS IS CRITICAL FOR ECTOPTIC NEW BONE FORMATION IN ANKYLOSING SPONDYLITIS / H. Li* - X. Li - J. Wang

FRI0150
MTOR BLOCKADE BY RAPAMYCIN DECREASES ARTHRITIS AND SPONDYLITIS DEVELOPMENT AND SEVERITY IN HLA-B27 TRANSGENIC RATS / S. Chen - M. van Tok - D. Pots - J. Taurog - M. van de Sande - D. Baeten - L. van Duijvenvoorde*

FRI0151

FRI0152

FRI0153

FRI0154

FRI0155

FRI0156

FRI0157

* Presenting author
FRI0165  

FRI0166  

FRI0167  
EXPRESSION LEVELS OF IL-17, IL-22 AND IL-23 RECEPTORS IN FOUR OSTEoblAST MODELS AND THE EFFECTS OF IL-17, IL-22 AND IL-23 ON OSTEoblASTS / J.-R. Zhang - S.-M. Dai  

FRI0168  
PHENOTYPIC, FUNCTIONAL AND MOLECULAR CHARACTERISATION OF IL-17+CD8+ T CELLS IN HUMAN HEALTH AND PSORIATIC ARTHRITIS / U. Srenathan* - K. J. Steel - M. L. Ridley - B. W. Kirkham - L. S. Taams  

TOPIC: SPONDYLOARTHRITIS - CLINICAL ASPECTS (OTHER THAN TREATMENT)  

Poster tour F5:  
Spondyloarthritis: it looks as if it is only imaging that matters  
Chair(s): Robert B. M. Landewé (Netherlands), Anna Moltó (France)  
Abstracts N°: FRI0169-FRI0177  

FRI0169  

FRI0170  

FRI0171  

FRI0172  
INFLAMMATION ON MRI OF THE SACROILIAC JOINTS IS HIGHLY PREDICTIVE OF STRUCTURAL DAMAGE IN AXIAL SPONDYLOARTHRITIS PATIENTS IN CLINICAL PRACTICE: DATA FROM THE ASAS AND DESIR COHORTS / A. Sepriano* - S. Ramiro - R. Landewé - M. Dougdas - D. van der Heijde - M. Rudwaleit  

FRI0173  

FRI0174  

FRI0175  
RATES AND PREDICTORS OF RADIOGRAPHIC SACROLIITIS PROGRESSION AFTER CENTRAL READING IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FROM THE ASAS COHORT: A 5-YEAR FOLLOW-UP STUDY / M. Protopopov* - F. Proft - A. Sepriano - R. Landewé - D. van der Heijde - J. Sieper - M. Rudwaleit - D. Poddubnyy  

FRI0176  
PERFORMANCE OF SPINAL AND SACROILIAC JOINT MRI FINDINGS IN PATIENTS WITH AXSPA / S. Lee* - I. Sari - E. S. Tunc - R. D. Imman - N. Haroon  

FRI0177  

FRI0178  

FRI0179  

FRI0180  

FRI0181  

FRI0182  

FRI0183  

FRI0184  

FRI0185  
HIGH PREVALENCE OF AKRADENITIS SUPPURATIVA, ESPECIALLY IN FEMALE AXIAL SPONDYLOARTHRITIS PATIENTS WITH HIGH DISEASE ACTIVITY AND POOR QUALITY OF LIFE / A. Rondags - S. Arends - F. Wink - B. Horvath - A. Spooerenberg  

FRI0186  
FACTORS DETERMINING WORK INSTABILITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / A. S. Buche* - L. Preston - N. Barkham  

FRI0187  

* Presenting author


FRI0189 PERIPHERAL MANIFESTATIONS IN SPONDYLOARTHRITIS: IMPACT ON PATIENT-REPORTED OUTCOMES (PROs) AND TREATMENT. Data from AsAS-COMOSPA / C. López-Medrét - A. Molto - M. Dougados


FRI0193 PROGNOSTIC MARKERS IN AXIAL SPONDYLOARTHRITIS (PROMISE) - CROSS SECTIONAL EVALUATION OF SERUM BIOMARKERS IN AXSPA, MECHANICAL BACK PAIN AND HEALTHY CONTROLS / E. Reilly* - C. Fisher - R. Sengupta


FRI0195 CLINICAL CHARACTERISTICS OF 897 CHINESE ANKYLOSING SPONDYLITIS/SPONDYLOARTHRITIS REAL WORLD COHORT: DATA FROM A CHINESE COHORT WITH SMART MANAGEMENT SYSTEM FOR SPONDYLOARTHROPATHY (SMSP) / X. Ji - J. Zhu - J. ZHANG - F. Huang* on behalf of SMSP co-authors

FRI0196 TRADITIONAL DXA UNDERESTIMATES BONE MINERAL DENSITY OF THE SPINE IN AXIAL SPONDYLOARTHRITIS: AN ASIAN PERSPECTIVE / G. Fitzgerald* - T. Anachebe - F. O'Shea


FRI0199 FUNCTIONING CATEGORIES BY ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND CONCOMITANT FIBROMYALGIA / L. Bessette - B. Haraoui - B. Florica - Y. Setty - M. Teo - V. Remple


FRI0202 INERTIAL MOTION SENSORS USING THE VIMOVE© SYSTEM IS A VALID METHOD TO ASSESS SPINAL MOBILITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / T. Diekhoff - E. Collantes on behalf of iMaxSpA study group


FRI0205 COMPARISON OF WORK DISABILITY, DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS VS. PSORIATIC ARTHRITIS: INTERIM RESULTS FROM THE COMPLETE STUDY / M. Krahai* - L. Bessette - B. Haraoui - B. Florica - Y. Setty - M. Teo - V. Remple


* Presenting author
TOPIC: CRYSTAL DISEASES, METABOLIC BONE DISEASES AND BONE DISEASES OTHER THAN OSTEOPOROSIS

Poster tour F6: Gout epidemiology and therapy
Chair(s): Alexander So (Switzerland), Abhishek Abhishek (United Kingdom)
Abstracts N°: FR10220-FR10229

FR10220 ULTRASOUND IN ASSESSMENT OF DISEASE COURSE IN GOUT: THE 24 MONTH SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY / E. Norkuiiene* - M. Petroitis - I. Apanavičienė - S. Ottaviani - A. Baranauskaitė

FR10221 GOUT IS ASSOCIATED WITH AN INCREASED RISK OF CANCER - A NATIONWIDE COHORT STUDY INCLUDING OVER 70,000 GOUT PATIENTS / K. Zobbe* - D. Prieto-Alhambra - R. Cordtz - L. Mellemkjær - P. Højgaard


FR10224 MANAGEMENT TO REDUCING LIVER FUNCTION IMPAIRMENT WHEN INITIATING FEBUXOSTAT FOR GOUT BASED ON THE PREDICTION NOMOGRAM / J. Yu*


* Presenting author


FR10237  PEGLOTICASE TREATMENT SIGNIFICANTLY DECREASES MEAN ARTERIAL BLOOD PRESSURE IN PATIENTS WITH CHRONIC GOUT / H. Choi* - R. Johnson - A. Yeo - P. Lipsky

FR10238  THE LEVEL OF LEPTIN IN PATIENTS WITH GOUT AND ITS ASSOCIATION WITH THE GOUT ACTIVITY SCORE / I. Oriova* - M. Stanislavchuk

FR10239  ABSOLUTE NUMBERS OF PERIPHERAL TH17 AND TH2 CELLS INCREASED IN PATIENTS WITH GOUT / J. Yuan* - L. Zhao - J. Luo - C. Gao - X. Li - H. Gao - L. Shang - Q. Li


FR10241  THE EFFECT OF FEBUXOSTAT ON INFLAMMATORY AND CARDIOVASCULAR BIOMARKERS IN HYPERURICEMIC HYPERTENSIVE PATIENTS / L. McLean* - L. Gunamardhana - U. Thienel - J. Wu - G. Smithson


FR10243  ANAKINRA FOR CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS: AN EFFICIENT, SAFE ALTERNATIVE TREATMENT / M. Thomas* - M. Forien - E. Palazzo - P. Dieudé - S. Ottaviani


FR10246  INVESTIGATING THE EFFECT OF SERUM URATE LEVELS ON GOUT FLARE RATES IN A LARGE-SCALE U.S. ADMINISTRATIVE CLAIMS DATABASE / P. Herzog* - A.-C. Fu - J. Lim - D. C. Taylor

FR10247  GOUT CHARACTERISTICS AND ITS ASSOCIATION WITH THE PRESENCE OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY / S. J. Lopez Salguero* - M. Andrés Collado

FR10248  VALIDITY OF RANDOM URINARY URIC ACID-TO-CREATININE RATIO FOR ESTIMATING 24-HOUR URINE URIC ACID EXCRETION IN PATIENTS WITH GOUT / S. Choi* - S.-J. Moon - E.-J. Kang - K.-H. Lee


FR10253  TRENDS FOR GOUT IN ADULTS IN AN URBAN AREA FOR A 5-YEAR PERIOD: INCIDENCE, PREVALENCE AND TREATMENT / M. Thomas* - M. Forien - E. Palazzo - P. Dieudé - S. Ottaviani


* Presenting author

FRI0262 ASSESSMENT OF AUTOAPHA GE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS IN RESPECT OF HYPERLIPIDEMIA AND IMMUNOSUPPRESSIVE DRUGS / A. S. Hamada* - M. I. Aref - W. A. Salahdin


FRI0265 ROLE OF P-GP IN PATHOGENIC CONVERSION OF TH17 CELLS IN LUPUS NEPHRITIS LEADING TO GLUCOCORTICOID RESISTANCE / A. Jaisswal* - M. K. Rai - V. Agarwal - N. Prasad

FRI0266 ANGIOMETIC T CELLS IN PRIMARY SJÖGREN’S SYNDROME: A DOUBLE-ENDED SWORD / A. Alunno* - M. Manetti - O. Bistoni - S. Cipriani - L. Ibbá Manneschi - R. Gerli


FRI0269 GLUCOCORTICOID-INDUCED LEUCINE ZIPPER (GILZ) REPRESENTS A CHECKPOINT LIMITING TYPE I INTERFERON (IFN) PRODUCTION IN SLE / C. T. Nataraja* - E. F. Morand - J. Thomas - J. Harris - S. A. Jones


FRI0275 ALTERED PROTEIN TYROSINE PHOSPHATASES ACTIVITY AND DISEASE SPECIFIC EXPRESSION PATTERN OF CD45 AND CD148 ON VARIOUS LYMPHOCYTE SUBSETS IN AUTOIMMUNE DISEASES / F. Szelinski* - S. Fleischer - S. Weickert - K. Reller - T. Dörner

FRI0276 ABERRANT DISTRIBUTION OF CD3+CD56+ NKT-LIKE CELLS IN PATIENTS WITH SJÖGREN’S SYNDROME / H. Chen* - L. Zhao - W. Xu - Z. Chen - J. Sun - F. Zhang


FRI0278 DECREASED SINGHOSIN1-PHOSPHATE RECEPTOR 1 (S1P1) EXPRESSION IN ENDOTHELIAL PROGENITOR CELLS (EPCS) FROM SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS / J. Romo-Tena* - D. Gomez-Martin - L. P. Blanco - C. Carmona-Rivera - R. Carazo-Vargas - J. Alcocer-Varela - M. J. Kaplan


FRI0283 DYNAMIC CONTRAST ENHANCED MRI (DCE-MRI) DEMONSTRATES HIPPOCAMPUS PERMEABILITY IN SLE / M. Mackay* - B. Diamond - D. Eidelberg - A. Hoang - P. C. Sanelli

* Presenting author
Abstracts N°:  FRI0302-FRI0311

* Presenting author

**TOPIC: SLE, SJÖGREN’S AND APS - TREATMENT**

**Poster tour F8: Back to the future: how to mix the old and new treatments for SLE, Sjögren’s and APS**

**Chair(s):** Angela Tincani (Italy), Micaela Fredi (Italy)

**Abstracts No:** FRI0302-FRI0311

**FRI0302**

**FRI0305**

**FRI0306**

**FRI0307**

**FRI0308**
THYMIC STROMAL LYPHOPPOEITIN (TSLP) BIOLOGICAL EFFECTS ON HUMAN PERIPHERAL BLOOD B LYMPHOCYTES IN PRIMARY SJÖGREN’S SYNDROME / M. Bullfoni - C. Fabro - E. Doriguzzi Breatta - L. Quartuccio - C. Di Loreto - D. Cesselli - S. De Vita

**FRI0309**

**FRI0320**

**FRI0321**

**FRI0322**
DYSFUNCTION OF TFH, TREG AND TR1 CELLS IN APOE-/- FASLGDL C57BL/6 MICE WITH LUPUS SYMPTOMS AND ATEROSCLEROSIS / S. Wang* - G. Yao - L. Sun

**FRI0323**

**FRI0324**
INJURED PODOCYTES EXPRESS COMPLEMENT FACTOR H AND PROCESS IMMUNE COMPLEX DEPOSITION IN GLOMERULAR SUBENDOTHELIAL AREA / T. Zoshima* - S. Hara - M. Nagata - M. Kawano

**FRI0325**
INHIBITION OF CATHEPSIN S LEADS TO SUPPRESSION OF ANTISENS SPECIFIC T CELLS FROM PATIENTS WITH PRIMARY SJÖGREN SYNDROME / P. Hargreaves - M. Theron - F. A. Kolb - M. Manchester - B. Reis - A. Tidlen - D. Kyburz - T. Manigold

**FRI0326**

**FRI0327**
MACROPHAGE-DERIVED LCN2 CONTRIBUTES TO DEVELOPMENT OF LUPUS NEPHRITIS / W. Chen* - L. Sun

**FRI0328**
ALtered Frequencies of circulating innate lymphoid cells and its subsets are correlated with disease activity in systemic lupus erythematous patients / Y. Jiang - Y. Zhao - X. Mo

**FRI0329**
MUCOSAL-ASSOCIATED INVARIANT T CELL DEFICIENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS / J. Yang - Z. Gu

**FRI0330**
POLYMORPHISM OF 5,10-METHYLENEDIOXYHYDROFOLATE REDUCTASE (C677T) IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME, ITS ASSOCIATION WITH CARDIOVASCULAR LESIONS / Y. Seheda* - S. Shevchuk - H.-M. Jin - S.-J. Kee

**FRI0331**

**FRI0332**

**FRI0333**

**FRI0334**
Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis / C. Aranow* - M. Dall’Era - M. Byron - L. Ding - D. Smiley - B. Diamond - D. Wofsy on behalf of the CALIBRATE investigators and Lupus Nephritis Trials Network

* Presenting author


FRI0333 B CELLS DEPLETION AS RESCUE THERAPY FOR EXTRA-CRITERIA MANIFESTATIONS OF PRIMARY ANTIPHOSPHOLIPID SYNDROME / S. Sciascia* - M. Radin - I. Cecchi - E. Rubini - D. Rossi - M. Bazzan - D. Roccatello

FRI0334 COMPARISON OF DIFFERENT DEFINITIONS OF REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - A STUDY BASED ON THE BLISS-76 CLINICAL TRIAL / S. Emamikia - M. Piga - G. Cappelazzero - E. Chessa - M. Congia - A. Culi - A. Mathieu


FRI0338 HYDROXYCHLOROQUINE MAY HELP TO IMPROVE THE IN VITRO FERTILIZATION-EMBRYO TRANSFER OUTCOMES IN ANA AND DS-DNA POSITIVE PATIENTS / F. Lian - J. Zhou - Y. Wang* - H. Xu - X. Yang


FRI0340 DOSAGE OF HYDROXYCHLOROQUINE (PLAQUENIL) ONLINE SURVEY BY PATIENT ORGANISATION NVL / Z. Osmanli* - W. Zacouris-Verweij - S. Otter on behalf of Lupus APS committee

TOPIC: SLE, SJÖGREN’S AND APS - CLINICAL ASPECTS (OTHER THAN TREATMENT)


FRI0342 DOES UNDERSTANDING SLE MATTER TO CLINICAL ACTIVITY IN SLE PATIENTS? / A. S. Meara* - P. Hackenberger - J. Yedimenko - C. Rodman - S. P. Ardoin - E. Peters


FRI0345 ASSOCIATION BETWEEN CIGARETTE SMOKING AND SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - AN UPDATED META-ANALYSIS OF CASE-CONTROL AND COHORT STUDIES / M. H. Y. Chua - I. A. T. Ng - A. Mak*


FRI0347 PERFORMANCE OF POTENTIAL DEFINITIONS OF REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) VERSUS QUALITY OF LIFE OVER 5 YEARS IN SWEDISH PATIENTS WITH RECENT-ONSET SLE / M. Björk - F. Heijke - M. Frodlund - S. Ramagopalan - E. Alemao - C. Sjöwall*

FRI0348 B CELLS DEPLETION AS RESCUE THERAPY FOR EXTRA-CRITERIA MANIFESTATIONS OF PRIMARY ANTI-PHOSPHOLIPID SYNDROME / S. Sciascia* - M. Radin - I. Cecchi - E. Rubini - D. Rossi - M. Bazzan - D. Roccatello

FRI0349 LOW TITER ANTI-PHOSPHOLIPID ANTIBODIES CONVEY AN INCREASED OBSTETRIC RISK / C. B. Chighizola - M. Orlandi - S. Gandorfer - S. Da Vita - S. Bombardi on behalf of Italian Rheumatology Society-pSS study group


* Presenting author
FRI0354 URINE METABOLOMICS FINGERPRINT AS DIAGNOSTIC BIOMARKER FOR LUPUS NEPHRITIS / D. A. Herrera Van Oostdam* - C. Abud Mendoza - R. Flores Ramirez - M. Rodriguez Aguilar - M. Pierdant Perez - M. U. Martinez Martinez


FRI0357 VALIDATION OF A DISEASE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE MEASURE FOR RUSSIAN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: LUPUSQOL-RUSSIAN / E. Aseeva* - L. Vorobyova - S. Soloviev - G. Kollubaeva - S. Glukhova


FRI0363 POSITIVE REMODELING INDEX AND LOW ATTENUATION NON-CALCIFIED CORONARY PLAQUES: MARKERS OF VULNERABLE CORONARY PLAQUES IN SYSTEMIC LUPUS? / G. Stojan* - L. Magder - M. Petrini


FRI0366 FACTORS ASSOCIATED WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / I.-W. Baek* - K.-J. Kim - Y.-J. Park - W.-U. Kim - C.-S. Cho


* Presenting author
**FRIO375**

**FRIO376**

**FRIO377**

**FRIO378**
ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION / M. Jordhani* - J. Seiti - V. Duraj - D. Ruci

**FRIO379**
INFLAMMATORY JOINT INVOLVEMENT IS ASSOCIATED WITH SEVERE DRY EYE IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME / M. Fernandez Castro* - C. Sanchez-Piedra - J. L. Andreu - V. Martinez Taboada - A. Olive - J. Rosas on behalf of SJÖGRENSER project (GEEAS-SER)

**FRIO380**
ASSESSMENT OF SUBMANDIBULAR GLAND QUALITATIVE CHANGES USING SHEAR WAVE ELASTOGRAPHY IN PATIENTS WITH SJÖGREN'S SYNDROME / N. Hashimoto* - S. Uchiyama - M. Kitano - T. Nakazawa - T. Iwasaki - T. Hashimoto

**FRIO381**
ARE THE ANTIPHOSPHOLIPID ANTIBODIES A 'NEW' INDEPENDENT RISK FACTOR FOR ACCELERATED ATEROSCEROSIS? / N. Stoilov* - V. Boyadzhieva - R. Rashkov - S. Stefanov

**FRIO382**
A STUDY OF MCP1 AND LIPocalin AS URINARY BIOMARKERS IN LUPUS NEPHRITIS / R. Ramamorthy* - T. N. Tamilselvam - B. Kumar

**FRIO383**

**FRIO384**
PRIMARY SJÖGREN'S SYNDROME STRATIFIED BASED ON THE SEVERITY OF PATIENT-REPORTED FATIGUE / S. Gandofto* - E. Doriguzzi Brescat - C. Fabro - S. Zandonella Callegher - L. Quartuccio - S. De Vita

**FRIO385**
CLINICAL CHARACTERISTIC FEATURES OF BRAINSTEM ENCEPHALITIS IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / S. Hirohata* - Y. Matsuueda - Y. Arinuma - H. Kikuchi

**FRIO386**
WORK DISABILITY AND QUALITY OF LIFE AMONG MULTICULTURAL MALAYSIAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS / S. S. Shaharir - F. Abu Bakar - M. S. Mohamed Said - R. Mohd

**FRIO387**

**FRIO388**

**FRIO389**
BIOMARKERS AS DISEASE ACTIVITY INDICANTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / V. Zivkovic* - T. Cvetkovic - B. Mitic - B. Stamenkovic - S. Stojanovic - B. Radovanovic Dinic

**FRIO390**

**FRIO391**

**FRIO392**

**FRI0393**

**FRIO394**

**FRIO395**

**FRIO396**

**FRIO397**

---

**TOPIC: SYSTEMIC SCLEROSIS, MYOSITIS AND RELATED SYNDROMES - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS**

---

**Poster tour F9:**
Shaping pathophysiography: new molecules - new views on pathways in SSc, myositis and related syndromes

**Chair(s):** Ulf Müller-Ladner (Germany), Jeska de Vries (Netherlands)

**Abstracts N°:** FRIO396-FRIO406

**FRIO396**

**FRIO397**

* Presenting author
TOPIC: SCLERODERMA, MYOSITIS AND RELATED SYNDROMES


FRI0427 CAPILLAROSCOPY AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW / A. Vanhaecke* - V. Smith - M. Paolino - K. Meliens - Y. Piette - C. Pizzorni - E. Vandecasteele - S. Wijnant - C. Carton - F. De Keyser - M. Cutojo on behalf of the EULAR study group on microcirculation in Rheumatic diseases


FRI0430 EFFECT OF ORAL NUTRITIONAL INTERVENTION ON NUTRITIONAL STATUS IN PATIENTS WITH SYSTEMIC SCLEROSIS / A. Wojtecześ* - M. Ziętkiewicz - S. Malgorzewicz - Z. Zdrojewski


FRI0438 HOSPITALIZATION MORTALITY AND ASSOCIATED RISK FACTORS IN PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS: A RETROSPECTIVE CASE-CONTROL STUDY / C. Wu* - Q. Wang - L. HE - E. Yang - X. ZENG


FRI0442 LONG-TERM TREATMENT WITH RITUXIMAB IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS: OUR CLINICAL EXPERIENCE / F. Lumetti* - A. Ariani - E. Cocchiara - M. Colaci - M. Silva - N. Sverzellati - C. Ferri - C.Salvarani - D. Giuggioli


FRI0444 PERIOSTIN IN SYSTEMIC SCLEROSIS: SERUM LEVELS AND SKIN EXPRESSION OF A NOVEL POSSIBLE BIOMARKER / G. De Luca* - C. Campochiaro - S. Franchini - S. Burastero - S. Sartorelli - A. Giachi - G. Cavalli - C. Dogliani - L. Dagna


* Presenting author
FRIO447 WORLDWIDE EXPERT AGREEMENT ON UPDATED EULAR/ EUSTAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS / J. De Vries-Bouwstra - Y. Allanore - M. Matucci-Cerinic - A. Balbir-Gurman


FRIO450 ASSOCIATIONS OF ALTERATIONS OF PERIPHERAL REGULATORY T AND TH17 ABSOLUTE CELL NUMBERS WITH CLINICAL FEATURES IN PATIENTS WITH SYSTEMIC SCLEROSIS / L. Shang* - J. Luo - J. Yuan - Q. Li - X. Liu - C. Gao - X. Li - H. Gao


FRIO454 THE ONSET, CLINICAL COURSE AND OUTCOMES OF SSC- OVERLAP WITH PM/ DM OR RA (SSC-PM/DM AND SSC-RA) / O. Desinova* - M. Starovoytova - L. Ananieva

FRIO455 MICROVASCULAR CHANGES AND ANGIOGENIC FACTORS IN SYSTEMIC SCLEROSIS - A SINGLE CENTER STUDY / R. Bečvář - H. Hulejová - I. Půtová - M. Tomičk


FRIO458 CLINICAL FEATURES IN PATIENTS WITH SYSTEMIC SCLEROSIS / L. Shang* - J. Luo - J. Yuan - Q. Li - X. Liu - C. Gao - X. Li - H. Gao


FRIO462 THE RELATIONSHIP BETWEEN DIGITAL ULCERS AND SEVERITY OF LUNG FUNCTION TEST IN SYSTEMIC SCLEROSIS OVER A FIVE-YEAR PERIOD / O. B. Ovsyannikova* - O. Koneva - L. Ananieva

FRIO463 A NEW COMPUTED TOMOGRAPHY INDEX FOR QUANTIFICATION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS - A SINGLE CENTER STUDY / R. Bečvář - H. Hulejová - I. Půtová - M. Tomičk


* Presenting author


MPO-ANCA POSITIVITY IS RELATED TO INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS / Y. Ichimura* - Y. Kawaguchi - K. Takagi - A. Tochimoto - T. Higuchi - H. Yamanaka

TOPIC: VASCULITIS

Poster tour F10: Clinical and therapeutic advances in vasculitis

Chair(s): Leonard Calabrese (United States), Valentin Schäfer (Germany)

Abstracts N°: FRI0474-FRI0483


POTENTIAL PREDICTORS OF VISCERAL INVOLVEMENT IN ADULT IGA VASCULITIS (HENOCH-SCHÖNLEIN PURPURA) IN ADULTS / S. Giliaev* - A. Semenovýkh - A. F. Celik - H. Yazıcı - G. Hatemi


LUNG DAMAGE IN PATIENTS WITH MICROSCOPIC POLYANGITIS / E. Schegoleva* - A. Zykova - N. Bulanov - A. Meshkov - P. Novikov - S. Moiseev


POTENTIAL PREDICTORS OF VISCERAL INVOLVEMENT IN ADULT IGA VASCULITIS / A. Hocevar - Ž. Rotar - V. Jurič - M. Tomasič


INSUFFICIENT IMMUNOSUPPRESSIVE USE IS THE LEADING CAUSE OF VASCULAR RELAPSES IN BEHÇET'S DISEASE / A. Aksoy* - F. Alibaz Öner - T. Ergun - R. D. Hireskeneli

UTILITY OF APREMLAST IN REFRACTORY ORAL AND/ OR GENITAL ULCERS IN BEHÇET'S DISEASE / B. Atienza-Mateo - J. L. Moratin-Variñas - J. L. Hernández-Crespo - C. González-Vela - M. A. González-Gay - R. Blanco


SMOKING AS A RISK FACTOR FOR GIANT CELL ARTERITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS / D. Brennan* - P. Ungrasert - K. J. Warrington - M. J. Koster


* Presenting author

15 June 2018


FRI0495 BEHÇET’S SYNDROME IN NEW YORK AND AMSTERDAM: EVOLUTION FROM PROBABLE BEHÇET’S TO ISG CRITERIA POSITIVE BEHÇET’S / F. Kerstens* - F. Turkstra - C. J. Sweering - Y. Yazici


FRI0503 RISK FACTORS OF CARDIAC VALVULAR INVOLVEMENT IN PATIENTS WITH TAKAYASU’S ARTERITIS / L. Pan*


* Presenting author
**TOPIC: OSTEOARTHRITIS**

**Poster tour F11: Novelties in osteoarthritis: clinical aspects**

**Chair(s):** Francis Berenbaum (France), Féline Kroon (Netherlands)

**Abstracts N°:** FRI0520-FRI0529

**FRI0515**
EFFECTIVENESS OF DIRECT-ACTING ANTIVRAL THERAPY ON CRYOGLOBULINEMIA ASSOCIATED WITH HEPATITIS C VIRUS / S. Zegarra Mondragon* - J. R. Quiñones - J. Bachiller Corral - M. Vazquez Diaz

**FRI0516**

**FRI0517**
VESSEL WALL MORPHOLOGY IN GIANT CELL ARTERITIS- A LONGTERM SONOGRAPHIC FOLLOW-UP STUDY / E. Scheeg - C. T. Berger - S. Imfeld - D. Staub - M. Recher - D. Kyburz - M. Aschwanden - T. Daikeler*

**FRI0518**
INCIDENCE, CHARACTERISTICS AND MANAGEMENT OF GIANT CELL ARTERITIS IN FRANCE: A STUDY BASED ON NATIONAL HEALTH INSURANCE CLAIMS DATA / V. Devauchelle Pensier* - E. Hackulla - M. Paccalini - S. Gandon - I. Idier - M. Nollin - M. Belhasen - A. Mahr

**FRI0519**
WORK PRODUCTIVITY IS IMPAIRED IN PATIENTS WITH BEHÇET’S SYNDROME / N. Serin - Y. Ozguler* - S. N. Esatoglu - V. Hamuryuyan - G. Hatemi

---

**Presenting author**

FRI0540   IDENTIFICATION OF BIOMARKERS OF OA ASSOCIATED TO DEFECTIVE AUTOPHAGY / I. Lorenzo-Gomez* - N. Oreiro - J. A. Pinto-Tasende - F. J. Blanco - B. Carames


FRI0542   POTENTIAL NOCICEPTIVE PAIN RELIEF OF INTRA-ARTICULAR SALINE CONTROL IN CLINICAL TRIALS OF KNEE OSTEOARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED TRIALS / L. Simsek* - T. Philipp - A. Bedenbaugh - J. Tambiah


FRI0544   URINARY 6-SULFATOXYMELATONIN EXCRETION AND GALECTIN-3 PLASMA LEVEL IN PATIENTS WITH OSTEOARTHRITIS / K. Zaičko* - O. Gumeniuk - M. Stanislavčuk


FRI0547   IN HAND OSTEOARTHRITIS, DECREASE IN SYNOVITIS RESULTS IN LESS JOINT PAIN; A LONGITUDINAL MAGNETIC RESONANCE IMAGING STUDY / S. Van Beest* - W. Dammann - R. Liu - M. Reijnierse - F. R. Rosendaal - J. L. Bloom - M. Kloppenburg


FRI0549   OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA) PATIENTS HAVE SIMILAR DISEASE BURDENS AT FIRST VISIT TO AN ACADEMIC RHEUMATOLOGY SETTING, BUT OA PATIENTS HAVE A HIGHER BURDEN AT A 6-MONTH FOLLOW-UP VISIT / J. Chu - I. Castrejon - J. A. Block - A.-M. Malfait - T. Pincus*


FRI0552   SM04690, A WNT PATHWAY INHIBITOR: ANTI-INFLAMMATORY AND CARTILAGE PROTECTIVE EFFECTS IN PRECLINICAL OA MODELS / V. Deshmukh* - T. Seo - C. Swearingen - Y. Yazici

FRI0553   THE ROLE OF AGE-RELATED SARCOPENIA IN OSTEOARTHRITIS OF LOWER EXTREMITY / Y. Safonova* - E. Zotkin

** TOPIC: DIAGNOSTICS AND IMAGING PROCEDURES **

FRI0554   WHICH AXIAL MAGNETIC RESONANCE IMAGING COMBINATION IS OPTIMAL FOR ASSESSING ACTIVITY IN SPONDYLOARTHRITIS? / M. Pifer - F. Lecouvet - N. Michoux - M. S. Stoenuoiu - B. R. Lauwerys - A. Nzeusseu Toukap*


FRI0556   AUTOMATED SCORING OF KNEE OSTEOARTHRITIS (OA) ON ROUTINE RADIOGRAPHS IDENTIFIES DISEASE SEVERITY IN OA / A. Law* - L. Assi - A. Harrison - F. A. Howe - N. Sofat

FRI0557   THERMOGRAPHIC ANALYSIS OF HANDS AND WRISTS OF RHEUMATOID ARTHRITIS PATIENTS / A. Gatt - A. Borg* - C. Mercieca - A. Grech Scalfello - L. Camilleri - C. Gatt - N. Chockalingam - C. Formosa


FRI0563   MUSCULOSKELETAL ULTRASOUND (MSUS) IS SUPERIOR TO CLINICAL EXAMINATION REGARDING DETECTION OF ARTHRITIS IN PATIENTS WITH SYSTEMIC SCLEROSIS / D. Feldmann* - R. E. Voil - F. Kollett - S. Finzel

* Presenting author
FRIO564  ULTRASONOGRAPHIC EVALUATION OF SHOULDER TENDONS IN PATIENTS WITH HASHIMOTO’S DISEASE / D. E. Buyukisireci* - D. Teker - B. Bolayir - M. E. E. Yon - M. Akturk - F. Gogus

FRIO565  ERAMRS: A NEW MR SCORING SYSTEM FOR EARLY RHEUMATOID ARTHRITIS / F. Xiao* - J. Yue - L.-S. Tam - J. Griffith


FRIO570  SERUM KL-6 LEVEL REFLECTS SEVERITY OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH CONNECTIVE TISSUE DISEASE / J. S. Lee* - E. Y. Lee - J. K. Park - Y.-J. Ha - E. H. Kang - Y. J. Lee - Y. W. Song


FRIO572  PREVALENCE OF ECHOCARDIOGRAPHIC FINDINGS IN CONNECTIVE TISSUE DISEASES - A RETROSPECTIVE COHORT STUDY / K. Weiss* - W. A. Schmidt - A. Krause - V. S. Schäfer

FRIO573  ULTRASOUND AND HISTOLOGICAL DIAGNOSIS CONCORDANCE IN PATIENTS WITH SUSPECTED PRIMARY SJÖGREN SYNDROME / L. Barrio Nogal* - C. Bohórquez - A. Perez Gómez - A. Casteló - M. J. León - P. Pretel - M. Álvarez de la Mon


FRIO575  EVALUATION OF SCREENING QUESTIONNAIRES FOR PSORIASIC ARTHRITIS IN A SAMPLE OF PATIENTS WITH PSORIASIS IN A THIRDS LEVEL HOSPITAL / M. D. Ruiz Montesino* - V. MOREIRA NAVARRETE - A. M. Carrizzosa Esquivel - C. León Caro - J. J. Pérez Venegas - D. Mendoza Mendoza


FRIO577  MRI-BONE MARROW ODEMA COMBINED WITH LOW-DOSE CT SCANNING PERFORM OPTIMALLY IN THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS / L. Ye - M. A. Brown* - D. Chen


FRIO580  QUANTITATIVE MRI OF SINGLE vs. MULTIPLE JOINTS IN JUVENILE IDIOPATHIC ARTHRITIS AS PREDICTIVE MEASURE OF CLINICAL OUTCOMES / N. Tzanarachev* - O. Kubassova - M. Hinton - H. Haslacher - M. Boesen


FRIO584  FLUORESCENT OPTICAL IMAGING ENHANCEMENT IS ASSOCIATED WITH JOINT PAIN IN HAND OSTEARTHRITIS / O. Maugesten* - S. Ohrndorf - S. V. Hestetun - B. Slatkowsky-Christensen - T. K. Kvaal - T. Ulhig - I. K. Haugen


FRIO586  LONGITUDINAL ASSESSMENT OF CORTICAL INTERRUPTIONS AND VBMD IN RA AND HEALTHY SUBJECTS USING HR-PQCT / M. Peters - J. van den Bergh - P. Geusens* - A. Scharma - D. Loeffen - R. Weijers - B. van Rietbergen - A. van Tubergen

FRIO587  LOW BACK PAIN DUE TO ENTHESOPATHY OF ERECTOR SPINE MUSCLE: A COMPARATIVE US AND MRI STUDY IN PATIENTS WITH ILLAC CREST PAIN SYNDROME / P. Todorov* - M. Kalcheva - A. Marinkov - A. Batalov


FRIO589  A JOINT PROCEDURAL RECOMMENDATION ON FDG-PET/CT(A) IMAGING IN LARGE VESSEL VASCULITIS AND POLYMYALGIA RHEUMATICA FROM THE CARDIOVASCULAR AND INFLAMMATION & INFECCTION COMMITTEES OF THE EANM, THE CARDIOVASCULAR COUNCIL OF THE SNMMI, THE PET INTEREST GROUP (PIG), AND ENDORSED BY THE ASNC / R. Slart* on behalf of Members of EANM Cardiovascular, EANM Infection & Inflammation Councils, SNMMI Cardiovascular Council, PET Interest Group, and ASNC

FRIO590  ULTRASOUND EXAMINATION OF THE WRIST JOINTS: FREQUENCY OF CRISTAL DEPOSITS (CHONDROCALCINOSIS) IN PATIENTS WITH DIFFERENT ARTHROPATHIES / R. Olisypants* - M. Eliseev - S. Vladimirov - K. Ilyin

* Presenting author


RETROCALCANEAL BURSITIS PRECEDES OR ACCOMPANIES ACHILLES TENDON ENTHESITIS IN THE EARLY PHASE OF RHEUMATOID ARTHRITIS / T. Suzuki* - Y. Hidaka - Y. Seri


THE AGREEMENTS BETWEEN CLINICAL SIGNS AND ULTRASOUND-DETERMINED JOINT INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / X. Sun* - X. Deng - W. Xie - Y. Geng - L. Ji - X. Zhang - Z. Zhang


ERYTHEMATOSUS / S. P. Gavan* - I. N. Bruce - K. Warren - R. Terbrueggen*


THE DEVELOPMENT PROCESS OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES IS HETEROGENEOUS AND OFTEN INCOMPLETE: RESULTS OF A SYSTEMATIC LITERATURE REVIEW / A. Najm* - E. Nikiforourov - L. Gossec - F. Berenbaum
USEFULNESS OF SMARTPHONES APPLICATIONS IN THE FOLLOW-UP OF PATIENTS WITH INFLAMMATORY RHEUMATOLOGICAL DISEASES: ARE THEY REALLY BENEFICIAL IN OBJECTIVE TERMS? / C. A. Guillén-Astete* - B. Laso-Jimeno

PHYSICIAN-PATIENT INTERACTIONS IN AFRICAN AMERICAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. Drenkard* - G. Bao - T. T. Lewis - B. F. Pobiner - J. Priest - S. S. Lim

NORMALISED TOXICITY TO PREGABALIN DID NOT INCREASE WITH CHANGES IN APPROVAL MECHANISM AND USE IN AUSTRALIA / C. McMaster - D. F. L. Liew* - E. Joules - J. Robinson - S. Greene - R. R. C. Buchanan - A. G. Frauman


CONCORDANCE WITH LATEST GUIDELINES FOR DMARD SCREENING AND MONITORING IN SECONDARY CARE / E. Cefaï* - D. Xhaixo - C. Mercieca - A. Borg


LOW EDUCATIONAL ATTAINMENT IS ASSOCIATED WITH POOR PATIENT STATUS AT THE INITIAL VISIT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) OR OSTEOARTHRITIS (OA) AT THE INITIAL VISIT TO A RHEUMATOLOGY SETTING. WITH SIMILAR PATTERNS IN PATIENTS WITH EITHER DIAGNOSIS / J. Schmukler - I. Castrejon* - T. Pincus - J. Block


TRENDS IN ENCOUNTERS WITH RHEUMATOLOGISTS IN A PUBLICLY-FUNDED SINGLE PAYER HEALTHCARE SYSTEM / J. Widdifield* - S. Bernatsky - V. A. Ahluwalia - C. Barber - L. Eder - B. Kuriya - V. Ling - A. Lyddiatt - M. Paterson - J. Pope - C. Thorne

COST-EFFECTIVENESS ANALYSIS FOR THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) COMPARED TO STANDARD OF CARE IN SINGAPORE / N. Chua* - M. Lahiri - P. Cheung - J. Yang

MUSCULOSKELETAL PROBLEMS AMONGST TRAIN OPERATORS: A COLLABORATIVE APPROACH TO IDENTIFY SOLUTIONS / J. Erwin* - J. Howarth - L. Chauhan - A. Webster - A. Woolf


SCREENING FOR TUBERCULOSIS BEFORE TNF INHIBITOR THERAPY REMAINS SOFTOPTIMAL: A MULTI-SPECIALTY, REAL-WORLD, NATIONWIDE EXPERIENCE IN THE UNITED STATES / K. Ladak* - T. J. Pan - C. MacLean

INADVERTENT YELLOW FEVER VACCINATION OF PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE IN PRIVATE PRACTICE / L. Fernandes* - V. A. Ahluwalia - C. Barber - L. Eder - B. Kuriya - V. Ling - A. Lyddiatt - M. Paterson - J. Pope - C. Thorne


BARRIERS TO REMAIN IN WORK: RESULTS FROM THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY SURVEY (NRAS) / S. Verstappen* - L. Lunt - A. Bosworth - M. Bezzant - K. Walker-Bone

SCREENING FOR TUBERCULOSIS BEFORE TNF INHIBITOR THERAPY REMAINS SOFTOPTIMAL: A MULTI-SPECIALTY, REAL-WORLD, NATIONWIDE EXPERIENCE IN THE UNITED STATES / K. Ladak* - T. J. Pan - C. MacLean

INADVERTENT YELLOW FEVER VACCINATION OF PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE IN PRIVATE PRACTICE / L. Fernandes* - V. A. Ahluwalia - C. Barber - L. Eder - B. Kuriya - V. Ling - A. Lyddiatt - M. Paterson - J. Pope - C. Thorne


BARRIERS TO REMAIN IN WORK: RESULTS FROM THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY SURVEY (NRAS) / S. Verstappen* - L. Lunt - A. Bosworth - M. Bezzant - K. Walker-Bone

* Presenting author
**FRI0638**
A NOVEL GROUP CLINIC MODEL FOR NEW PATIENTS ENHANCES PATIENT ACTIVATION / T. Jones* - A. Morbi - M. Grove - F. Birrell

**FRI0639**
THE IMPACT OF DISEASE ACTIVITY AND PAIN LEVEL ON PRODUCTIVITY IN RHEUMATOID ARTHRITIS (RA) PATIENTS / J. Galloway - J.-P. Capron - F. De Leonardis - W. Fakhouri - T. Burke

---

**TOPIC: VALIDATION OF OUTCOME MEASURES AND BIOMARKERS**

**Poster tour F13: Searching for outcome measures**

**Chair(s):** João E. Fonseca (Portugal), Vasco C. Romao (Portugal)

**Abstracts N°:** FRI0640-FRI0649

**FRI0640**
AUTOANTIBODIES TO TWO NOVEL PEPTIDES IN SERONEGATIVE AND EARLY RHEUMATOID ARTHRITIS IN THREE LARGE INDEPENDENT COHORTS / L. De Winter - P. Vandormael* - V. Stouten - H. W. van Steenbergen - P. Geusens - J. Lenaerts - A. H. M. van der Helm-van Mil - P. Verschueren - V. Somers

**FRI0641**

**FRI0642**

**FRI0643**
AUTOANTIBODY STATUS IS NOT ASSOCIATED WITH EARLY TREATMENT RESPONSE TO FIRST-LINE METHOTREXATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / J. S. Dekkers* - S. A. Bergstra - C. Chopra - M. Tikly - J. E. Fonseca - K. Salomon-Escoto - T. Huizinga - D. van der Woude

**FRI0644**
The use of MRI-detected synovitis to determine the number of involved joints for the 2010 aCR/eULAR CLASSIFICATION CRITERIA FOR RHEUMATOID ARTHRITIS - IS IT OF ADDITIONAL BENEFIT? / A. C. Boer* - D. Boeters - A. H. M. van der Helm-van Mil

**FRI0645**

**FRI0646**

**FRI0647**
ESTIMATION OF MINIMUM CLINICALLY IMPORTANT DIFFERENCE IN FIBROMYALGIA FOR FIQR USING BPI AS THE ANCHOR MEASURE / S. Surendran* - C. B. Mithun

**FRI0648**
DIRECTLY COMPARING LATENT FUNCTIONAL ABILITY IN ADOLESCENTS WITH JIA USING THE CHAQ AND HAQ: AN ITEM RESPONSE THEORY ANALYSIS / S. J. W. Shoop-Worrall* - M. O. Voshaar - M. van de Laar - W. Thomson - K. L. Hyrich - J. E. McDonagh - S. M. M. Verstappen on behalf of CAPS

**FRI0649**
SYSTEMIC LEVELS OF TYPE VI COLLAGEN METABOLITES ARE ELEVATED IN RA PATIENTS AND MODULATED BY TREATMENT WITH ANTI-IL6R THERAPY / C. S. Thudium* - N. S. Gudmann - M. Karsdal - A.-C. Bay-Jensen

**FRI0650**

**FRI0651**

**FRI0652**
THE DEVELOPMENT AND VALIDATION OF FAMILIAL MEDITERRANEAN FEVER QUALITY OF LIFE SCALE (FMF-QOL) / C. Unal* - M. T. Durouz

**FRI0653**
VALIDITY OF POLYMYALGIA RHEUMATICA DIAGNOSES, AND CLASSIFICATION CRITERIA, IN PRIMARY HEALTH CARE / C. Fons - U. Bergström - M. Willim - E. Pilman - C. Turesson*

**FRI0654**
IS THE PATIENT-ACCEPTABLE STATUS SIMILAR ACROSS 7 DOMAINS OF HEALTH IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)? POST-HOC ANALYSES FROM THE VALIDATION IN 549 PATIENTS OF THE RHEUMATOID ARTHRITIS IMPACT OF DISEASE (RAI-D) SCORE / C. Duarte* - T. Kvien - N. Boll - E. Lie

**FRI0655**

**FRI0656**

**FRI0657**

**FRI0658**
PROGNOSTIC MARKERS FOR RESPONSE ACCORDING TO THE NEW ACR/EULAR 2016 RESPONSE CRITERIA FOR IDIOPATHIC INFLAMMATORY MYOSITIS / F. Espinosa-Ortega* - M. Holmqvist - M. Dastmalchi - I. Lundberg - H. Alexanderson

**FRI0659**
INVESTIGATION OF SELF-REPORTED PAINFUL JOINT COUNT AS OUTCOME MEASURE IN HAND OSTEOARTHRITIS / F. Kroon* - A. Boersma - A. Boonen - S. van Beest - F. Rosendaal - M. Kloppenburg

**FRI0660**
USEFULNESS OF MICHIGAN HAND OUTCOMES QUESTIONNAIRE (MHQ) IN HAND OSTEOARTHRITIS / F. Kroon* - M. Kloppenburg

**FRI0661**
AUTOANTIBODIES TO TWO NOVEL PEPTIDES IN SERONEGATIVE AND EARLY RHEUMATOID ARTHRITIS IN THREE LARGE INDEPENDENT COHORTS / L. De Winter - P. Vandormael* - V. Stouten - H. W. van Steenbergen - P. Geusens - J. Lenaerts - A. H. M. van der Helm-van Mil - P. Verschueren - V. Somers
TOPIC: REHABILITATION


FRI0664 BIOMARKERS FOR RELAPSE IN PATIENTS WITH ADULT ONSET STILL’S DISEASE TREATED WITH IL-6 INHIBITOR / H. Yamada* - Y. Kaneko - T. Takeuchi

FRI0665 IMPACT OF THE MULTI-BIOMARKER DISEASE ACTIVITY SCORE RESULTS ON WHETHER RHEUMATOLOGISTS CHANGED BIOLOGIC THERAPY FOR RA PATIENTS / J. Curtis* - K. Ford - L. Chen - H. Yun - F. Xie


FRI0669 PHYSICIAN GLOBAL ASSESSMENTS FOR DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS ARE ALL OVER THE MAP! / M. A. Turk* - J. Pope

FRI0670 VALIDATION OF THE ERS-RA RISK SCORE IN THE DUTCH CARRÉ STUDY / M. Baniaamarn* - M. Nurmohamed


FRI0674 APPLICABILITY OF THE PSAID12 QUESTIONNAIRE AS A CORE OUTCOME MEASUREMENT IN PSA CLINICAL TRIALS: AN EVALUATION USING OMERACT FILTER 2.1 INSTRUMENT SELECTION CRITERIA / R. Holland* - M. Guerra - S. Pimenta - M. Bernardes - L. Costa


FRI0681 FOUR COMORBIDITY INDEXES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS / Y. J. Huang* - C. F. Kuo - J. S. Chen - S. F. Luo

* Presenting author
FRI0685  HAND FUNCTIONS ARE AFFECTED DEPENDING ON THE CURVE PATTERN IN IDIOPATHIC SCOLIOSIS / G. Yagci* - D. A. Ozcan - G. Ayhan - Y. Yakut


FRI0687  EFFECT OF PERINEURAL INJECTION THERAPY IN MODERATE AND SEVERE KNEE OSTEOARTHRITIS: A COMPARATIVE STUDY / M. H. Abu-Zaid* - S. A. Tabra - S. Elmosry


FRI0689  A CONSERVATIVE TREATMENT OPTION FOR CARPAL TUNNEL SYNDROME: EXTRACORPOREAL SHOCK WAVE THERAPY. PROSPECTIVE, RANDOMISED, DOUBLE BLIND PLACEBO CONTROLLED STUDY / R. Kocak Ulucaköy* - F. G. Yurdakul - H. Bodur

FRI0690  COMPARISON OF EFFECTIVENESS OF DIFFERENT STRETCHING EXERCISES COMBINED WITH PRESSURE RELEASE TECHNIQUE ON LATENT TRIGGER POINTS IN THE PECTORALIS MINOR MUSCLE / T. Birinci* - R. Mustafaoğlu - E. Kaya Mutlu - A. Razak Ozdinçler

TOPIC: EDUCATION

Poster tour F14: Education for better patients care
Chaiperson(s): Nemanja Damjanov (Serbia), Mirjana Bukilica (Serbia)

Abstracts N°:  FRI0691-FRI0700

FRI0691  EFFECT OF AN EDUCATIONAL INTERVENTION BASED ON CLINICAL SIMULATION IN THE DIAGNOSIS OF PSORIATIC ARTHRITIS IN LATIN AMERICAN DERMATOLOGISTS / S. A. Mora Alfonso* - D. G. Fernández Ávila on behalf of Sociedad para la Investigación, atención y educación en enfermedades reumáticas INVEDER SAS


FRI0693  FEARS AND MISCONCEPTIONS OF WOMEN WITH CHRONIC RHEUMATIC DISEASES ON THEIR JOURNEY TO MOTHERHOOD / A. Tincani* - P. Taylor - R. Fischer-Betz - C. Ecoffet - E. Chakravarty

FRI0694  TWITTER: A NEW PLATFORM FOR PUBLIC HEALTH CAMPAIGNS: SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS AS EXAMPLES / M. Mohameden* - B. Alkhairi - C. Yuvienco

FRI0695  DMARD MONITORING GUIDELINES AND SHARED PRESCRIBING IN PRIMARY CARE - IS MORE EDUCATION REQUIRED? / G. Choudhury - M. K. Nisar*


FRI0697  EXPECTATIONS, MOTIVATING FACTORS AND BARRIERS TO BASIC RESEARCH AMONG YOUNG RHEUMATOLOGISTS IN GERMANY- RESULTS OF A NATIONAL ONLINE SURVEY / J. Mucke* - M. Schneider - U. Wagner - H. Schulze-Koops - A. Skapenko - J. Leipe

FRI0698  SURVEY OF 1,318 PATIENTS ON THEIR KNOWLEDGE OF THE PULMONARY MANIFESTATIONS OF RHEUMATOID ARTHRITIS AND THEIR NEEDS IN TERMS OF INFORMATION AND FOLLOW-UP / C. Beller - P. Preiss - Y. Allanore*

FRI0699  RHEUMATOLOGY TALKS TO THE COMMUNITY: RESULTS OF AN EDUCATIONAL INTERVENTION / S. P. Chinchilla* - J. Atxotegi - I. Uriñagüena Onaindia - F. Perez-Ruiz

FRI0700  PATIENTS AND RELATIVES COPING WITH INFLAMMATORY ARTHRITIS: A TEAM WORK / M. Brignon - C. Viozac - E. Boujut - C. Delannoy - C. Beauvais - J.-S. Giraudet Lequintrec - D. Poivret - J. Kivits - A. Untas - A.-C. Rat*


* Presenting author
Scientific Programme Saturday 16 June 2018

**What is New (WIN) & How to Treat (HOT) session**

**WIN & HOT Lancet session**

**Chair(s):**
Johannes W. J. Bijlsma (Netherlands)
Jennifer Sargent (United States)
Douglas Veale (Ireland)

**09:05**

Filip van den Bosch (Belgium)

**09:15**

Yannick Allanore (France)

**09:45**

Kristina Clark (United Kingdom)

**09:55**

Christopher Denton (United Kingdom)

**Challenges in Clinical Practice session**

**The GI tract in systemic sclerosis - is there light at both ends?**

**Learning objectives:**
- To understand the current diagnostic options
- To understand the different clinical challenges
- To outline the current treatment options

**Chair(s):**
Maurizio Cutolo (Italy)
Rebecca Hassell (Germany)

**Camelia Frantz (France)**
**Abstract N° SP0143**
Case 1 presentation: Armful hidden telangiectasia

**Yannick Allanore (France)**
**Abstract N° SP0144**
Case 1 discussion: Light at the upper GI tract

**Kristina Clark (United Kingdom)**
**Abstract N° SP0145**
Case 2 presentation: The importance of maintaining control

**Christopher Denton (United Kingdom)**
**Abstract N° SP0146**
Case 2 discussion: Light at the lower GI tract

**Clinical Science session**

**RA: is it all in your head?**

**Learning objectives:**
- To explore the mechanisms that link inflammation to depression
- To outline the social psychological factors that influence RA
- To present an overview of neuro-imaging features in RA

**Chair(s):**
John D. Isaacs (United Kingdom)
Thomas Huegle (Switzerland)
Neil Harrison (United Kingdom)

**09:05**

Christian Apfelbacher (Germany)

**09:25**

Jonathan Cavanagh (United Kingdom)

**09:45**

V. Bykerk (United States)

**10:05**

G. E. Fragoulis (United Kingdom)

**10:15**

J. Cavanagh, M. H. Derakhshan, C. Paterson, D. Porter, I. B. McInnes, S. Siebert

**Abstract N° OP0349**
Remaining pain and widespread pain distribution during the first 12 months after RA diagnosis

**Abstract N° OP0350**
Depression and anxiety in an early rheumatoid arthritis inception cohort. Associations with epidemiological, socioeconomic and disease features
Paediatric Rheumatology session

Battling hyperinflammation in paediatric rheumatic diseases

Learning objectives:
• Understand the mechanisms of (hyper) inflammation
• Recognise clinical patterns of macrophage activation syndrome
• Knowledge of the newest therapeutic options for hyperinflammation

Chair(s):
Lovro Lamot (Croatia)
Michael Beresford (United Kingdom)
Sebastian Vastert (Netherlands)

09:05
Understanding inflammation in systemic JIA; a bird eye’s view
Angelo Ravelli (Italy)

09:30
The clinical conundrum of diagnosing macrophage activation syndrome
Fabrizio de Benedetti (Italy)

09:55
From pathogenic insight to novel therapeutic approaches of hyperinflammation
R. Davies (United Kingdom)
D. De Cock, L. Kearsley-Fleet, A. Ramanan, K. L. Hyrich on behalf of British Society for Paediatric and Adolescent Rheumatology

Etanercept Cohort Study
Abstract N° OP0351
First diagnosis of uveitis is not higher among juvenile idiopathic arthritis (JIA) patients receiving etanercept compared to methotrexate

Basic and Translational Science session

Gut bacteria: the boss of the immune system

Learning objectives:
• To recognise the link between microbiota, immune responses and chronic inflammatory rheumatic diseases
• To learn how diets influence inflammation

Chair(s):
Gabriela Riemekasten (Germany)
Yi Zhao (China)
Sara Vieira-Silva (Belgium)

09:05
The microbiota and inflammation
Mario Zaiss (Germany)

09:30
Abstract N° SP0147
How the gut microbiota and its metabolites impact on bone homeostasis

Harry Sokol (France)

09:55
Microbiota in Crohn’s disease

K. Mankia (United Kingdom) 10:20
Z. Cheng, T. Do, J. Kang, L. Hunt, J. Meade, V. Clerehugh, A. Speirs, A. Tugnait, E. Hensor, D. Devine, P. Emery
Abstract N° OP0352
An increased prevalence of periodontal disease, porphyromonas gingivalis and aggregatibacter actinomycetemcomitans in anti-CCP positive individuals at-risk of inflammatory arthritis

Health Professionals session

Multi-disciplinary management of complex persistent pain

Learning objectives:
• To be aware of the bio-psychosocial impact of persistent pain from the patient and clinician perspectives
• To understand how people with complex regional pain syndrome present in clinical practice and how to manage their pain through multidisciplinary interventions
• To be aware of current and emerging functional rehabilitation strategies for pain management

Chair(s):
Emma Dures (United Kingdom)
Yeliz Prior (United Kingdom)

09:05
Pain: the role of psychology
Florian Brunner (Switzerland)

09:23
CRPS - early diagnosis and first therapeutic measures
Robyn Connett (United Kingdom)

09:41
The patient’s perspective of living with complex regional pain syndrome
Candy McCabe (United Kingdom)

09:59
Functional rehabilitation for the relief of complex persistent pain
A. Hammond (United Kingdom) 10:17
Y. Prior, C. Sutton, S. Cotterill, C. Heal, E. Camacho on behalf of the A-GLOVES research team

Abstract N° OP0353-HPR
The effects of arthritis gloves on hand pain in people with rheumatoid or inflammatory arthritis: a randomised controlled trial (A-GLOVES trial)
09:00 - 10:30  Emerald

From Bench to Bedside
Osteoarthritis: a vascular disease

Learning objectives:
• Understand why subchondral bone angiogenesis could be a driver of osteoarthritis initiation and progression
• Understand how imaging methods could help to support the role of vessels in osteoarthritis
• Learn the epidemiological evidence and the basic hypothesis on the potential role of hypertension as a risk factor for osteoarthritis

Chair(s):
Ellen M. Gravallese (United States)
Francis Berenbaum (France)
Marie-Hélène Lafage-Proust (France)

09:05
Marie-Hélène Lafage-Proust (France)
OA and angiogenesis: what is special about blood vessels in bone?

09:30
Philip Conaghan (United Kingdom)
Abstract N° SP0151
Does imaging support the vascular nature of OA?

09:55
David Felson (United States)
Abstract N° SP0152
Hypertension and OA

10:20
Ø. Maugesten (Norway)
S. Ohrndorf, S. V. Hestetun, T. K. Kvien, T. Uhlig, I. K. Haugen
Abstract N° OP0354
Radiographic erosions are associated with fluorescence optical imaging enhancement in hand osteoarthritis

09:00 - 10:30  PARE Room

PARE session
Workshop: Is there a diet for people with RMDs?

Learning objectives:
• Share evidence based knowledge on nutrition
• Share best practice by patient organisations

Chair(s):
Dieter Wiek (Germany)
Nele Caeyers (Belgium)
Asta Linauskas (Denmark)

09:05
Asta Linauskas (Denmark)
Abstract N° SP0153
What evidence is there that diets help people with RMDs?

09:20
Corinna Elling-Audersch (Germany)
Abstract N° SP0154
How to offer seminars on nutrition

09:35
Valerie Krafft (Switzerland)
Abstract N° SP0155
Nutrition - how to talk about it

09:50
Faculty
Group discussion and Q&A

10:20
Dieter Wiek (Germany)
Resume of the group discussions

09:00 - 10:30  E106/E107

EULAR Projects in Education and Training
Challenging projects in education and training

Learning objectives:
To illustrate and discuss the ongoing projects in education and training

Chair(s):
Annamaria Iagnocco (Italy)
José A. P. da Silva (Portugal)
Maarten Boers (Netherlands)

09:05
Maarten Boers (Netherlands)
Abstract N° SP0156
Theory of poster design and presentation**

09:40
Annamaria Iagnocco (Italy)
Abstract N° SP0157
The EULAR School of Rheumatology. A challenging educational EULAR Project. Where are we now?

09:55
José A. P. da Silva (Portugal)
How to deliver a presentation?

** Session followed by a poster tour on poster design led by Maarten Boers, please register at the poster tours & workshops desk, located in the registration area, Hall 2

10:30 - 12:00  E106/E107

EULAR Projects in Education and Training
Challenging projects in education and training

Learning objectives:
To illustrate and discuss the ongoing projects in education and training

Chair(s):
Annamaria Iagnocco (Italy)
José A. P. da Silva (Portugal)
Maarten Boers (Netherlands)

09:05
Maarten Boers (Netherlands)
Abstract N° SP0156
Theory of poster design and presentation**

09:40
Annamaria Iagnocco (Italy)
Abstract N° SP0157
The EULAR School of Rheumatology. A challenging educational EULAR Project. Where are we now?

09:55
José A. P. da Silva (Portugal)
How to deliver a presentation?

** Session followed by a poster tour on poster design led by Maarten Boers, please register at the poster tours & workshops desk, located in the registration area, Hall 2

10:30 - 12:00  Poster area

Guided poster tours
Guided poster tours on various topics are taking place during the official poster viewing. For details on the various tours on Saturday, please refer to page 137.
Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a “first-come-first-served” basis the day of the poster tour.
EULAR Projects in Clinical Affairs
Recommendation session ESSCA

Chair(s):
Ulf Müller-Ladner (Germany)
Désirée van der Heijde (Netherlands)
Ori Elkayam (Israel)

12:05
Abstract N° SP0158
2018 EULAR Recommendations for vaccinations

Soledad Retamozo (Spain)
12:25
2018 EULAR Recommendations for Sjögren’s syndrome

Frank Buttgereit (Germany)
13:05
2018 EULAR Recommendations for the use of glucocorticoid therapy

Margreet Kloppenburg (Netherlands)
13:25
2018 EULAR Recommendations for management of hand osteoarthritis

Challenges in Clinical Practice session
Fractures: more than bone alone

Learning objectives:
To learn about frailty and cardiovascular comorbidities in patients with a (recent) fracture

Chair(s):
Willem F. Lems (Netherlands)
Roland D. Chapurlat (France)
Karine Briot (France)

12:05
Abstract N° SP0162
Case 1 presenter: Look at the cascade

Christian Roux (France)
12:15
Case 1 discussant: Frail patients with a fracture: how to handle?

Gayani Weerasinghe (United Kingdom)
12:45
Abstract N° SP0163
Case 2 presenter: A case of severe osteoporosis and ischaemic heart disease; what will be the future cardiovascular risk?

Daniel Prieto-Alhambra (United Kingdom)
12:55
Case 2 discussant: Cardiovascular disease after a recent fracture

Clinical Science session
Emerging topics in the management of the antiphospholipid syndrome

Learning objectives:
• To understand the different risk profiles and consequent need of prophylactic treatment for healthy subjects carrying a stable positivity for antiphospholipid antibodies
• To analyse the impact of antiphospholipid antibodies on the outcome of patients with systemic lupus erythematosus
• To recognise and differentiate the antiphospholipid antibody-related kidney damage and to apply the proper treatments

Chair(s):
Fabrizio Conti (Italy)
Maarten Limper (Netherlands)
Laura Andreoli (Italy)

12:05
Abstract N° SP0164
How to manage asymptomatic carriers of antiphospholipid antibodies

12:25
Abstract N° SP0165
The complex interplay between systemic lupus erythematosus and antiphospholipid syndrome

Maria Tektonidou (Greece)
12:45
Abstract N° SP0166
All you need to know about kidney disease in antiphospholipid syndrome

C. Li (China)
13:05
J. L. Zhao, Y. Zhao, S. Liu, Q. Wang, M. T. Li
Abstract N° OP0355
Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with primary antiphospholipid syndrome: a retrospective cohort study

R. Hisada (Japan)
13:15
M. Kato, E. Sugawara, Y. Fujieda, K. Oku, T. Bohgaki, O. Amengual, S. Yasuda, T. Atsumi
Abstract N° OP0356
Plasmablast proliferation is associated with toll like receptor 7 polymorphisms and upregulation of type I interferon, contributing to the antibody production in antiphospholipid syndrome
**12:00 - 13:30**  
**Forum**

**From Bench to Bedside**  
**The links between gout and kidney function**

**Learning objectives:**  
- Understand the recent advances in the genetics of hyperuricemia and gout  
- Become familiar with the function and clinical implications of different renal transporters  
- Understand the influence of reduced renal function on the use of urate lowering treatments

**Chair(s):**  
Alexander So (Switzerland)  
Nicola Dalbeth (New Zealand)  
Anna Koettgen (Germany)

**12:05**  
**Fernando Perez-Ruiz** (Spain)  
**Abstract N° SP0167**  
Renal urate transporters

**Nicola Dalbeth** (New Zealand)  
**Abstract N° SP0168**  
The use of XO inhibitors in CKD - pros and cons

**12:00 - 13:30**  
**Elicium 1**

**Basic and Translational Science session**

**Big data in pre-clinical research**

**Learning objectives:**  
- To provide an overview of normal sleep patterns; sleep physiology, sleep and RMD; sleep quality; measuring sleep (outcome measure); treatment sleep  
- To present clinical research on sleep issues in RMD

**Chair(s):**  
Joke Vriezekolk (Netherlands)  
Lurdes Barbosa (Portugal)  
Bente Appel Esbensen (Denmark)

**12:05**  
**K. M. Tran** (Vietnam)  
**Abstract N° OP0357**  
Hyperechoic deposits in the renal medulla are associated with severe gout and decreased EGFR: a transversal study in 503 Vietnamese patients

**12:15**  
**M. Sellmayr**, F. Preitner, H.-J. Anders, S. Steiger  
**Abstract N° OP0358**  
Why do not all chronic kidney disease patients get gout? Impaired neutrophil chemotaxis in hyperuricemia-related CK

**12:25**  
**J. Ding**, B. Mulhearn, S. Viatte, S. Eyre  
**Abstract N° OP0359**  
Exploration of T cell signatures following TCR stimulation using single cell RNA-seq to inform treatment response studies in rheumatoid arthritis

**12:35**  
**Mark Coles** (United Kingdom)  
Combining systems modelling with experimentation to identify novel therapeutic targets

**12:55**  
**Z. Makowska**, S. Hayat, A. Buttgereit, G. Barturen, J. Kageyama, B. Weiss, J. Wojcik, R. Lesche, M. Alarcón Riquelme, F. McDonald on behalf of PRECISESADS Clinical Consortium  
**Abstract N° OP0360**  
RNA-sequencing of 800 human blood samples reveals shared and unique expression profiles across seven systemic autoimmune diseases

**13:05**  
**Leonid Padyukov** (Sweden)  
**Abstract N° SP0169**  
Integration of Omics data for predicting response to anti-TNF

**12:00 - 13:30**  
**Amtrium**

**Health Professionals session**

**How do you sleep?**

**Learning objectives:**  
- To provide an overview of normal sleep patterns; sleep physiology, sleep and RMD; sleep quality; measuring sleep (outcome measure); treatment sleep  
- To present clinical research on sleep issues in RMD

**Chair(s):**  
Joke Vriezekolk (Netherlands)  
Lurdes Barbosa (Portugal)  
Bente Appel Esbensen (Denmark)

**12:05**  
**J. S. Malmborg** (Sweden)  
**Abstract N° OP0361-HPR**  
Sleeping problems and anxiety is associated to chronic multisite musculoskeletal pain in Swedish high school students

**12:23**  
**Katie Hackett** (United Kingdom)  
**Abstract N° SP0170**  
Re-evaluate life when broken sleep has a negative effect on inflammatory arthritis

**12:41**  
**Sean.G. McKenna** (Ireland)  
**Abstract N° SP0171**  
What effect does exercise have on sleep in RMDs?

**12:05**  
**Bente Appel Esbensen** (Denmark)  
**Abstract N° SP0172**  
Sleep disturbances in primary Sjögren’s syndrome: evidence from the literature, patient sleep diaries and a qualitative focus group study

**12:23**  
**Katie Hackett** (United Kingdom)  
**Abstract N° SP0173**  
Sleep disturbances in primary Sjögren’s syndrome: evidence from the literature, patient sleep diaries and a qualitative focus group study

**12:35**  
**Mark Coles** (United Kingdom)  
Combining systems modelling with experimentation to identify novel therapeutic targets

**12:55**  
**Leonid Padyukov** (Sweden)  
**Abstract N° SP0174**  
Integration of Omics data for predicting response to anti-TNF

**11:00 - 11:30**  
**Elicium 1**

**Basic and Translational Science session**

**Big data in pre-clinical research**

**Learning objectives:**  
- To learn about the challenges and opportunities of big data analysis  
- To understand how big data analysis can be used to identify biomarkers and therapeutic targets

**Chair(s):**  
Costantino Pitzalis (United Kingdom)  
Mojca F. Bertoncelj (Slovenia)  
Peter Lipsky (United States)

**12:05**  
**P. Martin** (United Kingdom)  
**J. Ding**, B. Mulhearn, S. Viatte, S. Eyre  
**Abstract N° OP0359**  
Exploration of T cell signatures following TCR stimulation using single cell RNA-seq to inform treatment response studies in rheumatoid arthritis

**12:25**  
**Z. Makowska**, S. Hayat, A. Buttgereit, G. Barturen, J. Kageyama, B. Weiss, J. Wojcik, R. Lesche, M. Alarcón Riquelme, F. McDonald on behalf of PRECISESADS Clinical Consortium  
**Abstract N° OP0360**  
RNA-sequencing of 800 human blood samples reveals shared and unique expression profiles across seven systemic autoimmune diseases

**12:35**  
**Mark Coles** (United Kingdom)  
Combining systems modelling with experimentation to identify novel therapeutic targets

**12:55**  
**Leonid Padyukov** (Sweden)  
**Abstract N° SP0169**  
Integration of Omics data for predicting response to anti-TNF

**13:05**  
**Leonid Padyukov** (Sweden)  
**Abstract N° SP0169**  
Integration of Omics data for predicting response to anti-TNF

**13:15**  
**M. Sellmayr**, F. Preitner, H.-J. Anders, S. Steiger  
**Abstract N° OP0358**  
Why do not all chronic kidney disease patients get gout? Impaired neutrophil chemotaxis in hyperuricemia-related CK

**13:05**  
**Abstract N° OP0357**  
Hyperechoic deposits in the renal medulla are associated with severe gout and decreased EGFR: a transversal study in 503 Vietnamese patients

**13:15**  
**Q. Ma** (Germany)  
**Abstract N° OP0358**  
Why do not all chronic kidney disease patients get gout? Impaired neutrophil chemotaxis in hyperuricemia-related CK

**13:25**  
**J. Ding**, B. Mulhearn, S. Viatte, S. Eyre  
**Abstract N° OP0359**  
Exploration of T cell signatures following TCR stimulation using single cell RNA-seq to inform treatment response studies in rheumatoid arthritis

**12:05**  
**Abstract N° OP0357**  
Hyperechoic deposits in the renal medulla are associated with severe gout and decreased EGFR: a transversal study in 503 Vietnamese patients

**12:15**  
**M. Sellmayr**, F. Preitner, H.-J. Anders, S. Steiger  
**Abstract N° OP0358**  
Why do not all chronic kidney disease patients get gout? Impaired neutrophil chemotaxis in hyperuricemia-related CK

**12:45**  
**Nicola Dalbeth** (New Zealand)  
**Abstract N° SP0168**  
The use of XO inhibitors in CKD - pros and cons

**12:05**  
**Fernando Perez-Ruiz** (Spain)  
**Abstract N° SP0167**  
Renal urate transporters
12:00 - 13:30  Emerald

From Bench to Bedside
Stratifying connective tissue diseases

Learning objectives:
To provide an update on recent advances in straification of systemic autoimmune diseases

Chair(s):
John D. Isaacs (United Kingdom)
Martin Aringer (Germany)

Wan-Fai Ng (United Kingdom) 12:05
Abstract N° SP0173
Stratifying primary Sjögren’s

Lars Rönnblom (Sweden) 12:25
Abstract N° SP0174
The value of type I IFN signature to stratify patients

Jiri Vencovsky (Czech Republic) 12:45
Abstract N° SP0175
Heterogeneity of myositis and therapeutic consequences

D. Leonard (Sweden) 13:05
Abstract N° OP0362
Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis

R. Knevel (Netherlands) 13:15
C. Terao, J. Cui, K. Slowikowski, T. Huizinga, B. Karlson, K. Liao, S. le Cessie, S. Raychaudhuri
Abstract N° OP0363
Optimising precision medicine by using genetics to assign diagnostic prior probabilities to patients with synovitis - proof of principle

Gerlinde Bendzuck (Germany) 12:05
Abstract N° SP0176
It works?! Employment support for people with RMDs

Erika Mosor (Austria) 12:25
Abstract N° SP0177
Quality of life at the workplace - how early interventions of health professionals can support people with RMDs

Sarah Copsey (Spain) 12:45
Abstract N° SP0178
The contribution of occupational safety and health to working with RMDs

M. Klokkerud (Norway) 13:05
E. Hasselknippe, A. Renningen, H. Haveråan, A.-L. Sand-Svartrud
Abstract N° OP0364-PARE
Work status and work barriers in patients receiving BDMARDs as infusions in rheumatology hospital clinics in Norway. A cross-sectional study

M. Bezzant (United Kingdom) 13:15
A. Bosworth, L. Lunt, S. Verstappen
Abstract N° OP0365-PARE
Work matters: a UK wide survey of adults with rheumatoid arthritis and juvenile idiopathic arthritis on the impact of their disease on work

12:00 - 13:30  E106/E107

The Young Rheumatologist
The challenges of rheumatology trainees in the clinical learning environment

Learning objectives:
• To learn more about communication competencies in general and patient-education competencies in particular
• To understand, by using videoed outpatient consultations during the session at EULAR, how you can improve and refine your communication skills when dealing with challenging situations in daily practice

Chair(s):
Marloes van Onna (Netherlands)
Alessia Alunno (Italy)

Peter Boyd (Ireland) 12:05
Abstract N° SP0179
Patient perspective: what could clinicians do better in clinical communication?

Simone Gorter (Netherlands) 12:25
Abstract N° SP0180
Communication skills, an essential competency in daily practice

Elena Nikiphorou (United Kingdom) 12:45
The use of social media: weighing the risks and benefits

12:00 - 13:30  PARE Room

Joint session PARE/HPR
Work and rehabilitation - key priorities for people with RMDs

Learning objectives:
• To explore the current developments at EU level and the impact on member states
• To explore the impact of work rehabilitation on the quality of life and on employment
• To show the value of early intervention, prevention and better management of RMDs

Chair(s):
Tanja Stamm (Austria)
Elsa Mateus (Portugal)
13:05
L. Ward
Abstract N° OP0366
Ambulatory rheumatology teaching day - a 360-degree evaluation of stakeholder experiences

13:15
R. Sengewein (Germany)
E. Schmok
Abstract N° OP0367
Using youtube to teach the fundamentals of rheumatology: a two-year retrospective analysis of four online lectures

13:45 - 14:45  Auditorium

Highlight session
Clinical and Basic Translational
Highlight session

Chair(s):
Thomas Dörner (Germany)
Robert B. M. Landewé (Netherlands)

Leonie Taams (United Kingdom) 13:50
Basic and translational highlights

John D. Isaacs (United Kingdom) 14:15
Clinical Highlights

13:45 - 14:45  Amtrium

Highlight session
HPR Highlight session

Chair(s):
Yeliz Prior (United Kingdom)
Rikke H. Moe (Norway)
Fernando Estévez-López (Spain) 13:50
Abstract N° SP0181
Highlights from the Health Professionals in Rheumatology sessions

Iain B. McInnes (United Kingdom) 14:08
Highlights from the scientific programme

Trond Haugmark (Norway) 14:26
Abstract N° SP0182
Highlights from the PARE programme

13:45 - 14:45  PARE Room

Highlight session
PARE Highlight session

Learning objectives:
To provide an overview of learning and outcomes from the EULAR 2018 Congress from health professionals and the scientific perspectives, and first feedback from the PARE delegates

Chair(s):
Dieter Wiek (Germany)
Nele Caeyers (Belgium)

Elena Nikiphorou (United Kingdom) 13:50
Highlights from the scientific programme

Yvonne van Eijk-Hustings (Netherlands) 14:15
Highlights from the HPR programme
Guided Poster Tours

**Saturday, 16 June 2018**

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a 'first-come-first-served' basis on the date of the poster tour.

**10:30 - 12:00**

**Poster area**

**Poster tour S1: Born to be wild**
Chair(s): Martin Herrmann (Germany)  
Mario Zaiss (Germany)  
Abstracts N°: SAT0001-SAT0007  
See page 138

**Poster tour S2: The good, the bad and the ugly: soluble mediators in inflammation**
Chair(s): Leonie Taams (United Kingdom),  
Mike O. Becker (Switzerland)  
Abstracts N°: SAT0016-SAT0025  
See page 139

**Poster tour S3: The joint connection: cartilage, bone and synovial tissue**
Chair(s): Elena Neumann (Germany)  
Kerstin Klein (Switzerland)  
Abstracts N°: SAT0048-SAT0057  
See page 140

**Poster tour S4: Predicting tomorrow today: prognosis, predictors and outcomes of RA**
Chair(s): John D. Isaacs (United Kingdom)  
Meghna Jani (United Kingdom)  
Abstracts N°: SAT0073-SAT0082  
See page 141

**Poster tour S5: Breakout news on non-TNF biologics in RA**
Chair(s): Xavier Mariette (France)  
Diane van der Woude (Netherlands)  
Abstracts N°: SAT0165-SAT0174  
See page 145

**Poster tour S6: Novel insights on non-biologics in RA**
Chair(s): Alexander So (Switzerland)  
Diego Kyburz (Switzerland)  
Abstracts N°: SAT0212-SAT0220  
See page 147

**Poster tour S7: Treatment in SpA: does it matter?**
Chair(s): Sofia Ramiro (Netherlands),  
Victoria Navarro-Compañ (Spain)  
Abstracts N°: SAT0259-SAT0268  
See page 150

**Poster tour S8: PsA: a whole range of (subclinical) (co)morbidities!**
Chair(s): Filip van den Bosch (Belgium)  
Francesco Carubbi (Italy)  
Abstracts N°: SAT0302-SAT0311  
See page 152

**Poster tour S9: Beware the bug!**
Chair(s): Elena Nikiphorou (United Kingdom)  
James Galloway (United Kingdom)  
Abstracts N°: SAT0380-SAT0389  
See page 155

**Poster tour S10: SLE, Sjögren’s and APS - novel predictors of disease activity and long-term outcomes**
Chair(s): Lai-Shan Tam (China)  
Priscilla Wong (China)  
Abstracts N°: SAT0414-SAT0423  
See page 157

**Poster tour S11: SSc, myositis, related syndromes - novel ideas take place**
Chair(s): Ulf Müller-Ladner (Germany)  
Ingrid Lundberg (Sweden)  
Abstracts N°: SAT0468-SAT0477  
See page 159

**Poster tour S12: Be familiar with orphan diseases**
Chair(s): Nemanja Damjanov (Serbia),  
Predrag Ostojic (Serbia)  
Abstracts N°: SAT0587-SAT0596  
See page 164

**Poster tour S13: Imaging strategies in the management of arthritis**
Chair(s): Lene Terslev (Denmark)  
Mads Ammitzboll (Denmark)  
Abstracts N°: SAT0630-SAT0639  
See page 166

**Poster tour S14: This poster tour might be risky!**
Chair(s): Laure Gossec (France)  
Paul Studenic (Austria)  
Abstracts N°: SAT0677-SAT0686  
See page 168

**Special poster tour S15: Theory of poster design and presentation**
Chair(s): Maarten Boers (Netherlands)  
Attendance of the session EULAR Projects - challenging projects in education and training, 09:00-10:30, Room E106/E107 is required in order to participate in this special poster tour.
TOPIC: INNATE IMMUNITY IN RHEUMATIC DISEASES

**Poster tour S1: Born to be wild**

**Chair(s):** Martin Herrmann (Germany), Mario Zaiss (Germany)

**Abstracts N°:** SAT0001-SAT0007

**SAT0001** MECHANISM AND SIGNIFICANCE OF COMPLEMENT C3 RECEPTOR IN COLLAGEN-INDUCED RHEUMATOID ARTHRITIS MICE MODEL / L. Dan* - L. Ke


**SAT0004** INTRA-ARTICULAR INJECTION OF ADIPOSE-DERIVED MESENCHYMAL Stromal CELLS REDUCE EXPERIMENTAL OA PATHOLOGY VIA IL-18-MEDIATED REALLOCATION AND ENHANCED PHAGOCYTOSIS OF POLYMORPHONUCLEAR LEUCOCYTES / S. van Dalen* - M. van den Bosch - A. Blom - P. van der Kraan - T. Vogl - L. Casteilla - P. van Lent


**SAT0006** P2X7 RECEPTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). EXPLORING A NOVEL PATHOGENETIC PATHWAY IN LUPUS RELATED SEROSITIS / F. Furini* - A. Bortoluzzi - A. L. Giuliani - F. Di Virgilio - M. Govoni


**SAT0008** DYSREGULATION OF THE CIRCULATING AND RENAL CLUSTERIN IN LUPUS NEPHRITIS / H.-J. Ma* - C. Liu - B.-Y. Shi - L.-Y. Sun

**SAT0009** TYROSINE KINASE PATHWAYS IN MONOSODIUM-URATE CRYSTAL-INDUCED INFLAMMATORY RESPONSES / K. Futosi* - T. Nemeth - A. Mocsi

* Presenting author


IL-1A AND ADAMTS5 MEDIATED TISSUE DAMAGE IN HUMAN CARTILAGE EXPLANTS LEADS TO GENERATION OF TLR2 ACTIVATING DAMPS / N. Sharm* - T. G. Christiansen - M. Karsdal - A.-C. Bay-Jensen - C. S. Thudium

DRUG REPURPOSING TO BLOCK TLR4-ASSOCIATED INFLAMMATION IN OA CHONDROCYTES / E. Franco-Trepat - A. Alonso-Perez - M. Guillon Fresco - A. Jorge Mora - V. Lopez - O. Quaillo - R. Gomez* on behalf of Musculoskeletal Pathology group


TOPIC: CYTOKINES AND INFLAMMATORY MEDIATORS

**Poster tour S2: The good, the bad and the ugly: soluble mediators in inflammation**

**Chair(s):** Leonie Taams (United Kingdom), Mike O. Becker (Switzerland)

**Abstracts N°:** SAT0016-SAT0025

---

**SAT0016** IL-12 SUPPRESSES TR1 CELLS IN THE SJÖGREN’S SYNDROME / G. Yao* - J. Qi - L. Sun

**SAT0017** THE RHEUMATOID FACTOR RESPONSE IS COMPOSED OF MULTIPLE REACTIVITIES AGAINST DIFFERENT EPITOPES / W. Falkenberg* - J. Koers - P. Olievaar-de Heer - D. van Schaardenburg - G. Wolbink - T. Rispens


**SAT0020** IMPACT OF IL12B SINGLE NUCLEOTIDE POLYMORPHISMS ON CIRCULATING PRO-INFLAMMATORY CYTOKINES IL-12P40 AND IL-23 IN ANKYLOSING SPONDYLITIS / M. G. Ivanova* - I. Manolova - R. Stoiilov - L. Miteva - S. Stanilova


**SAT0024** IL-36 AXIS IS AN EMERGING THERAPEUTIC TARGET IN PSORIATIC ARTHRITIS SYNOVIAL TISSUE / M.-A. Boutet - A. Nerviani* - G. Liiso-Ribera - K. Goldmann - M. Lewis - C. Pitzalis

**SAT0025** CXCL4 ALTERS TRANSCRIPTOMIC AND EPIGENETIC IMPRINTING OF DENDRITIC CELLS THEREBY DRIVING FIBROSIS THROUGH EXTRACELLULAR MATRIX FORMATION / S. Silva-Cardoso - W. Tao - C. Angiolilli - A. Nerviani* - G. Lliso-Ribera - K. Goldmann - M. Lewis - C. Pitzalis

**SAT0026** MERTK+ MONOCYTES ARE EXPANDED IN THE PERIPHERAL BLOOD OF PATIENTS WITH ACTIVE IGG4-RELATED DISEASE / A. A. Alshevskaya* - A. Antanaviciute - I. Carr - M. Wittmann - P. Emery - G. Tsokos - E. M. Vital


**SAT0028** CO-EXPRESSION OF RECEPTORS TO TNFA AMONG NAÏVE T CELLS AND MEMORY T CELLS IS ALTERED IN RHEUMATOID ARTHRITIS AND THE CHANGES CORRELATE WITH DISEASE ACTIVITY / A. A. Alshevskaya - J. Lopatnikova - O. Chumasova - N. Shkaruba - A. Sizikov - V. Gladikikh - S. Sennikov

**SAT0029** IMPACT OF GLUCOCORTICOIDS ON SIRTUIN 1 EXPRESSION AND PROINFLAMMATORY CYTOKINE PRODUCTION IN RATS WITH ADJUVANT-INDUCED ARTHRITIS / D. Wendling* - W. Abbas - A. Kumar - S. Pasquereau - F. Verhoeven - C. Prati - C. Demougeot - G. Herbein


**SAT0031** INTERLEUKIN 29 INHIBITS OSTEOCLAST DIFFERENTIATION AND FUNCTION IN RANKL-INDUCED OSTEOCLASTOGENESIS / F. Wang* - A. Luo - Q. Wu - Z. Zhou - O. Peng - W. Xuan - W. Tan

**SAT0032** MESENCHYAL STEM CELLS ALLEVIATE EXPERIMENTAL AUTOIMMUNE CHOLANGITIS THROUGH IMMUNOSUPPRESSION MEDIATED BY GALECTIN-9 / J. Fan* - X. Tang - H. Chen - L. Sun - Q. Wang

* Presenting author


SAT0035  THE EFFECTS OF VISFATIN, RESISTIN AND IL-17 ON SYNOVIAL FIBROBLASTS FROM DIFFERENT RHEUMATIC DISEASE BACKGROUNDS / K. Frommer* - S. Rehart - M. Sauerbier - U. Müller-Ladner - E. Neumann

SAT0036  NICOTINE PROMOTES MMP-3 AND RANKL SECRETION THROUGH OVEREXPRESSED NICOTINIC ACETYLCHOLINE RECEPTOR A7 IN RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES / J.-O. Ma - Y.-S. Mou - T. Yan - J. Jing - Y.-Q. Mo - Y.-L. Chen - L. Dai*

SAT0037  IGRURATIMOD AMELIORATES BLEOMYCIN-INDUCED ALVEOLAR INFLAMMATION AND PULMONARY FIBROSIS IN MICE BY SUPPRESSING EXPRESSION OF MMP-9 / L. Zhao* - B. Mu - R. Zhou - C. Huang


SAT0041  COMPARISON OF DIFFERENT TYPE 1 IFN SIGNATURES DEMONSTRATES CONCORDANCE IN A REAL WORLD, HOME MONITORED SYSTEMIC LUPUS ERYTHEMATOSUS COHORT / M. Abedi - F. Flores - P. Naranatt - J. Spangler - L. Pan - R. Trerueggen*

SAT0042  EVIDENCE OF NETOSIS IN CIRCULATING NEUTROPHILS AND SKIN LESIONS WITH VASCULITIS AND PANNICULITIS IN BEHÇET’S DISEASE / R. Kallas* - R. Safi - R. Hamam - I. Uthman - D. Nassar


SAT0044  LIN28A IS OVEREXPRESSED IN OSTEARTHITIS AND IS ESSENTIAL FOR THE STABILITY AND HIGH LEVEL EXPRESSION OF IL-6 AND COX-2 IN HUMAN CHONDROCYTES / I. Ahmad - M. Y. Ansari - M. N. Khan - T. M. Haqqi*


SAT0047  PTEN REGULATION ALLEVIATES THE ALCOHOL-INDUCED OSTEOPENIA IN RAT VIA AKT/GSK-3/β-CATENIN/ PTEN REGULATION ALLEVIATES THE ALCOHOL-INDUCED OSTEOPENIA IN RAT VIA AKT/GSK-3

TOPIC: CARTILAGE, SYNOVIOLOGY AND BONE

Poster tour S3: The joint connection: cartilage, bone and synovial tissue

Chair(s): Elena Neumann (Germany), Kerstin Klein (Switzerland)

Abstracts N°: SAT0046-SAT0057


SAT0051  EXAMINING THE ROLE OF TRPC5 IN OSTEOARTHRITIS PAIN / J. Sousa-Valente* - F. Ayaz - X. Kodji - S. D. Brain

SAT0052  THE COLL2-1 PEPTIDE OF COLLAGEN TYPE II: A NEW ACTOR OF SYNOVITIS IN OSTEOARTHRITIS / C. Lambert - D. Borderie - F. Rannou - Y. Henrotin*

SAT0053  IDENTIFICATION OF NOVEL DRUGS WITH SENOLYTIC ACTIVITY AS OSTEOARTHRITIS THERAPEUTICS / A. Damerau - Y. Chen - F. Buttgereit - T. Gaber

SAT0054  SIGNIFICANT DECREASE OF T CELLS BUT NOT MACROPHAGES IN THE SYNOVIA OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB / K. Chatzidionysiou* - M. Engström - E. af Klint - E. Morand

SAT0055  THE COLL2-1 PEPTIDE OF COLLAGEN TYPE II: A NEW ACTOR OF SYNOVITIS IN OSTEOARTHRITIS / C. Lambert - D. Borderie - F. Rannou - Y. Henrotin*

SAT0056  IDENTIFICATION OF NOVEL DRUGS WITH SENOLYTIC ACTIVITY AS OSTEOARTHRITIS THERAPEUTICS / A. Damerau - Y. Chen - F. Buttgereit - T. Gaber

* Presenting author
SAT0057 THE EFFECT OF EXOSOMES FROM BONE MARROW MESENCHYMAL STEM CELLS ON OSTEOARTHRITIS / H. Zhu* - J. Ji - T. Fu - J. Yang - Z. Gu

SAT0058 ADALIMUMAB: TNF COMPLEXES ARE CLEARED MORE EFFICIENTLY BY HUMAN OSTEOCLASTS THAN THOSE WITH ETANERCEPT THROUGH FCG-RECEPTOR BINDING AND INTERNALIZATION / B. P. Harvey* - J. Cohen-Solal - Z. Kaymakcalan

SAT0059 IMPAIRMENT IN HYDROGEN SULFIDE SYNTHESIS IN OSTEOARTHRITIC CHONDROCYTES FROM DIABETIC PATIENT AND UNDER A HIGH GLUCOSE STRESS / C. Vaamonde-Garcia* - F. Blanco - R. Mejide-Falide

SAT0060 PROTEOMIC ANALYSIS OF OSTEOBLASTS SECRETOME PROVIDES NEW INSIGHTS IN MECHANISMS UNDERLYING OSTEOARTHRITIS SUBCHONDRAL BONE SCLEROSIS / C. Sanchez* - G. Mazzucchelli - F. Combain - C. Lambert - E. DePauw - Y. Henrotin


SAT0065 CHONDROCYTES UNDER PATHOLOGICAL CONDITIONS PREFERENTIALLY DEGRADES SELECTED TRNAS TO INHIBIT PROTEIN SYNTHESIS / J. Green* - T. Haqqi


SAT0067 ROLE OF NOX2-DERIVED REACTIVE OXYGEN SPECIES IN S100A8/A9-DRIVEN INFLAMMATORY OSTEOARTHRITIS / N. Kruitbergen* - S. van Dalen - M. van den Bosch - A. Blom - P. van Lent


SAT0069 ABNORMAL BONE AND CARTILAGE METABOLISM COULD BE ANTAGONIZED BY PULSED ELECTROMAGNETIC FIELDS (PEMFS) AND TNF-A AND IL-6 GENE KNOCKOUTS IN A SIMILAR MECHANISM / S. Z. Zhu* - H. He - Q. Wang - D. Wang - H. Wang - C. Gao - C. Zhang - X. Yu - C. He


SAT0072 MIRNA-146A IS A KEY PLAYER IN BONE METABOLISM AND OSTEOPOROSIS / V. Saferding* - M. Hofmann - T. Hügle*

SAT0073 PROTEOMIC ANALYSIS OF OSTEOBLASTS SECRETOME PROVIDES NEW INSIGHTS IN MECHANISMS UNDERLYING OSTEOARTHRITIS SUBCHONDRAL BONE SCLEROSIS / C. Sanchez* - G. Mazzucchelli - F. Combain - C. Lambert - E. DePauw - Y. Henrotin

SAT0074 TREATMENT EXPECTATIONS INFLUENCE BOTH SUBJECTIVE AND OBJECTIVE OUTCOME PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS- A PROSPECTIVE COHORT STUDY / J. Mickx* - R. Brinks - A. Dimitriou - J. Richter - M. Schneider

**Topic: Rheumatoid Arthritis - Prognosis, Predictors and Outcome**

**Poster session S4:** Predicting tomorrow today: prognosis, predictors and outcomes of RA

**Chair(s):** John D. Isaacs (United Kingdom), Meghna Jani (United Kingdom)

**Abstracts N°:** SAT0073-SAT0082

**SAT0073** ACPA AND RF AS PREDICTORS OF SUSTAINED CLINICAL REMISSION IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / J. E. Pope* - M. Movahedi - E. Rampakakis - A. Cesta - J. S. Sampalis - C. Bombardier on behalf of other OBRI investigators

**SAT0074** IDENTIFICATION OF A PROTEIN PANEL USEFUL FOR THE PREDICTION OF RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS / C. Ruiz-Romero* - F. Picchi - L. González-Rodríguez - P. Fernández-Puente - R. Hands - V. Calamia - M. Camacho-Encina - C. Bessant - C. Pitzalis - F. J. Blanco


**SAT0076** SYNOVIAL MAST CELLS AND RESPONSES TO SYNTHETIC AND BIOLOGIC DMARDS IN EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS / F. Rivellese* - A. Nerviani - D. Mauro - S. Pagani - F. Humby - C. Pitzalis

**SAT0077** CHANGE IN FREQUENCY OF ARTHROPLASTY SURGERY IN RHEUMATOID ARTHRITIS: A 13 YEAR POPULATION HEALTH STUDY / J. G. Hanly* - L. Lethbridge - C. Kombe

**SAT0078** WHICH CDMAR STRATEGY IS MOST EFFECTIVE IN NEWLY DIAGNOSED SERONEGATIVE RHEUMATOID ARTHRITIS PATIENTS; POST-HOC ANALYSIS OF THE TREACH STUDY / N. Luurssen-Masurel - A. E. A. M. Weel - J. M. W. Hazes - P. H. P. de Jong

**SAT0079** TREATMENT EXPECTATIONS INFLUENCE BOTH SUBJECTIVE AND OBJECTIVE OUTCOME PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS-A PROSPECTIVE COHORT STUDY / J. Mickx* - R. Brinks - A. Dimitriou - J. Richter - M. Schneider


SAT0082 OSTEOPONTINE AND OSTEOPROTEGERINE AS MARKERS OF ALTERED PRECLINICAL BONE METABOLISM IN RHEUMATOID ARTHRITIS / S. Disanto* - E. A. Zelinski - A. A. Alhadi


SAT0089 INITIATING TOFACITINIB IN A TREAT TO TARGET STRATEGY FOR RHEUMATOID ARTHRITIS LEADS TO BLUNTED MULTI-BIOMARKER DISEASE ACTIVITY SCORES AS COMPARED TO ANTI-TUMOR NECROSIS FACTOR AGENTS / C. Wiesenhammer*


SAT0091 CLINICAL REMISSION PREDICTION USING BASELINE GENE EXPRESSION IN THE PERIPHERAL BLOOD OF DMARD-NAIVE RHEUMATOID ARTHRITIS PATIENTS TREATED WITH METHOTREXATE / E. V. Tchetina* - N. V. Demidova - G. A. Markova

SAT0092 PALINDROMIC RHEUMATISM (PR): EXPERIENCE IN A REAL WORLD SETTING - THE NOTTINGHAM CASEMIX REGISTER (NCR) / F. Kynaston-Pearson* - I. Pande - C. Turesson

SAT0093 MALE SEX PREDICTS A FAVOURABLE OUTCOME IN SERONEGATIVE EARLY RHEUMATOID ARTHRITIS / G. Cagnotto* - E. Rydell - L. Jacobsson - C. Turesson

SAT0094 PHYSICAL FUNCTION AND HEALTH RELATED QUALITY OF LIFE IN EARLY RHEUMATOID ARTHRITIS PATIENTS WHO ACHIEVED ONLY LOW DISEASE ACTIVITY COMPARED WITH REMISSION / H. M. Lam* - M. C. Wan - L. S. Tam on behalf of the Hong Kong CRYSTAL study group


SAT0098 PATIENT AND DISEASE CHARACTERISTICS THAT PREDICT SWITCHING FROM A TNF INHIBITOR TO ANOTHER BIOLOGIC OR TARGETED SYNTHETIC DMARD IN PATIENTS WITH RA IN CLINICAL PRACTICE / L. R. Harrold* - H. J. Litman - S. E. Connolly - E. Alemo - S. Kelly - S. Rebello - T. Blachley - J. M. Kremer


SAT0100 THE DETERMINANTS OF REFRACTORY RHEUMATOID ARTHRITIS / M. Bécède* - J.-S. Chen* - D. Prati - D. Wendling - P. Totoson - C. Demougeot


SAT0102 PRISTANE-INDUCED ARTHRITIS IN DARK AGOUTI RAT: A NEW ANIMAL MODEL TO STUDY CARDIOVASCULAR DYSFUNCTION IN RHEUMATOID ARTHRITIS / M. Chour* - R. Bordy - J. M. Moretto - M. Tournier-Nappey - C. Prati - D. Wendling - P. Totoson - C. Demougeot

SAT0103 THREE-MONTHLY ULTRASOUND MONITORING OF RHEUMATOID ARTHRITIS PATIENTS TAPERING THEIR MEDICATION HAS LIMITED VALUE IN PREDICTING DISEASE RELAPSE / M. van der Ven* - M. Kuiper - A. Gerards - I. Tchetverikov - A. Weel - D. van Zeben - C. Bijkerk - Y. de Man - M. Hazes - J. Luime

* Presenting author
SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 143


SAT0107 SEQUENTIAL ULTRASOUND SHOWS A LATE INCREASE IN INFLAMMATORY BURDEN IN ANTI-CCP POSITIVE PATIENTS WITH NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS JUST BEFORE PROGRESSION TO INFLAMMATORY ARTHRITIS / P. Pentony* - K. Mankia - E. M. Hensor - J. L. Nam - L. Hunt - L. Garcia-Montoya - L. Duquenne - P. Emery

SAT0108 EFFICACY OF ABATAcept VERSUS ADALIMUMAB ON THE PROPORTION OF PATIENTS WITH SEROPOSITIVE, EROSIve EARLY RA ACHIEVING DAS28 (CRP) <2.6 OR VALIDATED MEASURES OF REMISSION: A POST HOC ANALYSIS OF THE 2-YEAR AMPLE TRIAL / R. Fleischmann* - M. E. Weinblatt - H. A. Ahmad - M. A. Maldonado - E. Alemao - Y. Elbeiz - M. Schiff

SAT0109 ULTRASONIC EVALUATION OF JOINT INVOLVEMENT IN ESTABLISHED RA: ACTIVE SYNOVITIS PREDICTS SUSTAINED TREATMENT CHANGES IN SUSPECTED BIOLOGIC FAILURE / R. L. Battern* - O. Mohammed - L. Probert - D. Wright - I. Atchia


SAT0116 THE STUDY OF BASELINE SERUM SICAM-1 AND CXCL13 LEVELS IN PREDICTING RESPONSE TO TUMOR NECROSIS FACTOR-Α INHIBITOR THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS / X. Ye* - J. Zhao - A. C. S. Silva - A. M. Kakehasi*

TOPIC: RHEUMATOID ARTHRITIS - COMORBIDITY AND CLINICAL ASPECTS


SAT0119 PHYSICAL ACTIVITY IN TUNISIAN ADULTS WITH RHEUMATOID ARTHRITIS / M. Feki* - A. Fazaa - S. Miladi - A. C. S. Silva - A. M. Kakehasi*


SAT0124 AORTIC STIFFNESS AND TIME TO WAVE REFLECTION ARE ASSOCIATED WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION MEASURES IN RHEUMATOID ARTHRITIS / A. M. Mil len* - L. Mokotedi - S. Gunter - C. Robinson - F. Michel - A. J. Woodiwiss - L. Tsang - G. R. Norton - P. H. Dessein

* Presenting author
SAT0125 THE IMPACT OF SELECTED COMORBIDITIES ON TREATMENT OUTCOME IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN EXPLORATORY COHORT STUDY / A. Emanuelsen* - I. M. Jensen Hansen


SAT0130 IMPROVEMENT OF NUTRITIONAL CONDITIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS STARTING FIRST DISEASE MODIFYING ANTI-RHEUMATIC DRUGS / D. Kobayashi* - S. Ito - E. Hasegawa - I. Narita - K. Nakazono

SAT0131 THE ROLE OF ULTRASOUND FOR THE ASSESSMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS / S. Farrieta - E. Castilho* - D. Buitrago-Garcia - L. Villarreal - P. Santos-Moreno

SAT0132 COMORBIDITIES AFFECT THE RETENTION RATE BUT NOT THE CLINICAL RESPONSE IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS / E. G. Favalli* - M. Biggioggero - A. Becciolini - C. Cotti - L. Sinigaglia


SAT0135 CYTOKINE ACTIVATION AND FORMATION OF NEPHROPATHY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND PATHOPHYSIOLOGICAL PARALLELS / D. Rekalov - G. Grytkova* - R. Kulynych

SAT0136 THE INFLUENCE OF HDL-CHOLESTEROL AND CRP ON INCREASED INSULIN RESISTANCE AND IMPAIRED BETA-CELL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS / G. G. Riist" - V. Subota - D. Stanisavljevic - B. Glisic - M. Petronjevic - D. Stefanovic

SAT0137 CAROTID INTIMA-MEDIA THICKNESS AND ATHEROSCLEROTIC PLAQUE IN PATIENTS WITH REACTIVE AND RHEUMATOID ARTHRITIS / H. Palhuyeva* - A. Litvaiakov - N. Podolinskaya

SAT0138 A DELAY TO DIAGNOSIS, BUT NOT TO TREATMENT INITIATION, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IS ASSOCIATED WITH ETHNIC GROUP AT ONE US ACADEMIC SITE / I. Castrejon* - T. Pincus - J. Chua - N. Shakoor - S. Hassan - J. A. Block


SAT0143 SUBCLINICAL IMPAIRMENT OF MYOCARDIAL FUNCTIONALITY DURING THE VERY EARLY STAGE OF RHEUMATOID ARTHRITIS: AN EXPLORATORY COHORT STUDY / A. Emamifar* - I. M. Jensen Hansen

SAT0144 THE IMPACT OF SELECTED COMORBIDITIES ON TREATMENT OUTCOME IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN EXPLORATORY COHORT STUDY / A. Emanuelsen* - I. M. Jensen Hansen


SAT0148 ORAL CARE AND HEALTH IN RHEUMATOID ARTHRITIS PATIENTS BASED ON A SELF- ASSESSMENT QUESTIONNAIRE INVESTIGATION / L. L. Strandbygaard* - M. Radwan-Oczko - I. Dus - A. M. Thomsen - K. Schmøkel - C. Rasmussen

* Presenting author
SAT0149 IS ESTABLISHED SERONEGATIVE RHEUMATOID ARTHRITIS EVEN A MILD FORM OF THE DISEASE? / L. D. Fajardo-Hernosillo*


SAT0151 CARDIORESPIRATORY FITNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. H. Liff* - M. Hoff - T. Fresno - U. Wisloff - R. Thomas - V. Videm

SAT0152 SYSTEMIC AND RENAL AA AMYLOIDOSIS IN RHEUMATOID ARTHRITIS - A COMPARATIVE POSTMORTEM CLINICOPATHOLOGIC STUDY OF 161 PATIENTS / M. Bély* - Â. Apáthy


SAT0154 ASSESSMENT OF BONE TURNOVER MARKERS IN PRE- AND POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS / O. Garmiah* - T. Oryk - A. Romanovskiy - T. Gavrylenko


SAT0156 ASSOCIATION BETWEEN CUMULATIVE METHOTREXATE DOSE, NON-INVASIVE SCORING SYSTEM AND HEPATIC FIBROSIS DETECTED BY FIBROSCAN IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING MÉTROTREXATE / R. Lertnawapan* - S. Chonprasertsuk - S. Siramolpiwat

SAT0157 THE PREVALENCE OF DYSLIPIDEMIA AND DAILY NUTRITIONAL INTAKE IN RHEUMATOID ARTHRITIS PATIENTS: A STUDY OF THE KOREAN NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (KNHANES) / S. H. Joo* - Y. W. Song


SAT0159 THYROID FUNCTION IN EARLY VERSUS ESTABLISHED RHEUMATOID ARTHRITIS / S. Hannawi* - H. Hannawi - I. Al Salmi

SAT0160 EFFECT OF PERIODONTAL TREATMENT ON E-SELECTIN LEVEL IN RHEUMATOID ARTHRITIS PATIENTS / S. A. Kusumo* - H. Isbagio - S. Marhamah - C. Intan - D. Antono - K. Harimurti

SAT0161 INFLUENCE OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS ON RADIOGRAPHIC PROGRESSION OF CONCOMITANT INTERPHALANGEAL JOINT OSTEARTHritis / C. Lechtenboehmer - V. Jaeger - D. Kyburz - U. A. Walker - T. Hülge*


SAT0163 ABSOLUTE NUMBER OF PERIPHERAL CD4-CD25+FOXP3+T CELLS DECREASES AND RESTORES AFTER LOW-DOSE INTERLEUKIN-2 TREATMENT IN RHEUMATOID ARTHRITIS / X. Jia* - H. An - K. Fan - F. Li - C. Gao - X. Li


SAT0165 STUDY OF PERIODONTAL TREATMENT ON T-SELECTIN LEVEL IN RHEUMATOID ARTHRITIS PATIENTS / P. Bird - H. Griffiths - L. Roberts - K. Tymms - G. Littlejohn

SAT0166 WHICH BIOLOGIC AGENT IS MOST SUITABLE FOR AN EXTENDED-INTERVAL TREATMENT FOR RHEUMATOID ARTHRITIS? RESULTS FROM A MULTICENTER STUDY / K. Katayama* - H. Matsuno - T. Matsubara


SAT0168 MRI RESULTS FOLLOWING DISCONTINUATION OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS / Y. H. Lee* - Y. H. Seo

SAT0169 NO EVIDENCE THAT CONCOMITANT GLUCOCORTICOID THERAPY AFFECTS EFFICACY AND SAFETY OF TOCILIZUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS CLINICAL TRIALS / M. Safy* - J. W. G. Jacobs - C. Peterfy - J. Kremer - W. Rigby - N. Singer - C. Birchwood - D. Gill - W. Reis - J. Pei - M. Michalska


SAT0171 REVERSIBLE DECREASES IN ABSOLUTE NEUTROPHIL COUNT (ANC) IN RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS) ON SIRULUMAB: COMPARISON OF DOSE DELAY AND DOSE DECREASE VS CONTINUED TREATMENT / J. R. Curtis* - G. St John - M. Panucci - J. A. Maldonado-Cocco

** Presenting author


SAT0175 RESPONSE TO BIOLOGIC TREATMENT IMPROVES SEXUAL HEALTH ASSESSED BY THE QUALISEX SCORE IN RA / A. Perdriger* - C. Lucas - J. Sibilia - J.-E. Gottenberg

SAT0176 CONTRIBUTION OF CD4+ T CELLS DECREASE ON CLINICAL RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS / A. Bensalem* - D. Mullemel - G. Thibault - N. Azzopardi - G. Paintaud - P. Goupil - D. Ternant


SAT0178 PREDICTORS OF DRUG SURVIVAL IN RHEUMATOID ARTHRITIS - RESULTS FROM A LARGE NATIONAL QUALITY REGISTER COHORT STUDY / G. Cagnotto - M. Willim - J.-A. Nilsson - S. Saevsuddottir - C. Vuorinen*

SAT0179 THE BLOOD B CELL SUBSETS AND EFFECT OF TOCILIZUMAB THERAPY ON THEM IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Gerasimova* - T. Popkova - A. Aleksankin - S. Davydyan - A. Martinova - E. Aleksandrova

SAT0180 TWO-YEAR CONSOLIDATED SAFETY DATA FOR ABP 501 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS / E. Krishnan* - N. Zhang - H. Wang


SAT0187 GOLIMUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA). ANKLYOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA). 1-YEAR RESULTS FROM A NON-INTERVENTIONAL TRIAL IN GERMANY / L. Turesson*


SAT0192 COMPETITIVE ELISA AND BRIDGING ELISA WITH ACID DISSOCIATION DETECT ANTI-DRUG ANTIBODIES IN A GREATER PROPORTION OF PATIENTS TREATED WITH TNF-ALPHA INHIBITORS THAN CLASSICAL BRIDGING ELISA / M. Ogric* - P. Žigon - K. Lakota - S. Prapatrnik - D. Drobné - B. Štabuc - S. Sodin-Semrl - S. Čučnik


* Presenting author
SAT0194  SIGNIFICANT OVERTREATMENT WITH BIOLOGICAL DRUGS IS COMMON IN ROUTINE CARE FOR PATIENTS WHERE SERUM DRUG LEVELS ARE MONITORED / M. E. Perry


SAT0196  TIME TO DISCONTINUATION OF BIOLOGIC THERAPY BY MECHANISM OF ACTION IN RHEUMATOID ARTHRITIS: RESULTS FROM THE ONTARIO BEST PRACTICE RESEARCH INITIATIVE (OBRI) COHORT / M. Movahedi* - S. Couta - A. Cesta - C. Bombardier on behalf of Other OBRI Investigators


SAT0198  DRUG SURVIVAL AND EFFICACY OF ABATACTEP IN RHEUMATOID ARTHRITIS PATIENTS IN ROUTINE CARE - 7 YEAR EXPERIENCE FROM A SINGLE CENTRE IN THE UNITED KINGDOM / N. Nolka* - T. Sheeran - S. Venkatachalam

SAT0199  SWITCH FROM INNOVATOR ETANECETP TO BIOSIMILAR ETANECETP IN INFLAMMATORY RHEUMATIC DISEASES: THE EXPERIENCE OF COCHIN UNIVERSITY HOSPITAL PARIS-FRANCE / O. Al Tabaa* - A. Etcheto - C. Miceli-Richard - M. Anna - M. Dougados


SAT0201  REAL WORLD EVIDENCE ON SWITCHING BETWEEN ETANECETP AND ITS BIOSIMILAR IN RHEUMATOID DISEASES / R. Alten* - H. Jones - C. Curiale - T. Meng - L. Lucchese - C. Miglio


SAT0203  OPTIMIZATION OF BIOLOGIC TAPERING USING ULTRASOUND IN RA PATIENTS / S. Bawa* - M. Todd - J. France

SAT0204  NÀVE AND RECENT THYMIC EMIGRANT CD4+ T CELLS INCREASE IN RHEUMATOID PATIENTS TREATED WITH ABATACTEP / S. Planton* - F. Regola - A. Tincani - P. Airo

SAT0205  COMPARISON OF DISEASE STATUS IN UK PATIENTS WITH RA RECEIVING TNFI VS CDMARD / J. Addison - S. Lobosco* - B. Hoskin - E. Sullivan - J. Pike - S. Fenwick


SAT0210  TREATMENT RETENTION RATE OF BIOLOGICAL TREATMENT IN ELDERLY RHEUMATOID ARTHRITIS PATIENTS COMARED WITH YOUNGER RHEUMATOID ARTHRITIS PATIENTS - A SINGLE CENTER COHORT STUDY / Y. Hirano* - K. Hattori - R. Yamada - Y. Oishi


**TOPIC: RHEUMATOID ARTHRITIS - NON BIOLOGIC TREATMENT AND SMALL MOLECULES**

**Poster tour S6: Novel insights on non-biologics in RA**

**Chair(s):** Alexander So (Switzerland), Diego Kyburz (Switzerland)

**Abstracts N°:** SAT0212-SAT0220


**SAT0213**  TIGHT TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN THE EARLY STAGES OF DISEASE LEADS TO HIGH LEVELS OF REMISSION AND REDUCED USE OF BIOLOGICS / K. Levasseur - S. Raizada*

**SAT0214**  EFFECTIVENESS OF A RANDOMISED STEP-DOWN TO METHOTREXATE OR LEFLUNOMIDE MAINTENANCE THERAPY IN PATIENTS WITH LOW DISEASE ACTIVITY, 40 WEEKS AFTER STARTING COMBINED METHOTREXATE-LEFLUNOMIDE REMISSION INDUCTION THERAPY IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE CARERA TRIAL / V. Stouten* - S. Michiels - A. Belba - R. Westhovens - P. Verschuere on behalf of the CareRA study group

* Presenting author
SAT0215 LIVER BLOOD TEST ABNORMALITIES ARE RARE IN PATIENTS ON METHOTREXATE: EVIDENCE FROM A LARGE COHORT OF INFLAMMATORY ARTHRITIS PATIENTS / T. Malley* - G. Corfield - D. Heneghan - J. Kitchen


SAT0217 IDENTIFICATION OF DISTINCT DISEASE ACTIVITY TRAJECTORIES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OVER 12 MONTHS / V. P. Bykerk - R. van Vollenhoven - C. Connell - D. Gruben - L. Fallon - J. Woolcott - E. Keystone* 


SAT0219 UPADACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF A SELECTIVE JAK1 INHIBITOR / M. C. Genovese* - R. Fleischmann - B. Combe - S. Hall - Y. Zhang - Y. Zhou - M. F. Mohamed - S. Meerwein - A. L. Pangan


SAT0222 CLINICAL RISK STRATIFICATION FOR HYDROXYCHLOROQUINE PRESCRIBING IN A LARGE URBAN DISTRICT GENERAL HOSPITAL / A. Saravanan* - T. Ahmed


SAT0224 AMELIORATION OF INFLAMMATORY DISEASE ACTIVITY AND VASCULAR INFLAMMATION WITH HMG-COA REDUCTASE INHIBITION AND ANGIOTENSIN RECEPTOR BLOCKADE IN RHEUMATOID ARTHRITIS / A. Syngle* - N. Garg - P. Krishan


SAT0227 METHOTREXATE TREATMENT WITH COMBINATION OF THREE CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) AND ITS EFFECTIVENESS ON DISEASE CONTROL IN A SHORT TERM COMPARED TO BIOLOGIC DMARDS TREATMENT AFTER PROPENSITY SCORE MATCHING PROCEDURE IMPLEMENTED / I. Yoshii* - T. Chijiwa


SAT0229 COMPARISON OF EFFICACY OF TOFACITINIB VS. ETANERCEPT TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS WITH HIGH ACTIVITY DISEASE BY ULTRASOUND EVALUATION WITH POWER DOPPLER (1 YEAR COMPARISON) / I. Menshikova* - N. Dzhenzhera - Y. Pak - I. Kolosova


SAT0232 METHOTREXATE TREATMENT IN RHEUMATOID ARTHRITIS AND ELEVATED LIVER ENZYMES: A LONG-TERM FOLLOW-UP OF OCCURRENCE, PREDICTORS, SURVEILLANCE, AND OUTCOME IN CLINICAL PRACTICE / J. Sundbaum* - N. Ericsson - P. Hallberg - N. Lehto - M. Wadelius - E. Baeklund

SAT0233 METHOTREXATE TREATMENT IN RHEUMATOID ARTHRITIS AND ELEVATED LIVER ENZYMES: A LONG-TERM FOLLOW-UP OF OCCURRENCE, PREDICTORS, SURVEILLANCE, AND OUTCOME IN CLINICAL PRACTICE / J. Sundbaum* - N. Ericsson - P. Hallberg - N. Lehto - M. Wadelius - E. Baeklund


SAT0236 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN LABEL EXTENSION STUDY / M. C. Genovese* - J. Kremer - S. Zhong - A. Friedman

* Presenting author
Efficacy of Baricitinib in Patients with Rheumatoid Arthritis Who Failed 2 or More DMARDs / M. C. Genovese* - M. Doudagos - S. Schwartzman - D. Schlichting - C. Beig - L. Xie - A. Cardoso - J. S. Smolen


Rapid response with upadacitinib treatment in patients with rheumatoid arthritis and an inadequate response to csdmards or bdmards / O. FitzGerald* - A. Rubbert-Roth - K. Chen - S. Meerwein - J. Enejosa - T. Shaw - A. F. Wells


Patients' perspective on the efficacy and risks of glucocorticoids in RA - an initiative under the Gloria project / P. D. Cervalto - N. Goel - M. Voshavar - M. Boers - J. A. P. D. Silva


At which point and for which reasons are oral MTX formulations switched to injectable ones in RA patients? Combined results from 3 independent observational and clinical trials / R. M. Filpo* - A. Saraux - C. Hudry - C. Gaujoux-Viala - E. Senbel - S. Tropé - E. Zinovieva - H. Herman-Demars


The dosing of intra-articular triamcinolone hexacetonide for knee synovitis in chronic polyarthritis: A randomised controlled study / T. Weitott* - K. Öberg


* Presenting author

TOPIC: SPONDYLOARTHITIS - TREATMENT

Poster tour S7: Treatment in SpA: does it matter?
Chair(s): Sofia Ramiro (Netherlands), Victoria Navarro-Compán (Spain)
Abstracts N°: SAT0259-SAT0268


SAT0265  THE RESPONSE TO TNF-BLOCKERS TREATMENT OF SPA PATIENTS IS INFLUENCED BY THE INTERPLAY BETWEEN HLA-B27 AND GUT MICROBIOTA COMPOSITION AT BASELINE / M. Vallier* - M. Chamaillard - S. Ferreira - S. Menegatti - E. Bianchi - L. Rogge - M. Dougados - C. Miceli-Richard


SAT0275  VITAMIN D INSUFFICIENCY IS ASSOCIATED WITH VERTEBRAL FRACTURES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / C. Romero-Lopez* - C. Fernández-Carbaillo - M. P. Martínez-Vidal - T. Pedraz

SAT0276  UVEITIS DURING ANTI-TNF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A PARADOXICAL EVENT OR DISEASE MANIFESTATION? / A. Ancuta* - C. Pompeirleau - R. Paiu - G. Strugaru - L. Petrariu - C. Bran - E. Ancuta - R. Chirieac
SAT0277 IMMUNOGENICITY AND LOSS OF RESPONSE TO TNF INHIBITORS IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM AN OBSERVATIONAL COHORT STUDY / C. I. Ancuta* - C. Pomirleanu - R. Paiu - G. Strugaru - L. Petarau - E. Ancuta - C. Jodache - R. Chiriac

SAT0278 NSAIDS REDUCES RADIOGRAPHIC PROGRESSION IN SACROILIAC JUNTS IN EARLY AXIAL SPONDYLOARTHRITIS / D. Rumiantceva* - T. Dubinina - O. Rumyantseva - A. Demina - S. Erdes


SAT0280 RAPAMYCIN RESTORES THE BALANCE BETWEEN TH17 AND REGULATORY T CELLS IN USPA PATIENTS / F. Jinnan* - X. Dan - G. Chong - L. Xiaofeng

SAT0281 BIOLOGICS IN SAPHO SYNDROME. A SYSTEMATIC REVIEW / D. Daoussis - G. Konstantopoulou* - I. Antonopoulos - S.-N. Lioussis

SAT0282 OCCURRENCE OF ANTERIOR UVEITIS IN PATIENTS WITH SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS: A RETROSPECTIVE MONOCENTRIC STUDY COMPARING THE SOLUBLE RECEPTOR TO THE MONOClonAL ANTIBODIES / G. Khoury* - B. Combe - J. Morel - C. Lukas


SAT0289 LONG-TERM EFFECTS OF TNF-ALPHA INHIBITORS ON BONE MINERAL DENSITY AND THE INCIDENCE OF VERTEBRAL FRACTURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS / K. Beek* - M. van der Weijden - T. Rusman - W. Lems - C. van den Denderen - M. Murmohamed - I. van der Horst-Bruinsma


SAT0293 SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY / P. J. Mease* - T. Ruzman - W. Lems - C. van denderen - M. Nurmohamed - I. van der Horst-Bruinsma

SAT0294 ASSOCIATION OF ENTHESITIS WITH ACHIEVEMENT OF NORMAL QUALITY OF LIFE AND CLINICAL RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS TREATED WITH ADALIMUMAB / P. J. Mease* - F. van den Bosch - P. Kiltz - P. Zeugner - K. Chen - M. Wu - J. K. Anderson

SAT0295 TOOL FOR THE PRESCRIPTION OF EXERCISE IN Spondylitis With Multimedia Animations (EJES-3D): PILOT STUDY / R. Almodóvar* - M. T. Florez - P. Zarco - L. Carmona on behalf of EJES-3D GROUP

SAT0296 PATIENTS WITH DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS AND LOW BACK PAIN - EVALUATION AND REHABILITATION / R. Trastaru* - D. Kamal - A. M. Bumbee - C. Kamal - O. Rogoveanu


SAT0298 TRANSCUTANEOUS VAGUS NERVE STIMULATION IN PATIENTS WITH PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS / S. E. Rasmussen* - C. Brock - A. Mohr Drewes - M. Pfeiffer Jensen

* Presenting author
SAT0302 EVALUATION OF SUBCLINICAL GUT INFLAMMATION USING FECAL CALPROTEIN LEVEL AND COLONIC MUCOSAL BIOPSY IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS / M. B. Adarsh* - S. K. Sinha - S. Dogra - K. Vaiphei - C. Vaishnavi - A. Sharma


SAT0306 FINGER FLEXOR TENDON PULLEY COMPLEX INVOLVEMENT IN PSA DACTYLITIS: AN ULTRASONOGRAPHY STUDY / C. M. Goonagle - A. Zabotti - P. Macchioni - S. Z. Aydin


SAT0310 THE ASSOCIATIONS OF SERUM IL18 AND OSTEOPROTEGERIN (OPG) LEVELS WITH THE LIPID PROFILE IN PSORIASIS PATIENTS / K. Bond* - P. Gluszo* - E. Konty

SAT0311 PREVALENCE AND FACTORS RELATED TO INAPPROPRIATELY HIGH LEFT VENTRICULAR MASS IN PATIENTS WITH PSORIATIC ARTHRITIS WITHOUT OVERCARDIAC DISEASE / A. Gioli* - N. Farina - G. Orsolini - G. Cioffi - F. Oginiem - L. Idolazzi - D. Gatti - M. Rossini - O. Viapiana

SAT0312 INCIDENCE OF INFECTIONS IN CLINICAL TRIALS OF TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS / J. Crowley - C. Leonardi - S. Sturgill-Koszycki - A. Menter - A. M. Mendelsohn* - Q. Li - N. Cichanowitz - C. La Rosa

SAT0313 LIPID PROFILE OF PSORIATIC ARTHRITIS PATIENTS. A FIVE-YEAR STUDY / M. Migkos - E. Kaltsonoudis - N. Cichanowitz - C. La Rosa


SAT0315 ABSTRACT OF PSORIATIC ARTHRITIS: A SINGLE CENTRE, PLACEBO-CONTROLLED, CROSSOVER STUDY IN 20 PATIENTS: A PILOT PROTEOMIC FEASIBILITY STUDY / A. Kwasnik* - S. Pennington - O. FitzGerald

SAT0316 RAPID AND SUSTAINED IMPROVEMENTS IN BOTH SKIN AND MUSCULOSKELETAL SYMPTOMS CORRELATES WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS / A. F. Kavanaugh* - J. Birt - C.-Y. Lin - O. Benichou - M. Hufford - A. B. Gottlieb


SAT0320 RELIABILITY ANALYSIS OF THE MADRID SONOGRAPHIC ENTHESIS INDEX (MASEI) AND DIFFERENT DOPPLER SUBGROUPS IN PSORIATIC ARTHRITIS / C. Macia Villa* - S. Falcao - E. De Miguel

TOPIC: PSORIATIC ARTHRITIS

Poster tour S8: PsA: a whole range of (subclinical) (co) morbidities!

Chair(s): Filip van den Bosch (Belgium), Francesco Carubbi (Italy)

Abstracts N*: SAT0302-SAT0311

* Presenting author


SAT0323  ADVERSE DRUG REACTIONS RELATED TO DISEASE-MODIFYING DRUGS (DMARD) IN PSORIATIC ARTHRITIS PATIENTS IN DAILY CLINICAL PRACTICE / D. Freites Nuñez* - Z. Rosales - L. León - J. Font - P. Lois - C. Vadillo - E. Pato - B. Fernández - L. Rodriguez-Rodríguez - J. A. Jover - L. Abasalo


SAT0325  COMPARATIVE ANALYSIS OF GENDER DIFFERENCES, HLA-B27 STATUS AND SKIN LESION SEVERITY IN EARLY AXIAL AND PERIPHERAL PSORIATIC ARTHRITIS PATIENTS / E. E. Gubar* - E. Y. Loginova - T. V. Koroteava - S. I. Glukhova

SAT0326  DURATION OF REMISSION AND MINIMAL DISEASE ACTIVITY AFTER STARTING AND DISCONTINUATION OF BIOLOGIC (B) DMARDs IN EARLY PSORIATIC ARTHRITIS PATIENTS TREATED ACCORDING TO TREAT-TO-TARGET STRATEGY (RESULTS OF AN OPEN-LABEL REMARCA STUDY) / E. Loginova* - T. Koroteava - E. Gubar - S. Glukhova - E. Nasonov


SAT0328  WEIGHT-LOSS IMPROVES DISEASE ACTIVITY IN OBESE PATIENTS WITH PSORIATIC ARTHRITIS / E. Klingsberg* - A. Bilberg - S. Björkman - B. Eliasson - I. Larsson

SAT0329  FIBROMyalgia IN PATIENT WITH PSORiATIC ARTHRiTIS: RELATIONSHIP WITH ENTHESOPATHY, SLEEP, FATIGUE AND QUALITY OF LIFE / F. Ulutatar* - C. Unal - M. T. Duruöz


SAT0333  DRUG SURVIVAL ON FIRST TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: COMPARISON ACROSS ETANERCEPT, ADAлимумаб, ГОЛИмумаб AND INFLIXIMAB / C. García-Porrúa - F. Maceiras-Pan - L. Fernandez-Dominguez - J. A. Mosquera-Martínez - B. Correa-Rey - M. Pombo-Suazo - J. Pinto-Tasende*


SAT0335  SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 / L. Coates* - D. McGonagle - G. Schett - P. J. Mease - E. Quebe-Fehling - D. L. Asquith - L. Rasouliyan - S. Mpofu - C. Gaillez on behalf of the FUTURE 2 and FUTURE 3 study groups


SAT0338  PREDICTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PSORIATIC ARTHRITIS: PERFORMANCE OF FIVE RISK ALGORITHMS IN AN ITALIAN BICENTRIC STUDY / L. Navarini* - D. P. Sfikakis - P. Nash - K. Winthrop - P. Smirnov - E. Theander - J. S. Smolen

SAT0339  IMPACT OF ALTERNATE MECHANISM OF ACTION BIOLOGICS ON TUMOR NECROSIS FACTOR INHIBITOR (TNF) PRESCRIBING IN PSORIATIC ARTHRITIS: RESULTS FROM A NATIONAL PATIENT CHART AUDIT / J. Robinson - L. Price*


SAT0341  EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY / M. C. Genovese* - B. Combe - J. Kremer - D. Adams - C. Lee - L. Kerr - P. Nash

SAT0342  INFLAMMATORY BACK PAIN IN PSORIATIC ARTHRITIS IS SIGNIFICANTLY MORE RESPONSIVE TO COCOSTEROIDS COMPARED TO BACK PAIN IN ANKYLODYSPLYSY: A PROSPECTIVE, OPEN-LABELLED, CONTROLLED PILOT STUDY / M. Haroon* - M. Ahmad - N. Baig - D. Mason - J. Rice - O. FitzGerald

SAT0343  CARDIOVASCULAR DISEASE RISK IN CLINICAL SUBTYPES OF PSORIATIC ARTHRITIS SUBTYPES / N. Hassan* - M. Bradley - R. Davies - E. Choy

* Presenting author
TOPIC: CRYSTAL DISEASES, METABOLIC BONE DISEASES AND BONE DISEASES OTHER THAN OSTEOPOROSIS


SAT0349 A NOVEL SCORING SYSTEM TO DIFFERENTIATE PSORIATIC ARTHRITIS FROM NODAL OSTEARTHRITIS ON PLAIN-FILM RADIOGRAPHS / R. Mandegaran - E. Nikiphorou* - S. Bahadur - C. Hughes - B. Kirkham - A. Zavareh


SAT0351 VERY LOW DISEASE ACTIVITY, DAPSA REMISSION, AND PATIENT-ACCEPTABLE SYMPTOME STATE IN PSORIATIC ARTHRITIS / R. Queiro* - J. D. Cañete - C. Montilla - M. A. Abad - S. Gómez - A. Cabez on behalf of MAAPs study group.

SAT0352 PREVALENCE AND CHARACTERISTICS OF CORONARY DISEASE AND CARDIOVASCULAR RISK FACTORS IN A COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS / S. A. Rodríguez Montero* - N. Plaza Aulestia - M. J. Pérez Quintana - M. L. Velloso Feijoo - J. L. Marenco de la Fuente


SAT0356 FACTORS INFLUENCING TOPHUS RESOLUTION IN PATIENTS WITH PERSISTENT URATE LOWERING RESPONSES TO PEGLOTICASE / B. Mandell* - A. Yeo - P. Lipsky


SAT0358 DIABETES AND GOUT: REAL-WORLD EVIDENCE EVALUATING PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH CARE UTILIZATION / D. C. Taylor* - A.-C. Fu - R. Morlock

SAT0359 EVOLUTION OF RENAL FUNCTION IN GOUT AFTER NORMALIZATION OF SERUM URIC ACID LEVEL / E. Gazaix-Fontaine* - A. Ostertag - H.-K. Ea - F. Liote


SAT0361 TRABECULAR BONE SCORE IN OSTEOGENESIS IMPERFECTA. IS IT USEFUL? / H. Florez - M. L. Velloso Feijoo - J. L. Marenco de la Fuente


SAT0366 SERUM URIC ACID INCREASES AFTER ABRUPTION OF SYSTEMIC INFLAMMATION BY TNF INHIBITION / L. Petru* - H. Hulejova - A. Mahajan - M. Herrmann - J. Zavada

* Presenting author
SAT0367

PATIENTS HOSPITALISED WITH GOUT AS MAIN DIAGNOSIS: COSTS AND EFFICIENCY ACCORDING TO HOSPITAL DEPARTMENTS / M. Hernández Hurtado* - M. A. Martínez Huedo - A. Balsa Criado - D. Peiteado López - E. De Miguel Mendieta

SAT0368


SAT0369

COMPARISON OF RISK FACTORS FOR CARDIOVASCULAR DISEASES IN PTS WITH CPPD GOUT AND OSTEOARTHRITIS / S. Vladimirov - M. Eiselev* - O. Zehlyabina - M. Chikina

SAT0370

ASSOCIATION OF RENAL FUNCTION AND DEVELOPMENT OF TOPHI IN SUBJECTS WITH CHRONIC REFRACTORY GOUT AND RESPONSE TO TREATMENT WITH PEGLOTICASE / N. L. Edwards* - J. Singh - O. Troum - A. A. Yeo - P. Lipsky

SAT0371

FACTORS ASSOCIATED WITH ALLOPURINOL ADHERENCE AND TREATMENT OUTCOME AMONG GOUT PATIENTS / S. Asaphant - P. Narongroeaknawin*

SAT0372


SAT0373

PREVENTING A LARGE MAJORITY OF INCIDENT GOUT CASES BY MODIFYING KEY RISK FACTORS: FINDINGS FROM A PROSPECTIVE COHORT OF 44,629 MEN OVER 26 YEARS / S. K. Rai* - N. Lu - C. Yokose - H. K. Choi

SAT0374


SAT0375

IMPACT OF FEBUXOSTAT ON RENAL FUNCTION AMONG GOUT PATIENTS WITH DIFFERENT RENAL FUNCTION / T.-T. Chung* - C.-F. Kuo - J.-S. Chen - M.-J. Chiou

SAT0376


SAT0377


SAT0378


SAT0379


TOPIC: INFECTION-RELATED RHEUMATIC DISEASES

Poster tour S9: Beware the bug!

Chair(s): Elena Nikiphorou (United Kingdom), James Galloway (United Kingdom)

Abstracts N°:

SAT0380-SAT0389

SAT0380


SAT0381


SAT0382


SAT0383

RHEUMATOLOGICAL DISORDERS FOLLOWING CHIKUNGUNYA INFECTION - A RETROSPECTIVE STUDY OF 882 CASES FROM NEW DELHI / N. Gupta*

SAT0384

Evolving patterns of reactive arthritis / K. M. Hayes* - R. Hayes - J. Pope

SAT0385


SAT0386


* Presenting author


SAT0391 CLINICAL SPECTRUM OF CHIKUNGUNYA EPIDEMIC- OBSERVATIONAL STUDY FROM A TERTIARY REFERRAL CENTRE IN CENTRAL INDIA / A. Pandey* - V. Prakash - M. Pandey

SAT0392 THE RELERENCE OF SERUM PROCALCITONIN QUANTIFICATION FOR DIFFERENTIAL DIAGNOSIS OF INFECTIONS AND RHEUMATIC DISEASES / A. Dilbaryan* - B. Belov - G. Tarasova - D. Bukhanova

SAT0393 DEVELOPMENT OF A SCORE FOR THE DIAGNOSIS OF INFECTIOUS ARTHRITIS IN DIFFICULT TO PUNCTURE JOINTS / C. A. Guillen-Astete* - B. Blanco Cáceres


SAT0396 THE RISK FACTORS OF SERIOUS INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Hasegawa* - D. Kobayashi - S. Itö - I. Narita - K. Nakazono

SAT0397 SAFETY AND IMMUNOGENICITY OF 23-VALENT PNEUMOCOCCAL VACCINE IN SLE PATIENTS / G. Tarasova* - B. Belov - D. Bukhanova - S. Soloviev - E. Aseeva - T. Popkova - M. Cherkasova


SAT0399 CHIKUNGUNYA FEVER IN KARACHI: CLINICAL AND LABORATORY FEATURES AND FACTORS ASSOCIATED WITH PERSISTENT ARTHRALGIA / H. Alamb* - T. P. Umer - L. Nazir


SAT0403 BLOOD B CELL SUBSET PROFILE DISTURBANCE IN WHIPPLE'S DISEASE / M. Le Goff* - D. Kobayashi - S. Ito - I. Narita - K. Nakazono


SAT0405 BLOOD B CELL SUBSET PROFILE DISTURBANCE IN WHIPPLE'S DISEASE / M. Le Goff* - D. Kobayashi - S. Ito - I. Narita - K. Nakazono

SAT0406 CLINICAL CHARACTERISTICS AND OUTCOME AFTER TREATMENT OF A NATIONAL COHORT OF PCR-POSITIVE LYME ARTHRITIS / M. Scherlinger* - A. Grillon - J. Sibilia - L. Arnaud - B. Jauhac

SAT0407 FINDINGS OF A COHORT OF PATIENTS WITH CHIKUNGUNYA IN A COLOMBIAN POPULATION / M. A. López* - R. Badillo - E. Rojas - M. Gelméz - Y. Santamaria on behalf of Association Colombian of rheumatology


SAT0409 BLOOD B CELL SUBSET PROFILE DISTURBANCE IN WHIPPLE'S DISEASE / M. Le Goff* - D. Kobayashi - S. Ito - I. Narita - K. Nakazono

SAT0410 CLINICAL CHARACTERISTICS AND OUTCOME AFTER TREATMENT OF A NATIONAL COHORT OF PCR-POSITIVE LYME ARTHRITIS / M. Scherlinger* - A. Grillon - J. Sibilia - L. Arnaud - B. Jauhac

SAT0411 INVESTIGATIONS FOR THE DIAGNOSIS OF SEPTIC ARTHRITIS IN THE ACUTE SETTING. RESULTS FROM A SINGLE TERTIARY CENTRE OVER 5 YEARS / P. Shamdasani* - D. Liew - C. Mcmaster - A. Foote - A. Hardidge - R. Buchanan* Presenting author


TOPIC: SLE, SJÖGREN'S AND APS - CLINICAL ASPECTS (OTHER THAN TREATMENT)

Poster tour S10: SLE, SJögren's and APS - novel predictors of disease activity and long-term outcomes

Chair(s): Lai-Shan Tam (China), Priscilla Wong (China)

Abstracts N°: SAT0414-SAT0423


* Presenting author
SAT0432

SAT0433

SAT0434

SAT0435

SAT0436

SAT0437
INITIAL MANIFESTATIONS OF CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF SINGLE CENTER RETROSPECTIVE STUDY / M. I. Kalada - E. A. Aseeva - I. P. Nikishina* - S. K. Soloviev

SAT0438

SAT0439

SAT0440

SAT0441

SAT0442
RISK FACTORS FOR HEART VALVE DISEASES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME / K. Hiramoto* - J. Kikuchi - Y. Kaneko - T. Takeuchi

SAT0443

SAT0444

SAT0445
THE CORRELATION BETWEEN THE TYPE OF CELLS IN MINOR SALIVARY GLANDS INFILTRATES AND THE SELECTED IMMUNOLOGICAL, CLINICAL AND LABORATORY PARAMETERS, IN PRIMARY SJÖGREN’S SYNDROME PATIENTS WITH HISTORY OF EPSTEIN - BARR VIRUS INFECTION / M. Maślińska* - M. Prochorec-Sobieszek - B. Kwiatkowska

SAT0446

SAT0447

SAT0448

SAT0449
JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS OUTCOME IN ADULTHOOD: A MONOCENTRIC RETROSPECTIVE COHORT / M. Pha* - A. Mathian - J. H. Kooh - F. Cohen Aubart - M. Hié - D. Lê Thi Huong - J. Kwon - Z. Amoura

SAT0450
ESTIMATING DURATION OF RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS TRIALS / M. Kim* - J. Merrill - K. Kalunian - L. Hanrahan - P. Izmirl

SAT0451
DISEASE COURSE PATTERNS IN SYSTEMIC LUPUS ERYTHEMATOSUS / K. Tseliis - D. Gladman - Z. Touma - J. Su - N. Anderson - M. Urowitz*

SAT0452
ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND WITHOUT Nephritis / N. Mohannad* - A. I. El Zawawy - M. Elbordeny - D. Emara - S. Ibrahim

SAT0453
ASSOCIATION OF COMORBID PULMONARY CONDITIONS WITH PATIENT-REPORTED OUTCOMES IN SYSTEMIC NEPHRITIS / N. I. Kaleda - E. A. Aseeva - I. P. Nikishina* - S. K. Soloviev

SAT0454
IN PRIMARY SJÖGREN’S SYNDROME BLOOD CD180-NEGATIVE B CELLS ARE INCREASED IN PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID ANTIBODY SYNDROME TREATED WITH ANTI-THEOMBOTIC DRUGS / G. Armentaro - F. Migliorati - M. Frassi - F. Franceschini - S. Calza - A. Tincani

SAT0455

SAT0456

SAT0457
ASSOCIATION OF COMORBID PULMONARY CONDITIONS WITH PATIENT-REPORTED OUTCOMES IN SYSTEMIC NEPHRITIS / N. Mohannad* - A. I. El Zawawy - M. Elbordeny - D. Emara - S. Ibrahim

SAT0458

* Presenting author

SAT0458 Urine Solluble Urokinase Plasminogen Activator Receptor as a Potential Biomarker of Lupus Nephritis Activity / S. Burcsâr* - G. Toldi - B. Szalay - B. Vásárhelyi - L. Kovács - A. Balog


SAT0461 ULTRASONOGRAPHY OF SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME AND ASSOCIATION WITH DISEASE ACTIVITY, SEROLOGICAL MARKERS AND BIOPSY OF MINOR SALIVARY GLANDS / V. Milic* - G. Radunovic - J. Marinkovic - N. Danjanov

SAT0462 PD-1+CXCR5-CD4+ T Cells may play an important role in the severity of Systemic Erythematous Lupus / W. Chen* - Y. Yu - J. Lin

SAT0463 Olfactory Impairment in Patients with Primary Sjögren’s Syndrome and its Correlation with Organ Involvement and Immunological Abnormalities / X. Xu* - L.-Y. Geng - Z.-Y. Chen - J. Liang - L.-Y. Sun

SAT0464 Comparison of Disease Activity Scores Predicting Mortality in Patients with Systemic Lupus Erythematosus in Colombia / Y. Santamaria-Aíza* - J. D. Sánchez-Bautista - J. Fajardo-Rivero - C. L. Figueroa-Pineda

SAT0465 CLINICAL MANIFESTATIONS AND PROGNOSIS OF SLE WITH CLINICALLY SIGNIFICANT ANTIPHOSPHOLIPID ANTIBODIES / Y. Zhang* - X. Feng - L. Sun

SAT0466 Serum Vitamin D Deficiency is Associated with Active Renal Disease in Systemic Lupus Erythematosus / Y.-J. Park* - I.-W. Baek - K.-J. Kim - W.-U. Kim - C.-S. Cho


TOPIC: SCLERODERMA, MYOSITIS AND RELATED SYNDROMES

Poster tour S11: SSc, myositis, related syndromes - novel ideas take place

Chair(s): Ulf Müller-Ladner (Germany), Ingrid Lundung (Sweden)

Abstracts N°: SAT0468-SAT0477


SAT0472 Ulnar Occlusion is a Marker of Global Vascular Damage in Systemic Sclerosis: Results from a monocentric prospective study of 99 patients / C. M. Figueroa-Pineda - J. J. Bax - J. K. de Vries-Bouwstra - N. Ajmone-Marsan

SAT0473 CLINICAL AND ECHOCARDIOGRAPHIC ASSOCIATES OF ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH SYSTEMIC SCLEROSIS / S. E. van Wijngaarden - M. Boonstra* - B. Bloem - L.-Y. Sun


* Presenting author

SAT0477  INTENSIFIED B CELL DEPLETION THERAPY IN PROGRESSIVE SYSTEMIC SCLEROSIS PATIENTS: 24 MONTHS FOLLOW-UP / D. Rossi - I. Cecchi* - S. Sciscia - M. Radin - E. Rubini - D. Roccatello  

SAT0478  DISEASE-SPECIFIC AUTOANTIBODIES ASSOCIATE WITH REMARKABLY DIFFERENT RISK OF DEVELOPMENT OF SIGNIFICANT LUNG FIBROSIS IN SYSTEMIC SCLEROSIS / A. Sari* - S. I. Nihytanov - A. Gill - V. H. Ong - C. P. Denton  

SAT0479  LASER SPECKLE CONTRAST ANALYSIS: A PILOT STUDY AND SYSTEMATIC LITERATURE REVIEW OF RELIABILITY OF THE QUANTITATIVE ASSESSMENT OF PERIPHERAL BLOOD PERFUSION IN SYSTEMIC SCLEROSIS / A. Vanhaecke* - M. Cutolo - B. Ruauro - L. Deroo - C. Hickinger - K. Melenser - Y. Piette - F. De Keyser - V. Smith on behalf of the EULAR study group on microcirculation in Rheumatic disease  

SAT0480  EVALUATION OF STANDARDIZED TEACHING OF MODIFIED RODNAN SKIN SCORE ASSESSMENT IN SYSTEMIC SCLEROSIS / A. H. Low* - S.-A. Ng - V. Berrocal - B. Brennan - G. Chan - S.-C. Ng - D. Khanna  

SAT0481  SETTING THE STANDARD FOR LONGITUDINAL FOLLOW-UP OF SYSTEMIC SCLEROSIS; A EUSTAR DELPHI-BASED EXPERT CONSENSUS / A.-M. Hoffmann-Vold* - O. Distler - M. Baron - O. Kowal-Bielecka - D. Khanna - Y. Allanore on behalf of EUSTAR, SCTCT  

SAT0482  UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE AT RISK FOR SYSTEMIC SCLEROSIS: PREDICTIVE ROLE OF ANTI-TOPOISOMERASE AND AVASCULAR AREAS / A. Riccardi* - V. Messinetti - S. Fasano - G. Valentini  


SAT0485  WHAT IS THE EFFECT OF CYCLOPHOSPHAMIDE IV PULSE THERAPY IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS ON SKIN INVOLVEMENT: AN OBSERVATIONAL STUDY / B. Kersten* - N. den Broeder - F. van den Hoogen - E. van den Ende - M. Vonk  


SAT0487  A COHORT STUDY OF MACROVASCULAR INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS / C. Caimmi* - S. De Marchi - G. Astorino - E. Bertoldo - P. Caramaschi - M. Rossini  


SAT0489  ASSESSMENT OF PERSISTENT ORGAN DAMAGE ACCORDING TO IMACS (INTERNATIONAL MYOSITIS ASSESSMENT AND CLINICAL STUDIES) MYOSITIS DAMAGE INDEX IN 92 PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS / E. Oguz* - E. Sahin - M. Erdugan - B. A. Eisen - A. Gul - L. Ocal - M. Inanc  


SAT0494  CLINICAL AND ELECTROPHYSIOLOGICAL DIAGNOSIS OF SYM METRICAL POLYNEUROPATHY IN SYSTEMIC SCLEROSIS / J. J. Alegre-Sancho* - M. Robustillo-Villarino - M. Aguilar-Zamora - L. Montolío-Chiva - L. P. Ramanaidu - J. Raja*  

SAT0495  LASER SPECKLE CONTRAST ANALYSIS: A PILOT STUDY AND SYSTEMATIC LITERATURE REVIEW OF RELIABILITY OF THE QUANTITATIVE ASSESSMENT OF PERIPHERAL BLOOD PERFUSION IN SYSTEMIC SCLEROSIS / A. Vanhaecke* - M. Cutolo - B. Ruauro - L. Deroo - C. Hickinger - K. Melenser - Y. Piette - F. De Keyser - V. Smith on behalf of the EULAR study group on microcirculation in Rheumatic disease  


* Presenting author
TOPIC: VASCULITIS


SAT0501  COMPARISON OF THE CREATININE-BASED AND THE CYSTATIN C-BASED ESTIMATED GLOMERULAR FUNCTION (EGFR) IN PATIENTS WITH SYSTEMIC SCLEROSIS PATIENTS / M. Krusche* - T. Kubacki - R. Osei-Davies - I. Kötter

SAT0502  ASSESSMENT OF PROSTANOIDS (ILOPROST, ALPROSTADIL) EFFICACY IN TREATMENT OF ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS / M. Starovoytova* - O. Desiniva - O. Koreva - O. Ovysannikova - L. Garzanova

SAT0503  THE ASSOCIATION OF MYOSITIS SPECIFIC ANTIBODIES IN PATIENTS WITH INFLAMMATORY MYOSITIS: PRELIMINARY DATA IN INDIAN PATIENTS / N. V. Negalur* - D. Raval - M. Bindroo - W. Kazi - U. Baveja - R. Gupta

SAT0504  COMPARISON OF LONG-TERM CYCLOPHYLAMIDE (CYP) AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD) / O. Koreva* - O. Ovysannikova - O. Desiniva - L. Garzanova - L. Ananieva - M. Starovoytova


SAT0508  ACE-INHIBITORS IN ARTERIAL HYPERTENSION IN SSC PATIENTS DISPLAY A RISK FACTOR FOR SCLERODERMA RENAL CRISIS - A EUSTAR ANALYSIS / S. Adler* - P. A. Varisco - O. Distler - L. Buetikofer - O. Hunzelmann

SAT0509  HOW MONEY SHOULD BE SPENT: PATIENTS PERSPECTIVES ON SCLERODERMA RESEARCH FUNDING / S. Divani - J. Patrel* - R. Stratton

SAT0510  ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND OTHER SYSTEMIC AUTO-IMMUNE DISEASES: STUDY IN TWO UNIVERSITY HOSPITALS COHORTS / M. Scherlinger - J. Lutz* - J. Sibilla - E. Chatelus - M. E. Truchetet


SAT0512  ANTI-IL6-RECEPTOR TOCILIZUMAB IN REFRACTORY UVEITIS ASSOCIATED TO EXTRAOCULAR MANIFESTATIONS / C. Rojas - A. Kawakami - Y. Kawaguchi - S. Sato - M. Kuwana on behalf of JAMI investigators

SAT0513  COMPARISON OF LONG-TERM CYCLOPHYLAMIDE (CYP) AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD) / O. Koreva* - O. Ovysannikova - O. Desiniva - L. Garzanova - L. Ananieva - M. Starovoytova

SAT0514  PATIENTS WITH TAKAYASU'S ARTERITIS (TAKASIM): PRELIMINARY DATA / C. Campochiaro* - A. Tomelleri - A. Kawakami - Y. Kawaguchi - S. Sato - M. Kuwana on behalf of JAMI investigators


SAT0519  MYOCARDIAL INVOLVEMENT AT MAGNETIC RESONANCE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND MYOCARDIAL INVOLVEMENT AT MAGNETIC RESONANCE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND OTHER SYSTEMIC AUTO-IMMUNE DISEASES: STUDY IN TWO UNIVERSITY HOSPITALS COHORTS / M. Scherlinger - J. Lutz* - J. Sibilla - E. Chatelus - M. E. Truchetet

SAT0520  GENDER DIFFERENCES INFLUENCES CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS: AN ITALIAN MONOCENTRIC STUDY / A. Cariddi - G. Cavalli - E. Baldissera - L. Dagna

SAT0521  COMPARISON OF THE CREATININE-BASED AND THE CYSTATIN C-BASED ESTIMATED GLOMERULAR FUNCTION (EGFR) IN PATIENTS WITH TAKAYASU ARTERITIS: AN ITALIAN MONOCENTRIC STUDY / A. Cariddi - G. Cavalli - E. Baldissera - L. Dagna


SAT0522 VASCULAR AND JOINT INFLAMMATION ARE NEGATIVELY CORRELATED IN PATIENTS WITH POLYMYALGIA RHEUMATICA, GIANT CELL ARTERITIS AND FEVER OF UNKNOWN ORIGIN / D. Camellino* - M. Bauckneht - S. Morbelli - M. Marchiano - G. Pesce - D. Saverino - M. Bagnasco - M. A. Cimmino


SAT0527 RITUXIMAB PRESCRIPTION PATTERNS AND EFFICACY IN THE INDUCTION TREATMENT OF ANCA-ASSOCIATED VASCULITIS IN A BELGIAN MULTICENTRIC COHORT / F. Vanderheynst* - P. Chasseur - J.-B. Nicolas - C. von Frencell - D. Blockmans


SAT0529 SHORT-TERM EFFICACY AND SAFETY OF BIOSIMILAR RITUXIMAB IN PATIENTS WITH SYSTEMIC VASCULITIDES / I. Smittenko* - P. Novikov - S. Moiseev - A. Zykov - T. Shevtsova

SAT0530 CLINICAL FEATURES ASSOCIATION WITH HLA-B ALLELIC TYPES (B27, B51) IN KOREAN PATIENTS OF BEHÇET’S DISEASE / J. H. Kim* - J. H. Jung - S. J. Choi - Y. H. Lee - J. D. Ji - G. G. Song


SAT0532 TREATMENT WITH METHOTREXATE AND RISK OF ISCHEMIC RELAPSES IN PATIENTS WITH GIANT CELL ARTERITIS IN CLINICAL PRACTICE / J. Font Urgelles* - Z. Rosales Rosado - D. D. Freites Núñez - P. M. Loiz Bermejo - L. Leon Mateos - I. C. Morado Quiñoa - J. A. Jover Jover - L. Abásolo Alcázar


SAT0534 ANNUAL INCIDENCE OF GIANT CELL ARTERITIS IN URBAN AND RURAL AREAS IN WESTERN NORWAY 1972-2012 / L. K. Birkke* - B.-T. S. Fervang - G. Myklebust


SAT0536 POLYVASCULAR INVOLVEMENT IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS / S. Moiseev


SAT0539 THE FREQUENCY OF RECURRENT ORAL ULCERS IN FAMILY MEMBERS OF PATIENTS WITH BEHÇET’S DISEASE / N. Çakır - B. Çelik Yıldırım - N. İmeryüz

SAT0540 TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN IN THE VASCULITIS ANCA POSITIVE. 27 CASES STUDIED IN A SINGLE REFERENCE CENTRE / N. Aviles Mendez* - V. Calvo-Rio - J. Loricera - B. Atienza Mateo - J. L. Martin Varillas - J. Blanco - R. Blanco - M. A. Gonzalez-Gay


* Presenting author
TOPIC: OSTEOARTHRITIS

SAT0552

SAT0553

SAT0554
PREOPERATIVE PHYSICAL FUNCTION INFLUENCES ON STAIR CLIMBING ABILITY 1 MONTH AFTER TOTAL KNEE ARTHROPLASTY/ B. R. Kim*

SAT0555
ON THE WAY TO KNEE REPLACEMENT: TRAJECTORY AND CORRELATION OF KNEE OA MRI CARTILAGE THICKNESS, RADIOGRAPHIC JOINT SPACE WIDTH, AND WOMAC KNEE PAIN IN THE OAI / C. K. Kwoh* - E. L. Ashbeck - M. J. Hannon - S. Wax - J. Kraines

SAT0556
COST-EFFECTIVENESS OF A BLENDED PHYSIOTHERAPY INTERVENTION IN PATIENTS WITH HIP AND/OR KNEE OSTEOARTHRITIS: A CLUSTER RANDOMISED CONTROLLED TRIAL / C. Kloek* - J. M. van Dongen - D. Bossen - J. Dekker - C. Vanmuylem

SAT0557
10-YEAR TRAJECTORIES OF PAIN IN EARLY KNEE AND HIP OSTEOARTHRITIS; THE CHECK STUDY / J. Runhaar - J. Waarsing - D. Schiphof* - W. van Spil - M. van Middelkoop - S. Bierma-Zeinstra

SAT0558
PHARMACOTHERAPY OF OBESITY IN PATIENTS WITH KNEE OSTEOARTHRITIS AND METABOLIC SYNDROME / E. Strebkova* - L. Alekseeva

SAT0559
SYSTEMATIC LITERATURE REVIEW (SLR) FOR THE 2018 UPDATE OF THE EULAR MANAGEMENT RECOMMENDATIONS FOR HAND OSTEOARTHRITIS (OA) / F. Kroon* - M. Kloppenburg - J. Schoones - L. Carmona

SAT0560
FROM A 2-YEAR MULTICENTRE CLINICAL TRIAL IN KNEE OSTEOARTHRITIS, A METABOLOMIC ANALYSIS REVEALS THAT OVER ACTIVATION OF THE CONVERSION PATHWAY OF PHOSPHATIDYLCHOLINE TO LYSOPHOSPHATIDYLCHOLINE IS ASSOCIATED WITH KNEE CARTILAGE VOLUME LOSS OVER TIME / G. Zhai* - J.-P. Pelletier - M. Liu - E. Randall - J. Martel-Pelletier

SAT0561

SAT0562

SAT0563

SAT0564
EFFECTS OF EDUCATION AND INCOME ON PREVALENCE, INCIDENCE, AND PROGRESSION OF RADIOGRAPHIC KNEE OSTEOARTHRITIS: AN ANALYSIS OF THE OSTEOARTHRITIS INITIATIVE DATA / I. Shirinsky* - V. Shirinsky

SAT0565
ADJUSTING FOR THE INTRA-ARTICULAR PLACEBO EFFECT IN KNEE OSTEOARTHRITIS THERAPIES / H. G. Ahedi - R. M. Aspden - M. Phillips - J. Tahmaib*

SAT0566
ASSOCIATIONS OF OSTEOCLASTS AND MACROPHAGES IN SUBCHONDRAL BONE WITH SYMPTOMS IN PEOPLE WITH KNEE OA / K. Aso* - M. Shahtaheri - R. Hill - D. Wilson - D. A. Walsh

SAT0567

SAT0568

SAT0569

* Presenting author
TOPIC: OTHER ORPHAN DISEASES

Poster tour S12: Be familiar with orphan diseases

Chair(s): Nemanja Damjanov (Serbia), Predrag Ostojic (Serbia)

Abstracts N°: SAT0587-SAT0596

SAT0587  MAJOR SALIVARY GLANDS ULTRASONOGRAPHY IN DIFFERENTIAL DIAGNOSIS OF IGG4-RELATED DISEASE AND PRIMARY SJÖGREN’S SYNDROME / E. Sokol* - E. Rodionova - V. Vasilyev - S. Palshina - M. Burtseva


SAT0591  PROGRESSIVE FIBROUS INTERSTITIAL LUNG DISEASE (PF-ILD) IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES / A. Fischer* - M. Wijsenbeek - M. Kreuter - B. Mounir - L. Zoud-Lejour - V. Accial - C. D. Wells - M. Quaresma - C. Denton

* Presenting author

SAT0595 ANALYSIS OF RECURRENCES AFTER SUSPENSION OF IMMUNOSUPPRESSIVE TREATMENT IN NON-INFECTIONOUS UVEITIS / M. Uriarte* - C. Martin - J. Gonzalez - R. Garcia de Vicuña - E. Pató - M. Gorroño - Á. Aparicio - M. Cordero


SAT0597 NEW AUTOINFLAMMATORY PHENOTYPE MANIFESTING AS HYPOCOMPLEMENTEMIC URTICARIAL VASCULITIS AND ASSOCIATED WITH HOMOZYGOTIC AGBL3 VARIANT / A. Güir - N. Nabaci - S. Simra Ekmecki


SAT0603 CAN HOMOZYGOTIC OR HETEROZYGOTIC MEVF MUTATIONS LEAD TO DIFFERENT PRESENTATION OF FAMILIAL MEDITERRANEAN FEVER? / A. Aktaş - M. Karadavut - D. Üsküdar Cansu - C. Korkmaz*


SAT0606 DISEASE MODIFYING ANTI RHEUMATIC DRUGS IN THE TREATMENT OF SAPHO SYNDROME: SYSTEMATIC LITERATURE ANALYSIS / M. Monet - C. Prati - X. Guillot - M. Sondag - F. Verhoeven - F. Aubin - D. Wendling*


SAT0613 INCREASED SERUM LEVEL OF IL-36 RECEPTOR ANTAGONIST IS ASSOCIATED WITH ACTIVE DISEASE IN PATIENTS WITH ADULT-ONSET STILL’S DISEASE / H. Kim* - J. Kang - B. Nam - J. S. Kim - D.-H. Yoo


SAT0615 SYMPATHETIC JOINT EFFUSION IN AN URBAN HOSPITAL / J. L. Barlow* - I. J. Tan


* Presenting author
SAT0617  COMORBIDITY IN PATIENTS AFFECTED BY AVASCULAR NECROSIS OF THE FEMORAL HEAD AND IMPACT OF COEXISTENT DISEASES ON CONTRALATERAL JOINT INVOLVEMENT / K. Gudkovich* - N. Martusevich - A. Murzich

SAT0618  RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND DISEASE DURATION IN BEHÇET’S DISEASE / K. Ayar* - B. Sensoy - M. E. Aslanli - T. Teker - S. Cekic

SAT0619  ASSOCIATIONS BETWEEN CLINICAL MANIFESTATIONS OF BEHÇET’S SYNDROME AND WORK OUTCOMES: RESULTS FROM A UK CROSS-SECTIONAL ANALYSIS / L. Chadwick* - N. J. Goodson - R. J. Moots


SAT0621  CLINICAL SIGNIFICANCE OF INTERLEUKIN-18 AND INTERLEUKIN-6 ON DISEASE COURSE OF ADULT-ONSET STILL’S DISEASE / M. G. Ahmed*


SAT0623  CLINICAL FEATURES AND TREATMENT OF IDIOPATHIC RECURRENT ACUTE PLEURO-PERICARDITIS / K. Dietz - H.-M. Lorenz - N. Blank*

SAT0624  INCIDENCE AND BASELINE CHARACTERISTICS OF RELAPSE OR EXACERBATION IN PATIENTS WITH PULMONARY SACRODIosIS: A SINGLE CENTER LONG-TERM OBSERVATIONAL COHORT STUDY / O. Murata* - A. Kudo - K. Suzuki

SAT0625  SACRODIosIS IS ASSOCIATED WITH AN INCREASED RISK OF GASTROINTESTINAL EVENTS: A POPULATION-BASED RETROSPECTIVE COHORT STUDY 1976-2013 / P. Ungprasert* - C. S. Crowson - E. L. Matteson

SAT0626  ANAKINRA TREATMENT IN REFRACtORY CASES OF ADULT-ONSET STILL DISEASE: CASE SERIES / S. Ugurlu* - B. Yurttus - G. Guzelant - B. Ergezen - H. Ozdogan

SAT0627  FABRY DISEASE: DIAGNOSTIC ERRORS IN RHEUMATOLOGY PRACTICE / S. Moiseev* - P. Novikov - N. Bulanov - E. Karovakina - A. Moiseev - V. Fomin

SAT0628  A RETROSPECTIVE OBSERVATIONAL STUDY OF AZATHIOPRINE MAINTENANCE THERAPY ON BEHÇET’S DISEASE WITH VASCULAR INVOLVEMENT / S. Girgin* - S. Yurumez - A. Omma - C. Bes - S. Celik - N. Alpay Kanitez


TOPIC: DIAGNOSTICS AND IMAGING PROCEDURES

Poster tour S13: Imaging strategies in the management of arthritis

Chair(s): Lene Terslev (Denmark), Mads Ammitzboll (Denmark)

Abstracts N°: SAT0630-SAT0639


SAT0634  DOES THE PRESENCE OF MRI-DETECTED OSTEITIS AT DIAGNOSIS WITH RHEUMATOID ARTHRITIS LOWERS THE RISK FOR ACHIEVING DMARD-FREE SUSTAINED REMISSION? RESULTS OF A LONGITUDINAL STUDY / L. E. Burgers* - D. M. Boeters - M. Reijnierse - A. H. M. van der Helm-van Mil

SAT0635  MAGNETIC RESONANCE IMAGING OF THE CERVICAL SPINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANAESTHETIC SPONDYLOARTHRITIS PRESENTING WITH CHRONIC NECK PAIN - A SYSTEMATIC COMPARISON OF CLINICAL ASSESSMENTS / X. Baraliakos* - M. Soltani - U. Kiltz - J. Braun


SAT0637  RADIOGRAPHIC AND MRI DETECTED SACROILIITIS IS MORE OFTEN OBSERVED IN PATIENTS WITH LUMBOSACRAL TRANSITIONAL VERTEBRA IN THE DESIR COHORT / G. Carvajal Alegria* - M. Voirin-Hertz - F. Garrigues - A. Simon - A. Feydy - D. van der Heijde - M. Reijnierse - D. Loeuille - P. Claudepierre - T. Marhadour - A. Saura on behalf of In behalf of the DESIR cohort


* Presenting author


SAT0643 ULTRASOUND ABNORMALITIES IN WRIST, MCP2 AND MTP5 ARE MOST DISCRIMINATIVE IN PREDICTING ARTHRITIS DEVELOPMENT IN SEROPOSITIVE ARTHRALGIA PATIENTS / A. Blanken* - M. van Beers-Tas - M. Nielen - M. Meursinge Reyners - F. Turkstra - C. van der Laken - D. van Schaardenburg


SAT0645 DIAGNOSTIC ACCURACY OF SERUM AUTOANTIBODES MULTI-TESTING IN RHEUMATOID ARTHRITIS AND ECONOMIC CONSEQUENCES ACROSS EUROPE / B. Mascialino* - S. Swiniarski - I. Gehring - M. Poorafshar


SAT0648 COXALGIA IN HEMOPHILIC PATIENTS. SONOGRAPHIC EVALUATION OF A NOT TARGET JOINT / D. Melchiorre* - G. Castaman - S. Linari - M. Matucci-Cerinic


SAT0650 MUSCULOSKELETAL ULTRASOUND IN FIRST DEGREE RELATIVES OF RHEUMATOID ARTHRITIS PATIENTS / E. Soliman*


SAT0653 RELATIONSHIP BETWEEN CARDIAC VALVULAR CALCIFICATION, CAROTID ATHEROSCLEROSIS, AND CORONARY CALCIFICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / H. Udachkina* - D. Novikova - T. Popkova - E. Markelova - I. Krilova - E. Gerasimova

SAT0654 ASSOCIATION OF PREDNISON AND ANTIMALARIALS AND ECHOCARDIOGRAPHIC FINDINGS IN ASYMPTOMATIC CARDIOVASCULAR PATIENTS WITH SLE / I. Yoshina* - L. M. H. Mota - L. Muniz - D. F. Vasconcelos - L. Santos-Neto


SAT0657 MICROWAVE RADIOMETRY-DERIVED THERMAL CHANGES OF SACROILIAC JOINTS AS A BIOMARKER OF SACRITISITIS IN PATIENTS WITH SPONDYLOARTHRITIS / K. Laskar* - A. Pitsilis - G. Pentazos - E. Siores - M. G. Tektinidou - P. P. Sfikakis


SAT0663 A NEW OPERATOR INDEPENDENT AUTOMATIC TOOL FOR ACCURATE IDENTIFICATION OF VERTEBRAL FRAGILITY FRACTURES / F. Conversano - R. Franchini - E. Quarta - P. Pisani - E. Casolari - D. Lobreglio - M. Muratore*


SAT0665 SYNOVITIS AS A PREDICTOR OF EROSIONS IN THE HAND OSTEOARTHRITIS / O. Balueva* - A. Sarapulova - O. Teplyakova


SAT0668 ARTICULAR INVOLVEMENT IN CHRONIC HEPATIS C INFECTION - A PRELIMINARY ULTRASOUND STUDY / R. A. Ionescu* - L. M. Pana - V. M. Pompilian - A. Voicu - S. Caroila - D. Ramba - C. R. Baics - A. Dan


SAT0674 THE USE OF QUANTITATIVE MUSCLE ULTRASOUND AS A FOLLOW-UP TOOL IN INFLAMMATORY MYOSITIS AND DUCHENNE MUSCULAR DYSTROPHY IN CHILDREN / W. A. Hassan* - A. E. S. Elbrashy - S. S. Ganeb - D. R. Lasheen - E. A. Mohammady

SAT0675 SOLUBLE VASCULAR ADHESION MOLECULE-1 IS OVEREXPRESSED IN PATIENTS WITH VASCULITIS, RHEUMATOID ARTHRITIS AND ANKYLOSING SPONYLODYSPLASIA / W. Laaraj* - M. F. Seidel

SAT0676 ULTRASOUND DETECTED INFLAMMATION IN RHEUMATOID ARTHRITIS: ELUCIDATING THE RELATIONSHIP WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS / W. A. Hassan* - A. E. S. Elbrashy - S. S. Ganeb - D. R. Lasheen - E. A. Mohammady

TOPIC: EPIEMIOLOGY, RISK FACTORS FOR DISEASE OR DISEASE PROGRESSION

Poster tour S14: This poster tour might be risky!

Chairperson(s): Laure Gossec (France), Paul Studenic (Austria)
Abstracts No*: SAT0677-SAT0686


SAT0682 ‘INCIDENCE AND REGIONAL VARIATION OF ANKYLOSING SPONYLITIS AND SPONYLOARTHRITIS 2000-2013: A NATIONWIDE COHORT STUDY’ / A. Nygaard* - P. M. Ljungdalh - M. Iachina - B. Schiøttz-Christensen


* Presenting author

SAT0685 TEMPERATURE AND SMALL PARTICULATE MATTER POLLUTION ARE ASSOCIATED WITH ORGAN SPECIFIC LUPUS FLARES: A SPATIO-TEMPORAL ANALYSIS / G. Stojan* - A. Kvit - F. Curriero - M. Petri

**SAT0686 ARE MRI-DETECTED EROSIONS IN PATIENTS WITH UNDIFFERENTIATED ARTHRITIS PREDICTIVE FOR THE DEVELOPMENT OF RHEUMATOID ARTHRITIS? A LARGE LONGITUDINAL STUDY / D. M. Boeters* - A. C. Boer - A. H. van der Helm-van Mil


**SAT0688 PROGRESSIVE DRIFT OF PATIENT POPULATIONS IN RHEUMATOID ARTHRITIS CLINICAL TRIALS OVER TIME / A. Kerschbaumer* - B. Bierbaumer - J. S. Smolen - D. Aletaha

SAT0689 THYMECTOMY IN PATIENTS WITH MYASTHENIA GRAVIS AND THE RISK OF AUTOIMMUNE RHEUMATIC DISEASES: A NATIONWIDE COHORT STUDY / C. C. Chang* - J.-H. Chen


**SAT0694 DETECTION OF MARKERS OF TRANSCRIPTOS OF MULTI-SITE PAIN IN KNEE OSTEOARTHRITIS: A 10.7-YEAR PROSPECTIVE STUDY IN OLDER ADULTS / F. Pan* - F. C. Pan - J. Tian - F. Cicuttini - C. Ding - G. Jones


**SAT0696 ASSOCIATIONS BETWEEN ANTIBIOTICS FOR NON-TUBERCULOUS MYCOBACTERIAL INFECTION AND INCIDENT SJÖGREN’S SYNDROME: A NATIONWIDE, POPULATION-BASED CASE-CONTROL STUDY / H.-H. Chen* - W.-C. Chao


**SAT0698 MORTALITY OF PATIENTS WITH DIAGNOSED RHEUMATOID ARTHRITIS (RA) IN GERMANY 2012: ANALYSIS OF CLAIMS DATA FROM 60 MILLION PEOPLE / I. Haase* - G. Pongratz - O. Sander - M. Schneider - R. Brinks

**SAT0699 PREDICTION OF CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS USING A MULTI-BIOMARKER OF DISEASE ACTIVITY / F. Xie - L. Chen - H. Yun - J. R. Curtis*


**SAT0701 PREGNANCY OUTCOME IS IMPROVED AND SIMILAR TO THAT OF THE GENERAL OBSTETRIC POPULATION IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO FOLLOW THE ‘IDEAL CLINICAL PATHWAY’ BEFORE AND DURING PREGNANCY / L. Andreoli* - A. Bortoluzzi - G. Carrara - V. Ramoni - M. Padovan - M. Govoni - A. Tincani - C. A. Scire on behalf of RECORD SIR


**SAT0703 RACIAL DISPARITIES IN GOUT AND HYPERURICEMIA - A UNITED STATES GENERAL POPULATION STUDY / M. Chen-Xu* - C. Yokose - H. K. Choi

**SAT0704 COLLECTION OF ANTI-RHEUMATIC MEDICATION DATA FROM BOTH PATIENTS AND RHEUMATOLOGISTS SHOWS STRONG AGREEMENT IN A REAL WORLD CLINICAL COHORT: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / M. Movahedi* - A. Cesta - X. Li - C. Bombardier on behalf of other OBRI Investigators

**SAT0705 ASSOCIATION BETWEEN FRACTURE SITES IN PATIENTS WITH A HISTORY OF PARENTAL FRACTURE / M. Dey* - M. Bukhari

**SAT0706 INCIDENCE OF PSORIATIC ARTHRITIS IN GERMANY: ANALYSIS OF CLAIMS DATA FROM 65 MILLION PEOPLE FROM 2009 TO 2012 / P. Sewerin* - I. Haase - M. Schneider - B. Ostendorf - R. Brinks


**SAT0708 WILLINGNESS TO PARTICIPATE IN RESEARCH AND REPRESENTATIVENESS OF AN ONLINE HEALTH COMMUNITY AND A PATIENT ORGANISATION POPULATION WITH RHEUMATOID ARTHRITIS / R. Costello* - J. McBeth - W. G. Dixon


* Presenting author
SAT0711  SENSE OF COHERENCE PREDICTS DEVELOPMENT OF CHRONIC WIDESPREAD PAIN OVER TIME / S. Hägerström - S. Bergman*

SAT0712  EVALUATION OF STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW / T. Gudu* - I. Janta - R. Ionescu


* Presenting author
13 June 2018

HEALTH PROFESSIONALS / WEDNESDAY 13 JUNE 2018 / 171

HPR Programme
Health Professionals in Rheumatology

WEDNESDAY, 13 JUNE 2018

13:00 - 14:00  Hall 7.1

EULAR 2018 Opening Plenary session

14:15 - 15:45  Amtrium

Joint session HPR/PARE

New drugs - new perspectives: clinical and regulatory issues concerning biosimilars

Learning objectives:
To provide healthcare professionals with reference information on both science and regulation underpinning the use of biosimilars

Chair(s):
Yvonne van Eijk-Hustings (Netherlands)
Dieter Wiek (Germany)

Tore K. Kvien (Norway)  16:20
Abstract N° SP0024
An up-date on biosimilars

Tracy French (United Kingdom)  16:38
Abstract N° SP0025
Shared decision making in switching to biosimilars

Franz König (Austria)  16:56
Statistical and regulatory aspects of biosimilars

Dieter Wiek (Germany)  17:14
Abstract N° SP0026
Biosimilars - the changing views of EULAR’s Member Organisations of PARE

M. Cvancarova Småstuen (Norway)  17:32
M. Brandvold, R. Andenæs
Abstract N° OP0070-HPR
Is patients’ satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey

18:15 - 19:45  Amtrium

Health Professionals session

Delay in treatment and the role of health professionals

Learning objectives:
• To provide awareness of different types of treatment delay in RMDs
• To provide knowledge of reasons and present possible interventions to address patient delay

Chair(s):
Jette Primdahl (Denmark)
Erika Mosor (Austria)

Rebecca Stack (United Kingdom)  18:20
Abstract N° SP0030
Reasons for delay in help seeking at the onset of symptoms

15:45 - 16:15  Exhibition and EULAR Village (Hall 1)

Coffee break
Kristien van der Elst (Belgium) 18:38
Abstract N° SP0031
Are illness perception and coping style associated with patient delay?

Souzi Makri (Belgium) 18:56
Abstract N° SP0032
The patients’ perspective on delay in treatment

Bruno Fautrel (France) 19:14
Abstract N° SP0033
Delay in treatment from the GP perspective

S. J. Bartlett (Canada) 19:32
Abstract N° OP0106
Who is not reaching remission in early RA and why? Predictors for persistent disease activity in the first year differ in men and women and are related to lifestyle and treatment

E. Santos (Portugal) 10:50
C. Duarte, R. Ferreira, A. M. Pinto, R. Geenen, J. A. P. da Silva on behalf of ‘Promoting happiness through excellence of care’
Abstract N° OP0160-HPR
Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modeling approach

S. Halls (United Kingdom) 11:00
E. Dures, S. Hewlett, S. Ryan, R. Jenkins, J. van Tonder
Abstract N° OP0161-HPR
The development of self-management training for innovative departments (STRIDE): a skills-training programme for rheumatology teams to enhance support for self-management

F. Pérez-Ruiz (Spain) 11:10
A. So, P. Kandaswamy, R. Karra, K. Kelton, S. Perk, T. Bardin
Abstract N° OP0162-HPR
Estimating health-related quality of life for gout patients: a post-hoc analysis of utilities from the clear trials

Y. Prior (United Kingdom) 11:20
L. Sammut, C. Vasilica on behalf of the MSKHUB Patient and Public Research Advisory Group (PRAG) and the MSKHUB Health Professionals Reference Group (HPRG)
Abstract N° OP0163-HPR
Development of an online self-management platform for people with rheumatic and musculoskeletal conditions (mskhub.com)

A. Moltó (France) 11:30
Abstract N° OP0164-HPR
Impact of a nurse-led program of patient self-assessment and self-management axial spondyloarthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDSPA)

Guided poster tour
The HPR guided poster tour is taking place during the official poster viewing. For details on the tour refer to page 177. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.
Health Professionals session

Sustainable healthcare in rheumatology and the role of health professionals

Learning objectives:
- To describe how integrated care in rheumatology contributes to sustainable healthcare
- To provide and overview of the roles of various members of the integrated healthcare team
- To discuss barriers and challenges towards expanding the role of integrated care

Chair(s):
Annette de Thurah (Denmark)
Sandra Mintz (United States)

Hubertus J.M. Vrijhoef (Netherlands) 13:35
Abstract N° SP0055
How can integrated healthcare contribute to sustainable healthcare in rheumatology?

Yvonne van Eijk-Hustings (Netherlands) 14:00
Sustainable healthcare, and the role of the nurses

Barbara Slusher (United States) 14:25
Abstract N° SP0056
Sustainable healthcare - it takes a village

A.-M. T. Sweeney (Denmark) 14:50
O. R. Madsen, L. Dreyer, A. Hansen
Abstract N° OP0206-HPR
Outpatient follow up on demand for patients with rheumatoid arthritis - a two-year randomised controlled trial

Karen Hambly (United Kingdom) 16:11
The patient perspective on physical activity and work participation in RMDs

Maura D. Iversen (United States) 16:29
Abstract N° SP0079
Major achievements and future challenges in physical activity

T. Thomsen (Denmark) 16:47
M. Aadahl, N. Beyer, M. L. Hetland,
K. B. Løppenthin, J. Midtgaard, R. Christensen,
S. M. Nielsen, M. Østergaard, P. Jennum,
B. A. Esbensen
Abstract N° OP0219-HPR
The efficacy of motivational counselling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: 22 months follow-up of a randomised, parallel-group trial

EULAR Projects in Health Professionals

The EULAR Exercise Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis

Learning objectives:
To learn about the work of the task force that developed the EULAR Recommendations for physical activity in inflammatory and osteoarthritis, i.e. the process and its results

Chair(s):
Bente Appel Esbensen (Denmark)
Thijs Swinnen (Belgium)

Maura D. Iversen (United States) 15:35
Abstract N° SP0084
Why physical activity and exercise works

Anne-Kathrin Rausch Osthoff (Switzerland) 15:53
Abstract N° SP0085
The evidence for physical activity in inflammatory arthritis and osteoarthritis

Karim Niedermann (Switzerland) 16:11
Abstract N° SP0086
The development and purpose of the EULAR Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis

Michael Nurmohamed (Netherlands) 16:29
Abstract N° SP0087
How to deal with cardiovascular risk factors for physical activity and implement the PA recommendations in the rheumatologic practice
S. Pettersson (Sweden) 16:47
I. Demmelmaier, B. Nordgren, A. B. Dufour, C. H. Opava
Abstract N° OP0222-HPR
Physical capacity contributes marginally in explaining variations of fatigue in persons moderately affected by rheumatoid arthritis

FRIDAY, 15 JUNE 2018

10:15 - 11:45  Amtrium

Abstract session HPR
Supporting self-management

Chair(s):
Mwidimi Ndosi (United Kingdom)
Fernando Estévez-López (Spain)

G. Fernandes (Brazil) 10:20
F. Jennings, M. Cabral, R. Santos, J. Natour
Abstract N° OP0274-HPR
A functional exercise programme improves pain and health related quality of life in patients with fibromyalgia: a randomised controlled trial

S. G. Mckenna (Ireland) 10:30
M. P. Herring, A. Donnelly, A. Fraser, L. Comber, N. Kennedy
Abstract N° OP0275-HPR
The effects of exercise on depressive and anxiety symptoms in rheumatoid arthritis: a systematic review and meta-analysis

I. Ahlstrand (Sweden) 10:40
P. Wagman, C. Håkansson, M. Björk
Abstract N° OP0276-HPR
Occupational balance and its relation to performance of valued life activities in persons with rheumatoid arthritis in working age

S. G. Mckenna (Ireland) 10:40
M. P. Herring, A. Donnelly, A. Fraser, L. Comber, N. Kennedy
Abstract N° OP0275-HPR
The effects of exercise on depressive and anxiety symptoms in rheumatoid arthritis: a systematic review and meta-analysis

M. C. Vassalli (Brazil) 10:50
A. Jones, J. Natour, R. Silva
Abstract N° OP0277-HPR
Evaluation of the effectiveness of a progressive resistance training program for patients with fibromyalgia: a randomised controlled trial

S. A. Just (Denmark) 11:00
Abstract N° OP0278-HPR
Patient reported outcomes and safety in patients undergoing synovial biopsy: comparison of arthroscopic, ultrasound-guided portal-forceps and ultrasound-guided needle biopsy techniques, in five centres across Europe

M. Martin (United Kingdom) 11:10
A. Gilbert, C. Jeffries
Abstract N° OP0279-HPR
A national survey of the utilisation and experience of hydrotherapy in the management of axial spondyloarthritis: the patients’ perspective

A. Bremander (Sweden) 11:20
K. Malm, M. L. Andersson on behalf of the BARFOT study group
Abstract N° OP0280-HPR
Preferences of patients with rheumatoid arthritis regarding disease modifying anti-rheumatic drugs: a discrete choice experiment

11:45 - 13:30  Exhibition, EULAR Village (Hall 1) and Poster areas
Poster viewing and lunch

11:50 - 13:30  Poster area
Guided poster tour
The HPR guided poster tour is taking place during the official poster viewing. For details on the tour refer to page 180. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

13:30 - 15:00  Amtrium
Health Professionals session
New approaches in measuring what matters to patients

Learning objectives:
To be able to describe and discuss new quantitative approaches in the area of measuring what matters to patients

Chair(s):
Anthony Redmond (United Kingdom)
Valentin Ritschl (Austria)

Valentin Ritschl (Austria) 13:35
Abstract N° SP0107
What can Bayes statistics contribute to measuring patient perspectives?
Hilary Bekker (United Kingdom) 13:55
Abstract N° SP0108
Decision aid tools

Mara Kaldeweide (Germany) 14:15
Patient’s view on measuring what matters to patients

J. Primdahl (Denmark) 14:35
Abstract N° OP0328-HPR
Patients’ views on routine collection of patient-reported outcomes in rheumatology care - a DANBIO focus group study

M. Oude Voshaar (Netherlands) 14:45
Z. Das Gupta, M. A. van de Laar, H. E. Vonkeman on behalf of International Consortium for Health Outcome Measurement (ICHOM) working group for inflammatory arthritis minuscules
Abstract N° OP0329-HPR
Outcomes that matter to people living with inflammatory arthritis; a global standard set, developed by the international consortium for health outcome measurement (ICHOM) working group for inflammatory arthritis

15:00 - 15:30 Exhibition and EULAR Village (Hall 1)
Coffee break

15:30 - 17:00 Amtrium
Health Professionals session
Navigating the world of digital health

Learning objectives:
To discuss the challenges for patients to seek, find and appraise health information from electronic resources

Chair(s):
Ann Bremander (Sweden)
Mari Klokkerud (Norway)

Elizabeth Heron (United Kingdom) 15:35
Abstract N° SP0131
Digital health literacy, state of the art

Constance Drossaert (Netherlands) 15:53
Abstract N° SP0132
Measuring digital health literacy

Maria Suarez-Almazor (United States) 16:11
Multi-media patient education based on entertainment education delivered to patients with low HL

Line Raunsbaek - Knudsen (Denmark) 16:29
Abstract N° SP0133
Patient experiences from a tele-health intervention on disease activity in RA. The keen and the reluctant patient

M. Ferwerda (Netherlands) 16:47
Abstract N° OP0343-HPR
An economic evaluation of a tailored guided internet-based cognitive behavioural intervention for patients with rheumatoid arthritis as an addition to usual care

SATURDAY, 16 JUNE 2018

09:00 - 10:30 Amtrium
Health Professionals session
Multi-disciplinary management of complex persistent pain

Learning objectives:
• To be aware of the bio-psychosocial impact of persistent pain from the patient and clinician perspectives
• To understand how people with complex regional pain syndrome present in clinical practice and how to manage their pain through multidisciplinary interventions
• To be aware of current and emerging functional rehabilitation strategies for pain management

Chair(s):
Emma Dures (United Kingdom)
Yeliz Prior (United Kingdom)

Lone Knudsen (Denmark) 09:05
Abstract N° SP0148
Pain: the role of psychology

Florian Brunner (Switzerland) 09:23
CRPS - early diagnosis and first therapeutic measures

Robyn Connett (United Kingdom) 09:41
Abstract N° SP0149
The patient’s perspective of living with complex regional pain syndrome

Candy McCabe (United Kingdom) 09:59
Abstract N° SP0150
Functional rehabilitation for the relief of complex persistent pain

A. Hammond (United Kingdom) 10:17
Y. Prior, C. Sutton, S. Cotterill, C. Heal, E. Camacho on behalf of the A-GLOVES research team
Abstract N° OP0353-HPR
The effects of arthritis gloves on hand pain in people with rheumatoid or inflammatory arthritis: a randomised controlled trial (A-GLOVES trial)

10:30 - 12:00 Exhibition, EULAR Village (Hall 1) and Poster areas
Poster viewing and coffee break
Health Professionals session

How do you sleep?

Learning objectives:
• To provide overview of normal sleep patterns; sleep physiology, sleep and RMD; sleep quality; measuring sleep (outcome measure); treatment sleep
• To present clinical research on sleep issues in RMD

Chair(s):
Joke Vriezekolk (Netherlands)
Lurdes Barbosa (Portugal)

Bente Appel Esbensen (Denmark) 12:05
Abstract N° SP0170
Re-evaluate life when broken sleep has a negative effect on inflammatory arthritis

Katie Hackett (United Kingdom) 12:23
Abstract N° SP0171
Sleep disturbances in primary Sjögren’s syndrome: evidence from the literature, patient sleep diaries and a qualitative focus group study

Sean.G. McKenna (Ireland) 12:41
Abstract N° SP0172
What effect does exercise have on sleep in RMDs?

Poul J. Jennum (Denmark) 12:59
How did you sleep last night?

J. S. Malmborg (Sweden) 13:17
A. Brezander, M. C. Olsson, A.-C. Bergman, S. Brorsson, S. Bergman
Abstract N° OP0361-HPR
Sleeping problems and anxiety is associated to chronic multisite musculoskeletal pain in Swedish high school students

12:00 - 13:30  Amtrium

Joint session PARE/HPR

Work and rehabilitation - key priorities for people with RMDs

Learning objectives:
• To explore the current developments at EU level and the impact on member states
• To explore the impact of work rehabilitation on the quality of life and on employment
• To show the value of early intervention, prevention and better management of RMDs

Chair(s):
Tanja Stamm (Austria)
Elsa Mateus (Portugal)

Gerlinde Bendzuck (Germany) 12:05
Abstract N° SP0176
It works?! Employment support for people with RMDs

Erika Mosor (Austria) 12:25
Abstract N° SP0177
Quality of life at the workplace - how early interventions of health professionals can support people with RMDs

Sarah Copsey (Spain) 12:45
Abstract N° SP0178
The contribution of occupational health and to working with RMDs

M. Klokkerud (Norway) 13:05
E. Hasselknippe, A. Ronningen, H. Haaverøen, A.-L. Sand-Svartrud
Abstract N° OP0364-PARE
Work status and work barriers in patients receiving BDMARDs as infusions in rheumatology hospital clinics in Norway. A cross-sectional study

M. Bezzant (United Kingdom) 13:15
A. Bosworth, L. Lunt, S. Verstappen
Abstract N° OP0365-PARE
Work matters: a UK wide survey of adults with rheumatoid arthritis and juvenile idiopathic arthritis on the impact of their disease on work

13:45 - 14:45  Amtrium

Highlight session

HPR Highlight session

Chair(s):
Yeliz Prior (United Kingdom)
Rikke H. Moe (Norway)
Fernando Estévez-López (Spain) 13:50
Abstract N° SP0181
Highlights from the Health Professionals in Rheumatology sessions

Iain B. McInnes (United Kingdom) 14:08
Highlights from the scientific programme
Trond Haugmark (Norway) 14:26
Highlights from the PARE programme
HPR Guided Poster Tours & Posters
Health Professionals in Rheumatology

**Thursday, 14 June 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Poster area</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45-13:30</td>
<td>Poster viewing</td>
<td>11:45-13:30</td>
</tr>
<tr>
<td>11:50-13:30</td>
<td>Guided poster tours</td>
<td>11:50-13:30</td>
</tr>
</tbody>
</table>

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a 'first-come-first-served' basis on the date of the poster tour.

**Poster tour T14: Winds of change**

**Chair(s):** Annette de Thurah (Denmark), Anne-Kathrin Rausch Osthoff (Switzerland)

**Abstracts N°:** THU0710-HPR-THU0719-HPR

- **THU0710-HPR** QUALITIES OF PARTICIPATION AS DESCRIBED BY PEOPLE WITH EARLY RA IN WORKING AGE / A. Sverker* - I. Thyberg - E. Valtersson - M. Björk - G. Östlund - S. Hjalmarsson
- **THU0711-HPR** WIDESPREAD PAIN IN AXIAL SPONDYLOARTHRITIS: CLINICAL IMPORTANCE AND GENDER DIFFERENCES / T. W. Swinnen* - W. Dankaerts - R. Westhooven - K. de Vlam
- **THU0712-HPR** TRAJECTORIES OF PAIN AND PHYSICAL FUNCTION IN PATIENTS WITH SYMPTOMATIC KNEE AND HIP OSTEOARTHRITIS: RESULTS FROM THE FRENCH POPULATION-BASED KOALA COHORT / M. Wieczorek - C. Rotonda - F. Guillemin - A.-C. Rat
- **THU0713-HPR** BEHAVIOUR CHANGE INTERVENTIONS TARGETING PHYSICAL ACTIVITY IN ADULTS WITH FIBROMYALGIA SYNDROME: A SYSTEMATIC REVIEW / T. O’Dwyer* - L. Durcan - S. Maguire - D. Mockler - F. Wilson
- **THU0714-HPR** INTERPROFESSIONAL COLLABORATION IN RHEUMATOLOGY REHABILITATION - THE CLASH BETWEEN IDEOLOGY AND PRACTICE / T. M. Kristiansen* - M. H. Persson - M. Stauner - J. Primm dal
- **THU0718-HPR** THE PSYCHOSOCIAL IMPACT OF JOINT HYPERMOBILITY SYNDROME AND EHLERS-DANLOS SYNDROME (HYPERMOBILITY TYPE): A QUALITATIVE INTERVIEW STUDY / S. E. Bennett* - S. Palmer - N. Walsh - T. Moss
- **THU0719-HPR** NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: ROOM FOR IMPROVEMENT? / J. K. Stöcker* - J. Spierings - C. H. M. van den Ende - M. C. Vonk on behalf of ARCH study group

**TOPIC: HPR INTERVENTIONS (EDUCATIONAL, PHYSICAL, SOCIAL AND PSYCHOLOGICAL)**

- **THU0720-HPR** FACTORS ASSOCIATED WITH POOR SLEEP QUALITY IN PATIENTS WITH CHRONIC WIDESPREAD PAIN: RESULTS FROM THE AMSTERDAM PAIN COHORT / A. de Rooij* - M. van der Leeden - L. D. Roorda - M. Rinkema - W. Beuving - J. Dekker
- **THU0721-HPR** THE EFFECTS OF UPPER AND LOWER LIMB EXERCISE ON THE MICROVASCULAR REACTIVITY IN SYSTEMIC SCLEROSIS PATIENTS / A. M. Mitropoulos* - A. Gumber - H. Crank - M. Aki - M. Klonizakis
- **THU0722-HPR** PHYSICAL THERAPY IS EFFECTIVE IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A RANDOMISED CONTROLLED TRIAL / A. Ünal Enginar* - H. Uğurlu
- **THU0723-HPR** NICE GUIDANCE ON SPONDYLOARTHRITIS: RECOMMENDATIONS SUPPORTING RECOGNITION AND REFERRAL BY PHYSIOTHERAPISTs / C. McCrum
- **THU0724-HPR** INVESTIGATION OF IMMEDIATE EFFECT OF CERVICAL STABILIZATION EXERCISES ON PROPRIOCEPTION IN PATIENTS WITH NECK PAIN / E. Tonga* - E. Timurtaş - G. M. Polat
- **THU0725-HPR** EULAR POINTS TO CONSIDER/RECOMMENDATIONS FOR THE HEALTH PROFESSIONALS’ PREVENTION AND MANAGEMENT OF OSTEOPOROTIC FRACTURES / E. Hurkmans* - N. Wilson - T. Stamm - J. Adams on behalf of task force group HP management osteoporotic fractures
- **THU0726-HPR** ADHERENCE TO BIOLOGICAL THERAPY IN CHRONIC INFLAMMATORY RHEUMATISM: RESULTS OF A RETROSPECTIVE STUDY IN AUVERGNE, FRANCE / F. Fayet* - M. R. Rodere - C. Savel - B. Pereira - M. Soubrier - M. Couderc
- **THU0728-HPR** A MIXED METHODS STUDY OF A GROUP PHYSIOTHERAPY PROGRAMME INCORPORATING EXERCISE AND EDUCATION IN FIBROMYALGIA PATIENTS / J. Parreira* - C. Caeiro - R. Fernandes - E. Cruz
- **THU0729-HPR** PATIENT WITH RHEUMATOID ARTHRITIS ARE STILL NOT SUFFICIENTLY PHYSICAL ACTIVE. TIME FOR A PERSONALISED PHYSICAL ACTIVITY PROGRAMME? / J. Weijers* - S. Rongen-van Dartel - P. van Riel

* Presenting author
THU0730-HPR A SYSTEMATIC REVIEW OF ONLINE INTERVENTIONS FOR ADDRESSING PSYCHOLOGICAL DISTRESS IN RHEUMATOID ARTHRITIS AND OTHER LONG-TERM CONDITIONS / K. Fishpool* - B. Jones - S. Hewlett - M. Ndosi

THU0731-HPR THE ABDOMINAL HYPOPRESSIVE TECHNIQUE CAN BE USED TO TREAT LOW BACK PAIN? / L. Soriano - L. Carmona - J. B. Negrón*

THU0732-HPR INDIVIDUAL RESPONDER ANALYSIS OF THE EFFECTIVENESS OF MANUAL THERAPY AND EXERCISE VERSUS USUAL CARE IN PATIENTS WITH CHRONIC NONSPECIFIC NECK PAIN: PRELIMINARY RESULTS OF A RANDOMISED CONTROLLED TRIAL / L. A. Domingües* - F. M. Pimentel-Santos - E. B. Cruz - J. C. Branco

THU0733-HPR EFFECT OF CUSTOM-MADE FOOT ORTHOSES VERSUS PLACEBO IN PATIENTS WITH RHEUMATOID ARTHRITIS: RANDOMISED CLINICAL TRIAL / M. Reina-Bueno* - P. V. Munuera-Martínez - C. Vázquez-Bautista - S. Pérez-García - C. Rosende-Bautista


THU0737-HPR THE EFFECTIVENESS OF RELAXATION EXERCISES ON PAIN, FUNCTIONAL LEVEL AND MUSCLE STRENGTH IN PATIENTS WITH TOTAL KNEE ARTHROPLASTY: A PRELIMINARY RESULTS / M. Eymir* - B. Üner - V. Karatosun


THU0740-HPR DETERMINATION OF EXERCISE BEHAVIOR IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / N. Arman - E. Taraki - A. Adrovic - S. Sahin - K. Barut - O. Kasapcopur* on behalf of Cerrahpasa


THU0742-HPR HOW TO OPTIMIZE EXERCISE BEHAVIOUR IN AXIAL SPONDYLOARTHRITIS: RESULTS OF AN INTERVENTION MAPPING STUDY / S. Hilberdink* - S. van Weely - M. Nijkamp - N. Lopuhaä - T. Vliet Vlieland

THU0743-HPR SUPPORTED SELF-MANAGEMENT INTERVENTIONS FOR FAMILIES AND CHILDREN AGED 4 TO 11 YEARS OLD LIVING WITH ARTHRITIS, ASThma AND TYPE ONE DIABETES: AN INTEGRATIVE REVIEW / S. R. Stones* on behalf of iSMART research group


THU0745-HPR USE OF WEARABLE ACTIVITY TRACKERS TO IMPROVE PHYSICAL ACTIVITY BEHAVIOR IN RHEUMATIC CONDITIONS - A SYSTEMATIC REVIEW / T. Davergne* - A. Pallot - L. Gossec - B. Fautrel

THU0746-HPR EFFICACY OF SURGICAL TREATMENTS FOR PAIN ASSOCIATED WITH TRAPEZIOMETACARPAL (THUMB BASE) OSTEOARTHRITIS: A SYSTEMATIC REVIEW / T. Hamasaki* - S. Laprise - P. G. Harris - D. Ziegler - H. T. V. Zomahoun - L. Roselló

THU0747-HPR THE EFFECTIVENESS OF CLINICAL PILATES EXERCISES ON DISEASE SPECIFIC-INDICES, CORE STABILIZATION AND BALANCE IN PATIENTS WITH ANKYLOSING SPONDYLITIS / Y. Acar* - B. Gürpınar - G. Can - F. Şen - N. Özdemir

THU0748-HPR EVALUATION OF ADHERENCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH INFLAMMATORY ARTHRITIS / Y. C. Lim* - W. G. Teo - M. N. Eng - H. M. Cheen - X. Y. Tay - S. I. Yeo - T. G. Lim

---

**Friday, 15 June 2018**

<table>
<thead>
<tr>
<th>Poster area</th>
<th>11:45-13:30</th>
<th>11:50-13:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guided poster tours</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis on the date of the poster tour.

**TOPIC: HPR PATIENTS’ PERSPECTIVES, FUNCTIONING AND HEALTH (DESCRIPTIVE: QUALITATIVE OR QUANTITATIVE)**


FR0703-HPR EVALUATION OF AN INDIVIDUAL TARGETED INTERVENTION WITH THE PURPOSE OF REDUCING SEDENTARY TIME IN PEOPLE WITH RHEUMATOID ARTHRITIS - A MIXED METHODS STUDY BASED ON QUESTIONNAIRES AND FOCUS GROUP INTERVIEWS / B. A. Espensen* - T. Thomsen - M. R. Petersen - M. Aadahl

* Presenting author


FRI0706-HPR  VALUES UNDERLYING DISEASE-MODIFYING ANTI-RHEUMATIC DRUG PREFERENCES OF PATIENTS WITH RHEUMATOID ARTHRITIS / E. Mathijssen* - J. Vriezekolk - B. van den Bernt

FRI0707-HPR  PATIENTS’ EXPERIENCES OF HEALTH IN EARLY RHEUMATOID ARTHRITIS - A QUALITATIVE STUDY / E. Landgren* - A. Bremander - E. Lindqvist - K. van der Elst - I. Larsson


TOPIC: HPR SERVICE DEVELOPMENTS, INNOVATION AND ECONOMICS IN HEALTHCARE

FRI0726-HPR  STUDY ON THE EFFICACY OF CURCUMIN THERAPY IN EARLY STAGES OF JUVENILE OLIGOARTHRITIS / C. Ailioaie* - L. M. Ailioaie

FRI0727-HPR  IMPLEMENTATION OF A MODEL FOR THE MEDICATION RECONCILIATION PROCESS IN PATIENTS WITH RHEUMATOID ARTHRITIS / K. Urrego - P. Santostefano

FRI0728-HPR  COST-REDUCING AND IMPROVING QUALITY OF LIFE IN JUVENILE ARTHRITIS BY BLUE LASER AND ULTRABIOAVAILABLE CURCUMIN / L. M. Ailioaie - C. Ailioaie

FRI0729-HPR  RHEUMATOLOGY ADVANCED NURSE PRACTITIONERS TREAT TO TARGET PERSON CENTERED CARE: IRELAND’S POLICY FRAMEWORK / P. Minnock* - A.-M. Ryan on behalf of Irish Rheumatology Nursing Forum

FRI0730-HPR  THE CONCEPT OF PATIENT CENTERED CARE IN SPONDYLOARTHRITIS BASED ON A MULTIDISCIPLINARY MODEL / P. Santos-Moreno* - L. Villarreal - D. Buitrago-Garcia - M. Cabrera

* Presenting author
<table>
<thead>
<tr>
<th>Abstract N°</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI0731-HPR</td>
<td>SWITCH MANAGEMENT BETWEEN SIMILAR BIOLOGICAL MEDICINES, A COMMUNICATION INFORMATION GUIDE FOR NURSES</td>
<td>L. Moortgat - M. Pavic Nikolic - P. Crombez - B. Oomen on behalf of European Specialist Nurses Organisations (ESNO)</td>
</tr>
<tr>
<td>FRI0732-HPR</td>
<td>RHEUMATOLOGY NURSE SPECIALISTS AND CORTICOSTEROID PRESCRIBING - DOES IT CONFORM TO EULAR GUIDELINES</td>
<td>J. Begum* - M. K. Nisar</td>
</tr>
<tr>
<td>FRI0733-HPR</td>
<td>AN INTERACTIVE COURSE ON EXERCISE THERAPY FOR KNEE OSTEOARTHRITIS AND COMORBIDITY: A FEASIBILITY STUDY</td>
<td>M. van der Leeden - M. van der Sch - W. F. Lems - J. Meesters - W. F. Peter</td>
</tr>
<tr>
<td>FRI0735-HPR</td>
<td>KNOWLEDGE, CONFIDENCE AND EDUCATIONAL NEEDS OF PRIMARY CARE NURSES' ON PATIENT EDUCATION AND CONTINUITY CARE IN RHEUMATIC DISEASES</td>
<td>R. J. O. Ferreira* - A. Marques - I. Barbosa</td>
</tr>
<tr>
<td>FRI0736-HPR</td>
<td>A STUDY AIMING FOR THE IMPLEMENTATION OF THE EULAR RECOMMENDATIONS FOR THE ROLE OF THE NURSE IN THE MANAGEMENT OF CHRONIC INFLAMMATORY ARTHRITIS IN CHINA</td>
<td>Ying Wang, Susan M Oliver, Yan-ling Chen, Yi Zhao, Yu-qiong Cao, Xue-mei Liu, Zi-yun Zhang, Li-hong Chen, Yi Liu</td>
</tr>
<tr>
<td>FRI0737-HPR</td>
<td>WOMEN'S EXPERIENCES OF COPING WITH CHRONIC WIDESPREAD PAIN - A QUALITATIVE STUDY</td>
<td>K. Aili* - S. Bergman - A. Bremander - E. Haglund - I. Larsson</td>
</tr>
<tr>
<td>FRI0738-HPR</td>
<td>NURSE-LED SCREENING: CHANGES IN CARDIOVASCULAR RISK PROFILE AND ASSOCIATION TO SOCIO-ECONOMIC STATUS IN OUTPATIENTS WITH INFLAMMATORY ARTHRITIS</td>
<td>J. Primdahl* - A. Kjeldgaard - R. D. Christensen - J. Sandergaard</td>
</tr>
<tr>
<td>FRI0739-HPR</td>
<td>EXPERT RECOMMENDATIONS ON PSYCHOLOGICAL NEEDS OF PATIENTS WITH RHEUMATOID ARTHRITIS</td>
<td>L. León* - M. Redondo - A. Fernández-Nebro - S. Gómez - E. Loa - R. Garcia-Vicuña</td>
</tr>
<tr>
<td>FRI0740-HPR</td>
<td>RESPONDING RESILIENTLY TO CHRONIC DISEASE: RHEUMATOID ARTHRITIS PATIENTS' DISCOURSE ON COPING STRATEGIES AND CHALLENGES</td>
<td>Y. Shaw* - M. Bradley - A. Dominique - K. Michaud - D. McDonald</td>
</tr>
<tr>
<td>FRI0741-HPR</td>
<td>DISCUSSIONS OF LIFESTYLE HABITS AS AN INTEGRAL PART OF CARE MANAGEMENT IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS</td>
<td>K. Malm* - S. Bergman - A. Bremander - I. Larsson - M. L. Andersson</td>
</tr>
<tr>
<td>FRI0743-HPR</td>
<td>NURSE-LED OUTPATIENT MANAGEMENT FOR IMPROVED TREATMENT OF GIANT CELL ARTERITIS (GCA) AND POLYMyalGIA RHEUMATIC (PMR) IN A RHEUMATOLOGY OUTPATIENT CLINIC</td>
<td>B. A. Esbensen - M. B. T. Pedersen - N. G. Andersen - J. J. Lykkegaard</td>
</tr>
<tr>
<td>FRI0745-HPR</td>
<td>IMPLICIT AND EXPLICIT ATTITUDES AND ASSOCIATIONS OF RHEUMATOID ARTHRITIS PATIENTS TOWARDS CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AS POSSIBLE TARGETS FOR IMPROVING MEDICATION ADHERENCE</td>
<td>M. Van Heuckelum* - E. van den Ende - L. Vandeberg - S. van Dulmen - A. Lin - B. van den Bemt</td>
</tr>
</tbody>
</table>

* Presenting author
HEALTH PROFESSIONALS POSTER TOUR / WEDNESDAY 13 JUNE 2018 / 10:30-12:00

Saturday, 16 June 2018

Poster viewing

TOPIC: HPR MEASURING HEALTH (DEVELOPMENT AND MEASUREMENT PROPERTIES OF PROS, TESTS, DEVICES)

SAT0716-HPR  PATIENTS PREFERENCE GOES TO METHOTREXATE AUTOINJECTORS OVER PREFILLED SYRINGES: RESULTS FROM A PHASE III TRIAL, SELF1 / A. Saraux* - C. Hudry - E. Zinovieva - H. Herman-Demars on behalf of All investigators of SELF1 study


SAT0721-HPR  IMPROVEMENT IN CLINICAL RESULTS BY ENHANCING ADHERENCE TO A HEALTHCARE MODEL IN RHEUMATOID ARTHRITIS / D. Buitrago-Garcia* - L. Villarreal - F. Rodriguez - I. Mendez - P. Santos-Moreno

SAT0722-HPR  THE VALIDITY AND TEST-RETEST RELIABILITY OF THE TURKISH PATIENT SPECIFIC FUNCTIONAL SCALE IN CHRONIC NECK PAIN PATIENTS / G. Yalcinkaya* - B. Kara - M. N. Arda


SAT0724-HPR  TECHNOLOGICAL ASSISTED REHABILITATION FOLLOWING TOTAL KNEE JOINT REPLACEMENT. A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL / H. H. Andersen


SAT0729-HPR  FIRST EXPERIENCES WITH ONLINE REMOTE MONITORING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES / L. Renskers* - S. A. Rongen - A. M. P. Huis - P. L. C. M. van Riel

SAT0730-HPR  DEVELOPMENT OF PSYCHOMETRICALLY EQUIVALENT SHORT FORMS TO MEASURE DISEASE AND TREATMENT ASSOCIATED KNOWLEDGE IN RHEUMATOID ARTHRITIS: APPLICATION OF ITEM RESPONSE THEORY (IRT) / M. Oude Voshaar* - M. de Jonge - L. Renskers - S. Rongen - M. van de Laar - A. Huis - P. Van Riel

SAT0731-HPR  EARLY POSTOPERATIVE OUTCOMES OF UNILATERAL VERSUS BILATERAL TOTAL KNEE ARTHROPLASTY / M. Eymir* - B. Unver - V. Karatosun

SAT0732-HPR  RATING OF PERCEIVED EXERTION IN PATIENTS WITH RHEUMATOID ARTHRITIS - WHICH ARE THE CORRELATES? / N. Brodin* - N. Bobst - C. H. Opava


SAT0734-HPR  CORRELATES OF PAIN AND PREDICTORS OF PAIN RELIEF IN A CONTROLLED RA STUDY IN INDIAN PATIENTS / T. Kianifard* - M. Saluja - S. Samukaddam - A. Chopra

SAT0735-HPR  SEX DIFFERENCES IN ILLNESS PERCEPTIONS AND SELF-MANAGEMENT IN PATIENTS WITH GOUT / U. Bergsten* - M. Dehlin - E. Klingberg - A. Landgren - L. Jacobsson

SAT0736-HPR  COMPARISON OF CORE STABILIZATION AND BALANCE IN HEALTHY CONTROLS AND PATIENTS WITH ANKYLOSING SPONDYLITIS / Y. Acar* - G. Can - N. Ilicin

* Presenting author
TOPIC: HPR EPIDEMIOLOGY AND PUBLIC HEALTH (INCLUDING PREVENTION)

SAT0737-HPR MEASURES OF PHYSICAL ACTIVITY AND FEAR AVOIDANCE IN PEOPLE WITH CHRONIC PAIN / A. Bremander* - E. Haglund - S. Bergman

SAT0738-HPR FACTORS ASSOCIATED WITH RISK OF FALLING IN ADULTS WITH KNEE OSTEOARTHRITIS: A CROSS-SECTIONAL STUDY / D. G. Manlapaz* - P. Jayakaran - G. Sole - C. M. Chapple


SAT0742-HPR EUROPEAN LEAGUE AGAINST RHEUMATISM RECOMMENDATIONS FOR THE ROLE OF THE NURSE (EULAR-RN) IN THE MANAGEMENT OF CHRONIC INFLAMMATORY ARTHRITIS (CIA): RESULTS OF PATIENTS IN NORDIC COUNTRIES / M. L. Kukkurainen* - M. Kauppi - Y. van Eijk-Hustings

SAT0743-HPR RELATION BETWEEN SERUM ALBUMIN AND PHYSICAL PERFORMANCE AND MOBILITY IN A COMMUNITY-BASED ELDERLY PEOPLE WITH OSTEOPOROSIS / M. Karapinar* - A. Abit Kocaman - N. Kirdi - B. Balam Yavuz

SAT0744-HPR PREVALENCE OF COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND CORRELATION WITH DISEASE ACTIVITY AND TYPE OF THERAPY / M. Cabrera* - L. Villarreal - D. Buitrago-Garcia - P. Santos-Moreno


PARE Programme
People with Arthritis/Rheumatism in Europe

13 June 2018

PARE Programme / Wednesday 13 June 2018 / 183

PARE session
E-health for better care

Learning objectives:
- To present digital health care solutions that enable better access to health care
- To show how apps can contribute to patient health care and to organisation attractiveness
- To outline relevant issues of data protection and patient safety

Chair(s):
Kristijonas Mazuras (Lithuania)
Gerlinde Bendzuck (Germany)

Jutta Richter (Germany)
Abstract N° SP0017
Bits and bytes: fitting medical information - PICASO the platform for improved personal, coordinated care

Victoria Romero Pazos (Spain)
Abstract N° SP0018
Ésaude - a digital platform that unites tools to provide personalised health

Mitchell Silva (Belgium)
Abstract N° SP0018
Smart wearables - the right tool for health monitoring and improving quality of health?

S. R. Stones (United Kingdom)
15:20
on behalf of Young PARE working group
Abstract N° OP0011-PARE
A week to tweet: findings from young PARE’s online course for twitter novices

S. Trope (France)
15:30
Abstract N° OP0012-HPR
Creation of the first digital training designed for patients with rheumatoid arthritis by patient organisation in rheumatology

15:45 - 16:15  Exhibition and EULAR Village (Hall 1)
Coffee break

16:15 - 17:45  Amtrium

Joint session HPR/PARE
New drugs - new perspectives: clinical and regulatory issues concerning biosimilars

Learning objectives:
To provide healthcare professionals with reference information on both science and regulation underpinning the use of biosimilars

Chair(s):
Yvonne van Eijk-Hustings (Netherlands)
Dieter Wiek (Germany)

Tore K. Kvien (Norway)
16:20
Abstract N° SP0024
An up-date on biosimilars

Tracy French (United Kingdom)
16:38
Abstract N° SP0025
Shared decision making in switching to biosimilars

Franz König (Austria)
16:56
Statistical and regulatory aspects of biosimilars

Dieter Wiek (Germany)
17:14
Abstract N° SP0026
Biosimilars - the changing views of EULAR’s Member organisations of PARE

M. Cvancarova Småstuen (Norway)
17:32
M. Brandvold, R. Andenæs
Abstract N° OP0070-HPR
Is patients’ satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey
16:15 - 17:45  PARE Room

PARE session

Don’t Delay, Connect Today!

Learning objectives:
• To enable national patient organisations to adopt the EULAR Campaign at national level
• To share best practices of successful activities around the EULAR Campaign

Chair(s):
Helena Canhão (Portugal)
Boryana Boteva (Bulgaria)

Gerd R. Burmester (Germany) 16:20
Why we need the Don’t Delay Connect Today campaign

Tanja Stamm (Austria) 16:40
How HPRs can support the campaign

Ruxandra Ionescu (Romania) 17:00
Abstract N° SP0027
Don’t Delay, Connect Today - implementation of the EULAR Campaign in Romania

H. L. Bankova (Bulgaria) 17:20
B. Boteva
Abstract N° OP0079-PARE
Awareness week for rheumatic diseases - 8-14 May 2017

K. Koutsogianni (Greece) 17:30
E. Tsourlidaki, J. Papadakis, R. Stara, L. Papadaki on behalf of the Arthritis Foundation of Crete
Abstract N° OP0080-PARE
Photo album of people with rheumatic diseases under the title: ‘there are some people... our people!!!’

11:45 - 13:30  Exhibition, EULAR Village (Hall 1) and Poster areas

12:00 - 13:30  Poster area

Guided poster tour
The PARE guided poster tour is taking place during the official poster viewing. For details on the tour, please refer to page 188. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

13:30 - 15:00  PARE Room

PARE session

Patient involvement in research:
The future of collaborative research. Lessons from the field of rheumatology and beyond

Learning objectives:
• To learn from best practices of patient engagement in different disease areas
• To explore patient involvement in guideline development and health care innovations
• To explore how to evaluate patient involvement

Chair(s):
Jürgen Clausen (Germany)
Laure Gossec (France)

Courtney Coleman (United Kingdom) 13:35
Abstract N° SP0058
Patient involvement in research in pneumology
Iain B. McInnes (United Kingdom)  13:55
EULAR’s RheumaMap - research to transform the lives of people with RMDs

Codruta Zabalan (Romania)  14:15
Abstract N° SP0059
EULAR’s Patient research partner network - patients’ future involvement in research

E. R. Dorris (Ireland)  14:35
N. Nestor, A. G. Wilson
Abstract N° OP0209-PARE
The patient voice in arthritis research: a collaborative approach to embedding PPI into research strategy

C. G. Schoemaker (Netherlands)  14:45
W. Armbrust, J. F. Swart, E. Versluis, W. Olsder, N. M. Wulffraat
Abstract N° OP0210-PARE
Dutch juvenile idiopathic arthritis patients, carers and clinicians creating a research agenda together following the James Lind alliance method

15:00 - 15:30  Exhibition and EULAR Village (Hall 1)
Coffee break

15:30 - 17:00  PARE Room

PARE session

Challenges of patient organisations’ in the 21st century

Learning objectives:
• To outline organisations’ challenges in a society that is getting older - less - more colorful
• To showcase how organisations can achieve sustainability
• To portrait organisations’ efforts to overcome gaps in patient health care

Chair(s):
Neil Betteridge (United Kingdom)
Corinna Elling-Audersch (Germany)

Winfried Kösters (Germany)  15:35
Abstract N° SP0081
Patient organisations’ challenges in a world that is getting older - less - more colorful

Elsa Mateus (Portugal)  15:55
Abstract N° SP0082
How a user-led organisation for RMDs enables citizen participation in Portugal

Katerina Koutsogianni (Greece)  16:15
Abstract N° SP0083
Gaps in patient treatment - what patient organisations can do

V. Krafft (Switzerland)  16:35
S. M. Engel
Abstract N° OP0220-PARE
Development of the Swiss national strategy ‘musculoskeletal diseases’ 2017-2022 by the Swiss league against rheumatism

T. Ngcozana (United Kingdom)  16:45
A. Bhatia
Abstract N° OP0221-PARE
Know their numbers: what do RA patients know about their own biomedical data?

FRIDAY, 15 JUNE 2018

10:15 - 11:45  PARE Room

Abstract session

PARE Abstract session

Learning objectives:
From abstract to concrete - the variety of activities of PARE organisations

Chair(s):
Kate Betteridge (United Kingdom)
Polina Pchelnikova (Russian Federation)
Magdalena Misuno (Poland)  10:20
Edgar Stene Prize 2018: My personal champion - supporting my everyday life with a rheumatic and musculoskeletal disease (RMD)

C. R. Ziegler (Denmark)  10:30
Abstract N° OP0290-PARE
Keep an eye out for invisible pains - a Danish campaign

J. F. M. Holla (Netherlands)  10:40
J. Brontsema, N. Schenk, R. Jansen, R. Vreenegoor, M. F nuit, W. F. Peter, I. E. Bultink
Abstract N° OP0291-PARE
Running with rheumatism: a 7-week training programme for novice runners with inflammatory rheumatic disease

A. Lacovou (Cyprus)  10:50
Abstract N° OP0292-PARE
The creation of the ‘aqua re-action’. A methodologically based aquatic physical intervention/rehabilitation program for people with RMDs

P. Wegscheider (Austria)  11:00
G. Schaffer
Abstract N° OP0293-PARE
Problems, goals and urgent wishes of young Austrians diagnosed with rheumatic disorders: a report

S. De Jong (Netherlands)  11:20
Abstract N° OP0295-PARE
*Kweek begrip*: the launch of our creative campaign across the Netherlands on Worldarthritisday aims to increase awareness about RMDs in general and people living with RMDs in particular
11:30  Abstract N° OP0296
B. Kuriya (Canada)  
J. Widdifield, J. Luo, S. Vigod, N. Haroon
The risk of deliberate self-harm in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study

11:45 - 13:30  Exhibition, EULAR Village (Hall 1) and Poster areas
Poster viewing and lunch

12:00 - 13:30  Poster area
Guided poster tour
The PARE guided poster tour is taking place during the official poster viewing. For details on the tour, please refer to page 188. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis the day of the poster tour.

13:30 - 15:00  PARE Room
Joint session PARE/Clinical
Innovative treatments for a better quality of life
Learning objectives:
• To present new innovative drugs
• To outline health interventions and technology assessment in support of people with RMDs
• To learn what drug safety parameters the patient has to consider when being treated with innovative drugs
Chair(s):
José A. P. da Silva (Portugal)  
Eva Tzigounaki-Kritza (Greece)
Johannes W. J. Bijlsma (Netherlands)  13:35
Why JAK inhibitors can make a difference?
Jürgen Clausen (Germany)  13:55
Involvement of a patient organisation in health technology assessment
Ailsa M. Bosworth (United Kingdom)  14:15
Patient rights and safety concerns in an era of innovative therapies
A. M. Bosworth (United Kingdom)  14:35
S. Arora
Abstract N° OP0330-PARE
Love your heart, an online, interactive cardiovascular risk assessment programme for people with RA/IA

14:45  Abstract N° OP0331-PARE
L. Alemo Munters (Sweden)  
A. Beerman
Behavior change experiences and needs of persons with rheumatic disease

15:00 - 15:30  Exhibition and EULAR Village (Hall 1)
Coffee break

15:30 - 17:00  PARE Room
PARE session
What’s new: Latest advances in treatment in JIA and osteoarthritis
Learning objectives:
To show the latest advances in treatment and care in JIA and osteoarthritis
Chair(s):
Philip Conaghan (United Kingdom)  
Victoria Romero Pazos (Spain)
Margreet Kloppenburg (Netherlands)  15:35
Latest advances in treatment and management of OA
L. Campbell (United Kingdom)  16:05
Abstract N° OP0346-PARE
A partnership in implementation: adapting an osteoarthritis guidebook across European cultures - with patients, for patients
Tadej Avcin (Slovenia)  16:15
Latest advances in treatment and management of JIA
Y. El Miedany (United Kingdom)  16:45
Abstract N° OP0347
Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking
PARE PROGRAMME / SATURDAY 16 JUNE 2018 / 187

SATURDAY, 16 JUNE 2018

09:00 - 10:30  PARE Room

PARE session

Workshop: Is there a diet for people with RMDs?

Learning objectives:
• Share evidence based knowledge on nutrition
• Share best practice by patient organisations

Chair(s):
Dieter Wiek (Germany)
Nele Caeyers (Belgium)

Asta Linauskas (Denmark) 09:05
Abstract N° SP0153
What evidence is there that diets help people with RMDs?

Corinna Elling-Audersch (Germany) 09:20
Abstract N° SP0154
How to offer seminars on nutrition

Valerie Krafft (Switzerland) 09:35
Abstract N° SP0155
Nutrition - how to talk about it

Faculty 09:50
Group discussion and Q&A

Dieter Wiek (Germany) 10:20
Resume of the group discussions

10:30 - 12:00  Exhibition, EULAR Village (Hall 1) and Poster areas

Poster viewing and coffee break

12:00 - 13:30  PARE Room

Joint session PARE/HPR

Work and rehabilitation - key priorities for people with RMDs

Learning objectives:
• To explore the current developments at EU level and the impact on member states
• To explore the impact of work rehabilitation on the quality of life and on the employment
• To show the value of early intervention, prevention and better management of RMDs

Chair(s):
Tanja Stamm (Austria)
Elsa Mateus (Portugal)

Gerlinde Bendzuck (Germany) 12:05
Abstract N° SP0176
It works?! Employment support for people with RMDs

Erika Mosor (Austria) 12:25
Abstract N° SP0177
Quality of life at the workplace - how early interventions of health professionals can support people with RMDs

Sarah Copsey (Spain) 12:45
Abstract N° SP0178
The contribution of occupational safety and health to working with RMDs

M. Klokkerud (Norway) 13:05
E. Hasselknippe, A. Rønningen, H. Haveråen, A.-L. Sand-Svartrud
Abstract N° OP0364-PARE
Work status and work barriers in patients receiving BDMARDs as infusions in rheumatology hospital clinics in Norway. A cross-sectional study

M. Bezzant (United Kingdom) 13:15
A. Bosworth, L. Lunt, S. Verstappen
Abstract N° OP0365-PARE
Work matters: a UK wide survey of adults with rheumatoid arthritis and juvenile idiopathic arthritis on the impact of their disease on work

13:45 - 14:45  PARE Room

Highlight session

PARE Highlight session

Learning objectives:
To provide an overview of learning and outcomes from the EULAR 2018 Congress from health professionals and the scientific perspectives, and first feedback from the PARE delegates

Chair(s):
Dieter Wiek (Germany)
Nele Caeyers (Belgium)

Elena Nikiphorou (United Kingdom) 13:50
Highlights from the scientific programme

Yvonne van Eijk-Hustings (Netherlands) 14:15
Highlights from the HPR programme
### PARE Guided Poster Tours & Posters

**People with Arthritis/Rheumatism in Europe Poster Session**

#### Thursday, 14 June 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45-13:30</td>
<td>Poster viewing</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Guided poster tours</td>
</tr>
</tbody>
</table>

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis on the date of the poster tour.

**Poster tour T15: PARE Poster Tour I**

**Chair(s):** Dieter Wiek (Germany), Elsa Mateus (Portugal)

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARE0001</td>
<td>#DOESNTSHOWDOESNTEXIST / #SYNSINTEFINNSINTE - AN AWARENESS CAMPAIGN FOR PUBLIC TRANSPORT BY SWEDISH NATIONAL ORGANIZATION FOR YOUNG RHUMATICS / K. Nordlund* - M. Beermann</td>
</tr>
<tr>
<td>PARE0004</td>
<td>LET’S MOVE WITH ARTHRITIS! - NORDIC WALKING FOR PEOPLE WITH RMDS / P. Balazova* - J. Dobsovícová Cernáková</td>
</tr>
</tbody>
</table>
| PARE0005  | DEVELOPMENT & DISSEMINATION OF A RESOURCE ABOUT METHOTREXATE USE FOR AND BY PATIENTS WITH INFLAMMATORY ARTHRITIS / D. Richards* - N. Robertson - L. Wilhelm - L. Proulx - A. McKinnon - J. Gunderson - C. Reece - A. Sirois *
| PARE0006  | A SUMMARY OF KEY FINDINGS FROM THE SJÖGREN’S SYNDROME FOUNDATION’S NATIONAL PATIENT SURVEY RELATED TO TREATMENTS AND MEDICATIONS USED / S. Taylor - K. M. Hammitt* |
| PARE0007  | FAMILY DAY BY THE SWISS LEAGUE AGAINST RHEUMATISM: A NETWORKING EVENT FOR CHILDREN AFFECTED BY JIA AND THEIR FAMILIES / M. Roffler* - V. Krafft |
| PARE0008  | SURVEY RESULTS FROM A NATIONWIDE ONLINE AWARENESS CAMPAIGN SUGGEST A CLEAR DIFFERENCE IN TREATMENT AND PERCEPTION OF QUALITY OF HEALTHCARE FOR PATIENTS DIAGNOSED WITH PSORIASIS ARTHRITIS, PSA, VERSUS PATIENTS WITH SYMPTOMS SIMILAR TO PSORIASIS ARTHRITIS I.E. PSORIASIS AND JOINT PAIN / N. Unlesi* - E.-M. Dufva - L. Häkansson |

#### Friday, 15 June 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45-13:30</td>
<td>Poster viewing</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Guided poster tours</td>
</tr>
</tbody>
</table>

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a ‘first-come-first-served’ basis on the date of the poster tour.

**Poster tour F16: PARE Poster Tour II**

**Chair(s):** Nele Caeyers (Belgium), Boryana Boteva (Bulgaria)

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARE0010</td>
<td>NATURALLY HEALING THE CHRONIC PAIN AND HEALTH MAINTENANCE / A. Phoka Charalambous*</td>
</tr>
<tr>
<td>PARE0011</td>
<td>FUNKA UTAN SKAM - TO FUNCTION WITHOUT SHAME / T. Diao*</td>
</tr>
<tr>
<td>PARE0013</td>
<td>SOURCES OF INFORMATION AND KNOWLEDGE ABOUT RHEUMATIC DISEASES AMONG PEOPLE WITH RHEUMATIC DISEASES IN POLAND AND IN OTHER EUROPEAN COUNTRIES / J. Grygielska* - A. Klak - J. Owoc - E. Gawrińska-Drużba - F. Raciborski</td>
</tr>
<tr>
<td>PARE0015</td>
<td>LARGE-SCALE SURVEY OFFERS GENERAL INSIGHT AND BASIS FOR POLICY DRAFTING / S. De Jong* - I. Koopmans - M. Feith</td>
</tr>
<tr>
<td>PARE0016</td>
<td>THE ROLE OF EMPATHY QUOTIENT IN PATIENT-PHYSICIAN COMMUNICATION: A TOOL TO IMPROVE MEDICATION ADHERENCE / A. Celano*</td>
</tr>
<tr>
<td>PARE0017</td>
<td>SUPPORTING YOUNG PEOPLE WITH RMDS IN MANAGING ISSUES AROUND RELATIONSHIPS, PREGNANCY AND SEXUALITY / W. Olsder* - L. van Nieuwkoop - A. A. J. Haenen</td>
</tr>
</tbody>
</table>

* Presenting author
# EULAR Related Meetings

By invitation only

## Wednesday, 13 June 2018

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>D304</td>
<td>EULAR Standing Committee on Clinical Affairs Business meeting</td>
</tr>
<tr>
<td>09:00 - 12:00</td>
<td>D407</td>
<td>IMI2 project RTCure: Criteria and outcome measures in RTCure Cohorts - WP2</td>
</tr>
<tr>
<td>10:30 - 12:30</td>
<td>E102</td>
<td>GRAPPA Adjacent to EULAR 2018</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>D302</td>
<td>Arthritis Research &amp; Therapy Section and Associate Editor meeting</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>D404</td>
<td>Meeting of the ScleroID Study Group</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>E103</td>
<td>ARD Editorial Board meeting</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>D301</td>
<td>OMERACT handbook group</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>D304</td>
<td>Synovitis study group</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>D402</td>
<td>TICOSPA investigators meeting</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>D403</td>
<td>EULAR Recommendations for the use and interpretation of laboratory diagnostic tests for the management of systemic autoimmune rheumatic diseases</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>D406</td>
<td>GLORIA investigators meeting</td>
</tr>
<tr>
<td>18:00 - 20:00</td>
<td>E101</td>
<td>ASIF Ankylosing Spondylitis International Federation meeting</td>
</tr>
<tr>
<td>18:15 - 19:45</td>
<td>E104</td>
<td>EULAR Standing Committee of PARE Business meeting</td>
</tr>
<tr>
<td>19:00 - 20:00</td>
<td>E103</td>
<td>RMD Open Editorial Board meeting</td>
</tr>
</tbody>
</table>

## Thursday, 14 June 2018

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>D301</td>
<td>OMERACT PRP’s</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D302</td>
<td>SLEuro Board meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D303</td>
<td>World Scleroderma Foundation Board meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D304</td>
<td>EULAR Standing Committee on Health Professionals Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D402</td>
<td>EULAR Study Group for Collaborative Research</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D406</td>
<td>AGORA meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D408</td>
<td>EULAR Standing Committee on Musculoskeletal Imaging Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>E101</td>
<td>Steering Committee meeting ATACC-RA</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>E102</td>
<td>EMEUNET Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>E103</td>
<td>MyoNet study group</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>E104</td>
<td>UEMS Rheumatology Section and Board</td>
</tr>
<tr>
<td>08:15 - 09:45</td>
<td>D401</td>
<td>EULAR Public Affairs Group meeting</td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td>D403</td>
<td>EULAR Standing Committee on Paediatric Rheumatology</td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td>E105</td>
<td>EULAR Study Group on Microcirculation in Rheumatic Diseases</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>D407</td>
<td>Rheumatology Editorial Board meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>D304</td>
<td>Clinical Nurse study group</td>
</tr>
</tbody>
</table>
### Thursday, 14 June 2018

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 18:00</td>
<td>D402</td>
<td>EULAR Study Group on Patient Education</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>D404</td>
<td>Nurse Research &amp; Strategy Group study group meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>D406</td>
<td>Online courses author LMS tutoring</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>D407</td>
<td>EMEUNET Country Liaison meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>D408</td>
<td>Foot &amp; Ankle study group</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>D302</td>
<td>Study group for Epidemiology and Registries of Observational Studies (RODS)</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>D301</td>
<td>OMERACT MRI Taskforce</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>D303</td>
<td>Editorial Board meeting - Rheumatology International</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>D403</td>
<td>EULAR Standing Committee on Investigative Rheumatology Business meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>E103</td>
<td>Study group for Risk Factors for RA</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>E104</td>
<td>Business meeting ATACC-RA</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>E105</td>
<td>Journal of Scleroderma and Related Disorders - Editorial Board meeting</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>D304</td>
<td>Physical Activity &amp; Exercise study group</td>
</tr>
</tbody>
</table>

### Friday, 15 June 2018

<table>
<thead>
<tr>
<th>Start - End</th>
<th>Room</th>
<th>Meeting Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:30</td>
<td>E103</td>
<td>EULAR Standing Committee on Education and Training Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D301</td>
<td>OMERACT Consensus</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D302</td>
<td>Board meeting Scandinavian Society of Rheumatology</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D304</td>
<td>EULAR HPR Scientific and Educational Subcommittee meeting 2018</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D401</td>
<td>SLE Classification Criteria Steering Committee</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D402</td>
<td>EuroSpa Collaboration Network, Scientific Committee meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D403</td>
<td>EUSTAR Board meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D404</td>
<td>EUROGOUT Consortium</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>D406</td>
<td>EMEUNET Mentor - Mentee meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>E101</td>
<td>EULAR PARE CEO Interim meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>E102</td>
<td>OMERACT Ultrasound Working group</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>E104</td>
<td>EULAR Sjögren’s syndrom study group - Essential</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>D303</td>
<td>German Commission of Students' Education</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>D302</td>
<td>SSc Subset meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>E101</td>
<td>HarmonicSS Project meeting Patient Group</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>E104</td>
<td>EULAR Standing Committee for Epidemiology and Health Services Research meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>D301</td>
<td>OMERACT Methods working group</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>D304</td>
<td>European Alliance for Patient Access Patient Advocacy meeting</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>E102</td>
<td>ASAS meeting</td>
</tr>
</tbody>
</table>
Satellite Symposia

Status as of 1 May 2018

**WEDNESDAY, 13 JUNE 2018**

**Vindico Medical Education supported by Bristol-Myers Squibb**

Rheumatic complications of cancer immunotherapy: a new and emerging field in rheumatology

**Chair(s):**
Leonard H. Calabrese (United States)
Jan Leipe (Germany)
Xavier Mariette (France)

Introduction and pre-test 18:15
Biology of T cell exhaustion and the evolution of immune checkpoint inhibitors 18:25
Diagnosis and management of rheumatic irAEs from cancer immunotherapy 18:50
Clinical cases 19:15
Post-test and question and answer 19:35

**AbbVie**

RA treatment beyond the conventional: will JAK inhibitors disrupt our treatment paradigms?

**Chair(s):**
Peter Nash (Australia)

Peter Nash (Australia) 18:15
Welcome and introduction 18:15
John Isaacs (United Kingdom) 18:25
Influencing the JAK pathway: does selective inhibition make mechanistic sense?

**Andrea Rubbert-Roth (Germany)** 18:40
Beyond methotrexate: the role of JAK inhibitors when csDMARDs fail

**Peter Nash (Australia)** 19:00
Beyond biologics: JAK inhibitors as a novel alternative in bDMARD-IR patients

**Pfizer**

Evolution or Revolution? How JAK inhibitors are changing the standard of care in RA

**Chair(s):**
Ronald van Vollenhoven (Netherlands)

Ronald van Vollenhoven (Netherlands) 18:15
Welcome and introductions

Eduardo Mysler (Argentina) 18:25
Where we are today: treatment trends in RA from the clinician’s perspective

Ernest Choy (United Kingdom) 18:50
JAK inhibitors: novel therapies offering efficacious options for patients with RA

Safety and real-world data offer a wider window into advanced therapies for patients with RA

Ronald van Vollenhoven (Netherlands) 19:40
RA therapy tomorrow: the road ahead
<table>
<thead>
<tr>
<th>18:15-19:45</th>
<th>Hall 7.2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GSK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Leading the way towards a holistic approach to managing SLE</strong></td>
<td></td>
</tr>
<tr>
<td>Welcome and introduction</td>
<td>18:15</td>
</tr>
<tr>
<td>Patient and physician priorities in SLE management</td>
<td>18:18</td>
</tr>
<tr>
<td>Why we shouldn’t be tired of hearing about fatigue</td>
<td>18:30</td>
</tr>
<tr>
<td>Reducing long-term organ damage: Are we shooting for the moon?</td>
<td>19:00</td>
</tr>
<tr>
<td>Summing up and concluding remarks</td>
<td>19:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18:15-19:45</th>
<th>Emerald</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UCB</strong></td>
<td></td>
</tr>
<tr>
<td><strong>The reality of risk – how are we responding to fragility fracture in rheumatology?</strong></td>
<td></td>
</tr>
<tr>
<td>Chair(s):</td>
<td></td>
</tr>
<tr>
<td>Socrates Papapoulos (Netherlands)</td>
<td>18:15</td>
</tr>
<tr>
<td><strong>Socrates Papapoulos (Netherlands)</strong></td>
<td></td>
</tr>
<tr>
<td>Why should we be vigilant for fragility fracture?</td>
<td></td>
</tr>
<tr>
<td>Ian Bruce (United Kingdom)</td>
<td>18:30</td>
</tr>
<tr>
<td><strong>Ian Bruce (United Kingdom)</strong></td>
<td></td>
</tr>
<tr>
<td>What are the complexities of decisions facing the rheumatologist? Clinical and behavioural perspectives</td>
<td></td>
</tr>
<tr>
<td>Ivo Vlaev (United Kingdom)</td>
<td>18:50</td>
</tr>
<tr>
<td><strong>Ivo Vlaev (United Kingdom)</strong></td>
<td></td>
</tr>
<tr>
<td>Improving the odds in fragility fracture: how can we act on risk factors in the rheumatology consultation?</td>
<td></td>
</tr>
<tr>
<td>Socrates Papapoulos (Netherlands)</td>
<td>19:10</td>
</tr>
<tr>
<td><strong>Socrates Papapoulos (Netherlands)</strong></td>
<td></td>
</tr>
<tr>
<td>How does our perception of risk influence how we make decisions in the rheumatology clinic?</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>19:30</td>
</tr>
<tr>
<td>Audience Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18:15-19:45</th>
<th>Forum</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Celltrion Healthcare</strong></td>
<td></td>
</tr>
<tr>
<td><strong>REdefining the future with InflixiMab bioSIMilAr</strong></td>
<td></td>
</tr>
<tr>
<td>Chair(s):</td>
<td></td>
</tr>
<tr>
<td>Rieke Alten (Germany)</td>
<td></td>
</tr>
<tr>
<td><strong>Rieke Alten (Germany)</strong></td>
<td>18:15</td>
</tr>
<tr>
<td>Welcome and introduction</td>
<td></td>
</tr>
<tr>
<td>Laurent Grange (France)</td>
<td>18:20</td>
</tr>
<tr>
<td>Perspectives on living with rheumatic diseases</td>
<td></td>
</tr>
<tr>
<td>Rieke Alten (Germany)</td>
<td>18:35</td>
</tr>
<tr>
<td>Physicians’ perspective on early introduction of biologics</td>
<td></td>
</tr>
<tr>
<td>Ki Chul Shin (Republic of Korea)</td>
<td>18:50</td>
</tr>
<tr>
<td>Drug retention of infliximab in ankylosing spondylitis: data from KOBIO</td>
<td></td>
</tr>
<tr>
<td>Rene Westhovens (Belgium)</td>
<td>19:05</td>
</tr>
<tr>
<td>Future of infliximab: introduction of the subcutaneous formulation</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>19:20</td>
</tr>
<tr>
<td>Panel discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18:15-19:45</th>
<th>E106/E107</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IBSA</strong></td>
<td></td>
</tr>
<tr>
<td><strong>The treatment of OA: new concepts for an ‘old’ disease</strong></td>
<td></td>
</tr>
<tr>
<td>Chair(s):</td>
<td></td>
</tr>
<tr>
<td>Cem Gabay (Switzerland)</td>
<td>18:15</td>
</tr>
<tr>
<td><strong>Cem Gabay (Switzerland)</strong></td>
<td></td>
</tr>
<tr>
<td>Welcome and introduction</td>
<td></td>
</tr>
<tr>
<td>Xavier Chevalier (France)</td>
<td>18:20</td>
</tr>
<tr>
<td><strong>Xavier Chevalier (France)</strong></td>
<td></td>
</tr>
<tr>
<td>Treat to target in osteoarthritis: towards a better benefit/risk ratio of oral drugs</td>
<td></td>
</tr>
<tr>
<td>Cem Gabay (Switzerland)</td>
<td>18:40</td>
</tr>
<tr>
<td><strong>Cem Gabay (Switzerland)</strong></td>
<td></td>
</tr>
<tr>
<td>Osteoarthritis of the hand: current evidence on its management</td>
<td></td>
</tr>
<tr>
<td>Jean Dudler (Switzerland)</td>
<td>19:00</td>
</tr>
<tr>
<td><strong>Jean Dudler (Switzerland)</strong></td>
<td></td>
</tr>
<tr>
<td>Additional analysis on CONCEPT study data</td>
<td></td>
</tr>
<tr>
<td>Chiara Schiraldi (Italy)</td>
<td>19:15</td>
</tr>
<tr>
<td><strong>Chiara Schiraldi (Italy)</strong></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical-grade chondroitin sulphate vs food supplements: are they equivalent?</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>19:30</td>
</tr>
<tr>
<td>Question and answer session</td>
<td></td>
</tr>
<tr>
<td>Cem Gabay (Switzerland)</td>
<td>19:40</td>
</tr>
<tr>
<td><strong>Cem Gabay (Switzerland)</strong></td>
<td></td>
</tr>
<tr>
<td>Concluding remarks</td>
<td></td>
</tr>
</tbody>
</table>
**THURSDAY, 14 JUNE 2018**

**08:15-09:45**

**Hall 3**

**AbbVie**

**Transforming developments: the dynamic face of rheumatology**

**Chair(s):**
Ferry Breedveld (Netherlands)

**Ferry Breedveld (Netherlands)** 08:15
Welcome and introduction
Transforming treatments: how TNF inhibitors led the field in the biologic revolution

**Boulos Haraoui (Canada)** 08:30
Transforming standards: treat to target and the PASSIONate revolution

**Wouter Bos (Netherlands)** 08:45
Transforming outcomes: the role of patients in assessing their own disease

**Lisa Olson (United States)** 09:05
Transforming targets: drug discovery and development

**All** 09:25
Panel discussion and Q&A

**08:15-09:45**

**Auditorium**

**Novartis**

**Making the invisible visible: the impact of IL-17A inhibition in psoriatic arthritis**

**Chair(s):**
Dafna Gladman (Canada)

**Dafna Gladman (Canada)** 08:15
Welcome and introductions

**Georg Schett (Germany)** 08:20
Enthesitis: the link between the skin and joints in PsA

**Laura Coates (United Kingdom)** 08:40
A 360 overview on the evolving unmet needs in PsA

**Philip Conaghan (United Kingdom)** 08:55
Insights into PsA from modern imaging

**Philip Mease (United States)** 09:10
GRAPPA treatment recommendations: are they met with IL-17A inhibition?

**All** 09:30
Panel discussion and conclusions

**08:15-09:45**

**Elicium 2**

**Lilly**

**IL-17A inhibition: optimising the PsA management**

**Chair(s):**
Michael Nurmohamed (Netherlands)

**Michael Nurmohamed (Netherlands)** 08:15
Welcome and introduction

**Helena Marzo-Ortega (United Kingdom)** 08:20
Is the management of patients with PsA optimal?

**Frank Behrens (Germany)** 08:35
Overview of ixekizumab benefits and safety results

**Diamant Thaçi (Germany)** 08:50
Peter Nash (Australia)
PsA management in the real world: the rheumatologist and dermatologist perspective

**All** 09:20
Panel discussion

**Michael Nurmohamed (Netherlands)** 09:30
Summary and symposium close

**08:15-09:45**

**Hall 7.2**

**Roche**

**Journey from clinical trials to patient care**

**Chair(s):**
Ernest Choy (United Kingdom)

**Ernest Choy (United Kingdom)** 08:15
Welcome & introduction

**Ernest Choy (United Kingdom)** 08:20
Exploring the value of real-world evidence (RWE)

**Deborah Symmons (United Kingdom)** 08:30
Confidence in treating the at-risk and elderly population

**Fabrizio de Benedetti (Italy)** 08:50
Advancing knowledge of the paediatric population

**Frank Buttgereit (Germany)** 09:10
Optimising the use of glucocorticoids in clinical practice

**Ernest Choy (United Kingdom)** 09:30
Summary

**All Faculty** 09:35
Question & answer session
### Biogen

**Anti-TNF in rheumatic diseases: inventory and outlook**

**Chair(s):**
Peter Taylor (United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Opening, intro &amp; overview: the treatment landscape in RA</td>
</tr>
<tr>
<td>08:30</td>
<td>Short presentations integrated at various time points into an interactive faculty/audience discussion</td>
</tr>
<tr>
<td>08:45</td>
<td>Raj Sengupta (United Kingdom) Preparing a switch: the perfect time to re-evaluate the clinical status of patients with RA/AS</td>
</tr>
<tr>
<td>09:00</td>
<td>Paul Enck (Germany) Preparing a switch: the perfect time to re-evaluate the patient’s psychosocial status</td>
</tr>
<tr>
<td>09:15</td>
<td>Juergen Braun (Germany) Successful switching: shared decision making with the patient is critical</td>
</tr>
<tr>
<td>09:30</td>
<td>Glenn Haugeberg (Norway) Post-switch patient follow-up in busy daily clinical practice - opportunities and challenges of remote patient monitoring</td>
</tr>
</tbody>
</table>

**All**
Summary and conclusion

---

### Menarini

**Multimodal approach for acute pain in rheumatology - a new paradigm targeting multiple mechanisms**

**Chair(s):**
Serge Perrot (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Introduction</td>
</tr>
<tr>
<td>08:30</td>
<td>Stefano Coaccioli (Italy) Low back pain and osteoarthritis: from clinical features to complex mechanisms</td>
</tr>
<tr>
<td>08:50</td>
<td>Serge Perrot (France) Multimodal approach, a step forward in the current therapeutic strategy</td>
</tr>
<tr>
<td>09:10</td>
<td>Magdi Hanna (United Kingdom) Rationale of the new oral fixed dose combination of dexketoprofen/Tramadol in targeting multiple mechanisms of moderate to severe acute pain</td>
</tr>
</tbody>
</table>

**Discussion and final remarks**

---

### Amgen

**Ready for the next biosimilar? Key stakeholder insights to guide choice**

**Chair(s):**
Thierry Thomas (France)
Fernando Perez-Ruiz (Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>08:25</td>
<td>Murray Aitken (United States) Assessing biosimilar attitudes and use: a marketplace evaluation</td>
</tr>
<tr>
<td>08:45</td>
<td>Fernando Perez-Ruiz (Spain) Clinical perspectives: what to consider when selecting the next anti-TNF biosimilar</td>
</tr>
<tr>
<td>09:10</td>
<td>Alison Kent (United Kingdom) Patient perspectives on anti-TNF biosimilars: understanding attitudes, beliefs and expectations</td>
</tr>
</tbody>
</table>

**All**
Panel discussion

**Fernando Perez-Ruiz (Spain)** Closing remarks
### AbbVie
**Solving the patient puzzle: a pragmatic approach to SpA management**

**Chair(s):**
Georg Schett (Germany)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Georg Schett (Germany)</td>
<td>17:30</td>
</tr>
<tr>
<td>Welcome and introduction</td>
<td></td>
</tr>
</tbody>
</table>

Disease progression: under control or still a cause for concern?

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denis Poddubnyy (Germany)</td>
<td>17:45</td>
</tr>
<tr>
<td>The many faces of SpA: how does inflammation lead to multifaceted disease?</td>
<td></td>
</tr>
</tbody>
</table>

Optimising long-term treatment: lessons from clinical practice

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philip Mease (United States)</td>
<td>18:05</td>
</tr>
<tr>
<td>Disease progression: under control or still a cause for concern?</td>
<td></td>
</tr>
</tbody>
</table>

Integrated care: a practical approach to patient management

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dirk Elewaut (Belgium)</td>
<td>18:25</td>
</tr>
<tr>
<td>Disease progression: under control or still a cause for concern?</td>
<td></td>
</tr>
</tbody>
</table>

Panel discussion and Q&A

<table>
<thead>
<tr>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:45</td>
</tr>
</tbody>
</table>

### Pfizer
**How to detect and treat unresolved symptoms in the patient with psoriatic arthritis**

**Chair(s):**
Désirée van der Heijde (Netherlands)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Désirée van der Heijde (Netherlands)</td>
<td>17:30</td>
</tr>
<tr>
<td>Welcome and introductions</td>
<td></td>
</tr>
</tbody>
</table>

Diagnostic ‘hot spots’: defining targets, detecting patients’ symptoms

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laure Gossec (France)</td>
<td>17:35</td>
</tr>
<tr>
<td>Diagnostic ‘hot spots’: defining targets, detecting patients’ symptoms</td>
<td></td>
</tr>
</tbody>
</table>

New products, new opportunities in PsA

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrique Soriano (Argentina)</td>
<td>17:55</td>
</tr>
<tr>
<td>New products, new opportunities in PsA</td>
<td></td>
</tr>
</tbody>
</table>

Optimising treatments: the physician and nurse practitioner partnership

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frank Behrens (Germany)</td>
<td>18:20</td>
</tr>
<tr>
<td>Optimising treatments: the physician and nurse practitioner partnership</td>
<td></td>
</tr>
</tbody>
</table>

Audience Q&A/panel discussion summary and close

<table>
<thead>
<tr>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:40</td>
</tr>
</tbody>
</table>

### Sanofi Genzyme
**The challenges of multi-morbidities in RA: IL-6 and chronic inflammation**

**Chair(s):**
Peter Taylor (United Kingdom)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Taylor (United Kingdom)</td>
<td>17:30</td>
</tr>
<tr>
<td>Meeting the challenge of multi-morbidities in RA</td>
<td></td>
</tr>
</tbody>
</table>

Multi-morbidities associated with RA: defining the systemic manifestations of the disease

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Nurmohamed (Netherlands)</td>
<td>17:40</td>
</tr>
<tr>
<td>Multi-morbidities associated with RA: defining the systemic manifestations of the disease</td>
<td></td>
</tr>
</tbody>
</table>

The multi-faceted role of IL-6 in RA and other RA-associated conditions

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ernest Choy (United Kingdom)</td>
<td>17:55</td>
</tr>
<tr>
<td>The multi-faceted role of IL-6 in RA and other RA-associated conditions</td>
<td></td>
</tr>
</tbody>
</table>

The effects of IL-6R blockade inside and outside the RA joint

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Genovese (United States)</td>
<td>18:15</td>
</tr>
<tr>
<td>The effects of IL-6R blockade inside and outside the RA joint</td>
<td></td>
</tr>
</tbody>
</table>

Moderated discussion with faculty and audience Q&A

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Taylor (United Kingdom)</td>
<td>18:55</td>
</tr>
<tr>
<td>Close</td>
<td></td>
</tr>
</tbody>
</table>

### Janssen
**A practical guide to new treatments in psoriatic arthritis and psoriasis**

**Chair(s):**
Dennis McGonagle (United Kingdom)  
Costantino Pitzalis (United Kingdom)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dennis McGonagle (United Kingdom)</td>
<td>17:30</td>
</tr>
<tr>
<td>Costantino Pitzalis (United Kingdom)</td>
<td>18:20</td>
</tr>
<tr>
<td>Welcome and introduction</td>
<td></td>
</tr>
</tbody>
</table>

Pathophysiology of joint and skin diseases and implications for treatment

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Costantino Pitzalis (United Kingdom)</td>
<td>17:35</td>
</tr>
<tr>
<td>Pathophysiology of joint and skin diseases and implications for treatment</td>
<td></td>
</tr>
</tbody>
</table>

Lessons from the skin: therapeutic options for psoriasis in clinical practice

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lluis Puig (Spain)</td>
<td>17:55</td>
</tr>
<tr>
<td>Lessons from the skin: therapeutic options for psoriasis in clinical practice</td>
<td></td>
</tr>
</tbody>
</table>

Lessons from the joint: therapeutic options for psoriatic arthritis in clinical practice

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dennis McGonagle (United Kingdom)</td>
<td>18:20</td>
</tr>
<tr>
<td>Lessons from the joint: therapeutic options for psoriatic arthritis in clinical practice</td>
<td></td>
</tr>
</tbody>
</table>

Conclusions and close of meeting

<table>
<thead>
<tr>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:55</td>
</tr>
</tbody>
</table>
**FRIDAY, 15 JUNE 2018**

**17:30-19:00**

**Bristol-Myers Squibb**

**Modulating the wayward T cell: the new horizon in autoimmunity and cancer**

**Chair(s):**

Leonard Calabrese (United States)

17:45

Welcome and introduction

Leonard Calabrese (United States)

17:47

T-cell co-stimulation in health and disease

Roberto Caporali (Italy)

18:12

T cell-B cell communication in autoimmune diseases, with a focus on RA

Christian Blank (Netherlands)

18:37

Expanding our understanding of T-cell modulation through learnings from cancer

All

19:02

Panel discussion and Q&A

---

**17:30-19:00**

**Samsung Bioepis**

**The era of biosimilars: reshaping the healthcare environment**

**Chair(s):**

Josef Smolen (Austria)

17:30

Welcome

Josef Smolen (Austria)

17:40

Anti-TNF biosimilars in rheumatology

João Gonçalves (Portugal)

17:55

Reinvestigating biologics quality excellence

Mark Quinn (United Kingdom)

18:10

Biosimilar adoption: improving rheumatology services for patients

Fabrizio Benedetti (Italy)

18:25

Understanding the nocebo effect

All

18:40

Q&A

Josef Smolen (Austria)

18:50

Closing

---

**08:15-09:45**

**Lilly**

**Challenging the rheumatoid arthritis treatment standards with JAK inhibitors**

**Chair(s):**

Désirée van der Heijde (Netherlands), Mark C. Genovese (United States)

08:15

Welcome and introduction

Désirée van der Heijde (Netherlands)

08:15

Mark C. Genovese (United States)

08:20

JAK inhibitors - are they all the same?

Paul Emery (United Kingdom)

08:35

JAK inhibitor baricitinib: how is it different from the standard of care (anti-TNF)?

Ronald van Vollenhoven (Netherlands)

08:50

JAK inhibitors position in the treatment algorithm of rheumatoid arthritis

Ulf Müller-Ladner (Germany)

09:05

JAK inhibitors in clinical practice

Désirée van der Heijde (Netherlands)

09:20

Mark C. Genovese (United States)

09:45

Panel discussion and Q&A

---

**08:15-09:45**

**Novartis**

**IL-17A inhibition in axial spondyloarthritis: new insights and implications for clinical practice**

**Chair(s):**

Filip van den Bosch (Belgium)

08:15

Welcome and introductions

Filip van den Bosch (Belgium)

08:15

Merryn Jongkees (Netherlands)

08:20

Axial spondyloarthritis: what matters to a patient?

Atul Deodhar (United States)

08:35

Clinical intervention in axial spondyloarthritis: why, when and how?

Rik Lories (Belgium)

08:55

Underlying pathophysiology of axial spondyloarthritis: clinical assessments and implications

Xenofon Baraliakos (Germany)

09:10

IL-17A inhibition in axial spondyloarthritis: current and future perspectives

All

09:30

Panel discussion and conclusions
**Integritas supported by Gilead Sciences, Inc.**

**Clinical issues in rheumatoid arthritis: discussions and debates on the evolving roles of targeted synthetic DMARDs**

**Chair(s):**  
Rieke Alten (Germany)

**08:15**  
Rieke Alten (Germany)  
Welcome and pre-activity questionnaire

**08:20**  
Josef Smolen (Austria)  
Pathophysiology: a focus on JAK enzymes

**08:35**  
Joel Kremer (United States)  
Long-term assessment of patient with RA: understanding treatment targets as a foundation for therapeutic tailoring

**08:55**  
Rieke Alten (Germany)  
Targeted synthetic DMARDs in the treatment of RA

**09:15**  
All  
Case study panel discussion: putting the evidence to practice

**09:30**  
All  
Post-activity questionnaire and Q&A session

**UCB**

**Axial spondyloarthritis in 2018: new data, less compromise?**

**Chair(s):**  
Martin Rudwaleit (Germany)

**08:15**  
Martin Rudwaleit (Germany)  
Welcome and introduction from the symposium chair

**08:20**  
Lianne Gensler (United States)  
Diagnostic delay, establishing disease control and starting a family

**08:45**  
Maxime Dougados (France)  
The right management strategy for the right patient

**09:05**  
Denis Podubnyy (Germany)  
Taking control of structural damage progression and exploring new horizons

**09:25**  
Martin Rudwaleit (Germany)  
Wrap-up and conclusion

**09:40**  
All  
Question and answer session moderated by the symposium chair

**Celgene**

**Towards a targeted approach in psoriatic arthritis with PDE4 inhibition**

**Chair(s):**  
Laure Gossec (France)

**08:15**  
Laure Gossec (France)  
Opening statement

**08:20**  
Laure Gossec (France)  
Guidelines in evolution and their applicability in treatment decisions

**08:35**  
Frank Behrens (Germany)  
Evidence from homogeneous clinical trials for a diverse patient population – the challenge in PsA patient care

**09:00**  
Philip J. Mease (United States)  
Optimising the clinical utility of PDE4 inhibition  
Audience Q&A

**09:20**  
Laure Gossec (France)  
Summary and close

**Boehringer Ingelheim**

**Interstitial lung disease in autoimmune rheumatic diseases – moving towards better patient care**

**Chair(s):**  
Frank van den Hoogen (Netherlands)

**08:15**  
Frank van den Hoogen (Netherlands)  
How relevant is ILD in autoimmune rheumatic diseases?

**08:25**  
Athol Wells (United Kingdom)  
How should we diagnose and monitor ILD?

**08:45**  
Christopher Denton (United Kingdom)  
Treatment of ILD in autoimmune rheumatic diseases

**09:05**  
Jörg Distler (Germany)  
Future perspectives on the treatment of fibrosis

**09:25**  
All  
Questions and answers
17:30-19:00 Auditorium

**Pfizer**

**Unraveling chronic pain: from defining to modulating**

**Chair(s):**
Francis Berenbaum (France)

**Francis Berenbaum (France)** 17:30
Welcome and faculty introductions

**Francis Berenbaum (France)** 17:35
Defining the humanistic and societal burden of chronic pain

**Martin Koltzenburg (United Kingdom)** 17:55
Overview of pain pathways and mediators of pain sensitization

**Richard Langford (United Kingdom)** 18:20
Current and future approaches to modulate chronic pain

All 18:45
Panel discussion and Q&A

**Francis Berenbaum (France)** 18:55
Closing remarks

17:30-19:00 Forum

**RMEI supported by Sanofi Genzyme & Regeneron**

**Global perspectives in RA: the role of new biologics for optimal management**

**Chair(s):**
Paul Emery (United Kingdom)

**Speakers:**
Paul Emery (United Kingdom)
Leonard H. Calabrese (United States)
Josef F. Smolen (Austria)

**Paul Emery (United Kingdom)** 17:30
Introductions and overview of panel topics

**Faculty Panel Discussion #1** 17:40
The patient with RA who fails to respond

**Faculty Panel Discussion #2** 18:05
The patient with RA who becomes non-responsive

**Faculty Panel Discussion #3** 18:30
The patient with poor response and comorbidities

**Paul Emery (United Kingdom)** 18:55
Summary remarks

17:30-19:00 Amtrium

**Rheumatology Today**

**Highlights of EULAR 2018**

**Chair(s):**
Matthias Schneider (Germany)

**Speakers:**
Peer M. Aries (Germany)
Xenofon Baraliakos (Germany)
Frank Behrens (Germany)
Christof Iking-Konert (Germany)
Christof Specker (Germany)
Torsten Witte (Germany)

**Round table experts:**
Frank Buttgereit (Germany)
Jens Gert Kuipers (Germany)
Ulf Müller-Ladner (Germany)

Presentation of six trials presented at EULAR 2018 featuring the following topics:
- Axial spondylarthritis
- Biologica monotherapy
- Collagenoses
- Novelties in RA treatment
- Psoriatic arthritis
- Vasculitis

17:30-19:00 Emerald

**Janssen**

**Lupus: now and in the future**

**Chair(s):**
David Isenberg (United Kingdom)
Ronald van Vollenhoven (Netherlands)

**David Isenberg (United Kingdom)** 17:30
Angela Tincani (Italy)
Welcome and introduction

**Eisabet Svenungsson (Sweden)** 17:40
Current options: limitations of current treatment in lupus

**Ronald van Vollenhoven (Netherlands)** 18:00
How to assess lupus in clinical care

**David Isenberg (United Kingdom)** 18:20
Biologics: what’s coming next?

**David Isenberg (United Kingdom)** 18:40
Eisabet Svenungsson (Sweden)
Angela Tincani (Italy)
Ronald van Vollenhoven (Netherlands)
Panel discussion

**Angela Tincani (Italy)** 18:55
Ronald van Vollenhoven (Netherlands)
Conclusions and close of meeting
Menarini

Hyperuricemia with deposition: a multisystemic disease

Chair(s):
Fernando Perez-Ruiz (Spain)

Fernando Perez-Ruiz (Spain)
Introduction

Claudio Borghi (Italy)
Hyperuricemia with deposition: a cardio metabolic disorder

Leonardo Punzi
Interaction between hyperuricemia with deposition and rheumatic diseases

Fernando Perez-Ruiz (Spain)
Hyperuricemia with deposition: the importance of adherence to treatment

Fernando Perez-Ruiz (Spain)
Summary and meeting close
Systemic sclerosis (also known as scleroderma) is a rare autoimmune disease and highly heterogeneous in terms of organ involvement and clinical progression.1–4

The symptoms of systemic sclerosis include: Raynaud’s phenomenon,* puffy hands or fingers,* acid reflux or epigastric discomfort, tight or thickening skin, dyspnoea, tiredness and fatigue, joint and muscle aches, and dysphagia.5–7

You can ensure a prompt diagnosis of systemic sclerosis with capillaroscopy and a blood test to check for antibodies specific to the disease.6

Please visit us at Stand 660 to find out more.

Discover morethanscleroderma.com


*Very early signs of systemic sclerosis.
ABBVIE

1 North Waukegan Road
North Chicago, IL 60064
United States

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

AGORA

6 Kosmon
71202 Heraklion-Crete
Greece
www.agora-platform.eu
www.agora-pait.com

Agora is a platform of organizations representing people with Rheumatic and Musculoskeletal Diseases in Southern Europe, which has been active since 2011. Agora aims to raise awareness, create a stronger voice for people with RMDs and motivate them to become more active and conscious through its various projects and initiatives. Furthermore, Agora aims in assisting the foundation and development towards user-led organizations of people with RMDs in Southern Europe, as well as promote supportive attitudes towards RMDs and enable patients to live independently and participate fully in society.
ALPINION MEDICAL SYSTEMS

7FL Verdi Tower
72, Digital-ro 26-gil
52-848 Guro-gu, Seoul
Korea
www.alpinion.com

ALPINION has focused on acoustic engineering and front-end technology since we initiated our ultrasound business. There has traditionally been a strong focus on back-end processing in ultrasound; however, we shifted the attention to the front-end with a focus on the signal quality sent to system processors. Based upon proprietary superior acoustic technology, ALPINION provides users with uniform image quality and continuous support throughout the product lifetime. ALPINION continuously strives to expand the medical business from diagnostic ultrasound (E-CUBE) to therapeutic ultrasound (ALPIUS).

AMERICAN COLLEGE OF RHEUMATOLOGY

2200 Lake Boulevard, NE
Atlanta, GA 30319
United States
www.rheumatology.org

The American College of Rheumatology is a professional membership society that serves over 9,500 physicians, health professionals and scientists worldwide and is committed to improving the care of patients with rheumatic disease and advancing the rheumatology subspecialty. Stop by the ACR stand for information on: the Annual Meeting, October 19-24, Chicago, Illinois; educational programs and products, such as ACR Beyond; the Rheumatology Image Library; Arthritis & Rheumatology, Arthritis Care & Research, The Rheumatologists; and the benefits of membership.

AMGEN (EUROPE) GmbH

Dammstrasse 23,
P.O Box 1557, CH 6301 Zug,
Switzerland
www.amgen.com

Amgen is at the forefront of biotechnology, helping invent the processes and tools that built the global biotechnology industry into the leading source of therapies for patients with few other options. Since 1980, Amgen has developed a range of innovative therapies focusing on biologic medicines. This expertise is now also used to develop high quality, therapeutic biosimilars in order to deliver more value to patients and healthcare systems. Our mission is to serve patients. We dedicate our days to turning the tide on serious illnesses - pushing the boundaries of science to transform medicine.

ARHTREX GMBH

Erwin-Hielscher-Straße 9
81249 München
Germany
www.arthrex.com

We are a global medical device company and leader in new product development and medical education in orthopedics. With a corporate mission of Helping Surgeons Treat Their Patients Better, Arthrex has pioneered the field of arthroscopy and developed more than 12 000 innovative products and surgical procedures to advance minimally invasive orthopedics worldwide.

ARTHRITIS RESEARCH UK AND ARTHRITIS CARE

Saffron House,
6-10 Kirby Street
London, EC1N 8EQ
United Kingdom
www.arthritisresearchuk.org
https://arthritiscare.org.uk/

Last year, Arthritis Research UK and Arthritis Care joined together so that we can do more to help people with arthritis live full and active lives. We invest in breakthrough treatments, the best information and vital support for everyone affected by arthritis. We believe in harnessing the power of exceptional science and supporting those living with the condition. Whether it’s through our helpline, online information or face to face services, everything we do is about helping people overcome the pain, isolation and fatigue arthritis causes.

To date, our work has already uncovered breakthrough treatments and helped support millions of people living with arthritis. Together, we are determined to do more and uncover new ideas to help more people live the pain free life they deserve.
Booth N° V24

Ankylosing Spondylitis International Federation (ASIF)

27 Old Gloucester Street
London WC1N 3AX
United Kingdom
www.asif.info
office@asif.info

ASIF is a global umbrella organisation established to increase public awareness of Ankylosing Spondylitis and to disseminate knowledge of the disease around the world. Ankylosing Spondylitis (AS) is a rheumatic inflammatory auto-immune disease primarily affecting the spine and sacroiliac joints, it is also called ‘Morbus Bechterew’ in some European countries.

ASIF has 39 Patient Organisation members 37 countries. Our most recent members are Chile, Columbia and South Africa. We aim to share the most up-to date in science and treatment with our members around the world and we encourage the sharing of information between our member societies.

ASIF leads on World AS Day which falls on the first Saturday in May each year.

---

Booth N° V01

BMJ

BMA House
Tavistock Square
London WC1H 9JP
United Kingdom
www.bmj.com/company

Annals of the Rheumatic Diseases (ARD), a collaboration between EULAR and BMJ, is the #1 ranked journal in the field of rheumatology (impact factor 12.811) and the flagship in the Essential Rheumatology portfolio. It is supported by RMD Open, an open access journal expanding the breadth of rheumatic and musculoskeletal diseases, and Lupus Science & Medicine – the world's first lupus-specific open access journal.

The package also comprises the newest edition of the EULAR Textbook on Rheumatic Diseases, the EULAR textbook on Systemic Sclerosis and the EULAR Textbook on Musculoskeletal Ultrasound in Rheumatology.

---

Booth N° V20

ASSOCIATION OF WOMEN IN RHEUMATOLOGY

2125 Valleygate Drive
Fayetteville, NC 28304
United States
www.awirgroup.org

Our mission is to promote the science and practice of rheumatology, foster the advancement and education of women in rheumatology, and advocate access to the highest quality health care, and management of patients with rheumatic diseases.

---

Booth N° 700

BIOGEN INTL GMBH

Landis Gyr Strasse 3
6300 Zug
Switzerland
www.biogen.com

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients’ worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is the world’s oldest independent biotechnology company. In 2012, Biogen entered into a joint venture with Samsung Biologics to form Samsung Bioepis to develop, manufacture and market biosimilars of advanced biologics. Biogen has commercialization rights to three anti-TNF biosimilar candidates in Europe, Japan, Turkey and Russia. These therapies will be manufactured in the company’s large-scale manufacturing facility in Hillerød, Denmark, which is one of the largest in the world.

---

Booth N° 660

BOEHRINGER INGELHEIM

Binger Strasse 173
55216 Ingelheim am Rhein
Germany
www.boehringer-ingelheim.com

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a family owned company we plan in generations. Aiming to make significant contributions to health care, we focus on diseases which have so far not been satisfactorily treated. We innovate to make breakthrough therapies and life-enhancing improvements available to patients and to provide advanced, preventive animal healthcare. Wherever we are active, we feel responsible for our communities and are respectful of our resources.

For more information, go to www.boehringer-ingelheim.com

---

Booth N° 480

BRISTOL-MYERS SQUIBB

3401 Princeton Pike
Lawrenceville, NJ 08648
United States
www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through the Bristol-Myers Squibb Foundation, we promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.
BRITISH SOCIETY OF RHEUMATOLOGY

Bride House, 18-20 Bride Lane EC4Y 8EE, London United Kingdom www.rheumatology.org

British Society for Rheumatology is the leading United Kingdom membership society for rheumatology and musculoskeletal care health professionals. We are member driven, supporting them in delivering the best care, at all stages of the care pathway, improving the lives of children and adults with rheumatic and musculoskeletal disease.

Visit us at stand V23 to learn more about the society, including our conferences, courses, academic journal and the benefits of membership.

Tweet us @Rheumatologyuk

BÜHLMANN LABORATORIES AG

Baselstrasse 55 4124 Schönenbuch Switzerland www.buhlmannlabs.ch

Calprotectin is a very efficient biomarker for disease monitoring of chronic inflammation patients like rheumatoid arthritis and other inflammatory arthritis patients.

The Switzerland based company BÜHLMANN is the leading manufacturer of IVD CE certified calprotectin (MRP8/14) diagnostics tests on the market, as well as exclusively offering the only combination available of calprotectin (MRP8/14) and therapeutic drug monitoring on the quantitative rapid test device Quantum Blue® to provide a comprehensive characterization of patient with chronic inflammation treated with biologic drugs.

CELGENE

Morris Avenue 07901, Summit United States www.celgene.com

Celgene Corporation (Nasdaq: CELG) is a global biopharmaceutical company that is helping healthcare providers turn inurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide. For more information visit www.celgene.com

CELLTRION HEALTHCARE

4F, 19, Academy-ro51 beon-gil Yeonsu-gu 22014 Incheon South Korea www.celltrionhealthcare.com

Celltrion Healthcare is a global biopharmaceutical company which conducts worldwide marketing and distribution of Celltrion, Inc.’s biosimilars and biologics. Celltrion Healthcare endeavors to offer high-quality, cost-effective and advanced therapeutics for patients in rheumatology, gastroenterology, immunology and oncology.

CYTOKINE SIGNALLING FORUM

Gothic Cottage White Lion Street Stafford ST17 BW United Kingdom www.cytokinesignalling.com

Developed under the auspices of the University of Glasgow and with a Steering Committee of rheumatology experts the Cytokine Signalling Forum is an online resource providing rapid reviews and slide resources of the latest literature, CME courses to further learning, congress highlights with the key data from EULAR and ACR, and our new podcast channel with our monthly review and interviews with authors of key papers. All this is accessible for free by visiting our stand or logging on to www.cytokinesignalling.com

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

Via Santa Maria 31 56126 Pisa Italy www.clinexprheumatol.org

Clinical and Experimental Rheumatology is an international journal focused on the latest developments in rheumatology. Every issue contains original articles, editorials, reviews, case reports and articles on paediatric rheumatology, aimed at updating readers in this complex and growing field.

The journal also publishes regular annual supplements on monothematic topics, facing the most new and controversial aspects in rheumatology, such as Contemporary Advances in Clinical Rheumatology, Vasculitis, Behçet’s disease and Autoinflammatory conditions, Systemic Sclerosis, Fibromyalgia and Sjögren’s syndrome.
**Booth N° 217**

**DS MEDICA SRL**

**DS Medica srl STAND**  
Viale Monza 133  
20125 Milan  
Italy  
www.dsmedica.info  

Since 1979 DS Medica has been involved in project development, production, distribution and marketing of medical technologies (hardware and software) as well as in the pharmaceutical advertising.

DS Medical is a leader in capillaroscopic techniques for the early diagnosis of many rheumatologic diseases.

Videocap® is an epiluminescence video-bio-microscope product line for multi-modality microscopy (immersion microscopy, polarized light microscopy and contact mode).

Videocap® is the ultimate instrument suited for diagnostic and research applications in the fields of rheumatology and dermatology.

**Booth N° 400**

**ELI LILLY AND COMPANY**

Lilly Corporate Center  
Indianapolis, IN 46285  
United States  
www.lilly.com  

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.

**Booth N° V11**

**ERN ReCONNET**

Via Roma 67  
56126, Pisa  
Italy  
http://reconnet.ern-net.eu/  

The European Reference Network ReCONNET is a virtual network for rare and complex connective tissue diseases (CTDs). The Network involves healthcare providers across Europe and aims at improving the clinical approach to rare and complex CTDs, the quality of the specialized care provided to patients, the activity of the physicians, the empowerment of the patients. All these activities are addressed to create a highly specialized network, in which the knowledge travels rather than the patient.

**Booth N° V31**

**ESOR - EULAR School of Rheumatology**

Seestrasse 240  
8802 Kilchberg  
Switzerland  
www.eular.org  

EULAR School of Rheumatology (ESOR) is a pre-eminent provider and facilitator of high quality education for physicians, health professionals and people with rheumatic and musculoskeletal diseases. It is a fully integrated operational entity within EULAR, offering individual membership primarily to physicians, health professionals and people with RMDs. Recent activities and products of ESOR include: Online courses, mentored learning programs, live courses, educational content of the EULAR Annual Congress and others (textbooks, educational exchanges, transfer programs, grants, awards and bursaries).

**Booth N° V34**

**EULAR EXECUTIVE SECRETARIAT**

Seestrasse 240  
8802 Kilchberg  
Switzerland  
www.eular.org  

The European League against Rheumatism (EULAR) is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with RMDs. EULAR aims to reduce the burden of RMDs on individuals and society and to improve the treatment, prevention and rehabilitation of RMDs. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with RMDs by the EU institutions through advocacy action.
EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY

Seestrasse 240
8802 Kilchberg
Switzerland
www.eular.org

The EULAR Standing Committee of Health Professionals in Rheumatology represents non-physician health professionals including nurses, physio and occupational therapists, podiatrists, psychologists, social workers and pharmacists in the European rheumatology field. We aim to improve the standard of care for people with rheumatic and musculoskeletal diseases (RMDs), with them as active and empowered individuals. We collaborate to improve the quality of education and research undertaken and implemented by health professionals in their area of practice, and participate in activities to raise awareness of how health professionals contribute to the health and well-being of patients with RMDs.

EULAR PARE

Seestrasse 240
8802 Kilchberg
Switzerland
www.eular.org

The EULAR Standing Committee of PARE gathers representatives of rheumatic and musculoskeletal user groups around Europe to work together towards improving the quality of life for the more than 120 million people in Europe living with these conditions. The committee’s vision is of people with rheumatic and musculoskeletal diseases (RMDs) in Europe being empowered to lead full and independent lives. To achieve this, the committee organises a range of high-quality activities and programmes. Activities may include advocacy at the national level, e.g. raising awareness of the disease, defending the civil rights of people with RMDs, or having access to the latest and most appropriate treatments.

EULAR STUDY GROUPS

Seestrasse 240
8802 Kilchberg
Switzerland
www.eular.org

EULAR Study Groups are focus groups in the sphere of one of EULAR's Standing Committee that has received EULAR endorsement. These groups promote activities/scientific networking under their own guidance without any financial support from EULAR. They are open for participation to anyone who is interested in the field in question and who brings background knowledge in the subject area.

EXPANSCIENCE

1 Place des Saisons
92048 Paris La Défense Cedex
France
www.expanscience.com
www.awirgroup.org

In 2017, Expanscience generated a turnover of €271.2 million, 61.9% of which was through exports, and employed 1105 people.

Over more than 60 years, we have built up a solid international reputation as an innovator and expert. Our products are distributed in almost 100 countries (including 16 subsidiaries).

The whole value chain is an integral part of the business – from research to production and distribution. Our CSR policy was introduced 15 years ago and has been recognised as exemplary by the AFAQ 26000 assessment.

EYELED - HELP POINT FOR SMARTPHONES AND MOBILE DEVICES

Science Park 1
66123 Saarbrücken
Germany
www.eyeled.de

Eyeled – the mobile IT specialists

With our knowledge and experience from more than 250 mobility projects, we offer our customers comprehensive advice, implement mobile solutions and provide long-term support for them.

On site, we offer battery recharge, support for troubleshooting smartphones and other mobile devices as well as assistance for downloading the EULAR Congress App. Visit us at booth V13 in the EULAR Village.

F. HOFFMANN-LA ROCHE AG

Grenzacherstrasse 124
CH-4070 Basel
Switzerland
www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

For more information, please visit roche.com.
Booth N° V09

FESCA (FED OF SCLERODERM ASSOCIATIONS)

Le Versailles, Av. des Etats-Unis 20/32
7500 Tournai, Belgium
www.fesca-scleroderma.eu

FESCA aisbl., founded in 2007, is an umbrella group of currently 24 national scleroderma patient support and advocacy organizations in 19 European countries. Friends of FESCA aisbl, includes the United States, Canada, and Australia, giving us a global presence and unity of purpose with other groups in the world. FESCA’s objectives include encouraging the active involvement of politicians and pharmaceutical companies, working with doctors to secure earlier diagnosis and better treatments, and creating greater awareness of scleroderma so that those who suffer from it can access proper, equitable care.

Booth N° V33

FOREUM

FOREUM Foundation for Research in Rheumatology
Seestrasse 240
8802 Kilchberg, Switzerland
www.foreum.org

FOREUM Foundation for Research in Rheumatology is an independent non-profit organisation, devoted to promote research in rheumatic and musculoskeletal diseases (RMDs). FOREUM seeks to initiate research of the highest quality and periodically announces calls for research proposals.

FOREUM seeks to raise funds from donors sharing FOREUM’s vision and goals: recognising that research and innovation in this field are crucial for improving prevention and management of RMDs and, hence, the living, working and socio-economic conditions of the more than 120 million people in Europe afflicted by RMDs.

Booth N° 611

FIDIA FARMACEUTICI

Via Ponte della Fabbrica 3/A
35031 Abano Terme, Italy
www.fidiapharma.com

Fidia farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based on natural and functionalised hyaluronic acid (over 650 patents), in joint care, wound healing, ophthalmology, aesthetics and regenerative medicine. Manufacturing operations are FDA-inspected and approved, and the company extends its global reach through wholly-owned subsidiaries and partners in nearly 100 countries worldwide. Please visit the company website www.fidiapharma.com.

Booth N° 608

FRESENIUS KABI

Else-Kröner-Straße 1
61352 Bad Homburg, Germany
www.fresenius-kabi.de

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Products: I.V. generic drugs, infusion therapies, clinical nutrition products and medical devices for administering these products. Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. The company also develops biosimilars with a focus on oncology and autoimmune diseases.

Booth N° 215

GE HEALTHCARE

Beethovenstrasse 239
42665 Solingen, Germany
www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

Booth N° 720

GILEAD SCIENCE, INC

333 Lakeside Drive
94404, Foster City, CA
United States
www.gilead.com

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple conditions, including Rheumatoid Arthritis and other rheumatic diseases. We are pursuing a comprehensive clinical trial program evaluating novel agents with the goal of advancing the care of patients suffering from inflammatory conditions.
The GISEA registry is an independent database that was established by the Italian Group for the Study of Early Arthritis (GISEA) in 2008, funded by the Italian Association of Rheumatic Patients (ANMAR - ONLUS). In line with the network's epidemiological strategy, the initial protocol was designed to collect long-term follow-up data concerning patients with rheumatic diseases treated with biological agents in order to investigate the real-world characteristics in terms of disease activity, comorbidities and survival on treatment.

GSK’s purpose is to help people do more, feel better, and live longer. Our Pharmaceuticals business has a broad portfolio of innovative and established medicines. We are focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. To discover the next breakthrough for immune-mediated diseases, we are focusing on transformational medicines that could potentially alter the course of inflammatory disease and induce sustainable remission.

An experienced and trusted partner, Grifols advances patient care with innovative diagnostic solutions that improve disease detection and management and simplify laboratory operations. Today, we empower customers with diagnostic products that span the healthcare continuum – from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring – and that include a comprehensive transfusion medicine portfolio and a growing portfolio of specialized clinical diagnostics.

Grüenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 bn company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

More information: www.grunenthal.com
Follow us on LinkedIn: ‘Grunenthal Group’

Hemics is a medical device company active in the field of inflammatory joint diseases. Hemics developed the Hemics HandScan, a new non-invasive optical imaging device. It supports rheumatologists in objective assessment of inflammatory status in patients with Rheumatoid Arthritis (RA). The technique is time saving, non-invasive, safe and operator independent, perfectly fitting the workflow in the rheumatologist’s office.

IBSA Institut Biochimique SA is a pharmaceutical company headquartered in Lugano, Switzerland. With a focus on high quality manufacturing, IBSA's portfolio for OA and related syndromes includes different therapeutic options such as pharmaceutical-grade chondroitin sulphate for oral intake, a series of highly purified i.a. hyaluronic acids of biofermentative origin, topical/oral forms of diclofenac epolamine and an innovative low-dosage subcutaneous and iv bolus injection of diclofenac.
The International League of Associations for Rheumatology’s mission is to advance rheumatology in developing countries. The ILAR Executive Committee consists of the Presidents and Presidents-Elect of ACR, EULAR, PANLAR, APLAR and AFLAR. The collaboration of the leaders of these international organizations has resulted in a renewed commitment to provide grants to support programs that lead to progress in the practice and education of rheumatology in countries where there is an exceptional need. The ILAR Grants Program, a funding initiative, was developed in response to the growing need for global advancements in rheumatology. Since 2008 ILAR has donated over a million dollars to fund 50+ Projects Worldwide. ILAR’s next Call for Proposals will open July 2, 2018.

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis) and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on http://www.janssen.com/emea/. Follow us on www.twitter.com/janssenEMEA for our latest news.

The Japan College of Rheumatology (JCR) holds the Annual Scientific Meeting every spring and provides a platform for rheumatologists and other specialists to share knowledge on the prevention and treatment of rheumatic diseases. The Meeting welcomes thousands of rheumatologists and researchers from Japan, as well as from the rest of the world. The JCR publishes its official journal, Modern Rheumatology and Modern Rheumatology Case Reports, which provides information on the latest developments in rheumatic diseases.

La Lettre du Rhumatologue is a French monthly publication specialized in rheumatology, which editor in chief is Pr. Bernard Combe. The publication is released in 4.000 copies issued 10 times a year.

LCA Pharmaceutical is expert in design and manufacture of viscoelastic medical devices with sodium hyaluronate for osteoarthritis. All of our products have a high molecular weight and high concentration of sodium hyaluronate. We offer a wide range of products:
- Treatment of 3 weekly intra-articular injections (40mg-2mL);
- Single injection for knee osteoarthritis (75mg/3mL);
- Single injection for hip osteoarthritis (75mg/3mL);
- Small joints injection (20mg/mL);
Two other innovative products are also available with the first combination of chondroitin sulfate and sodium hyaluronate indicated for treatment of osteoarthritis: pain relief and joint function recovery.
- Single injection (60mg NaHA + 60mg CS / 3mL);
- Treatment of 3 weekly intra-articular injections (40mg NaHA + 40mg CS / 2mL)
LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area.

Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.

Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.

LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.

The Lupus Academy is a long-term initiative committed to improving patient outcomes in SLE and allied diseases and to building a community of practitioners and advocates of best practice. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research.

Medac is a privately held pharmaceutical company with a growing pharmaceutical and diagnostics business. Medicinal products from medac support doctors and patients throughout the world in overcoming acute and chronic diseases in the indication areas of oncology, haematology, urology and autoimmune disorders. In addition, medac develops and markets special diagnostic test systems.

Since 1970 medac has been committed to unifying therapeutic and diagnostic areas under one roof.

For more information or collaboration with LUPUS EUROPE, please contact secretariat@lupus-europe.org
## MENARINI GROUP

**Via Sette Santi 1**  
50131 Firenze  
Italy  
www.menarini.com

Menarini Group is an Italian pharmaceutical company, 12th in Europe out of 5,255 companies, and 36th in the world out of 20,862 companies, it has a turnover of over € 3.5 billion and more than 16,700 employees. The Menarini Group has always held two clear strategic objectives: research and internationalisation. It has a presence in the most important treatment areas, including cardiologic, gastroenterologic, pneumological/antibiotic, diabetic and anti-inflammatory/analgesic products. With 16 production plants and 6 Research and Development centres, the Menarini Group has a strong presence across Europe, Asia, Africa and central and South America. Menarini’s products are available in over 130 countries worldwide. For more information visit www.menarini.com. Menarini recently received the EMA approval for a New pain-killer indicated for symptomatic short term treatment of moderate to severe acute pain.

## NOVARTIS

**Fabrikstrasse 2**  
4056 Basel  
Switzerland  
www.novartis.com

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

## MSD

**2000 Galloping Hill Road**  
07033 Kenilworth, New Jersey  
United States  
www.merck.com

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.

## OXFORD UNIVERSITY PRESS

**Great Clarendon Street**  
OX2 6DP, Oxford  
United Kingdom  
www.oup.com

Oxford University Press is a leading publisher in rheumatology, publishing the official journals of the British Society for Rheumatology (BSR) and some of the most respected online resources, and books, including the Oxford Textbook of Rheumatology, the Oxford Handbook of Rheumatology, and Paediatric Rheumatology. Visit us to enter our prize draw, pick up a free copy of Rheumatology, find out more about our exciting new open access journal Rheumatology Advances in Practice, and browse our extensive collection of books, available to buy with an exclusive 20% conference discount.

## PFIZER

**Via Valbondione, 113**  
00188 Roma  
Italy  
www.pfizer.com

Pfizer Inc.: Working together for a healthier world®  
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Booth N° 500

REGENERON
777 Old Saw Mill River Road
10591, New York
United States
www.regeneron.com

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Booth N° V28

National Association ReumaZorg Nederland
PO Box 58
6500 AB Nijmegen
Netherlands
www.reumazorgnederland.nl

The National Association ReumaZorg Nederland is the Dutch independent user-led patient organisation that strives to make a difference in the lives of people with RMDs. We work and lobby for an early diagnosis of RMDs, good healthcare and a ‘healthy’ active life for our members and for the more than 1.95 million Dutch people, known to have an RMD. Our advocacy aims at supporting people with RMDs in the best way possible.
F https://www.facebook.com/reumazorgnederland
I https://www.instagram.com/reumazorgnederland
T @ReumaZorgNL
W https://reumazorgnederland.nl
E voorzitter@reumazorgnederland.nl

Booth N° V27

ROMANIAN SOCIETY OF RHEUMATOLOGY
Romania
www.srreumatologie.ro

Romanian Society of Rheumatology (SRR) is the professional medical association that brings together all Romanian rheumatologists. Each year we organize a national meeting that usually involves about 800 participants and a summer school (one week dedicated to our trainees). Regional events and border-free scientific meetings organized together with specialists from other medical areas populate the whole year with moments of scientific debate and opportunities for education. The Journal of SRR serve its readers as an authoritative resource for clinical and fundamental research in rheumatology.

Booth N° 209

SAMUMED, LLC
9381 Judicial Drive
92121 San Diego, CA
United States
www.samumed.com

Samumed, LLC is a pharmaceutical platform company that has made groundbreaking advances in the biology of tissue regeneration. Our platform is rooted in its discoveries of new targets and biological processes in the Wnt pathway, an essential component of cellular biology of tissue regeneration.

Samumed is currently conducting clinical trials in osteoarthritis, degenerative disc disease, idiopathic pulmonary fibrosis, psoriasis, tendinopathy, androgenetic alopecia, and oncology.

Booth N° 620A

SANDOZ
Industriest. 25
83607 Holzkirchen
Germany
www.sandoz.com

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to discover new ways to improve and extend people’s lives. We pioneer novel approaches to drive access to medicine. Our portfolio comprises approximately 1000 molecules and our products reach well over 500 million patients.

Rheumatology News is the leading independent newspaper for the practicing rheumatologist. With specialty-focused news and insightful commentary—in a clear, concise, accessible format—Rheumatology News keeps busy rheumatologists up-to-date on clinical advances that impact their daily practice of medicine.

Rheumatology News is published 18X/year and circulates to nearly 8,000 rheumatologists, selected primary care physicians, and NP and PA specialists in rheumatology. All articles are researched, written, and produced by professional medical journalists. Rheumatology News can be found online at www.mededge.com/rheumatologynews.
**SANOFI GENZYME**

50 Binney St  
Cambridge, MA 02142  
United States  
www.sanofigenzyme.com

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

**SCANDINAVIAN JOURNAL OF RHEUMATOLOGY**

Hospital, Norrebrogade 44  
8000 Aarhus  
Denmark  
www.scandjrheumatol.dk

The Scandinavian Journal of Rheumatology publishes international, peer reviewed, high quality, original reports of clinical and basic research, as well as editorials, review articles and informative case reports covering all aspects of rheumatology. Subscriptions include print, online access, and supplements to the Journal. Published since 1955 by the Scandinavian Society for Rheumatology. Detailed information is available on our website www.scandjrheumatol.dk

**EUROPEAN LUPUS SOCIETY**

Via G. Ripamonti 129  
20141 Milan  
Italy  
www.sleuro.org

The European Lupus Society is a non-profit association and pursues the following goals:

- Building up a community of clinicians and researchers interested in SLE at a European and international level, with special focus to engage younger physicians in the field
- Promoting and coordinating the organisation of research and educational meetings on SLE and related syndromes
- Promoting equal access to best standard of care for SLE patients across Europe
- Facilitating research projects and clinical trials in SLE

To learn more about SLEuro, please visit us at www.sleuro.org and follow us on Facebook and Twitter.

**MEDICINE MATTERS - SPRINGER HEALTHCARE**

The Campus,  
4 Crinan Street  
London N1 9XW  
United Kingdom  
http://medicinematters.com

Medicine Matter rheumatology is provided by Springer Healthcare part of the Springer Nature group. Medicine Matters is a free to access professional rheumatology resource for healthcare professionals working with patients with rheumatology. Guided by our Advisory Board, Medicine Matters rheumatology will:

- Be a trusted online source of daily news, medical information, and expert opinion
- Provide regularly updated, peer-reviewed content
- Serve as an access point to the foremost sources of rheumatology information on the web
- Deliver educational tools and (CME) to support professional development

**TILMAN**

ZI Sud, 15  
5377 Baillonville  
Belgium  
www.tilman.be

Tilman is a Belgian pharmaceutical laboratory developing, manufacturing and distributing plant-based medicines for 60 years. By using industrial equipment in compliance with the GMP (Good Manufacturing Practices) pharmaceutical standards, Tilman is one of the most modern phytotherapy laboratories in Europe. Scientific rigour and compliance with the strictest of standards both contribute to the design of medicines with NOC (Notice of Compliance) and a full range of safe and effective products distributed by health professionals in numerous countries all over the world.
The Partnership of Turkish League Against Rheumatism (TLAR) and Rheumatology Society of Turkey (RST/TRD)

Sisli
İstanbul
Turkey
www.romatoloji.org
www.trasd.org.tr

TURKISH LEAGUE AGAINST RHEUMATISM was established in 1947 by physical medicine and rehabilitation specialists. It became a member of EULAR in 1947. RHEUMATOLOGY SOCIETY OF TURKEY (TRD, Türkiye Romatoloji Derneği) is the representative scientific society for rheumatologists based on internal medicine with more than 300 members. It was founded in 1993 and has been organizing National Congresses of Rheumatology since 1996. (www.romatoloji.org) EULAR representation in Turkey has been carried on by the partnership of TRD and TLAR since 2014 aiming to promote and to improve the official and scientific connections between Turkish rheumatologists and EULAR.

UCB
Allée de la Recherche
601070 Brussels
Belgium
www.ucb.com

At UCB, we aspire to be the patient-preferred biotech leader. Everything we do starts with a simple question: ‘How will this create value for people living with severe diseases?’

UCB’s patient value strategy aims to deliver, through a deep understanding of patient subpopulations, unique outcomes and the best patient experience to as many lives as possible within specific populations where UCB can lead.

With more than 7,500 people in approximately 40 countries, UCB generated revenue of € 4.5 billion in 2017.

WISEPRESS LTD
15 Lyon Road
London, SW19 2RL
United Kingdom
www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
Acknowledgements

The EULAR 2018 Organising Committee wishes to express its gratitude to all satellite symposia organisers and exhibitors as well as to the following partners:

- **abbvie**
  - Mobile app

- **AMGEN®**
  - Itinerary planner

- CELLTRION
  - Mobile charging stations

- **Pfizer**
  - Wireless access & Pocket programme

---

The image in the document shows a picturesque view of traditional Amsterdam houses along a canal, with clear blue skies and reflections in the water.
# Exhibitors' List

Status as of 1 May 2018

## Commercial Exhibition - Exhibitors' List

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>220+240+360</td>
</tr>
<tr>
<td>ALPINION MEDICAL SERVICES</td>
<td>607</td>
</tr>
<tr>
<td>AMGEN</td>
<td>600B</td>
</tr>
<tr>
<td>ARTHREX</td>
<td>214</td>
</tr>
<tr>
<td>BIOGEN</td>
<td>700</td>
</tr>
<tr>
<td>BOEHRINGER INGELHEIM</td>
<td>660</td>
</tr>
<tr>
<td>BRISTOL-MYERS SQUIBB</td>
<td>480</td>
</tr>
<tr>
<td>BÜHLMANN LABORATORIES</td>
<td>620D</td>
</tr>
<tr>
<td>CELGENE</td>
<td>420</td>
</tr>
<tr>
<td>CELLTRION HEALTHCARE</td>
<td>120</td>
</tr>
<tr>
<td>DS MEDICA SRL</td>
<td>217</td>
</tr>
<tr>
<td>ELI LILLY AND COMPANY</td>
<td>400</td>
</tr>
<tr>
<td>EXPANSCIENCE</td>
<td>440A</td>
</tr>
<tr>
<td>FIDIA FARMACEUTICI</td>
<td>611</td>
</tr>
<tr>
<td>FRESENIUS KABI</td>
<td>608</td>
</tr>
<tr>
<td>GE HEALTHCARE</td>
<td>215</td>
</tr>
<tr>
<td>GILEAD SCIENCE</td>
<td>720</td>
</tr>
<tr>
<td>GLAXOSMITKLINE</td>
<td>520</td>
</tr>
<tr>
<td>GRIFOLS</td>
<td>620C</td>
</tr>
<tr>
<td>GRÜNENTHAL GMBH</td>
<td>201</td>
</tr>
<tr>
<td>HEMICS</td>
<td>218</td>
</tr>
<tr>
<td>IBSA INSTITUT BIOCHIMIQUE SA</td>
<td>340B</td>
</tr>
<tr>
<td>JANSSEN PHARMACEUTICA NV</td>
<td>680</td>
</tr>
<tr>
<td>LCA PHARMACEUTICAL</td>
<td>609</td>
</tr>
<tr>
<td>LG CHEM</td>
<td>600A</td>
</tr>
<tr>
<td>MEDAC</td>
<td>200</td>
</tr>
<tr>
<td>MENARINI GROUP</td>
<td>440B</td>
</tr>
<tr>
<td>MSD</td>
<td>140</td>
</tr>
<tr>
<td>NORDIC GROUP BV</td>
<td>620B/2</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>160+329+460</td>
</tr>
<tr>
<td>PFIZER</td>
<td>100+300</td>
</tr>
<tr>
<td>REGENERON</td>
<td>500</td>
</tr>
<tr>
<td>ROCHE</td>
<td>180+340B</td>
</tr>
<tr>
<td>SAMUMED, LLC</td>
<td>209</td>
</tr>
<tr>
<td>SANDOZ</td>
<td>620A</td>
</tr>
<tr>
<td>SANOFI GENZYME</td>
<td>500</td>
</tr>
<tr>
<td>TILMAN</td>
<td>213</td>
</tr>
<tr>
<td>UCB</td>
<td>640</td>
</tr>
<tr>
<td>XIRALITE GMBH</td>
<td>620E</td>
</tr>
</tbody>
</table>

## Publishers' corner - Exhibitors' List

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYTOKINE SIGNALLING FORUM</td>
<td>PC5</td>
</tr>
<tr>
<td>LA LETTRE DU RHUMATOLOGUE</td>
<td>PC1</td>
</tr>
<tr>
<td>OXFORD UNIVERSITY PRESS</td>
<td>PC2</td>
</tr>
<tr>
<td>MEDICINE MATTERS - SPRINGER HEALTHCARE</td>
<td>PC6</td>
</tr>
<tr>
<td>WISEPRESS LTD</td>
<td>PC4</td>
</tr>
</tbody>
</table>

## EULAR Village - Exhibitors’ List

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMERICAN COLLEGE OF RHEUMATOLOGY (ACR)</td>
<td>V16</td>
</tr>
<tr>
<td>AGORA</td>
<td>V25</td>
</tr>
<tr>
<td>APLAR</td>
<td>V04</td>
</tr>
<tr>
<td>ARTHRITIS RESEARCH UK &amp; ARTHRITIS CARE</td>
<td>V19</td>
</tr>
<tr>
<td>ANKYLOSING SPONDYLITIS INTERNATIONAL FEDERATION (ASIF)</td>
<td>V24</td>
</tr>
<tr>
<td>ASSOCIATION OF WOMEN IN RHEUMATOLOGY</td>
<td>V20</td>
</tr>
<tr>
<td>BRITISH SOCIETY OF RHEUMATOLOGY</td>
<td>V23</td>
</tr>
<tr>
<td>BMJ</td>
<td>V01</td>
</tr>
<tr>
<td>CLINICAL AND EXPERIMENTAL RHEUMATOLOGY</td>
<td>V18</td>
</tr>
<tr>
<td>NATIONAL ASSOCIATION REUMAZORG NEDERLAND</td>
<td>V28</td>
</tr>
<tr>
<td>EMEUNET</td>
<td>V32</td>
</tr>
<tr>
<td>ERN RECONNET</td>
<td>V11</td>
</tr>
<tr>
<td>ESOR (EULAR SCHOOL OF RHEUMATOLOGY)</td>
<td>V31</td>
</tr>
<tr>
<td>EULAR EXECUTIVE SECRETARIAT</td>
<td>V34</td>
</tr>
<tr>
<td>EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY</td>
<td>V30</td>
</tr>
<tr>
<td>EULAR PARE</td>
<td>V29</td>
</tr>
<tr>
<td>EULAR STUDY GROUPS</td>
<td>V35</td>
</tr>
<tr>
<td>EYELED - HELP POINT FOR SMARTPHONES AND MOBILE DEVICES</td>
<td>V13</td>
</tr>
<tr>
<td>FESCA (FED OF SCLERODERM ASSOCIATIONS)</td>
<td>V09</td>
</tr>
<tr>
<td>FOREUM</td>
<td>V33</td>
</tr>
<tr>
<td>GISEA</td>
<td>V22</td>
</tr>
<tr>
<td>INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (ILAR)</td>
<td>V16</td>
</tr>
<tr>
<td>JAPAN COLLEGE OF RHEUMATOLOGY</td>
<td>V05</td>
</tr>
<tr>
<td>LUPUS ACADEMY</td>
<td>V03</td>
</tr>
<tr>
<td>LUPUS EUROPE</td>
<td>V26</td>
</tr>
<tr>
<td>REUMAZORG NEDERLAND</td>
<td>V28</td>
</tr>
<tr>
<td>RHEUMATOLOGY FEDERATION OF TURKEY</td>
<td>V21</td>
</tr>
<tr>
<td>RHEUMATOLOGY NEWS</td>
<td>V07</td>
</tr>
<tr>
<td>ROMANIAN SOCIETY OF RHEUMATOLOGY</td>
<td>V27</td>
</tr>
<tr>
<td>SCANDINAVIAN JOURNAL OF RHEUMATOLOGY</td>
<td>V06</td>
</tr>
<tr>
<td>EUROPEAN LUPUS SOCIETY</td>
<td>V10</td>
</tr>
<tr>
<td>WORLD SCLERODERMA FOUNDATION</td>
<td>V08</td>
</tr>
</tbody>
</table>
Notes
EULAR Online Courses

All courses start in September 2018

• 13th EULAR Online Course on Rheumatic Diseases
• 5th EULAR Online Course in Paediatric Rheumatology
• 4th EULAR Online Course for Health Professionals
• 8th EULAR Online Course on Systemic Sclerosis
• 10th EULAR Online Course on Connective Tissue Diseases
• 7th EULAR Online Introductory Ultrasound Course

NEW! EULAR Online Course on Imaging in RMDs

Individual course cost: EUR 150; reduced prices available for EULAR School of Rheumatology members!

Learn more at www.eular.org/education
Amgen brings nearly four decades of experience in the research, development, manufacturing, and supply of innovator biologics to its portfolio of novel and biosimilar therapies for inflammatory diseases. To learn more, please visit www.AmgenBiosimilars.eu and www.AmgenPipeline.com